We O
also O
conclude O
that O
sources O
of O
the O
above O
four O
pollutants O
are O
similar O
but O
differ O
from O
the O
sources O
of O
polybrominated B
diphenyl I
ethers I
. O

The O
studies O
also O
resulted O
in O
the O
identification O
of O
two O
known O
tetronic B
acids I
, O
viridicatic B
acid I
and O
terrestric B
acid I
, O
found O
in O
ethyl B
acetate I
and O
n B
- I
butanol I
extracts O
. O

The O
main O
components O
in O
the O
oil O
were O
beta B
- I
caryophyllene I
( O
56 O
. O
87 O
% O
) O
, O
alpha B
- I
cadinol I
( O
12 O
. O
52 O
% O
) O
, O
8S B
, I
13 I
- I
cedran I
- I
diol I
( O
5 O
. O
41 O
% O
) O
, O
alpha B
- I
terpineol I
( O
3 O
. O
99 O
% O
) O
, O
beta B
- I
eudesmol I
( O
2 O
. O
54 O
% O
) O
, O
caryophyllene B
oxide I
( O
2 O
. O
51 O
% O
) O
and O
ethyl B
iso I
- I
allocholate I
( O
2 O
. O
03 O
% O
) O
along O
with O
beta B
- I
cubebene I
, O
gamma B
- I
cadinene I
, O
cubenol B
, O
1 B
, I
8 I
- I

The O
main O
components O
in O
the O
oil O
were O
beta B
- I
caryophyllene I
( O
56 O
. O
87 O
% O
) O
, O
alpha B
- I
cadinol I
( O
12 O
. O
52 O
% O
) O
, O
8S B
, I
13 I
- I
cedran I
- I
diol I
( O
5 O
. O
41 O
% O
) O
, O
alpha B
- I
terpineol I
( O
3 O
. O
99 O
% O
) O
, O
beta B
- I
eudesmol I
( O
2 O
. O
54 O
% O
) O
, O
caryophyllene B
oxide I
( O
2 O
. O
51 O
% O
) O
and O
ethyl B
iso I
- I
allocholate I
( O
2 O
. O
03 O
% O
) O
along O
with O
beta B
- I
cubebene I
, O
gamma B
- I
cadinene I
, O
cubenol B
, O
1 B
, I
8 I
- I

The O
main O
components O
in O
the O
oil O
were O
beta B
- I
caryophyllene I
( O
56 O
. O
87 O
% O
) O
, O
alpha B
- I
cadinol I
( O
12 O
. O
52 O
% O
) O
, O
8S B
, I
13 I
- I
cedran I
- I
diol I
( O
5 O
. O
41 O
% O
) O
, O
alpha B
- I
terpineol I
( O
3 O
. O
99 O
% O
) O
, O
beta B
- I
eudesmol I
( O
2 O
. O
54 O
% O
) O
, O
caryophyllene B
oxide I
( O
2 O
. O
51 O
% O
) O
and O
ethyl B
iso I
- I
allocholate I
( O
2 O
. O
03 O
% O
) O
along O
with O
beta B
- I
cubebene I
, O
gamma B
- I
cadinene I
, O
cubenol B
, O
1 B
, I
8 I
- I

The O
main O
components O
in O
the O
oil O
were O
beta B
- I
caryophyllene I
( O
56 O
. O
87 O
% O
) O
, O
alpha B
- I
cadinol I
( O
12 O
. O
52 O
% O
) O
, O
8S B
, I
13 I
- I
cedran I
- I
diol I
( O
5 O
. O
41 O
% O
) O
, O
alpha B
- I
terpineol I
( O
3 O
. O
99 O
% O
) O
, O
beta B
- I
eudesmol I
( O
2 O
. O
54 O
% O
) O
, O
caryophyllene B
oxide I
( O
2 O
. O
51 O
% O
) O
and O
ethyl B
iso I
- I
allocholate I
( O
2 O
. O
03 O
% O
) O
along O
with O
beta B
- I
cubebene I
, O
gamma B
- I
cadinene I
, O
cubenol B
, O
1 B
, I
8 I
- I

The O
main O
components O
in O
the O
oil O
were O
beta B
- I
caryophyllene I
( O
56 O
. O
87 O
% O
) O
, O
alpha B
- I
cadinol I
( O
12 O
. O
52 O
% O
) O
, O
8S B
, I
13 I
- I
cedran I
- I
diol I
( O
5 O
. O
41 O
% O
) O
, O
alpha B
- I
terpineol I
( O
3 O
. O
99 O
% O
) O
, O
beta B
- I
eudesmol I
( O
2 O
. O
54 O
% O
) O
, O
caryophyllene B
oxide I
( O
2 O
. O
51 O
% O
) O
and O
ethyl B
iso I
- I
allocholate I
( O
2 O
. O
03 O
% O
) O
along O
with O
beta B
- I
cubebene I
, O
gamma B
- I
cadinene I
, O
cubenol B
, O
1 B
, I
8 I
- I

The O
main O
components O
in O
the O
oil O
were O
beta B
- I
caryophyllene I
( O
56 O
. O
87 O
% O
) O
, O
alpha B
- I
cadinol I
( O
12 O
. O
52 O
% O
) O
, O
8S B
, I
13 I
- I
cedran I
- I
diol I
( O
5 O
. O
41 O
% O
) O
, O
alpha B
- I
terpineol I
( O
3 O
. O
99 O
% O
) O
, O
beta B
- I
eudesmol I
( O
2 O
. O
54 O
% O
) O
, O
caryophyllene B
oxide I
( O
2 O
. O
51 O
% O
) O
and O
ethyl B
iso I
- I
allocholate I
( O
2 O
. O
03 O
% O
) O
along O
with O
beta B
- I
cubebene I
, O
gamma B
- I
cadinene I
, O
cubenol B
, O
1 B
, I
8 I
- I

cineol I
, O
o B
- I
cymene I
, O
curcumenol B
, O
spathulenol B
, O
friedeline B
and O
beta B
- I
sitosterol I
as O
minor O
constituents O
. O

The O
formulation O
factors O
for O
such O
patches O
, O
including O
eudragit B
RL I
100 I
and O
eudragit B
RS I
100 I
as O
matrix O
forming O
polymers O
, O
olive O
oil O
, O
groundnut O
oil O
and O
jojoba O
oil O
in O
different O
concentrations O
as O
enhancers O
and O
amount O
of O
drug O
loaded O
were O
investigated O
. O

The O
formulation O
factors O
for O
such O
patches O
, O
including O
eudragit B
RL I
100 I
and O
eudragit B
RS I
100 I
as O
matrix O
forming O
polymers O
, O
olive O
oil O
, O
groundnut O
oil O
and O
jojoba O
oil O
in O
different O
concentrations O
as O
enhancers O
and O
amount O
of O
drug O
loaded O
were O
investigated O
. O

Trans B
- I
3 I
( I
10 I
) I
- I
caren I
- I
4 I
- I
ol I
( O
22 O
. O
3 O
% O
) O
, O
artemisia B
ketone I
( O
18 O
. O
6 O
% O
) O
, O
1 B
, I
8 I
- I
cineole I
( O
14 O
. O
9 O
% O
) O
, O
delta B
- I
selinene I
( O
13 O
. O
0 O
% O
) O
and O
alpha B
- I
pinene I
( O
8 O
. O
2 O
% O
) O
were O
the O
major O
compounds O
. O

Trans B
- I
3 I
( I
10 I
) I
- I
caren I
- I
4 I
- I
ol I
( O
22 O
. O
3 O
% O
) O
, O
artemisia B
ketone I
( O
18 O
. O
6 O
% O
) O
, O
1 B
, I
8 I
- I
cineole I
( O
14 O
. O
9 O
% O
) O
, O
delta B
- I
selinene I
( O
13 O
. O
0 O
% O
) O
and O
alpha B
- I
pinene I
( O
8 O
. O
2 O
% O
) O
were O
the O
major O
compounds O
. O

Recent O
observations O
suggest O
that O
transformed O
cells O
have O
a O
derangement O
in O
the O
cyclic B
adenosine I
monophosphate I
/ O
cAMP B
- O
dependent O
protein O
kinase O
( O
cAMP B
/ O
PKA O
) O
pathway O
, O
which O
is O
known O
to O
regulate O
several O
mitochondrial O
functions O
. O

Furthermore O
, O
sinensetin B
increased O
the O
phosphorylation O
of O
AMP B
- O
activated O
protein O
kinase O
( O
AMPK O
) O
and O
acetyl B
- I
CoA I
carboxylase O
. O

( O
Euphorbiaceae O
) O
were O
investigated O
for O
its O
diterpenoids B
and O
afforded O
three O
new O
five O
- O
membered O
ring O
, O
pentacyclic B
myrisinane I
polyester I
comprised O
of O
3 B
, I
5 I
, I
10 I
- I
O I
- I
triacetyl I
- I
8 I
- I
O I
- I
isobutanoyl I
- I
14 I
- I
O I
- I
benzoylcyclomyrsinol I
( O
1 O
) O
, O
3 B
, I
5 I
, I
10 I
, I
14 I
- I
O I
- I
tetraacetyl I
- I
8 I
- I
O I
- I
( I
2 I
' I
- I
methyl I
butanoyl I
) I
- I
cyclomyrsinol I
( O
2 O
) O
and O
3 B
, I

Monoterpene B
( O
25 O
. O
2 O
- O
84 O
. O
9 O
% O
) O
and O
sesquiterpene B
hydrocarbons I
( O
12 O
. O
2 O
- O
46 O
. O
8 O
% O
) O
were O
the O
principal O
subclasses O
of O
compounds O
, O
with O
alpha B
- I
pinene I
( O
15 O
- O
65 O
. O
4 O
% O
) O
, O
germacrene B
D I
( O
5 O
. O
9 O
- O
30 O
. O
5 O
% O
) O
, O
delta B
- I
3 I
- I
carene I
( O
2 O
- O
16 O
. O
6 O
% O
) O
and O
gamma B
- I
cadinene I
( O
1 O
. O
3 O
- O
9 O
. O
8 O
% O
) O
as O
the O
main O
constituents O
. O

Monoterpene B
( O
25 O
. O
2 O
- O
84 O
. O
9 O
% O
) O
and O
sesquiterpene B
hydrocarbons I
( O
12 O
. O
2 O
- O
46 O
. O
8 O
% O
) O
were O
the O
principal O
subclasses O
of O
compounds O
, O
with O
alpha B
- I
pinene I
( O
15 O
- O
65 O
. O
4 O
% O
) O
, O
germacrene B
D I
( O
5 O
. O
9 O
- O
30 O
. O
5 O
% O
) O
, O
delta B
- I
3 I
- I
carene I
( O
2 O
- O
16 O
. O
6 O
% O
) O
and O
gamma B
- I
cadinene I
( O
1 O
. O
3 O
- O
9 O
. O
8 O
% O
) O
as O
the O
main O
constituents O
. O

These O
oils O
were O
differentiated O
by O
the O
content O
of O
the O
major O
constituents O
( O
alpha B
- I
pinene I
, O
germacrene B
D I
, O
delta B
- I
3 I
- I
carene I
and O
gamma B
- I
cadinene I
) O
, O
geographical O
location O
and O
climatic O
characteristics O
. O

These O
oils O
were O
differentiated O
by O
the O
content O
of O
the O
major O
constituents O
( O
alpha B
- I
pinene I
, O
germacrene B
D I
, O
delta B
- I
3 I
- I
carene I
and O
gamma B
- I
cadinene I
) O
, O
geographical O
location O
and O
climatic O
characteristics O
. O

In O
this O
review O
, O
we O
highlight O
how O
PP2A O
holoenzyme O
biogenesis O
and O
enzymatic O
activity O
are O
controlled O
by O
a O
sophisticatedly O
coordinated O
network O
of O
five O
PP2A O
modulators O
, O
consisting O
of O
alpha O
4 O
, O
phosphatase O
2A O
phosphatase O
activator O
( O
PTPA O
) O
, O
leucine B
carboxyl I
methyl I
transferase O
1 O
( O
LCMT1 O
) O
, O
PP2A O
methyl B
esterase O
1 O
( O
PME O
- O
1 O
) O
and O
, O
potentially O
, O
target O
of O
rapamycin B
signaling O
pathway O
regulator O
- O
like O
1 O
( O
TIPRL1 O
) O
, O
which O
serve O
to O
prevent O

Among O
them O
, O
gamma B
- I
sitosterol I
was O
found O
to O
be O
the O
major O
constituent O
. O

Two O
lupeol B
- O
type O
pentacyclic B
triterpenoids I
characterised O
as O
lup B
- I
20 I
( I
29 I
) I
- I
en I
- I
3 I
beta I
- I
ol I
- I
27 I
- I
oic I
acid I
( O
moruslupenoic B
acid I
A I
) O
and O
lup B
- I
12 I
, I
20 I
( I
29 I
) I
- I
dien I
- I
3 I
beta I
- I
ol I
- I
26 I
- I
oic I
acid I
( O
moruslupenoic B
acid I
B I
) O
and O
lanst B
- I
5 I
, I
24 I
- I
dien I
- I
3 I
beta I
- I
yl I
acetate I
( O
moruslanosteryl B
acetate I
) O
along O
with O
the O
known O
triterpenoidal O

Two O
lupeol B
- O
type O
pentacyclic B
triterpenoids I
characterised O
as O
lup B
- I
20 I
( I
29 I
) I
- I
en I
- I
3 I
beta I
- I
ol I
- I
27 I
- I
oic I
acid I
( O
moruslupenoic B
acid I
A I
) O
and O
lup B
- I
12 I
, I
20 I
( I
29 I
) I
- I
dien I
- I
3 I
beta I
- I
ol I
- I
26 I
- I
oic I
acid I
( O
moruslupenoic B
acid I
B I
) O
and O
lanst B
- I
5 I
, I
24 I
- I
dien I
- I
3 I
beta I
- I
yl I
acetate I
( O
moruslanosteryl B
acetate I
) O
along O
with O
the O
known O
triterpenoidal O

Synergy O
between O
L B
- I
DOPA I
and O
a O
novel O
positive O
allosteric O
modulator O
of O
metabotropic O
glutamate B
receptor O
4 O
: O
implications O
for O
Parkinson O
' O
s O
disease O
treatment O
and O
dyskinesia O
. O

For O
this O
reason O
, O
group O
III O
mGlu O
receptors O
, O
in O
particular O
mGlu4 O
, O
have O
been O
considered O
as O
key O
strategic O
targets O
for O
non O
- O
dopaminergic O
pharmacological O
treatments O
aimed O
at O
modulating O
these O
synapses O
, O
without O
producing O
the O
well O
known O
side O
- O
effects O
of O
l B
- I
DOPA I
, O
in O
particular O
the O
highly O
disabling O
l B
- I
DOPA I
- O
induced O
dyskinesia O
( O
LID O
) O
. O

For O
this O
reason O
, O
group O
III O
mGlu O
receptors O
, O
in O
particular O
mGlu4 O
, O
have O
been O
considered O
as O
key O
strategic O
targets O
for O
non O
- O
dopaminergic O
pharmacological O
treatments O
aimed O
at O
modulating O
these O
synapses O
, O
without O
producing O
the O
well O
known O
side O
- O
effects O
of O
l B
- I
DOPA I
, O
in O
particular O
the O
highly O
disabling O
l B
- I
DOPA I
- O
induced O
dyskinesia O
( O
LID O
) O
. O

By O
in O
vitro O
electrophysiological O
recordings O
we O
demonstrate O
that O
Lu B
AF21934 I
inhibits O
corticostriatal O
synaptic O
transmission O
and O
enhances O
the O
effect O
of O
the O
orthosteric O
mGlu4 O
receptor O
- O
preferred O
agonist O
LSP1 B
- I
2111 I
. O

In O
hemiparkinsonian O
rats O
( O
unilateral O
6 B
- I
hydroxydopamine I
lesion O
of O
the O
substantia O
nigra O
pars O
compacta O
) O
, O
Lu B
AF21934 I
alone O
did O
not O
affect O
akinesia O
at O
the O
doses O
tested O
( O
10 O
and O
30 O
mg O
/ O
kg O
) O
. O

However O
, O
when O
Lu B
AF21934 I
was O
combined O
with O
sub O
- O
threshold O
doses O
of O
l B
- I
DOPA I
( O
1 O
and O
5 O
mg O
/ O
kg O
) O
, O
it O
acted O
synergistically O
in O
alleviating O
akinesia O
in O
a O
dose O
- O
dependent O
manner O
and O
, O
notably O
, O
also O
reduced O
the O
incidence O
of O
LID O
but O
not O
its O
severity O
. O

These O
results O
support O
the O
potential O
for O
antiparkinsonian O
clinical O
use O
of O
a O
combined O
treatment O
consisting O
in O
l B
- I
DOPA I
and O
a O
mGlu4 O
receptor O
PAM O
to O
reduce O
efficacious O
l B
- I
DOPA I
doses O
( O
generally O
known O
as O
l B
- I
DOPA I
sparing O
) O
, O
while O
maintaining O
the O
same O
benefit O
on O
PD O
motor O
troubles O
, O
and O
at O
the O
same O
time O
minimizing O
the O
development O
of O
LID O
. O

These O
results O
support O
the O
potential O
for O
antiparkinsonian O
clinical O
use O
of O
a O
combined O
treatment O
consisting O
in O
l B
- I
DOPA I
and O
a O
mGlu4 O
receptor O
PAM O
to O
reduce O
efficacious O
l B
- I
DOPA I
doses O
( O
generally O
known O
as O
l B
- I
DOPA I
sparing O
) O
, O
while O
maintaining O
the O
same O
benefit O
on O
PD O
motor O
troubles O
, O
and O
at O
the O
same O
time O
minimizing O
the O
development O
of O
LID O
. O

These O
results O
support O
the O
potential O
for O
antiparkinsonian O
clinical O
use O
of O
a O
combined O
treatment O
consisting O
in O
l B
- I
DOPA I
and O
a O
mGlu4 O
receptor O
PAM O
to O
reduce O
efficacious O
l B
- I
DOPA I
doses O
( O
generally O
known O
as O
l B
- I
DOPA I
sparing O
) O
, O
while O
maintaining O
the O
same O
benefit O
on O
PD O
motor O
troubles O
, O
and O
at O
the O
same O
time O
minimizing O
the O
development O
of O
LID O
. O

acetylmaprounate I
. O
Journal O
Natural O
Products O
, O
52 O
, O
212 O
) O
, O
3 B
alpha I
- I
hydroxytaraxer I
- I
14 I
- I
en I
- I
28 I
- I
oic I
acid I
or O
isoaleuritolic B
acid I
( O
6 O
) O
, O
3 B
alpha I
- I
acetyltaraxer I
- I
14 I
- I
en I
- I
28 I
- I
oic I
acid I
acetate I
or O
aleuritolic B
acid I
acetate I
( O
7 O
) O
( O
Chaudhuri O
, O
S O
. O
K O
. O
, O
Fullas O
, O
F O
. O
, O
Brown O
, O
D O
. O
M O
. O
, O
Wani O
, O
M O
. O
C O
. O
, O
Wall O
, O
M O
. O
E O
. O
, O
Cai O
, O
L O
. O
, O
. O
. O
. O

Kinghorn O
, O
A O
. O
D O
. O
( O
1995 O
) O
. O
Isolation O
and O
structural O
elucidation O
of O
pentacyclic O
triterpenoids O
from O
Maprounea O
africana O
. O
Journal O
of O
Natural O
Products O
, O
58 O
, O
1 O
- O
9 O
) O
, O
3 B
- I
oxo I
- I
taraxer I
- I
14 I
- I
ene I
or O
taraxerone B
( O
8 O
) O
beta B
- I
sitosterol I
( O
9 O
) O
and O
stigmasterol B
( O
10 O
) O
( O
Kamboj O
& O
Saluja O
, O
2011 O
) O
, O
together O
with O
fatty O
acids O
. O

Continuous O
infusion O
of O
20 B
- I
hydroxyecdysone I
increased O
mass O
of O
triceps O
brachii O
in O
C57BL O
/ O
6 O
mice O
. O

Phytoecdysteroids B
have O
been O
attributed O
with O
numerous O
pharmacological O
properties O
in O
animals O
, O
including O
increasing O
muscle O
mass O
, O
and O
20 B
- I
hydroxyecdysone I
( O
20E O
) O
is O
one O
of O
the O
most O
abundant O
phytoecdysteroids B
produced O
by O
plants O
. O

The O
latter O
part O
of O
this O
study O
focused O
on O
the O
roles O
of O
stabilizers O
( O
hydroxypropyl B
cellulose O
and O
sodium B
lauryl I
sulfate I
) O
and O
elucidation O
of O
the O
so O
- O
called O
Rehbinder O
effect O
( O
reduction O
in O
particle O
strength O
due O
to O
adsorbed O
stabilizers O
such O
as O
polymers O
and O
surfactants O
) O
. O

Two O
new O
C O
- O
15 O
enolic B
acyl I
phragmalin I
- O
type O
limonoids B
from O
Chukrasia O
tabularis O
var O
. O
velutina O
. O

Two O
new O
C O
- O
15 O
enolic B
acyl I
phragmalin I
- O
type O
limonoid B
orthoesters I
, O
chukvelutilide B
G I
( O
1 O
) O
and O
chukrasine B
F I
( O
2 O
) O
, O
were O
isolated O
from O
the O
stem O
barks O
of O
Chukrasia O
tabularis O
var O
. O
velutina O
. O

A O
new O
xanthone B
, O
calothorexanthone B
, O
together O
with O
five O
known O
compounds O
, O
garbogiol B
, O
1 B
, I
4 I
, I
8 I
- I
trihydroxyxanthone I
, O
delta B
- I
tocotrienol I
, O
1 B
, I
7 I
- I
dihydroxyxanthone I
and O
globuxanthone B
, O
was O
isolated O
from O
a O
petroleum O
ether O
extract O
of O
the O
bark O
of O
Calophyllum O
thorelii O
. O

To O
further O
improve O
dissolution O
characteristics O
, O
the O
physical O
mixtures O
of O
ITR B
and O
ITRDNT B
with O
two O
cyclodextrins O
, O
beta B
- I
cyclodextrin I
( O
beta B
- I
CD I
) O
and O
HP B
- I
beta I
- I
cyclodextrin I
( O
HP B
- I
beta I
- I
CD I
) O
were O
prepared O
and O
their O
molar O
ratios O
were O
optimized O
. O

To O
further O
improve O
dissolution O
characteristics O
, O
the O
physical O
mixtures O
of O
ITR B
and O
ITRDNT B
with O
two O
cyclodextrins O
, O
beta B
- I
cyclodextrin I
( O
beta B
- I
CD I
) O
and O
HP B
- I
beta I
- I
cyclodextrin I
( O
HP B
- I
beta I
- I
CD I
) O
were O
prepared O
and O
their O
molar O
ratios O
were O
optimized O
. O

PRS O
mice O
also O
showed O
an O
increased O
binding O
of O
DNMT1 O
and O
MeCP2 O
, O
and O
an O
increase O
in O
5 B
- I
methylcytosine I
and O
5 B
- I
hydroxymethylcytosin I
in O
specific O
CpG B
- O
rich O
regions O
of O
the O
reelin O
and O
GAD67 O
promoters O
. O

PRS O
mice O
also O
showed O
an O
increased O
binding O
of O
DNMT1 O
and O
MeCP2 O
, O
and O
an O
increase O
in O
5 B
- I
methylcytosine I
and O
5 B
- I
hydroxymethylcytosin I
in O
specific O
CpG B
- O
rich O
regions O
of O
the O
reelin O
and O
GAD67 O
promoters O
. O

Sm O
. O
: O
alpha B
- I
pinene I
, O
p B
- I
cymene I
, O
1 B
, I
8 I
- I
cineole I
, O
and O
limonene B
. O

Sm O
. O
: O
alpha B
- I
pinene I
, O
p B
- I
cymene I
, O
1 B
, I
8 I
- I
cineole I
, O
and O
limonene B
. O

The O
results O
indicated O
that O
the O
amount O
of O
alpha B
- I
pinene I
in O
the O
brain O
and O
liver O
was O
twofold O
greater O
after O
mixed O
- O
component O
inhalation O
than O
that O
after O
single O
- O
component O
inhalation O
. O

In O
a O
comparison O
of O
the O
components O
of O
the O
mixed O
inhalation O
, O
the O
ratio O
of O
alpha B
- I
pinene I
increased O
to O
about O
three O
times O
that O
of O
1 B
, I
8 I
- I
cineole I
. O

Total O
lipids O
were O
extracted O
using O
a O
solvent O
mixture O
of O
methanol B
/ O
chloroform B
( O
2 O
/ O
1 O
, O
v O
/ O
v O
) O
and O
further O
derivatised O
to O
FA B
methyl I
esters I
( O
FAME B
) O
. O

The O
most O
abundant O
saturated O
FA O
were O
palmitic B
( O
C16 B
: I
0 I
) O
and O
myristic B
( O
C14 B
: I
0 I
) O
, O
while O
oleic B
( O
C18 B
: I
1 I
n O
- O
9 O
) O
was O
the O
dominant O
monounsaturated B
acid I
. O

The O
most O
abundant O
saturated O
FA O
were O
palmitic B
( O
C16 B
: I
0 I
) O
and O
myristic B
( O
C14 B
: I
0 I
) O
, O
while O
oleic B
( O
C18 B
: I
1 I
n O
- O
9 O
) O
was O
the O
dominant O
monounsaturated B
acid I
. O

The O
most O
abundant O
saturated O
FA O
were O
palmitic B
( O
C16 B
: I
0 I
) O
and O
myristic B
( O
C14 B
: I
0 I
) O
, O
while O
oleic B
( O
C18 B
: I
1 I
n O
- O
9 O
) O
was O
the O
dominant O
monounsaturated B
acid I
. O

All O
seaweeds O
contained O
linoleic B
FA I
( O
C18 B
: I
2 I
n O
- O
6 O
) O
. O

The O
alpha B
- I
linolenic I
( O
C18 B
: I
3 I
n O
- O
3 O
) O
and O
eicosapentaenoic B
( O
20 O
: O
5 O
n O
- O
3 O
) O
acids O
were O
present O
only O
in O
Porphyra O
sp O
. O

The O
alpha B
- I
linolenic I
( O
C18 B
: I
3 I
n O
- O
3 O
) O
and O
eicosapentaenoic B
( O
20 O
: O
5 O
n O
- O
3 O
) O
acids O
were O
present O
only O
in O
Porphyra O
sp O
. O

Using O
pharmacologic O
and O
molecular O
approaches O
that O
suppress O
the O
prolyl B
- O
hydroxylase O
( O
PHD O
) O
- O
mediated O
inhibition O
of O
HIF1 O
alpha O
, O
we O
show O
that O
DCA B
inhibits O
HIF1 O
alpha O
by O
both O
a O
PHD O
- O
dependent O
mechanism O
( O
that O
involves O
a O
DCA B
- O
induced O
increase O
in O
the O
production O
of O
mitochondria O
- O
derived O
alpha B
- I
ketoglutarate I
) O
and O
a O
PHD O
- O
independent O
mechanism O
, O
involving O
activation O
of O
p53 O
via O
mitochondrial O
- O
derived O
H B
( I
2 I
) I
O I
( I
2 I
) I
, O
as O
well O
as O
activation O
of O
GSK3 O
beta O
. O

Here O
we O
review O
the O
effects O
of O
newly O
- O
designed O
group O
- O
III O
orthosteric O
agonists O
on O
neuroprotection O
, O
neurorestoration O
and O
reduction O
of O
l B
- I
DOPA I
induced O
dyskinesia O
in O
animal O
models O
of O
PD O
. O

A O
new O
bromobenzyl B
methyl I
sulphoxide I
from O
marine O
red O
alga O
Symphyocladia O
latiuscula O
. O

In O
the O
medium O
polar O
fraction O
, O
we O
isolated O
the O
two O
hydroxy B
- I
phenyl I
- I
ethyl I
alcohols I
( O
hydroxyl B
- I
tyrosol I
and O
tyrosol B
) O
that O
are O
the O
main O
component O
of O
olives O
. O

This O
study O
aimed O
to O
evaluate O
the O
antimicrobial O
effects O
, O
the O
radical O
scavenging O
activity O
( O
by O
DPPH B
and O
ABTS B
tests O
) O
and O
the O
antioxidant O
capacity O
( O
by O
beta B
- I
carotene I
bleaching O
test O
) O
of O
Betula O
aetnensis O
leaves O
extract O
. O

The O
experimental O
data O
demonstrated O
that O
the O
polyisoprenylated B
benzophenone I
GFC I
possesses O
cytotoxic O
and O
leishmanicidal O
activities O
. O

A O
new O
acylated B
flavone I
glycoside I
with O
antioxidant O
and O
radical O
scavenging O
activities O
from O
Teucrium O
polium O
leaves O
. O

On O
the O
basis O
of O
the O
comparable O
bioactivity O
of O
luteolin B
- O
based O
compounds O
, O
the O
presence O
of O
an O
ortho B
- I
dihydroxy I
substitution O
in O
the O
flavone B
B O
- O
ring O
is O
supposed O
to O
be O
the O
structural O
feature O
responsible O
for O
the O
antioxidant O
activity O
. O

The O
main O
components O
in O
the O
oil O
were O
butylated B
hydroxytoluene I
( O
BHT B
) O
( O
34 O
. O
17 O
% O
) O
, O
phytol B
( O
12 O
. O
66 O
% O
) O
, O
alpha B
- I
caryophyllene I
( O
11 O
. O
84 O
% O
) O
, O
delta B
- I
elemene I
( O
10 O
. O
65 O
% O
) O
, O
beta B
- I
caryophyllene I
( O
7 O
. O
82 O
% O
) O
, O
gamma B
- I
elemene I
( O
4 O
. O
24 O
% O
) O
and O
germacrene B
D I
( O
2 O
. O
82 O
% O
) O
. O

The O
main O
components O
in O
the O
oil O
were O
butylated B
hydroxytoluene I
( O
BHT B
) O
( O
34 O
. O
17 O
% O
) O
, O
phytol B
( O
12 O
. O
66 O
% O
) O
, O
alpha B
- I
caryophyllene I
( O
11 O
. O
84 O
% O
) O
, O
delta B
- I
elemene I
( O
10 O
. O
65 O
% O
) O
, O
beta B
- I
caryophyllene I
( O
7 O
. O
82 O
% O
) O
, O
gamma B
- I
elemene I
( O
4 O
. O
24 O
% O
) O
and O
germacrene B
D I
( O
2 O
. O
82 O
% O
) O
. O

The O
main O
components O
in O
the O
oil O
were O
butylated B
hydroxytoluene I
( O
BHT B
) O
( O
34 O
. O
17 O
% O
) O
, O
phytol B
( O
12 O
. O
66 O
% O
) O
, O
alpha B
- I
caryophyllene I
( O
11 O
. O
84 O
% O
) O
, O
delta B
- I
elemene I
( O
10 O
. O
65 O
% O
) O
, O
beta B
- I
caryophyllene I
( O
7 O
. O
82 O
% O
) O
, O
gamma B
- I
elemene I
( O
4 O
. O
24 O
% O
) O
and O
germacrene B
D I
( O
2 O
. O
82 O
% O
) O
. O

The O
main O
components O
in O
the O
oil O
were O
butylated B
hydroxytoluene I
( O
BHT B
) O
( O
34 O
. O
17 O
% O
) O
, O
phytol B
( O
12 O
. O
66 O
% O
) O
, O
alpha B
- I
caryophyllene I
( O
11 O
. O
84 O
% O
) O
, O
delta B
- I
elemene I
( O
10 O
. O
65 O
% O
) O
, O
beta B
- I
caryophyllene I
( O
7 O
. O
82 O
% O
) O
, O
gamma B
- I
elemene I
( O
4 O
. O
24 O
% O
) O
and O
germacrene B
D I
( O
2 O
. O
82 O
% O
) O
. O

An O
antileishmanial O
prenyloxy B
- I
naphthoquinone I
from O
roots O
of O
Plumbago O
zeylanica O
. O

This O
study O
discloses O
strong O
in O
vitro O
antileishmanial O
activity O
of O
2 B
- I
methyl I
- I
5 I
- I
( I
3 I
' I
- I
methyl I
- I
but I
- I
2 I
' I
- I
enyloxy I
) I
- I
[ I
1 I
, I
4 I
] I
naphthoquinone I
( O
1 O
) O
, O
a O
prenyloxy B
- I
naphthoquinone I
isolated O
and O
characterised O
from O
roots O
of O
the O
plant O
Plumbago O
zeylanica O
( O
family O
- O
Plumbaginaceae O
) O
. O

To O
investigate O
new O
neuroprotective O
mechanisms O
associated O
with O
I O
( O
2 O
) O
- O
imidazoline B
receptors O
, O
the O
effects O
of O
selective O
( O
2 B
- I
styryl I
- I
2 I
- I
imidazoline I
( O
LSL B
61122 I
) O
, O
2 B
- I
( I
2 I
- I
benzofuranyl I
) I
- I
2 I
- I
imidazoline I
( O
2 B
- I
BFI I
) O
, O
2 B
- I
( I
4 I
, I
5 I
- I
dihydroimidazol I
- I
2 I
- I
yl I
) I
quinoline I
hydrochloride I
( O
BU B
- I
224 I
) O
) O
and O
non O
- O
selective O
( O
idazoxan B
) O
I O
( O
2 O
) O
- O
drugs O
on O

To O
investigate O
new O
neuroprotective O
mechanisms O
associated O
with O
I O
( O
2 O
) O
- O
imidazoline B
receptors O
, O
the O
effects O
of O
selective O
( O
2 B
- I
styryl I
- I
2 I
- I
imidazoline I
( O
LSL B
61122 I
) O
, O
2 B
- I
( I
2 I
- I
benzofuranyl I
) I
- I
2 I
- I
imidazoline I
( O
2 B
- I
BFI I
) O
, O
2 B
- I
( I
4 I
, I
5 I
- I
dihydroimidazol I
- I
2 I
- I
yl I
) I
quinoline I
hydrochloride I
( O
BU B
- I
224 I
) O
) O
and O
non O
- O
selective O
( O
idazoxan B
) O
I O
( O
2 O
) O
- O
drugs O
on O

Similar O
chronic O
treatments O
with O
LSL B
60101 I
( O
the O
imidazole B
analogue O
of O
2 B
- I
BFI I
) O
and O
idazoxan B
( O
a O
mixed O
I O
( O
2 O
) O
/ O
alpha O
( O
2 O
) O
- O
ligand O
) O
did O
not O
induce O
significant O
alterations O
of O
pro O
- O
or O
anti O
- O
apoptotic O
proteins O
. O

With O
a O
trace O
fear O
conditioning O
paradigm O
, O
administration O
of O
the O
5HT2AR O
agonist O
TCB B
- I
2 I
( O
1 O
. O
0 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
before O
the O
extinction O
test O
facilitated O
the O
acquisition O
of O
extinction O
of O
fear O
memory O
as O
compared O
to O
vehicle O
treatment O
. O

Further O
, O
the O
post O
- O
conditioning O
administration O
of O
TCB B
- I
2 I
enhanced O
contextual O
and O
cued O
fear O
memory O
, O
possibly O
by O
facilitating O
the O
consolidation O
of O
fear O
memory O
. O

Administration O
of O
TCB B
- I
2 I
also O
facilitated O
the O
acquisition O
of O
extinction O
of O
fear O
memory O
in O
delay O
fear O
conditioned O
mice O
. O

Finally O
, O
administration O
of O
TCB B
- I
2 I
right O
after O
training O
in O
an O
object O
recognition O
task O
enhanced O
the O
consolidation O
of O
object O
memory O
. O

Rescue O
of O
this O
impaired O
extinction O
consolidation O
/ O
retrieval O
was O
achieved O
with O
d B
- I
cycloserine I
( O
N B
- I
methly I
- I
d I
- I
aspartate I
partial O
agonist O
) O
or O
MS B
- I
275 I
( O
histone O
deacetylase O
( O
HDAC O
) O
inhibitor O
) O
, O
applied O
after O
extinction O
training O
. O

Rescue O
of O
this O
impaired O
extinction O
consolidation O
/ O
retrieval O
was O
achieved O
with O
d B
- I
cycloserine I
( O
N B
- I
methly I
- I
d I
- I
aspartate I
partial O
agonist O
) O
or O
MS B
- I
275 I
( O
histone O
deacetylase O
( O
HDAC O
) O
inhibitor O
) O
, O
applied O
after O
extinction O
training O
. O

Rescue O
of O
both O
impaired O
extinction O
acquisition O
and O
deficient O
extinction O
consolidation O
/ O
retrieval O
was O
achieved O
with O
prior O
extinction O
training O
administration O
of O
valproic B
acid I
( O
a O
GABAergic O
enhancer O
and O
HDAC O
inhibitor O
) O
or O
AMN082 B
[ O
metabotropic O
glutamate B
receptor O
7 O
( O
mGlu7 O
) O
agonist O
] O
, O
while O
MS B
- I
275 I
or O
PEPA B
( O
AMPA B
receptor O
potentiator O
) O
failed O
to O
affect O
extinction O
acquisition O
in O
S1 O
mice O
. O

Geraniol B
, O
alpha B
- I
cedrene I
and O
p B
- I
cymene I
were O
determined O
as O
the O
main O
components O
. O

Geraniol B
, O
alpha B
- I
cedrene I
and O
p B
- I
cymene I
were O
determined O
as O
the O
main O
components O
. O

Geraniol B
was O
detected O
as O
a O
major O
component O
in O
C O
. O
cilicica O
( O
14 O
. O
64 O
% O
) O
, O
and O
alpha B
- I
cedrene I
was O
detected O
as O
a O
major O
component O
with O
26 O
. O
03 O
% O
for O
C O
. O
lycica O
, O
16 O
. O
93 O
% O
for O
C O
. O
scoparia O
, O
13 O
. O
01 O
% O
for O
C O
. O
davisiana O
and O
10 O
. O
94 O
% O
for O
C O
. O
paphlagonica O
. O

Cephalaria O
scoparia O
, O
C O
. O
davisiana O
and O
C O
. O
gazipashensis O
have O
considerable O
amount O
of O
p B
- I
cymene I
as O
12 O
. O
86 O
% O
, O
12 O
. O
70 O
% O
and O
11 O
. O
16 O
% O
, O
respectively O
. O

Recent O
studies O
indicate O
that O
auraptene B
( O
7 B
- I
geranyloxycoumarin I
, O
AUR B
) O
, O
a O
geranyloxycoumarin B
extracted O
from O
fruits O
of O
edible O
plants O
belonging O
to O
the O
Rutaceae O
family O
, O
may O
represent O
a O
novel O
lead O
compound O
for O
dietary O
colon O
cancer O
chemoprevention O
in O
rodents O
. O

MeOH B
and O
partitioned O
against O
n B
- I
hexane I
and O
chloroform B
( O
CHCl3 B
) O
to O
obtain O
MeOH B
, O
n B
- I
hexane I
and O
CHCl3 B
extracts O
. O

MeOH B
and O
partitioned O
against O
n B
- I
hexane I
and O
chloroform B
( O
CHCl3 B
) O
to O
obtain O
MeOH B
, O
n B
- I
hexane I
and O
CHCl3 B
extracts O
. O

In O
this O
multicenter O
, O
double O
- O
blind O
, O
placebo O
- O
controlled O
, O
randomized O
, O
four O
way O
cross O
- O
over O
proof O
- O
of O
- O
mechanism O
study O
, O
we O
tested O
the O
effect O
of O
the O
positive O
allosteric O
alpha O
7 O
nicotinic O
acetylcholine B
receptor O
( O
nAChR O
) O
modulator O
JNJ B
- I
39393406 I
in O
a O
key O
translational O
assay O
( O
sensory O
P50 O
gating O
) O
in O
39 O
regularly O
smoking O
male O
patients O
with O
schizophrenia O
. O

All O
patients O
were O
clinically O
stable O
and O
JNJ B
- I
39393406 I
was O
administered O
as O
an O
adjunct O
treatment O
to O
antipsychotics O
. O

No O
indication O
was O
found O
that O
JNJ B
- I
39393406 I
has O
the O
potential O
to O
reverse O
basic O
deficits O
of O
information O
processing O
in O
schizophrenia O
( O
sensory O
P50 O
gating O
) O
or O
has O
a O
significant O
effect O
on O
other O
tested O
electrophysiological O
markers O
( O
MMN O
, O
P300 O
and O
quantitative O
resting O
EEG O
) O
. O

The O
ameliorating O
action O
of O
nicotine B
on O
PPI O
deficits O
in O
DAT O
KO O
mice O
was O
blocked O
by O
mecamylamine B
, O
the O
alpha O
7 O
nACh O
receptor O
antagonist O
methyllycaconitine B
or O
WAY100635 B
, O
while O
the O
alpha O
4 O
beta O
2 O
nACh O
receptor O
antagonist O
dihydro B
- I
beta I
- I
erythroidinehydrobro I
( O
DH B
beta I
E I
) O
produced O
only O
a O
non O
- O
significant O
trend O
toward O
attenuation O
of O
nicotine B
effects O
. O

Monoisononyl B
phthalate I
( O
MiNP B
) O
, O
mono B
( I
carboxy I
- I
isooctyl I
) I
phthalate I
( O
MCiOP B
) O
, O
mono B
( I
hydroxyl I
- I
isononyl I
) I
phthalate I
( O
MHiNP B
) O
, O
mono B
( I
oxo I
- I
isononyl I
) I
phthalate I
( O
MOiNP B
) O
, O
and O
monoisononyl B
phthalate I
glucuronide I
( O
MiNP B
- I
G I
) O
were O
found O
in O
all O
measured O
tissues O
. O

Monoisononyl B
phthalate I
( O
MiNP B
) O
, O
mono B
( I
carboxy I
- I
isooctyl I
) I
phthalate I
( O
MCiOP B
) O
, O
mono B
( I
hydroxyl I
- I
isononyl I
) I
phthalate I
( O
MHiNP B
) O
, O
mono B
( I
oxo I
- I
isononyl I
) I
phthalate I
( O
MOiNP B
) O
, O
and O
monoisononyl B
phthalate I
glucuronide I
( O
MiNP B
- I
G I
) O
were O
found O
in O
all O
measured O
tissues O
. O

MCiOP B
was O
the O
major O
metabolite O
, O
followed O
in O
decreasing O
order O
by O
MiNP B
, O
MHiNP B
, O
MOiNP B
, O
and O
MiNP B
- I
G I
. O

Pharmacokinetic O
characterization O
of O
the O
novel O
TAZ O
modulator O
TM B
- I
25659 I
using O
a O
multicompartment O
kinetic O
model O
in O
rats O
and O
a O
possibility O
of O
its O
drug O
- O
drug O
interactions O
in O
humans O
. O

This O
study O
evaluated O
the O
pharmacokinetics O
of O
the O
novel O
TAZ O
modulator O
TM B
- I
25659 I
in O
rats O
following O
intravenous O
and O
oral O
administration O
at O
dose O
ranges O
of O
0 O
. O
5 O
- O
5 O
mg O
/ O
kg O
and O
2 O
- O
10 O
mg O
/ O
kg O
, O
respectively O
. O

Recovery O
of O
TM B
- I
25659 I
was O
43 O
. O
6 O
% O
in O
bile O
and O
< O
1 O
% O
in O
urine O
. O

TM B
- I
25659 I
was O
stable O
in O
plasma O
. O

TM B
- I
25659 I
showed O
high O
permeation O
of O
Caco O
- O
2 O
cells O
and O
did O
not O
appear O
to O
inhibit O
CYP450 O
. O

TM B
- I
25659 I
was O
metabolized O
in O
phase O
I O
and O
II O
steps O
in O
rat O
liver O
microsomes O
. O

In O
conclusion O
, O
the O
pharmacokinetics O
of O
TM B
- I
25659 I
was O
characterized O
for O
intravenous O
and O
oral O
administration O
at O
doses O
of O
0 O
. O
5 O
- O
5 O
and O
2 O
- O
10 O
mg O
/ O
kg O
, O
respectively O
. O

TM B
- I
25659 I
was O
eliminated O
primarily O
by O
hepatic O
metabolism O
and O
urinary O
excretion O
. O

Specifically O
, O
the O
sirtuin O
- O
catalyzed O
AcK O
side O
chain O
deacetylation O
is O
not O
merely O
an O
amide B
hydrolysis O
reaction O
, O
instead O
is O
coupled O
to O
the O
nicotinamide B
cleavage O
from O
beta B
- I
nicotinamide I
adenine I
dinucleotide I
( O
beta B
- I
NAD I
+ O
or O
NAD B
+ O
) O
with O
the O
generation O
of O
three O
enzymatic O
products O
, O
i O
. O
e O
. O
the O
deacetylated O
protein O
species O
, O
nicotinamide O
, O
and O
2 B
' I
- I
O I
- I
acetyl I
- I
ADP I
- I
ribose I
( O
2 B
' I
- I
O I
- I
AADPR I
) O
. O

Circulating O
25 B
- I
hydroxyvitamin I
D I
( O
25 B
- I
OHD I
) O
levels O
vary O
among O
human O
populations O
. O

We O
identified O
demographic O
determinants O
of O
circulating O
25 B
- I
OHD I
in O
a O
large O
cohort O
of O
minority O
children O
, O
and O
now O
extend O
our O
studies O
to O
examine O
potential O
roles O
of O
vitamin B
D I
binding O
protein O
( O
DBP O
) O
as O
a O
determinant O
of O
25 B
- I
OHD I
levels O
. O

We O
identified O
demographic O
determinants O
of O
circulating O
25 B
- I
OHD I
in O
a O
large O
cohort O
of O
minority O
children O
, O
and O
now O
extend O
our O
studies O
to O
examine O
potential O
roles O
of O
vitamin B
D I
binding O
protein O
( O
DBP O
) O
as O
a O
determinant O
of O
25 B
- I
OHD I
levels O
. O

The O
multivariate O
model O
incorporated O
previously O
identified O
demographic O
and O
nutritional O
determinants O
of O
25 B
- I
OHD I
in O
this O
cohort O
, O
as O
well O
as O
GC O
SNPs O
and O
circulating O
DBP O
. O

Circulating O
DBP O
was O
significantly O
correlated O
with O
25 B
- I
OHD I
. O

GC O
SNPs O
were O
associated O
with O
both O
circulating O
DBP O
and O
25 B
- I
OHD I
. O

It O
appears O
that O
progressive O
substitution O
of O
lysine B
for O
threonine B
at O
the O
436 O
position O
results O
in O
lower O
circulating O
25 B
- I
OHD I
. O

Multivariate O
analysis O
revealed O
that O
genetic O
variance O
in O
GC O
significantly O
contributes O
to O
circulating O
DBP O
as O
well O
as O
25 B
- I
OHD I
. O

Moreover O
, O
the O
effect O
of O
GC O
SNPs O
on O
25 B
- I
OHD I
are O
evident O
after O
adjusting O
for O
their O
effects O
on O
circulating O
DBP O
. O

Thus O
in O
young O
children O
genetic O
variance O
of O
the O
common O
GC O
T436K O
SNP O
affects O
circulating O
levels O
of O
the O
DBP O
protein O
, O
which O
in O
turn O
affects O
circulating O
25 B
- I
OHD I
. O

However O
, O
the O
GC O
genotype O
also O
affects O
circulating O
25 B
- I
OHD I
independently O
of O
its O
effect O
on O
circulating O
DBP O
. O

Additionally O
, O
Hg B
( I
2 I
+ I
) I
induced O
reactive O
oxygen B
species O
( O
ROS O
) O
generation O
accompanied O
by O
the O
loss O
of O
mitochondrial O
transmembrane O
potential O
, O
measured O
by O
Dihydrorhodamine B
and O
Rhodamine B
- I
123 I
, O
respectively O
. O

The O
antioxidant O
N B
- I
acetylcysteine I
partially O
reversed O
the O
toxic O
effects O
of O
Hg B
( I
2 I
+ I
) I
, O
pointing O
to O
an O
involvement O
of O
ROS O
. O

4 O
. O
The O
majority O
of O
the O
drug O
was O
excreted O
in O
urine O
as O
multiple O
open O
ring O
metabolites O
: O
M17 O
. O
3 O
( O
oxidative O
ring O
- O
opened O
product O
) O
and O
M22 O
. O
2 O
( O
di B
- I
cysteine I
conjugate O
of O
17 O
. O
3 O
) O
; O
unchanged O
PTZ601 B
in O
urine O
contributed O
to O
15 O
% O
of O
radioactivity O
. O

The O
specificities O
of O
these O
mAbs O
were O
evaluated O
by O
frontal O
affinity O
chromatography O
using O
142 O
kinds O
of O
2 B
- I
aminopyridine I
( O
PA O
) O
- O
derivatized O
oligosaccharides O
. O

In O
this O
work O
, O
the O
molecular O
effects O
of O
N B
, I
N I
- I
diethyldithiocarbama I
( O
DEDTC B
) O
were O
studied O
in O
human O
SH O
- O
SY5Y O
neuroblastoma O
cells O
to O
determine O
the O
role O
of O
copper B
in O
the O
DEDTC B
toxicity O
and O
the O
pathway O
trigged O
in O
cell O
by O
the O
complex O
Cu B
- I
DEDTC I
. O

The O
mechanism O
of O
DEDTC B
- O
induced O
apoptosis O
in O
neuronal O
model O
cells O
is O
thought O
to O
occur O
through O
the O
death O
receptor O
signaling O
triggered O
by O
DEDTC B
- I
copper I
complex O
in O
low O
concentration O
that O
is O
associated O
with O
the O
activation O
of O
caspase O
8 O
. O

Toxicity O
profile O
of O
small O
- O
molecule O
IAP O
antagonist O
GDC B
- I
0152 I
is O
linked O
to O
TNF O
- O
alpha O
pharmacology O
. O

GDC B
- I
0152 I
is O
a O
small O
- O
molecule O
drug O
that O
triggers O
tumor O
cell O
apoptosis O
by O
selectively O
antagonizing O
IAPs O
. O

GDC B
- I
0152 I
induces O
NF O
- O
kappa O
B O
transcriptional O
activity O
leading O
to O
expression O
of O
several O
chemokines O
and O
cytokines O
, O
of O
which O
tumor O
necrosis O
factor O
alpha O
( O
TNF O
- O
alpha O
) O
is O
the O
most O
important O
for O
single O
- O
agent O
tumor O
activity O
. O

The O
toxicity O
profile O
of O
GDC B
- I
0152 I
in O
dogs O
and O
rats O
was O
characterized O
after O
iv O
dose O
administration O
once O
every O
2 O
weeks O
for O
four O
doses O
. O

Furthermore O
, O
elevations O
in O
blood O
neutrophil O
count O
, O
serum O
monocyte O
chemoattractant O
protein O
- O
1 O
, O
and O
other O
markers O
of O
inflammation O
corresponded O
to O
GDC B
- I
0152 I
exposure O
and O
toxicity O
and O
thus O
may O
have O
utility O
as O
safety O
biomarkers O
. O

The O
increased O
detrusor O
contractions O
by O
1 O
- O
h O
acrolein B
treatment O
were O
significantly O
reversed O
by O
the O
PKC O
inhibitor O
RO32 B
- I
0432 I
, O
and O
the O
decreased O
detrusor O
contractions O
by O
24 O
- O
h O
acrolein B
treatment O
were O
significantly O
reversed O
by O
the O
iNOS O
inhibitor O
and O
IL O
- O
6 O
- O
neutralizing O
antibody O
. O

In O
the O
present O
studies O
, O
dose O
- O
response O
curves O
for O
d B
- I
amphetamine I
( O
AMPH B
) O
- O
induced O
hyperlocomotion O
were O
similar O
in O
standard O
B6 O
mice O
and O
in O
the O
BTBR O
mouse O
model O
of O
autism O
. O

Adenosine B
- I
monophosphate I
- O
activated O
protein O
kinase O
( O
AMPK O
) O
and O
acetyl B
- I
CoA I
carboxylase O
phosphorylation O
in O
liver O
from O
HFD O
plus O
GTE O
- O
fed O
mice O
was O
significantly O
elevated O
, O
and O
HMG B
- I
CoA I
reductase O
expression O
was O
also O
significantly O
decreased O
. O

Adenosine B
- I
monophosphate I
- O
activated O
protein O
kinase O
( O
AMPK O
) O
and O
acetyl B
- I
CoA I
carboxylase O
phosphorylation O
in O
liver O
from O
HFD O
plus O
GTE O
- O
fed O
mice O
was O
significantly O
elevated O
, O
and O
HMG B
- I
CoA I
reductase O
expression O
was O
also O
significantly O
decreased O
. O

Adenosine B
- I
monophosphate I
- O
activated O
protein O
kinase O
( O
AMPK O
) O
and O
acetyl B
- I
CoA I
carboxylase O
phosphorylation O
in O
liver O
from O
HFD O
plus O
GTE O
- O
fed O
mice O
was O
significantly O
elevated O
, O
and O
HMG B
- I
CoA I
reductase O
expression O
was O
also O
significantly O
decreased O
. O

Plasma O
concentrations O
of O
intramuscularly O
- O
administered O
atropine B
, O
diazepam B
and O
HI B
- I
6 I
reached O
a O
peak O
within O
15min O
and O
were O
eliminated O
rapidly O
within O
4h O
. O

In O
BCPAP O
and O
TPC1 O
cells O
also O
significant O
increase O
of O
radio B
- I
iodine I
uptake O
was O
induced O
. O

But O
NMDA B
and O
MK B
- I
801 I
do O
not O
affect O
the O
expression O
of O
IL O
- O
6 O
and O
TNF O
alpha O
. O

In O
previous O
studies O
, O
we O
have O
characterized O
three O
new O
synthesized O
guanidine B
and O
2 B
- I
aminoimidazoline I
aromatic O
derivatives O
( O
8b O
, O
17b O
and O
20b O
) O
as O
alpha O
2 O
- O
adrenoceptor O
antagonists O
that O
are O
able O
to O
increase O
extracellular O
concentration O
of O
noradrenaline B
in O
rat O
brain O
. O

Valproic B
acid I
but O
not O
D B
- I
cycloserine I
facilitates O
sleep O
- O
dependent O
offline O
learning O
of O
extinction O
and O
habituation O
of O
conditioned O
fear O
in O
humans O
. O

The O
effectiveness O
of O
D B
- I
cycloserine I
( O
DCS B
) O
, O
an O
N B
- I
methyl I
- I
D I
- I
aspartate I
glutamate I
receptor O
partial O
agonist O
, O
and O
valproic B
acid I
( O
VPA B
) O
, O
a O
histone O
deacetylase O
inhibitor O
, O
in O
facilitating O
the O
extinction O
of O
fear O
- O
conditioned O
memory O
has O
been O
explored O
in O
humans O
and O
animals O
. O

The O
production O
of O
reactive O
oxygen B
species O
( O
ROS O
) O
and O
changes O
in O
mitochondrial O
membrane O
potential O
( O
Delta O
Psi O
m O
) O
in O
cells O
exposed O
to O
Epo B
A I
, O
Epo B
B I
and O
PTX B
were O
studied O
using O
specific O
fluorescence O
probes O
, O
DCFH B
( I
2 I
) I
- I
DA I
( O
2 B
' I
, I
7 I
' I
- I
dichlorodihydrofluor I
diacetate I
) O
and O
JC B
- I
1 I
( O
5 B
, I
5 I
' I
, I
6 I
, I
6 I
' I
- I
tetrachloro I
- I
1 I
, I
1 I
' I
, I
3 I
, I
3 I
' I
- I
tetraethylbenzimidaz I
) O
. O

All O
probes O
were O
analyzed O
in O
both O
the O
presence O
and O
absence O
of O
the O
antioxidant O
N B
- I
acetylcysteine I
( O
NAC B
) O
. O

Combination O
of O
beta B
- I
cyclodextrin I
inclusion O
complex O
and O
self O
- O
microemulsifying O
drug O
delivery O
system O
for O
photostability O
and O
enhanced O
oral O
bioavailability O
of O
methotrexate B
: O
novel O
technique O
. O

In O
the O
present O
study O
, O
we O
prepared O
an O
inclusion O
complex O
of O
methotrexate B
( O
MTX B
) O
with O
beta B
- I
cyclodextrin I
( O
beta B
- I
CD I
) O
in O
order O
to O
decrease O
its O
photosensitivity O
and O
enhance O
its O
aqueous O
solubility O
. O

In O
the O
present O
study O
, O
we O
prepared O
an O
inclusion O
complex O
of O
methotrexate B
( O
MTX B
) O
with O
beta B
- I
cyclodextrin I
( O
beta B
- I
CD I
) O
in O
order O
to O
decrease O
its O
photosensitivity O
and O
enhance O
its O
aqueous O
solubility O
. O

The O
proper O
molecular O
ratio O
of O
MTX B
/ O
beta B
- I
CD I
was O
found O
to O
be O
of O
1 O
: O
7 O
, O
and O
the O
water O
- O
solubility O
of O
MTX B
was O
increased O
in O
an O
average O
of O
10 O
- O
fold O
. O

Construction O
of O
pseudoternary O
diagrams O
were O
investigated O
to O
prepare O
a O
MTX B
/ O
beta B
- I
CD I
inclusion O
complex O
loaded O
SMEDDS O
which O
was O
characterized O
by O
measuring O
the O
particle O
size O
and O
the O
zeta O
- O
potential O
. O

In O
vitro O
drug O
release O
in O
different O
pH O
media O
showed O
that O
the O
release O
profile O
of O
MTX B
from O
the O
MTX B
/ O
beta B
- I
CD I
loaded O
SMEDDS O
was O
influenced O
by O
the O
pH O
of O
the O
release O
medium O
and O
presented O
the O
characteristics O
of O
a O
sustained O
release O
profile O
. O

Finally O
, O
in O
- O
vivo O
studies O
showed O
an O
enhancement O
of O
the O
bioavailability O
of O
MTX B
from O
the O
MTX B
/ O
beta B
- I
CD I
loaded O
SMEDDS O
form O
of O
1 O
. O
57 O
- O
fold O
. O

We O
concluded O
that O
the O
beta B
- I
CD I
inclusion O
complex O
loaded O
SMEDDS O
improved O
the O
chemical O
and O
physiological O
properties O
of O
MTX B
and O
could O
be O
a O
promising O
means O
for O
the O
delivery O
of O
MTX B
and O
other O
unstable O
and O
lipophilic O
drugs O
by O
oral O
route O
. O

Protective O
effect O
was O
also O
observed O
against O
alkylating O
DNA O
damage O
induced O
by O
methyl B
- I
methanesulfonate I
, O
except O
for O
H O
. O
androsaemum O
. O

GS967 B
prevented O
and O
reversed O
proarrhythmic O
effects O
( O
afterdepolarizations O
and O
torsades O
de O
pointes O
) O
of O
the O
late O
I O
( O
Na B
) O
enhancer O
ATX O
- O
II O
and O
the O
I O
( O
Kr B
) O
inhibitor O
E B
- I
4031 I
in O
isolated O
ventricular O
myocytes O
and O
hearts O
. O

The O
formation O
of O
supramolecular O
inclusion O
complexes O
between O
rutin B
and O
four O
cyclodextrins O
, O
namely O
beta B
- I
cyclodextrin I
( O
beta B
- I
CD I
) O
, O
( B
2 I
- I
hydroxypropyl I
) I
- I
alpha I
- I
cyclodextrin I
( O
HP B
- I
alpha I
- I
CD I
) O
, O
( B
2 I
- I
hydroxypropyl I
) I
- I
beta I
- I
cyclodextrin I
( O
HP B
- I
beta I
- I
CD I
) O
and O
( B
2 I
- I
hydroxypropyl I
) I
- I
gamma I
- I
cyclodextrin I
( O
HP B
- I
gamma I
- I

The O
formation O
of O
supramolecular O
inclusion O
complexes O
between O
rutin B
and O
four O
cyclodextrins O
, O
namely O
beta B
- I
cyclodextrin I
( O
beta B
- I
CD I
) O
, O
( B
2 I
- I
hydroxypropyl I
) I
- I
alpha I
- I
cyclodextrin I
( O
HP B
- I
alpha I
- I
CD I
) O
, O
( B
2 I
- I
hydroxypropyl I
) I
- I
beta I
- I
cyclodextrin I
( O
HP B
- I
beta I
- I
CD I
) O
and O
( B
2 I
- I
hydroxypropyl I
) I
- I
gamma I
- I
cyclodextrin I
( O
HP B
- I
gamma I
- I

Results O
from O
phase O
- O
solubility O
studies O
showed O
that O
rutin B
formed O
1 O
: O
1 O
stoichiometric O
inclusion O
complexes O
with O
HP B
- I
alpha I
- I
CD I
, O
beta B
- I
CD I
, O
HP B
- I
beta I
- I
CD I
and O
HP B
- I
gamma I
- I
CD I
; O
the O
complexes O
formed O
with O
HP B
- I
gamma I
- I
CD I
and O
HP B
- I
beta I
- I
CD I
had O
the O
greatest O
stability O
constants O
, O
followed O
by O
beta B
- I
CD I
and O
HP B
- I
alpha I
- I
CD I
. O

Results O
from O
phase O
- O
solubility O
studies O
showed O
that O
rutin B
formed O
1 O
: O
1 O
stoichiometric O
inclusion O
complexes O
with O
HP B
- I
alpha I
- I
CD I
, O
beta B
- I
CD I
, O
HP B
- I
beta I
- I
CD I
and O
HP B
- I
gamma I
- I
CD I
; O
the O
complexes O
formed O
with O
HP B
- I
gamma I
- I
CD I
and O
HP B
- I
beta I
- I
CD I
had O
the O
greatest O
stability O
constants O
, O
followed O
by O
beta B
- I
CD I
and O
HP B
- I
alpha I
- I
CD I
. O

The O
highest O
doses O
of O
cannabinoid O
drugs O
yielded O
, O
on O
average O
, O
26 O
- O
32 O
g O
/ O
kg O
urine O
; O
comparable O
effects O
were O
obtained O
with O
10 O
mg O
/ O
kg O
furosemide B
and O
3 O
. O
0 O
mg O
/ O
kg O
trans B
- I
( I
- I
) I
- I
3 I
, I
4 I
- I
dichloro I
- I
N I
- I
methyl I
- I
N I
- I
[ I
2 I
- I
( I
1 I
- I
pyrrolidinyl I
) I
cyclohexyl I
] I
benzeneacetamide I
( O
U50 B
- I
488 I
) O
. O

Here O
the O
effect O
of O
reducing O
cortical O
GABA B
synthesis O
with O
l B
- I
allylglycine I
( O
LAG B
) O
on O
attention O
was O
tested O
using O
three O
different O
versions O
of O
the O
5 O
- O
choice O
serial O
reaction O
time O
task O
( O
5CSRTT O
) O
. O

In O
this O
study O
, O
we O
compared O
the O
effects O
of O
RSV B
and O
two O
glycosyl B
RSVs I
, O
resveratrol B
- I
3 I
- I
O I
- I
beta I
- I
d I
- I
glucoside I
( O
3G B
- I
RSV I
; O
polydatin B
/ O
piceid B
) O
and O
resveratrol B
- I
4 I
' I
- I
O I
- I
beta I
- I
d I
- I
glucoside I
( O
4 B
' I
G I
- I
RSV I
) O
, O
at O
the O
cellular O
level O
. O

In O
oxygen O
radical O
absorbance O
capacity O
and O
2 B
, I
2 I
- I
diphenyl I
- I
1 I
- I
picrylhydrazyl I
radical O
scavenging O
assays O
, O
the O
antioxidant O
activity O
of O
3G B
- I
RSV I
was O
comparable O
to O
that O
of O
RSV B
, O
whereas O
the O
radical O
- O
scavenging O
efficiency O
of O
4 B
' I
G I
- I
RSV I
was O
less O
than O
50 O
% O
of O
that O
of O
RSV B
. O

However O
, O
4 B
' I
G I
- I
RSV I
, O
but O
not O
3G B
- I
RSV I
, O
induced O
SIRT1 O
- O
dependent O
histone O
H3 O
deacetylation O
and O
SOD2 O
expression O
in O
mouse O
C2C12 O
skeletal O
myoblasts O
; O
as O
with O
RSV B
, O
SIRT1 O
knockdown O
blunted O
these O
effects O
. O

RSV B
and O
4 B
' I
G I
- I
RSV I
, O
but O
not O
3G B
- I
RSV I
, O
mitigated O
oxidative O
stress O
- O
induced O
cell O
death O
in O
C2C12 O
cells O
and O
primary O
neonatal O
rat O
cardiomyocytes O
. O

RSV B
and O
4 B
' I
G I
- I
RSV I
inhibited O
C2C12 O
cell O
proliferation O
, O
but O
3G B
- I
RSV I
did O
not O
. O

C2C12 O
cells O
did O
not O
deglycosylate O
3G B
- I
RSV I
. O

Then O
, O
the O
effect O
of O
UVA O
- O
irradiation O
over O
NCTC2544 O
cells O
treated O
with O
increasing O
concentrations O
of O
15 O
compounds O
including O
photoallergens O
( O
benzophenone B
, O
4 B
- I
ter I
- I
butyl I
- I
4 I
- I
methoxy I
- I
dibenzoylmethane I
, I
2 I
- I
ethylexyl I
- I
p I
- I
methoxycinnamate I
, O
ketoprofen B
, O
6 B
- I
methylcumarin I
) O
; O
photoirritant O
and O
photoallergen O
( O
4 B
- I
aminobenzoic I
acid I
, O
chlorpromazine B
, O
promethazine B
) O
; O
photoirritants O
( O
acridine B
, O

ibuprofen B
, O
8 B
- I
methoxypsoralen I
, O
retinoic B
acid I
) O
; O
and O
negative O
compounds O
( O
lactic B
acid I
, O
SDS B
and O
p B
- I
phenilendiamine I
) O
was O
investigated O
. O

ibuprofen B
, O
8 B
- I
methoxypsoralen I
, O
retinoic B
acid I
) O
; O
and O
negative O
compounds O
( O
lactic B
acid I
, O
SDS B
and O
p B
- I
phenilendiamine I
) O
was O
investigated O
. O

4 O
. O
All O
animals O
except O
the O
dog O
and O
cat O
converted O
zoniporide B
to O
2 B
- I
oxozoniporide I
( O
M1 O
) O
. O

We O
demonstrate O
that O
treatment O
with O
a O
highly O
- O
selective O
novel O
MC4R O
agonist O
( O
BIM B
- I
22493 I
or O
RM B
- I
493 I
) O
resulted O
in O
transient O
decreases O
in O
food O
intake O
( O
35 O
% O
) O
, O
with O
persistent O
weight O
loss O
over O
8 O
weeks O
of O
treatment O
( O
13 O
. O
5 O
% O
) O
in O
a O
diet O
- O
induced O
obese O
nonhuman O
primate O
model O
. O

We O
demonstrate O
that O
treatment O
with O
a O
highly O
- O
selective O
novel O
MC4R O
agonist O
( O
BIM B
- I
22493 I
or O
RM B
- I
493 I
) O
resulted O
in O
transient O
decreases O
in O
food O
intake O
( O
35 O
% O
) O
, O
with O
persistent O
weight O
loss O
over O
8 O
weeks O
of O
treatment O
( O
13 O
. O
5 O
% O
) O
in O
a O
diet O
- O
induced O
obese O
nonhuman O
primate O
model O
. O

Importantly O
, O
we O
observed O
no O
increases O
in O
blood O
pressure O
or O
heart O
rate O
with O
BIM B
- I
22493 I
treatment O
. O

Cu B
- O
dependent O
tyrosinase O
activity O
was O
also O
markedly O
reduced O
in O
both O
types O
of O
CLDN O
knockdown O
cells O
when O
incubated O
with O
the O
substrate O
l B
- I
DOPA I
. O

INO B
- I
8875 I
, O
a O
highly O
selective O
A1 O
adenosine B
receptor O
agonist O
: O
evaluation O
of O
chronotropic O
, O
dromotropic O
, O
and O
hemodynamic O
effects O
in O
rats O
. O

The O
purpose O
of O
the O
present O
study O
was O
to O
evaluate O
the O
cardiovascular O
profile O
of O
INO B
- I
8875 I
, O
a O
highly O
selective O
A O
( O
1 O
) O
R O
agonist O
, O
and O
to O
compare O
its O
properties O
with O
N B
- I
[ I
3 I
( I
R I
) I
- I
tetrahydrofuranyl I
] I
- I
6 I
- I
aminopurine I
riboside I
( O
CVT B
- I
510 I
) O
, O
which O
has O
already O
been O
shown O
to O
induce O
negative O
dromotropic O
effects O
with O
minimal O
cardiovascular O
side O
effects O
in O
animals O
and O
in O
clinical O
studies O
. O

The O
purpose O
of O
the O
present O
study O
was O
to O
evaluate O
the O
cardiovascular O
profile O
of O
INO B
- I
8875 I
, O
a O
highly O
selective O
A O
( O
1 O
) O
R O
agonist O
, O
and O
to O
compare O
its O
properties O
with O
N B
- I
[ I
3 I
( I
R I
) I
- I
tetrahydrofuranyl I
] I
- I
6 I
- I
aminopurine I
riboside I
( O
CVT B
- I
510 I
) O
, O
which O
has O
already O
been O
shown O
to O
induce O
negative O
dromotropic O
effects O
with O
minimal O
cardiovascular O
side O
effects O
in O
animals O
and O
in O
clinical O
studies O
. O

Dose O
- O
response O
experiments O
in O
the O
isolated O
hearts O
of O
rats O
were O
used O
to O
evaluate O
the O
functional O
selectivity O
of O
INO B
- I
8875 I
for O
the O
slowing O
of O
A O
- O
V O
- O
nodal O
conduction O
. O

Ventilated O
adult O
rats O
were O
used O
to O
study O
the O
effects O
of O
INO B
- I
8875 I
, O
in O
vivo O
, O
on O
arterial O
blood O
pressure O
as O
well O
as O
on O
supraventricular O
electrophysiology O
. O

Ex O
vivo O
, O
INO B
- I
8875 I
( O
100 O
nM O
to O
3 O
mu O
M O
) O
progressively O
prolonged O
A O
- O
V O
- O
nodal O
conduction O
without O
reducing O
left O
ventricular O
function O
or O
coronary O
resistance O
. O

In O
vivo O
, O
INO B
- I
8875 I
up O
to O
a O
dose O
of O
50 O
mu O
g O
/ O
kg O
did O
not O
reduce O
the O
carotid O
arterial O
blood O
pressure O
( O
n O
= O
4 O
) O
. O

INO B
- I
8875 I
( O
1 O
- O
50 O
mu O
g O
/ O
kg O
) O
and O
CVT B
- I
510 I
( O
20 O
and O
50 O
mu O
g O
/ O
kg O
) O
both O
induced O
a O
dose O
- O
dependent O
decrease O
in O
heart O
rate O
and O
atrial O
refractoriness O
, O
as O
well O
as O
slowing O
of O
A O
- O
V O
- O
nodal O
conduction O
. O

INO B
- I
8875 I
( O
1 O
- O
50 O
mu O
g O
/ O
kg O
) O
and O
CVT B
- I
510 I
( O
20 O
and O
50 O
mu O
g O
/ O
kg O
) O
both O
induced O
a O
dose O
- O
dependent O
decrease O
in O
heart O
rate O
and O
atrial O
refractoriness O
, O
as O
well O
as O
slowing O
of O
A O
- O
V O
- O
nodal O
conduction O
. O

However O
, O
compared O
with O
CVT B
- I
510 I
, O
the O
activity O
of O
INO B
- I
8875 I
was O
more O
pronounced O
in O
A O
- O
V O
- O
nodal O
function O
. O

However O
, O
compared O
with O
CVT B
- I
510 I
, O
the O
activity O
of O
INO B
- I
8875 I
was O
more O
pronounced O
in O
A O
- O
V O
- O
nodal O
function O
. O

INO B
- I
8875 I
exhibited O
a O
greater O
duration O
of O
action O
, O
lasting O
up O
to O
2 O
. O
5 O
hours O
post O
dosing O
, O
whereas O
the O
effects O
of O
CVT B
- I
510 I
dissipated O
over O
1 O
hour O
. O

INO B
- I
8875 I
exhibited O
a O
greater O
duration O
of O
action O
, O
lasting O
up O
to O
2 O
. O
5 O
hours O
post O
dosing O
, O
whereas O
the O
effects O
of O
CVT B
- I
510 I
dissipated O
over O
1 O
hour O
. O

INO B
- I
8875 I
demonstrates O
functional O
properties O
of O
a O
highly O
selective O
A O
( O
1 O
) O
R O
agonist O
. O

INO B
- I
8875 I
exhibits O
an O
increased O
dromotropic O
effect O
and O
greater O
duration O
of O
action O
compared O
with O
CVT B
- I
510 I
. O

INO B
- I
8875 I
exhibits O
an O
increased O
dromotropic O
effect O
and O
greater O
duration O
of O
action O
compared O
with O
CVT B
- I
510 I
. O

These O
biochemical O
variations O
include O
the O
degree O
and O
positioning O
of O
d B
- I
alanyl I
and O
glycosyl B
substitution O
in O
lipoteichoic O
acids O
, O
and O
acetylation O
of O
peptidoglycan O
. O

Owing O
to O
their O
unique O
physical O
and O
chemical O
properties O
, O
graphene B
and O
its O
derivatives O
such O
as O
graphene B
oxide I
( O
GO O
) O
, O
reduced B
graphene I
oxide I
( O
RGO B
) O
and O
GO O
- O
nanocomposites O
have O
attracted O
tremendous O
interest O
in O
many O
different O
fields O
including O
biomedicine O
in O
recent O
years O
. O

Perfluorooctane B
sulfonic I
acid I
( O
PFOS B
) O
is O
an O
organic O
contaminant O
that O
is O
ubiquitous O
in O
the O
environment O
. O

In O
the O
present O
study O
, O
ESB O
values O
are O
reported O
for O
34 O
polycyclic B
aromatic I
hydrocarbon I
, O
32 O
other O
organic O
contaminants O
, O
and O
seven O
metals O
( O
cadmium B
, O
chromium B
, O
copper B
, O
nickel B
, O
lead O
, O
silver B
, O
zinc B
) O
. O

The O
toxicity O
of O
the O
N B
- I
hydroxy I
and O
6 B
- I
hydroxy I
metabolites O
of O
3 B
, I
4 I
- I
dichloropropionanili I
does O
not O
depend O
on O
calcium B
release O
- O
activated O
calcium B
channel O
inhibition O
. O

The O
toxicity O
of O
the O
N B
- I
hydroxy I
and O
6 B
- I
hydroxy I
metabolites O
of O
3 B
, I
4 I
- I
dichloropropionanili I
does O
not O
depend O
on O
calcium B
release O
- O
activated O
calcium B
channel O
inhibition O
. O

Further O
biotransformation O
of O
DCA B
leads O
to O
the O
production O
of O
6 B
- I
hydroxy I
- I
3 I
, I
4 I
- I
dichloroaniline I
( O
6OH B
- I
DCA I
) O
and O
N B
- I
hydroxy I
- I
3 I
, I
4 I
- I
dichloroaniline I
( O
NOH B
- I
DCA I
) O
. O

Further O
biotransformation O
of O
DCA B
leads O
to O
the O
production O
of O
6 B
- I
hydroxy I
- I
3 I
, I
4 I
- I
dichloroaniline I
( O
6OH B
- I
DCA I
) O
and O
N B
- I
hydroxy I
- I
3 I
, I
4 I
- I
dichloroaniline I
( O
NOH B
- I
DCA I
) O
. O

However O
, O
exposure O
to O
6OH B
- I
DCA I
and O
NOH B
- I
DCA I
reduces O
IL O
- O
2 O
secretion O
and O
NFAT O
activity O
but O
has O
no O
effect O
on O
calcium B
flux O
. O

However O
, O
exposure O
to O
6OH B
- I
DCA I
and O
NOH B
- I
DCA I
reduces O
IL O
- O
2 O
secretion O
and O
NFAT O
activity O
but O
has O
no O
effect O
on O
calcium B
flux O
. O

Rat O
microsomal O
incubations O
and O
analyses O
by O
liquid O
chromatography O
- O
mass O
spectrometry O
( O
LC O
- O
MS O
) O
identified O
seven O
metabolites O
, O
characterized O
as O
O B
- I
deethyl I
, O
hydroxyl B
, O
and O
N B
- I
deethyl I
derivatives O
of O
nonradioactive O
DPA B
- I
714 I
, O
two O
of O
them O
having O
the O
same O
retention O
times O
than O
those O
detected O
in O
rat O
and O
baboon O
plasma O
. O

Rat O
microsomal O
incubations O
and O
analyses O
by O
liquid O
chromatography O
- O
mass O
spectrometry O
( O
LC O
- O
MS O
) O
identified O
seven O
metabolites O
, O
characterized O
as O
O B
- I
deethyl I
, O
hydroxyl B
, O
and O
N B
- I
deethyl I
derivatives O
of O
nonradioactive O
DPA B
- I
714 I
, O
two O
of O
them O
having O
the O
same O
retention O
times O
than O
those O
detected O
in O
rat O
and O
baboon O
plasma O
. O

Rat O
microsomal O
incubations O
and O
analyses O
by O
liquid O
chromatography O
- O
mass O
spectrometry O
( O
LC O
- O
MS O
) O
identified O
seven O
metabolites O
, O
characterized O
as O
O B
- I
deethyl I
, O
hydroxyl B
, O
and O
N B
- I
deethyl I
derivatives O
of O
nonradioactive O
DPA B
- I
714 I
, O
two O
of O
them O
having O
the O
same O
retention O
times O
than O
those O
detected O
in O
rat O
and O
baboon O
plasma O
. O

The O
nanoparticles O
prepared O
from O
the O
new O
beta B
- I
cyclodextrin I
derivatives O
have O
been O
characterized O
by O
dynamic O
light O
scattering O
and O
have O
an O
average O
size O
of O
120nm O
for O
the O
fluorinated O
derivatives O
and O
220nm O
for O
the O
hydrogenated O
analogs O
. O

Here O
, O
we O
examined O
the O
effect O
of O
FTY720 B
, O
its O
active O
metabolite O
, O
FTY720 B
- I
P I
, O
and O
sphingosine B
- I
1 I
- I
phosphate I
( O
S1P B
) O
on O
neuronal O
viability O
using O
a O
classical O
in O
vitro O
model O
of O
excitotoxic O
neuronal O
death O
. O

FTY720 B
, O
FTY720 B
- I
P I
, O
and O
S1P B
were O
all O
neuroprotective O
when O
applied O
18 O
- O
20 O
h O
prior O
to O
the O
NMDA B
pulse O
. O

Both O
FTY720 B
and O
FTY720 B
- I
P I
retained O
their O
protective O
activity O
in O
pure O
cultures O
of O
mouse O
or O
rat O
cortical O
neurons O
. O

Toxic O
effects O
of O
microcystin B
- I
LR I
on O
the O
reproductive O
system O
of O
male O
Rana O
nigromaculata O
in O
vitro O
. O

This O
study O
aims O
to O
demonstrate O
that O
microcystin B
- I
LR I
( O
MC B
- I
LR I
) O
has O
toxic O
effects O
on O
the O
reproductive O
system O
of O
male O
Rana O
nigromaculata O
in O
vitro O
. O

This O
study O
aims O
to O
demonstrate O
that O
microcystin B
- I
LR I
( O
MC B
- I
LR I
) O
has O
toxic O
effects O
on O
the O
reproductive O
system O
of O
male O
Rana O
nigromaculata O
in O
vitro O
. O

Results O
show O
that O
exposure O
to O
1 O
nmol O
/ O
L O
to O
100 O
nmol O
/ O
L O
of O
MC B
- I
LR I
decreased O
sperm O
motility O
and O
number O
of O
sperm O
cells O
and O
increased O
the O
sperm O
abnormality O
rate O
, O
whose O
values O
were O
significantly O
different O
from O
those O
of O
the O
control O
( O
P O
< O
0 O
. O
01 O
) O
. O

Moreover O
, O
the O
same O
dosage O
of O
MC B
- I
LR I
increased O
reactive O
oxygen B
species O
production O
and O
malondialdehyde B
content O
. O

The O
results O
demonstrate O
for O
the O
first O
time O
that O
MC B
- I
LR I
could O
induce O
toxicity O
in O
the O
male O
reproductive O
system O
of O
R O
. O
nigromaculata O
. O

The O
aim O
of O
the O
present O
study O
was O
to O
assess O
whether O
lactational O
exposure O
to O
polychlorinated B
biphenyl I
- I
153 I
( O
PCB B
- I
153 I
) O
, O
dichlorodiphenyldich B
( O
DDE B
) O
, O
or O
hexachlorobenzene B
( O
HCB B
) O
as O
estimated O
with O
a O
physiologically O
based O
pharmacokinetic O
( O
PBPK O
) O
model O
, O
is O
associated O
with O
decrements O
in O
mental O
and O
psychomotor O
development O
scores O
of O
the O
Bayley O
Scales O
of O
Infant O
Development O
( O
BSID O
) O
test O
in O
children O
aged O
around O
14 O
- O
months O
of O
a O
subsample O
( O
N O
= O

Although O
in O
the O
present O
study O
population O
PCB B
- I
153 I
, O
DDE B
and O
HCB B
exposure O
increased O
within O
the O
first O
months O
of O
postnatal O
life O
, O
no O
associations O
were O
found O
between O
different O
periods O
of O
postnatal O
exposure O
to O
these O
compounds O
and O
mental O
or O
psychomotor O
scores O
. O

Increasing O
prenatal O
PCB B
- I
153 I
concentrations O
were O
associated O
with O
worse O
mental O
and O
psychomotor O
scores O
, O
although O
significance O
was O
only O
reached O
for O
psychomotor O
development O
( O
beta O
[ O
95 O
% O
CI O
] O
= O
- O
1 O
. O
36 O
[ O
- O
2 O
. O
61 O
, O
- O
0 O
. O
11 O
] O
) O
. O

Results O
of O
the O
present O
study O
suggest O
that O
, O
although O
breastfeeding O
increases O
children O
' O
s O
blood O
persistent O
organic O
pollutants O
( O
POPs O
) O
levels O
during O
postnatal O
life O
, O
deleterious O
effects O
of O
PCB B
- I
153 I
on O
neuropsychological O
development O
are O
mainly O
attributable O
to O
prenatal O
exposure O
. O

Upregulated O
interleukin O
( O
IL O
) O
- O
1 O
beta O
maturation O
, O
IL O
- O
18 O
secretion O
, O
and O
caspase O
- O
1 O
cleavage O
were O
observed O
in O
MDMs O
from O
type O
2 O
diabetic O
patients O
after O
stimulation O
with O
various O
danger O
molecules O
( O
ATP B
, O
high O
- O
mobility O
group O
protein O
B1 O
, O
free O
fatty B
acids I
, O
islet O
amyloid O
polypeptide O
, O
and O
monosodium B
uric I
acid I
crystals O
) O
. O

Selenium B
and O
Hg B
were O
provided O
as O
L B
- I
selenomethionine I
( O
SeMet B
) O
and O
methylmercury B
( O
MeHg B
) O
, O
respectively O
. O

Blood O
pressure O
was O
increased O
in O
rats O
exposed O
to O
IH O
, O
and O
treatment O
with O
the O
PDK O
- O
1 O
inhibitor O
OSU B
- I
03012 I
[ O
2 B
- I
amino I
- I
N I
- I
{ I
4 I
- I
[ I
5 I
- I
( I
2 I
- I
phenanthrenyl I
) I
- I
3 I
- I
( I
trifluoromethyl I
) I
- I
1H I
- I
pyrazol I
- I
1 I
- I
yl I
] I
- I
phenyl I
} I
- I
acetamide I
] O
( O
33 O
mg O
/ O
day O
) O
lowered O
blood O
pressure O
in O
IH O
but O
not O
sham O
group O
rats O
. O

Little O
information O
is O
available O
on O
the O
absolute O
oral O
bioavailability O
and O
the O
toxicokinetic O
parameters O
of O
deoxynivalenol B
, O
T B
- I
2 I
and O
zearalenone B
in O
broilers O
. O

For O
zearalenone B
and O
T B
- I
2 I
no O
plasma O
levels O
above O
the O
limit O
of O
quantification O
were O
observed O
after O
an O
oral O
bolus O
. O

Regional O
permeability O
data O
showed O
a O
tendency O
for O
highly O
permeable O
compounds O
to O
have O
higher O
or O
similar O
P O
( O
app O
) O
in O
colon O
as O
in O
the O
small O
intestinal O
segments O
, O
while O
the O
colonic O
regions O
showed O
a O
lower O
P O
( O
app O
) O
for O
more O
polar O
compounds O
as O
well O
as O
for O
d B
- I
glucose I
and O
l B
- I
leucine I
. O

Regional O
permeability O
data O
showed O
a O
tendency O
for O
highly O
permeable O
compounds O
to O
have O
higher O
or O
similar O
P O
( O
app O
) O
in O
colon O
as O
in O
the O
small O
intestinal O
segments O
, O
while O
the O
colonic O
regions O
showed O
a O
lower O
P O
( O
app O
) O
for O
more O
polar O
compounds O
as O
well O
as O
for O
d B
- I
glucose I
and O
l B
- I
leucine I
. O

Reversal O
of O
the O
deleterious O
effects O
of O
chronic O
dietary O
HFCS B
- I
55 I
intake O
by O
PPAR O
- O
delta O
agonism O
correlates O
with O
impaired O
NLRP3 O
inflammasome O
activation O
. O

Although O
high B
- I
fructose I
corn I
syrup I
( O
HFCS B
- I
55 I
) O
is O
the O
major O
sweetener O
in O
foods O
and O
soft O
- O
drinks O
, O
its O
potential O
role O
in O
the O
pathophysiology O
of O
diabetes O
and O
obesity O
( O
" O
diabesity O
" O
) O
remains O
unclear O
. O

This O
study O
was O
designed O
to O
evaluate O
( O
i O
) O
the O
metabolic O
and O
renal O
consequences O
of O
HFCS B
- I
55 I
administration O
( O
15 O
% O
wt O
/ O
vol O
in O
drinking O
water O
) O
for O
30 O
weeks O
on O
male O
C57Bl6 O
/ O
J O
mice O
and O
( O
ii O
) O
the O
effects O
of O
the O
selective O
PPAR O
- O
delta O
agonist O
GW0742 B
( O
1 O
mg O
/ O
kg O
/ O
day O
for O
16 O
weeks O
) O
in O
this O
condition O
. O

HFCS B
- I
55 I
caused O
( O
i O
) O
hyperlipidemia O
, O
( O
ii O
) O
insulin O
resistance O
, O
and O
( O
iii O
) O
renal O
injury O
/ O
inflammation O
. O

In O
the O
liver O
, O
HFCS B
- I
55 I
enhanced O
the O
expression O
of O
fructokinase O
resulting O
in O
hyperuricemia O
and O
caused O
abnormalities O
in O
known O
insulin O
- O
driven O
signaling O
events O
. O

In O
the O
kidney O
, O
HFCS B
- I
55 I
enhanced O
the O
expression O
of O
the O
NLRP3 O
( O
nucleotide B
- O
binding O
domain O
and O
leucine B
- O
rich O
- O
repeat O
- O
protein O
3 O
) O
inflammasome O
complex O
, O
resulting O
in O
caspase O
- O
1 O
activation O
and O
interleukin O
- O
1 O
beta O
production O
. O

All O
of O
the O
above O
effects O
of O
HFCS B
- I
55 I
were O
attenuated O
by O
the O
specific O
PPAR O
- O
delta O
agonist O
GW0742 B
. O

Thus O
, O
we O
demonstrate O
for O
the O
first O
time O
that O
the O
specific O
PPAR O
- O
delta O
agonist O
GW0742 B
attenuates O
the O
metabolic O
abnormalities O
and O
the O
renal O
dysfunction O
/ O
inflammation O
caused O
by O
chronic O
HFCS B
- I
55 I
exposure O
by O
preventing O
upregulation O
of O
fructokinase O
( O
liver O
) O
and O
activation O
of O
the O
NLRP3 O
inflammasome O
( O
kidney O
) O
. O

Dithiolethione B
and O
its O
NSAID O
and O
other O
chimeras O
such O
as O
, O
L B
- I
DOPA I
, O
sildenafil B
, O
aspirin B
, O
diclofenac B
, O
naproxen B
, O
ibuprofen B
, O
indomethacin B
, O
and O
mesalamine B
have O
also O
been O
reviewed O
in O
detail O
. O

The O
newly O
reported O
NOSH B
- I
aspirin I
that O
releases O
both O
NO B
and O
H2S B
has O
also O
been O
discussed O
. O

Consequently O
, O
the O
relative O
effects O
of O
pulsed O
( O
2 O
and O
4 O
d O
) O
and O
continuous O
exposures O
of O
the O
duckweed O
Lemna O
minor O
to O
isoproturon B
, O
metsulfuron B
- I
methyl I
, O
and O
pentachlorophenol B
over O
a O
period O
of O
42 O
d O
were O
explored O
in O
the O
present O
study O
. O

At O
the O
highest O
test O
concentrations O
, O
exposure O
of O
L O
. O
minor O
to O
pulses O
of O
metsulfuron B
- I
methyl I
resulted O
in O
effects O
on O
growth O
similar O
to O
those O
of O
an O
equivalent O
continuous O
exposure O
. O

Syzygium O
aqueum O
leaf O
extract O
and O
its O
bioactive O
compounds O
enhances O
pre O
- O
adipocyte O
differentiation O
and O
2 B
- I
NBDG I
uptake O
in O
3T3 O
- O
L1 O
cells O
. O

The O
insulin O
- O
like O
and O
/ O
or O
insulin O
- O
sensitising O
effects O
of O
Syzygium O
aqueum O
leaf O
extract O
and O
its O
six O
bioactive O
compounds O
; O
4 B
- I
hydroxybenzaldehyde I
, O
myricetin B
- I
3 I
- I
O I
- I
rhamnoside I
, O
europetin B
- I
3 I
- I
O I
- I
rhamnoside I
, O
phloretin B
, O
myrigalone B
- I
G I
and O
myrigalone B
- I
B I
were O
investigated O
in O
3T3 O
- O
L1 O
adipocytes O
. O

The O
insulin O
- O
like O
and O
/ O
or O
insulin O
- O
sensitising O
effects O
of O
Syzygium O
aqueum O
leaf O
extract O
and O
its O
six O
bioactive O
compounds O
; O
4 B
- I
hydroxybenzaldehyde I
, O
myricetin B
- I
3 I
- I
O I
- I
rhamnoside I
, O
europetin B
- I
3 I
- I
O I
- I
rhamnoside I
, O
phloretin B
, O
myrigalone B
- I
G I
and O
myrigalone B
- I
B I
were O
investigated O
in O
3T3 O
- O
L1 O
adipocytes O
. O

The O
insulin O
- O
like O
and O
/ O
or O
insulin O
- O
sensitising O
effects O
of O
Syzygium O
aqueum O
leaf O
extract O
and O
its O
six O
bioactive O
compounds O
; O
4 B
- I
hydroxybenzaldehyde I
, O
myricetin B
- I
3 I
- I
O I
- I
rhamnoside I
, O
europetin B
- I
3 I
- I
O I
- I
rhamnoside I
, O
phloretin B
, O
myrigalone B
- I
G I
and O
myrigalone B
- I
B I
were O
investigated O
in O
3T3 O
- O
L1 O
adipocytes O
. O

These O
compounds O
were O
far O
better O
than O
rosiglitazone B
and O
the O
other O
isolated O
compounds O
in O
enhancing O
adipogenesis O
, O
stimulating O
2 B
- I
NBDG I
uptake O
and O
increasing O
adiponectin O
secretion O
at O
all O
the O
concentrations O
tested O
. O

The O
principal O
constituents O
of O
the O
oils O
were O
similar O
except O
for O
the O
minor O
compounds O
, O
including O
linalool B
, O
terpinen B
- I
4 I
- I
ol I
and O
alpha B
- I
terpineol I
, O
the O
levels O
of O
which O
increased O
after O
steam O
distillation O
. O

In O
the O
present O
study O
we O
report O
salicylic B
acid I
- O
mediated O
differential O
elicitation O
of O
different O
forms O
of O
folates B
- O
5 B
- I
methyltetrahydrofola I
, O
5 B
- I
formyltetrahydrofola I
and O
10 B
- I
formyltetrahydrofola I
- O
their O
stabilities O
during O
microwave O
- O
drying O
and O
bioaccessibilities O
from O
fresh O
and O
dried O
foliage O
. O

In O
the O
present O
study O
we O
report O
salicylic B
acid I
- O
mediated O
differential O
elicitation O
of O
different O
forms O
of O
folates B
- O
5 B
- I
methyltetrahydrofola I
, O
5 B
- I
formyltetrahydrofola I
and O
10 B
- I
formyltetrahydrofola I
- O
their O
stabilities O
during O
microwave O
- O
drying O
and O
bioaccessibilities O
from O
fresh O
and O
dried O
foliage O
. O

In O
the O
present O
study O
we O
report O
salicylic B
acid I
- O
mediated O
differential O
elicitation O
of O
different O
forms O
of O
folates B
- O
5 B
- I
methyltetrahydrofola I
, O
5 B
- I
formyltetrahydrofola I
and O
10 B
- I
formyltetrahydrofola I
- O
their O
stabilities O
during O
microwave O
- O
drying O
and O
bioaccessibilities O
from O
fresh O
and O
dried O
foliage O
. O

In O
addition O
, O
substances O
relevant O
for O
nutrition O
, O
such O
as O
beta B
- I
carotene I
, O
fatty B
acids I
, O
ascorbic B
acid I
and O
minerals O
were O
quantified O
in O
leaves O
and O
flowers O
. O

The O
occurrence O
of O
triterpene B
pentacyclic I
acids I
in O
plants O
is O
extensive O
, O
but O
little O
is O
known O
about O
their O
availability O
in O
commercial O
extracts O
. O

Changes O
in O
the O
oil O
were O
assessed O
by O
the O
free O
fatty B
acid I
( O
FFA O
) O
content O
, O
p B
- I
anisidine I
value O
( O
AnV O
) O
, O
colour O
, O
viscosity O
, O
fatty B
acid I
profile O
and O
concentration O
of O
tocols O
. O

There O
was O
a O
reduction O
in O
the O
loss O
of O
polyunsaturated B
fatty I
acids I
in O
the O
case O
of O
vacuum O
drainage O
after O
5 O
days O
of O
frying O
but O
differences O
in O
retention O
of O
tocols O
were O
only O
evident O
in O
the O
first O
two O
days O
of O
frying O
. O

This O
approach O
allowed O
the O
identification O
of O
four O
endocrine O
compounds O
( O
tetrahydroaldosteron B
- I
3 I
- I
glucuronide I
, O
cortolone B
- I
3 I
- I
glucuronide I
, O
testosterone B
- I
glucuronide I
and O
17 B
- I
hydroxyprogesterone I
) O
, O
which O
belonged O
to O
the O
steroid B
biosynthesis O
pathway O
as O
significant O
metabolites O
upregulated O
by O
citrus O
juice O
intake O
. O

This O
approach O
allowed O
the O
identification O
of O
four O
endocrine O
compounds O
( O
tetrahydroaldosteron B
- I
3 I
- I
glucuronide I
, O
cortolone B
- I
3 I
- I
glucuronide I
, O
testosterone B
- I
glucuronide I
and O
17 B
- I
hydroxyprogesterone I
) O
, O
which O
belonged O
to O
the O
steroid B
biosynthesis O
pathway O
as O
significant O
metabolites O
upregulated O
by O
citrus O
juice O
intake O
. O

CSEE O
enhanced O
the O
phosphorylation O
of O
AMP B
- O
activated O
protein O
kinase O
( O
AMPK O
) O
and O
its O
primary O
downstream O
targeting O
enzyme O
, O
acetyl B
- I
CoA I
carboxylase O
, O
up O
- O
regulated O
gene O
expression O
of O
carnitine B
palmitoyl B
transferase O
1 O
, O
and O
down O
- O
regulated O
sterol O
regulatory O
element O
- O
binding O
protein O
1 O
and O
fatty B
acid I
synthase O
protein O
levels O
in O
epididymal O
WAT O
of O
HFD O
- O
fed O
rats O
. O

beta B
- I
Asarone I
, O
an O
active O
principle O
of O
Acorus O
calamus O
rhizome O
, O
inhibits O
morphogenesis O
, O
biofilm O
formation O
and O
ergosterol B
biosynthesis O
in O
Candida O
albicans O
. O

Anti O
- O
Candida O
potential O
of O
Acorus O
calamus O
rhizome O
and O
its O
active O
principle O
, O
beta B
- I
asarone I
, O
was O
evaluated O
against O
the O
human O
fungal O
pathogen O
, O
Candida O
albicans O
. O

beta B
- I
Asarone I
exhibited O
promising O
growth O
inhibitory O
activity O
at O
0 O
. O
5mg O
/ O
ml O
and O
it O
was O
fungicidal O
at O
8 O
mg O
/ O
ml O
. O

Time O
dependant O
kill O
curve O
assay O
showed O
that O
MFC O
of O
beta B
- I
asarone I
was O
highly O
toxic O
to O
C O
. O
albicans O
, O
killing O
99 O
. O
9 O
% O
inoculum O
within O
120 O
min O
of O
exposure O
. O

beta B
- I
Asarone I
caused O
significant O
inhibition O
of O
C O
. O
albicans O
morphogenesis O
and O
biofilm O
development O
at O
sub O
- O
inhibitory O
concentrations O
. O

Our O
data O
indicate O
that O
the O
growth O
inhibitory O
activity O
of O
beta B
- I
asarone I
might O
be O
through O
inhibition O
of O
ergosterol B
biosynthesis O
. O

Hemolytic O
assay O
showed O
that O
beta B
- I
asarone I
is O
non O
- O
toxic O
, O
even O
at O
concentrations O
approaching O
MIC O
value O
. O

Our O
results O
suggest O
that O
beta B
- I
asarone I
may O
be O
safe O
as O
a O
topical O
antifungal O
agent O
. O

Our O
laboratories O
have O
synthesized O
and O
have O
initiated O
testing O
of O
novel O
phenoxyalkyl B
pyridinium I
oximes I
( O
patent O
pending O
) O
that O
are O
more O
lipophilic O
than O
currently O
approved O
oximes B
. O

This O
is O
a O
preliminary O
report O
on O
these O
novel O
oximes B
which O
have O
been O
tested O
in O
vitro O
in O
rat O
brain O
homogenates O
with O
highly O
relevant O
surrogates O
for O
sarin B
( O
phthalimidyl B
isopropyl I
methylphosphonate I
; O
PIMP B
) O
and O
VX O
( O
nitrophenyl B
ethyl I
methylphosphonate I
; O
NEMP B
) O
. O

This O
is O
a O
preliminary O
report O
on O
these O
novel O
oximes B
which O
have O
been O
tested O
in O
vitro O
in O
rat O
brain O
homogenates O
with O
highly O
relevant O
surrogates O
for O
sarin B
( O
phthalimidyl B
isopropyl I
methylphosphonate I
; O
PIMP B
) O
and O
VX O
( O
nitrophenyl B
ethyl I
methylphosphonate I
; O
NEMP B
) O
. O

An O
in O
vivo O
testing O
paradigm O
was O
developed O
in O
which O
the O
novel O
oxime B
was O
administered O
at O
the O
time O
of O
maximal O
brain O
AChE O
inhibition O
( O
about O
80 O
% O
) O
( O
1h O
) O
elicited O
by O
nitrophenyl B
isopropyl I
methylphosphonate I
( O
NIMP B
; O
sarin B
surrogate O
) O
. O

The O
addition O
of O
propargylglycine B
, O
a O
specific O
cystathionine B
gamma O
- O
lyase O
inhibitor O
, O
and O
buthionine B
sulfoximine I
, O
a O
specific O
gamma B
- I
glutamylcysteine I
ligase O
inhibitor O
, O
to O
TAMR O
- O
MCF O
- O
7 O
cells O
, O
but O
not O
to O
MCF O
- O
7 O
cells O
, O
resulted O
in O
cytotoxicity O
after O
sulfur B
amino B
acid I
deprivation O
. O

Additionally O
, O
the O
S B
- I
adenosylmethionine I
/ O
S B
- I
adenosylhomocysteine I
ratio O
, O
an O
index O
of O
transmethylation O
potential O
, O
in O
TAMR O
- O
MCF O
- O
7 O
cells O
increased O
to O
~ O
3 O
. O
6 O
- O
fold O
relative O
to O
that O
in O
MCF O
- O
7 O
cells O
, O
a O
finding O
that O
may O
result O
from O
upregulation O
of O
methionine B
adenosyltransferase O
IIa O
and O
S B
- I
adenosylhomocysteine I
hydrolase O
. O

Additionally O
, O
the O
S B
- I
adenosylmethionine I
/ O
S B
- I
adenosylhomocysteine I
ratio O
, O
an O
index O
of O
transmethylation O
potential O
, O
in O
TAMR O
- O
MCF O
- O
7 O
cells O
increased O
to O
~ O
3 O
. O
6 O
- O
fold O
relative O
to O
that O
in O
MCF O
- O
7 O
cells O
, O
a O
finding O
that O
may O
result O
from O
upregulation O
of O
methionine B
adenosyltransferase O
IIa O
and O
S B
- I
adenosylhomocysteine I
hydrolase O
. O

Additionally O
, O
the O
S B
- I
adenosylmethionine I
/ O
S B
- I
adenosylhomocysteine I
ratio O
, O
an O
index O
of O
transmethylation O
potential O
, O
in O
TAMR O
- O
MCF O
- O
7 O
cells O
increased O
to O
~ O
3 O
. O
6 O
- O
fold O
relative O
to O
that O
in O
MCF O
- O
7 O
cells O
, O
a O
finding O
that O
may O
result O
from O
upregulation O
of O
methionine B
adenosyltransferase O
IIa O
and O
S B
- I
adenosylhomocysteine I
hydrolase O
. O

Structures O
of O
the O
isolated O
compounds O
were O
elucidated O
as O
sclareol B
, O
beta B
- I
sitosterol I
, O
salvigenin B
, O
oleanolic B
acid I
and O
ursolic B
acid I
. O

Down O
- O
regulation O
of O
8 B
- I
oxoguanine I
DNA O
glycosylase O
1 O
expression O
in O
the O
airway O
epithelium O
ameliorates O
allergic O
lung O
inflammation O
. O

Our O
goal O
was O
to O
establish O
the O
role O
of O
8 B
- I
oxoguanine I
( O
8 B
- I
oxoG I
) O
, O
a O
common O
oxidatively O
damaged O
base O
, O
and O
its O
repair O
by O
8 B
- I
oxoguanine I
DNA O
glycosylase O
1 O
( O
Ogg1 O
) O
in O
allergic O
airway O
inflammatory O
processes O
. O

Our O
goal O
was O
to O
establish O
the O
role O
of O
8 B
- I
oxoguanine I
( O
8 B
- I
oxoG I
) O
, O
a O
common O
oxidatively O
damaged O
base O
, O
and O
its O
repair O
by O
8 B
- I
oxoguanine I
DNA O
glycosylase O
1 O
( O
Ogg1 O
) O
in O
allergic O
airway O
inflammatory O
processes O
. O

Our O
goal O
was O
to O
establish O
the O
role O
of O
8 B
- I
oxoguanine I
( O
8 B
- I
oxoG I
) O
, O
a O
common O
oxidatively O
damaged O
base O
, O
and O
its O
repair O
by O
8 B
- I
oxoguanine I
DNA O
glycosylase O
1 O
( O
Ogg1 O
) O
in O
allergic O
airway O
inflammatory O
processes O
. O

We O
utilized O
siRNA O
technology O
to O
deplete O
Ogg1 O
from O
airway O
epithelium O
; O
8 B
- I
oxoG I
and O
DNA O
strand O
break O
levels O
were O
quantified O
by O
Comet O
assays O
. O

Decreased O
Ogg1 O
expression O
and O
thereby O
8 B
- I
oxoG I
repair O
in O
the O
airway O
epithelium O
conveyed O
a O
lower O
inflammatory O
response O
after O
RWPE O
challenge O
of O
sensitized O
mice O
, O
as O
determined O
by O
expression O
of O
Th2 O
cytokines O
, O
eosinophilia O
, O
epithelial O
methaplasia O
, O
and O
airway O
hyperresponsiveness O
. O

In O
contrast O
, O
8 B
- I
oxoG I
repair O
in O
Ogg1 O
- O
proficient O
airway O
epithelium O
was O
coupled O
to O
an O
increase O
in O
DNA O
single O
- O
strand O
break O
( O
SSB O
) O
levels O
and O
exacerbation O
of O
allergen O
challenge O
- O
dependent O
inflammation O
. O

Decreased O
expression O
of O
the O
Nei O
- O
like O
glycosylases O
Neil1 O
and O
Neil2 O
that O
preferentially O
excise O
ring O
- O
opened O
purines O
and O
5 B
- I
hydroxyuracil I
, O
respectively O
, O
did O
not O
alter O
the O
above O
parameters O
of O
allergic O
immune O
responses O
to O
RWPE O
. O

These O
results O
show O
that O
DNA O
SSBs O
formed O
during O
Ogg1 O
- O
mediated O
repair O
of O
8 B
- I
oxoG I
augment O
antigen O
- O
driven O
allergic O
immune O
responses O
. O

The O
metallohormone O
cadmium B
modulates O
AhR O
- O
associated O
gene O
expression O
in O
the O
small O
intestine O
of O
rats O
similar O
to O
ethinyl B
- I
estradiol I
. O

Relieving O
visceral O
hyperalgesia O
effect O
of O
Kangtai O
capsule O
and O
its O
potential O
mechanisms O
via O
modulating O
the O
5 B
- I
HT I
and O
NO B
level O
in O
vivo O
. O

The O
neonatal O
maternal O
separation O
( O
NMS O
) O
on O
Sprague O
- O
Dawley O
pups O
was O
employed O
to O
evaluate O
the O
therapeutic O
effect O
of O
KT O
by O
virtue O
of O
various O
parameters O
including O
visceral O
hyperalgesia O
, O
serum O
nitric B
oxide I
( O
NO B
) O
level O
, O
and O
tissue O
5 B
- I
hydroxytryptamine I
( O
5 B
- I
HT I
) O
level O
. O

The O
neonatal O
maternal O
separation O
( O
NMS O
) O
on O
Sprague O
- O
Dawley O
pups O
was O
employed O
to O
evaluate O
the O
therapeutic O
effect O
of O
KT O
by O
virtue O
of O
various O
parameters O
including O
visceral O
hyperalgesia O
, O
serum O
nitric B
oxide I
( O
NO B
) O
level O
, O
and O
tissue O
5 B
- I
hydroxytryptamine I
( O
5 B
- I
HT I
) O
level O
. O

Furthermore O
, O
KT O
at O
three O
doses O
significantly O
decreased O
5 B
- I
HT I
content O
from O
distal O
colon O
of O
visceral O
hyperalgesia O
rats O
induced O
by O
NMS O
, O
while O
the O
significant O
decrease O
of O
5 B
- I
HT I
content O
in O
serum O
was O
only O
observed O
in O
the O
group O
with O
KT O
at O
high O
dose O
. O

Furthermore O
, O
KT O
at O
three O
doses O
significantly O
decreased O
5 B
- I
HT I
content O
from O
distal O
colon O
of O
visceral O
hyperalgesia O
rats O
induced O
by O
NMS O
, O
while O
the O
significant O
decrease O
of O
5 B
- I
HT I
content O
in O
serum O
was O
only O
observed O
in O
the O
group O
with O
KT O
at O
high O
dose O
. O

However O
, O
compared O
with O
that O
in O
NMS O
rats O
without O
KT O
, O
there O
was O
no O
apparent O
difference O
of O
5 B
- I
HT I
level O
from O
brain O
issue O
in O
the O
rats O
with O
various O
doses O
. O

Data O
from O
the O
pharmacological O
investigation O
suggested O
that O
the O
curative O
effect O
of O
KT O
to O
the O
visceral O
hypersensitivity O
may O
be O
concerned O
with O
the O
level O
of O
5 B
- I
HT I
and O
NO B
in O
vivo O
, O
promising O
its O
potential O
in O
irritable O
bowel O
syndrome O
treatment O
. O

11 B
- I
Ketotestosterone I
( O
11 B
- I
kT I
) O
was O
administered O
over O
a O
two O
- O
week O
period O
to O
assess O
population O
differences O
in O
sensitivity O
to O
androgens B
. O

11 B
- I
Ketotestosterone I
( O
11 B
- I
kT I
) O
was O
administered O
over O
a O
two O
- O
week O
period O
to O
assess O
population O
differences O
in O
sensitivity O
to O
androgens B
. O

11 B
- I
kT I
masculinized O
EODf O
significantly O
more O
in O
the O
population O
with O
the O
greater O
degree O
of O
sexual O
dimorphism O
. O

11 B
- I
kT I
had O
no O
effect O
on O
the O
sexually O
monomorphic O
chirping O
rates O
. O

Furthermore O
, O
TNF O
- O
alpha O
- O
induced O
CXCL8 O
secretion O
was O
( O
i O
) O
inhibited O
by O
the O
MR O
antagonist O
tiotropium B
and O
the O
M3R O
antagonist O
4 B
- I
DAMP I
and O
( O
ii O
) O
enhanced O
by O
the O
M1 O
/ O
M3R O
agonist O
pilocarpine B
and O
the O
cholinesterase O
inhibitor O
physostigmine B
. O

We O
studied O
the O
mechanism O
of O
aerobic O
inactivation O
of O
Desulfovibrio O
fructosovorans O
nickel B
- I
iron I
( O
NiFe B
) O
hydrogenase O
by O
quantitatively O
examining O
the O
results O
of O
electrochemistry O
, O
EPR O
and O
FTIR O
experiments O
. O

Mesalamine B
( O
5 B
- I
ASA I
) O
is O
widely O
used O
for O
the O
treatment O
of O
ulcerative O
colitis O
, O
a O
remitting O
condition O
characterized O
by O
chronic O
inflammation O
of O
the O
colon O
. O

Knowledge O
about O
the O
molecular O
and O
cellular O
targets O
of O
5 B
- I
ASA I
is O
limited O
and O
a O
clear O
understanding O
of O
its O
activity O
in O
intestinal O
homeostasis O
and O
interference O
with O
neoplastic O
progression O
is O
lacking O
. O

We O
sought O
to O
identify O
molecular O
pathways O
interfered O
by O
5 B
- I
ASA I
, O
using O
CRC O
cell O
lines O
with O
different O
genetic O
background O
. O

Microarray O
was O
performed O
for O
gene O
expression O
profile O
of O
5 B
- I
ASA I
- O
treated O
and O
untreated O
cells O
( O
HCT116 O
and O
HT29 O
) O
. O

Filtering O
and O
analysis O
of O
data O
identified O
three O
oncogenic O
pathways O
interfered O
by O
5 B
- I
ASA I
: O
MAPK O
/ O
ERK O
pathway O
, O
cell O
adhesion O
and O
beta O
- O
catenin O
/ O
Wnt O
signaling O
. O

PAK1 O
emerged O
as O
a O
consensus O
target O
of O
5 B
- I
ASA I
, O
orchestrating O
these O
pathways O
. O

We O
further O
investigated O
the O
effect O
of O
5 B
- I
ASA I
on O
cell O
adhesion O
. O

5 B
- I
ASA I
increased O
cell O
adhesion O
which O
was O
measured O
by O
cell O
adhesion O
assay O
and O
transcellular O
- O
resistance O
measurement O
. O

Moreover O
, O
5 B
- I
ASA I
treatment O
restored O
membranous O
expression O
of O
adhesion O
molecules O
E O
- O
cadherin O
and O
beta O
- O
catenin O
. O

PAK1 O
expression O
was O
elevated O
in O
APC O
( O
min O
) O
polyps O
and O
5 B
- I
ASA I
treatment O
reduced O
its O
expression O
. O

We O
propose O
that O
inhibition O
of O
PAK1 O
expression O
by O
5 B
- I
ASA I
can O
impede O
with O
neoplastic O
progression O
in O
colorectal O
carcinogenesis O
. O

The O
mechanism O
of O
PAK1 O
inhibition O
and O
induction O
of O
membranous O
translocation O
of O
adhesion O
proteins O
by O
5 B
- I
ASA I
might O
be O
independent O
of O
its O
known O
anti O
- O
inflammatory O
action O
. O

PBMCs O
, O
isolated O
from O
blood O
samples O
of O
four O
male O
and O
four O
female O
healthy O
individuals O
, O
were O
exposed O
in O
vitro O
for O
18h O
to O
either O
a O
dioxin B
- O
like O
polychlorinated B
biphenyl I
( O
PCB126 B
, O
1 O
mu O
M O
) O
, O
a O
non O
- O
dioxin B
- O
like O
polychlorinated B
biphenyl I
( O
PCB153 B
, O
10 O
mu O
M O
) O
, O
a O
brominated O
flame O
retardant O
( O
BDE47 B
, O
10 O
mu O
M O
) O
, O
a O
perfluorinated B
alkyl I
acid I
( O
PFOA B
, O
10 O
mu O
M O
) O
or O

Carvacrol B
decreased O
cell O
viability O
, O
which O
was O
not O
reversed O
when O
cytosolic O
Ca B
( I
2 I
+ I
) I
was O
chelated O
with O
BAPTA B
- I
AM I
( O
1 B
, I
2 I
- I
bis I
( I
2 I
- I
aminophenoxy I
) I
ethane I
- I
N I
, I
N I
, I
N I
' I
, I
N I
' I
- I
tetraacetic I
acid I
- I
acetoxymethyl I
ester I
) O
. O

The O
polycyclic B
aromatic I
hydrocarbon I
( O
PAH B
) O
benzo B
[ I
a I
] I
pyrene I
( O
BP O
) O
is O
metabolized O
into O
a O
complex O
pattern O
of O
BP O
derivatives O
, O
among O
which O
the O
ultimate O
carcinogen O
( B
+ I
) I
- I
anti I
- I
BP I
- I
7 I
, I
8 I
- I
diol I
- I
9 I
, I
10 I
- I
epoxide I
( O
BPDE B
) O
is O
formed O
to O
certain O
extents O
. O

CAPs O
off O
to O
the O
S B
- I
S I
bond O
: O
Application O
of O
a O
strategy O
involving O
the O
introduction O
of O
intramolecular O
disulfide B
bonds O
to O
amphipathic O
cationic O
antimicrobial O
peptides O
( O
CAPs O
) O
led O
to O
decreased O
alpha O
- O
helicity O
and O
hydrophobicity O
. O

IH O
significantly O
decreased O
beta O
- O
cell O
function O
, O
assessed O
both O
by O
the O
disposition O
index O
( O
insulin O
secretion O
corrected O
for O
IH O
- O
induced O
insulin O
resistance O
) O
and O
in O
isolated O
islets O
, O
in O
dp O
- O
BB O
, O
but O
not O
in O
dr O
- O
BB O
or O
WF O
, O
rats O
, O
and O
the O
effect O
of O
IH O
was O
inhibited O
by O
the O
antioxidant O
N B
- I
acetylcysteine I
. O

Using O
coumarin B
- I
6 I
as O
a O
model O
drug O
and O
fluorescent O
marker O
, O
we O
show O
that O
liposome O
surface O
modification O
by O
PLL B
dramatically O
increased O
delivery O
to O
mouse O
retina O
segments O
after O
eye O
drop O
administration O
. O

In O
this O
study O
, O
we O
investigated O
enhancers O
with O
amino B
acids I
( O
proline B
, O
sarcosine B
, O
alanine B
, O
beta B
- I
alanine I
, O
and O
glycine B
) O
attached O
to O
hydrophobic O
chain O
( O
s O
) O
via O
a O
biodegradable O
ester B
link O
. O

The O
proline B
derivative O
l B
- I
Pro2 I
reached O
enhancement O
ratios O
of O
up O
to O
40 O
at O
1 O
% O
concentration O
, O
which O
is O
higher O
than O
that O
of O
the O
well O
- O
established O
and O
standard O
enhancers O
Azone B
, O
DDAIP B
, O
DDAK B
, O
and O
Transkarbam B
12 I
. O

l B
- I
Pro2 I
acted O
synergistically O
with O
propylene B
glycol I
. O

Infrared O
studies O
revealed O
that O
l B
- I
Pro2 I
forms O
a O
separate O
liquid O
ordered O
phase O
in O
the O
stratum O
corneum O
lipids O
and O
has O
no O
significant O
effect O
on O
proteins O
. O

l B
- I
Pro2 I
action O
was O
at O
least O
partially O
reversible O
as O
measured O
by O
skin O
electrical O
impedance O
. O

Furthermore O
, O
l B
- I
Pro2 I
was O
rapidly O
decomposed O
in O
plasma O
. O

In O
vivo O
transdermal O
absorption O
studies O
in O
rats O
confirmed O
the O
enhancing O
activity O
of O
l B
- I
Pro2 I
and O
suggested O
its O
negligible O
skin O
toxicity O
and O
minimal O
effect O
on O
transepidermal O
water O
loss O
. O

These O
properties O
make O
l B
- I
Pro2 I
a O
promising O
candidate O
for O
potential O
clinical O
use O
. O

There O
is O
much O
attention O
to O
the O
role O
of O
psychotropic O
compounds O
acting O
on O
serotonin B
( O
5 B
- I
HT I
) O
receptors O
in O
ameliorating O
cognitive O
deficits O
of O
the O
disease O
. O

Among O
the O
5 B
- I
HT I
receptor O
subtypes O
, O
the O
5 B
- I
HT I
( O
1A O
) O
receptor O
is O
attracting O
particular O
interests O
as O
a O
potential O
target O
for O
enhancing O
cognition O
, O
based O
on O
preclinical O
and O
clinical O
evidence O
. O

Among O
the O
5 B
- I
HT I
receptor O
subtypes O
, O
the O
5 B
- I
HT I
( O
1A O
) O
receptor O
is O
attracting O
particular O
interests O
as O
a O
potential O
target O
for O
enhancing O
cognition O
, O
based O
on O
preclinical O
and O
clinical O
evidence O
. O

The O
neural O
network O
underlying O
the O
ability O
of O
5 B
- I
HT I
( O
1A O
) O
agonists O
to O
treat O
cognitive O
impairments O
of O
schizophrenia O
likely O
includes O
dopamine B
, O
glutamate B
, O
and O
gamma B
- I
aminobutyric I
acid I
neurons O
. O

Recent O
advances O
of O
electrophysiological O
measures O
, O
such O
as O
event O
- O
related O
potentials O
, O
have O
provided O
insights O
into O
facilitative O
effects O
on O
cognition O
of O
some O
atypical O
antipsychotic O
drugs O
or O
related O
compounds O
acting O
directly O
or O
indirectly O
on O
5 B
- I
HT I
( O
1A O
) O
receptors O
. O

Several O
brain O
metabolites O
can O
be O
measured O
by O
the O
means O
of O
( O
1 O
) O
H O
MRS O
: O
N B
- I
acetylaspartate I
( O
NAA B
) O
, O
choline B
containing O
compounds O
( O
Cho O
) O
, O
myo B
- I
inositol I
( O
mI O
) O
and O
glutamate B
( O
Glu B
) O
, O
glutamine B
( O
Gln B
) O
and O
GABA B
( O
together O
as O
Glx O
complex O
or O
separately O
) O
. O

Several O
brain O
metabolites O
can O
be O
measured O
by O
the O
means O
of O
( O
1 O
) O
H O
MRS O
: O
N B
- I
acetylaspartate I
( O
NAA B
) O
, O
choline B
containing O
compounds O
( O
Cho O
) O
, O
myo B
- I
inositol I
( O
mI O
) O
and O
glutamate B
( O
Glu B
) O
, O
glutamine B
( O
Gln B
) O
and O
GABA B
( O
together O
as O
Glx O
complex O
or O
separately O
) O
. O

Effects O
of O
molecular O
weight O
on O
permeability O
and O
microstructure O
of O
mixed O
ethyl B
- I
hydroxypropyl I
- O
cellulose O
films O
. O

Rats O
were O
dosed O
orally O
for O
7 O
days O
to O
determine O
( O
1 O
) O
if O
HDN O
( O
induced O
by O
2 B
- I
propanol I
or O
D B
- I
limonene I
) O
altered O
the O
newer O
renal O
biomarkers O
and O
not O
BUN O
or O
creatinine B
, O
( O
2 O
) O
if O
renal O
biomarkers O
could O
distinguish O
between O
HDN O
and O
oxidative O
stress O
- O
induced O
kidney O
injury O
( O
induced O
by O
potassium B
bromate I
) O
, O
( O
3 O
) O
sensitivity O
of O
HDN O
- O
induced O
renal O
biomarker O
changes O
relative O
to O
D B
- I
limonene I
dose O
, O
and O
( O
4 O
) O
reversibility O
of O
HDN O
and O
renal O
biomarkers O
, O
using O

Rats O
were O
dosed O
orally O
for O
7 O
days O
to O
determine O
( O
1 O
) O
if O
HDN O
( O
induced O
by O
2 B
- I
propanol I
or O
D B
- I
limonene I
) O
altered O
the O
newer O
renal O
biomarkers O
and O
not O
BUN O
or O
creatinine B
, O
( O
2 O
) O
if O
renal O
biomarkers O
could O
distinguish O
between O
HDN O
and O
oxidative O
stress O
- O
induced O
kidney O
injury O
( O
induced O
by O
potassium B
bromate I
) O
, O
( O
3 O
) O
sensitivity O
of O
HDN O
- O
induced O
renal O
biomarker O
changes O
relative O
to O
D B
- I
limonene I
dose O
, O
and O
( O
4 O
) O
reversibility O
of O
HDN O
and O
renal O
biomarkers O
, O
using O

Rats O
were O
dosed O
orally O
for O
7 O
days O
to O
determine O
( O
1 O
) O
if O
HDN O
( O
induced O
by O
2 B
- I
propanol I
or O
D B
- I
limonene I
) O
altered O
the O
newer O
renal O
biomarkers O
and O
not O
BUN O
or O
creatinine B
, O
( O
2 O
) O
if O
renal O
biomarkers O
could O
distinguish O
between O
HDN O
and O
oxidative O
stress O
- O
induced O
kidney O
injury O
( O
induced O
by O
potassium B
bromate I
) O
, O
( O
3 O
) O
sensitivity O
of O
HDN O
- O
induced O
renal O
biomarker O
changes O
relative O
to O
D B
- I
limonene I
dose O
, O
and O
( O
4 O
) O
reversibility O
of O
HDN O
and O
renal O
biomarkers O
, O
using O

vehicle O
or O
300 O
mg O
/ O
kg O
/ O
day O
D B
- I
limonene I
with O
7 O
days O
of O
dosing O
and O
necropsies O
scheduled O
over O
the O
period O
of O
Days O
8 O
- O
85 O
. O

HDN O
- O
induced O
renal O
biomarker O
changes O
in O
male O
rats O
were O
potentially O
compound O
specific O
: O
( O
1 O
) O
2 B
- I
propanol I
induced O
mild O
HDN O
without O
increased O
renal O
biomarkers O
, O
( O
2 O
) O
potassium B
bromate I
induced O
moderate O
HDN O
with O
increased O
clusterin O
, O
and O
( O
3 O
) O
D B
- I
limonene I
induced O
marked O
HDN O
with O
increased O
alpha O
GST O
, O
mu O
GST O
and O
albumin O
. O

HDN O
- O
induced O
renal O
biomarker O
changes O
in O
male O
rats O
were O
potentially O
compound O
specific O
: O
( O
1 O
) O
2 B
- I
propanol I
induced O
mild O
HDN O
without O
increased O
renal O
biomarkers O
, O
( O
2 O
) O
potassium B
bromate I
induced O
moderate O
HDN O
with O
increased O
clusterin O
, O
and O
( O
3 O
) O
D B
- I
limonene I
induced O
marked O
HDN O
with O
increased O
alpha O
GST O
, O
mu O
GST O
and O
albumin O
. O

The O
compound O
D B
- I
limonene I
induced O
a O
dose O
dependent O
increase O
in O
HDN O
severity O
and O
renal O
biomarker O
changes O
without O
altering O
BUN O
, O
creatinine B
or O
NAG O
: O
( O
1 O
) O
minimal O
induction O
of O
HDN O
and O
no O
altered O
biomarkers O
at O
10 O
mg O
/ O
kg O
/ O
day O
, O
( O
2 O
) O
mild O
induction O
of O
HDN O
with O
increased O
alpha O
GST O
and O
mu O
GST O
at O
50 O
mg O
/ O
kg O
/ O
day O
and O
( O
3 O
) O
marked O
induction O
of O
HDN O
with O
increased O
alpha O
GST O
, O
mu O
GST O
and O
albumin O
at O
300 O
mg O
/ O
kg O
/ O
day O
. O

HDN O
induced O
by O
D B
- I
limonene I
was O
reversible O
, O
but O
with O
a O
variable O
renal O
biomarker O
pattern O
over O
time O
: O
Day O
8 O
there O
was O
increased O
alpha O
GST O
, O
mu O
GST O
and O
albumin O
; O
on O
Day O
15 O
increased O
clusterin O
, O
albumin O
and O
Kim O
- O
1 O
. O

Concentrations O
of O
the O
products O
that O
caused O
50 O
% O
mortality O
were O
140 O
. O
5 O
and O
339 O
. O
8 O
mg O
/ O
L O
for O
259F B
and O
LC B
- I
95A I
, O
respectively O
, O
and O
could O
occur O
during O
accidental O
drops O
into O
aquatic O
habitats O
. O

Un O
- O
ionized O
ammonia O
levels O
, O
from O
259F B
, O
were O
sufficient O
to O
cause O
acute O
mortality O
; O
but O
additional O
factors O
, O
indicated O
by O
increased O
phagosome O
prevalence O
in O
the O
gills O
, O
might O
have O
contributed O
to O
mortality O
during O
LC B
- I
95A I
exposure O
. O

Supra O
- O
normal O
stimulation O
of O
dopamine B
D1 O
receptors O
in O
the O
prelimbic O
cortex O
blocks O
behavioral O
expression O
of O
both O
aversive O
and O
rewarding O
associative O
memories O
through O
a O
cyclic B
- I
AMP I
- O
dependent O
signaling O
pathway O
. O

Interestingly O
, O
both O
intra O
- O
PLC O
D O
( O
1 O
) O
- O
receptor O
mediated O
block O
of O
either O
fear O
- O
related O
or O
reward O
- O
related O
associative O
memories O
were O
dependent O
upon O
downstream O
cyclic B
- I
AMP I
( O
cAMP B
) O
signaling O
as O
both O
effects O
were O
rescued O
by O
co O
- O
administration O
of O
a O
cAMP B
signaling O
inhibitor O
. O

Pre O
- O
training O
peripheral O
injections O
of O
methyllycaconitine B
( O
MLA B
) O
or O
dihydro B
- I
beta I
- I
erythroidine I
( O
DH B
beta I
E I
) O
, O
which O
are O
specific O
alpha O
7 O
and O
alpha O
4 O
beta O
2 O
nicotinic O
receptor O
antagonists O
, O
respectively O
, O
dose O
- O
dependently O
impaired O
retention O
latencies O
in O
an O
inhibitory O
avoidance O
task O
when O
tested O
7 O
- O
days O
but O
not O
1 O
h O
after O
training O
. O

Immediate O
post O
- O
training O
glucose B
injections O
attenuated O
the O
impairments O
, O
but O
were O
more O
effective O
in O
attenuating O
the O
DH B
beta I
E I
- O
induced O
impairments O
. O

Likewise O
, O
peripheral O
or O
direct O
intrahippocampal O
injections O
of O
MLA B
or O
DH B
beta I
E I
dose O
- O
dependently O
impaired O
spatial O
working O
memory O
scores O
on O
a O
spontaneous O
alternation O
task O
. O

Concurrent O
administration O
of O
glucose B
reversed O
DH B
beta I
E I
- O
but O
not O
MLA B
- O
induced O
impairments O
. O

Both O
MLA B
and O
DH B
beta I
E I
impaired O
hippocampal O
CREB O
phosphorylation O
; O
glucose B
reversed O
DH B
beta I
E I
- O
but O
not O
MLA B
- O
induced O
deficits O
. O

Both O
MLA B
and O
DH B
beta I
E I
impaired O
hippocampal O
CREB O
phosphorylation O
; O
glucose B
reversed O
DH B
beta I
E I
- O
but O
not O
MLA B
- O
induced O
deficits O
. O

The O
effectiveness O
of O
glucose B
in O
reversing O
DH B
beta I
E I
- O
but O
not O
MLA B
- O
induced O
impairments O
in O
behavioral O
performance O
and O
CREB O
phosphorylation O
suggests O
that O
activation O
of O
alpha O
7 O
receptors O
may O
play O
an O
important O
role O
in O
memory O
enhancement O
by O
glucose B
. O

3 B
- I
Nitropropionic I
acid I
( O
3 B
- I
NP I
) O
, O
a O
mitochondrial O
toxin O
, O
has O
been O
reported O
to O
induce O
an O
acute O
cochlear O
damage O
. O

This O
study O
aimed O
to O
observe O
the O
protective O
effect O
of O
KRG O
in O
an O
ototoxic O
animal O
model O
using O
3 B
- I
NP I
intratympanic O
injection O
. O

BALB O
/ O
c O
mice O
were O
classified O
into O
5 O
groups O
( O
n O
= O
15 O
) O
and O
dose O
- O
dependent O
toxic O
effects O
after O
intratympanic O
injection O
with O
3 B
- I
NP I
( O
300 O
- O
5000 O
mM O
) O
on O
the O
left O
ear O
were O
investigated O
to O
determine O
the O
appropriate O
toxicity O
level O
of O
3 B
- I
NP I
. O

BALB O
/ O
c O
mice O
were O
classified O
into O
5 O
groups O
( O
n O
= O
15 O
) O
and O
dose O
- O
dependent O
toxic O
effects O
after O
intratympanic O
injection O
with O
3 B
- I
NP I
( O
300 O
- O
5000 O
mM O
) O
on O
the O
left O
ear O
were O
investigated O
to O
determine O
the O
appropriate O
toxicity O
level O
of O
3 B
- I
NP I
. O

For O
observation O
of O
the O
protective O
effects O
of O
KRG O
, O
23 O
mice O
were O
grouped O
into O
3 B
- I
NP I
( O
500 O
mM O
, O
n O
= O
12 O
) O
and O
KRG O
+ O
3 B
- I
NP I
groups O
( O
300 O
mg O
/ O
kg O
KRG O
for O
7 O
days O
before O
500 O
mM O
3 B
- I
NP I
administration O
, O
n O
= O
11 O
) O
. O

For O
observation O
of O
the O
protective O
effects O
of O
KRG O
, O
23 O
mice O
were O
grouped O
into O
3 B
- I
NP I
( O
500 O
mM O
, O
n O
= O
12 O
) O
and O
KRG O
+ O
3 B
- I
NP I
groups O
( O
300 O
mg O
/ O
kg O
KRG O
for O
7 O
days O
before O
500 O
mM O
3 B
- I
NP I
administration O
, O
n O
= O
11 O
) O
. O

For O
observation O
of O
the O
protective O
effects O
of O
KRG O
, O
23 O
mice O
were O
grouped O
into O
3 B
- I
NP I
( O
500 O
mM O
, O
n O
= O
12 O
) O
and O
KRG O
+ O
3 B
- I
NP I
groups O
( O
300 O
mg O
/ O
kg O
KRG O
for O
7 O
days O
before O
500 O
mM O
3 B
- I
NP I
administration O
, O
n O
= O
11 O
) O
. O

The O
ABR O
thresholds O
in O
the O
800 O
- O
5000 O
mM O
groups O
exceeded O
the O
maximum O
recording O
limit O
at O
16 O
and O
32 O
kHz O
1 O
day O
after O
3 B
- I
NP I
administration O
. O

The O
ABR O
threshold O
in O
the O
500 O
mM O
3 B
- I
NP I
+ O
KRG O
group O
was O
significantly O
lower O
than O
that O
in O
the O
500 O
mM O
3 B
- I
NP I
group O
from O
post O
1 O
week O
to O
1 O
month O
. O

The O
ABR O
threshold O
in O
the O
500 O
mM O
3 B
- I
NP I
+ O
KRG O
group O
was O
significantly O
lower O
than O
that O
in O
the O
500 O
mM O
3 B
- I
NP I
group O
from O
post O
1 O
week O
to O
1 O
month O
. O

The O
mean O
type O
II O
fibrocyte O
counts O
significantly O
differed O
between O
the O
control O
and O
3 B
- I
NP I
groups O
and O
between O
the O
3 B
- I
NP I
and O
3 B
- I
NP I
+ O
KRG O
groups O
. O

The O
mean O
type O
II O
fibrocyte O
counts O
significantly O
differed O
between O
the O
control O
and O
3 B
- I
NP I
groups O
and O
between O
the O
3 B
- I
NP I
and O
3 B
- I
NP I
+ O
KRG O
groups O
. O

The O
mean O
type O
II O
fibrocyte O
counts O
significantly O
differed O
between O
the O
control O
and O
3 B
- I
NP I
groups O
and O
between O
the O
3 B
- I
NP I
and O
3 B
- I
NP I
+ O
KRG O
groups O
. O

Spiral O
ganglion O
cell O
degeneration O
in O
the O
3 B
- I
NP I
group O
was O
more O
severe O
than O
that O
in O
the O
3 B
- I
NP I
+ O
KRG O
group O
. O

Spiral O
ganglion O
cell O
degeneration O
in O
the O
3 B
- I
NP I
group O
was O
more O
severe O
than O
that O
in O
the O
3 B
- I
NP I
+ O
KRG O
group O
. O

KRG O
administration O
ameliorated O
the O
deterioration O
of O
hearing O
by O
3 B
- I
NP I
. O

Reproductive O
and O
developmental O
toxicity O
screening O
test O
of O
3 B
- I
cyanopyridine I
in O
rats O
. O

Crl O
: O
CD O
( O
SD O
) O
rats O
were O
given O
3 B
- I
cyanopyridine I
by O
gavage O
at O
0 O
, O
5 O
, O
30 O
or O
180 O
mg O
/ O
kg O
/ O
day O
. O

Dunaliella O
bardawil O
was O
employed O
in O
the O
present O
research O
to O
test O
the O
toxic O
effects O
of O
SDBS B
, O
CTAC B
, O
and O
their O
mixture O
on O
cell O
growth O
, O
cellular O
morphology O
, O
beta B
- I
carotene I
accumulation O
, O
and O
enzymatic O
activities O
of O
superoxide B
dismutase O
( O
SOD O
) O
and O
catalase O
( O
CAT O
) O
. O

The O
results O
showed O
that O
SDBS B
at O
200 O
, O
550 O
, O
900 O
, O
1 O
, O
350 O
, O
1 O
, O
800 O
, O
and O
2 O
, O
400 O
mg O
/ O
L O
and O
CTAC B
at O
0 O
. O
4 O
, O
0 O
. O
7 O
, O
1 O
. O
0 O
, O
1 O
. O
3 O
, O
2 O
. O
8 O
, O
and O
3 O
. O
5 O
mg O
/ O
L O
inhibited O
algal O
growth O
and O
beta B
- I
carotene I
accumulation O
, O
both O
of O
which O
declined O
and O
then O
increased O
. O

The O
N B
- I
oxides I
of O
M1 O
, O
a O
mixture O
of O
two O
diastereomers O
designated O
as O
M2 O
and O
M3 O
, O
were O
also O
present O
in O
plasma O
and O
urine O
, O
accounting O
for O
up O
to O
13 O
. O
2 O
% O
of O
radioactivity O
in O
plasma O
. O

Regulation O
of O
serotonin B
( O
5 B
- I
HT I
) O
function O
by O
a O
VGLUT1 O
dependent O
glutamate B
pathway O
. O

Unraveling O
the O
mechanisms O
of O
5 B
- I
HT I
neuron O
control O
might O
provide O
new O
insights O
into O
depression O
pathophysiology O
. O

In O
addition O
to O
the O
inhibitory O
5 O
- O
HT1A O
autoreceptors O
, O
cortico O
- O
raphe O
glutamatergic O
descending O
pathways O
are O
suggested O
to O
modulate O
5 B
- I
HT I
activity O
in O
the O
DRN O
. O

Here O
we O
studied O
how O
decreased O
VGLUT1 O
levels O
in O
the O
brain O
stem O
affect O
glutamate B
regulation O
of O
5 B
- I
HT I
function O
. O

VGLUT1 O
expression O
in O
the O
DRN O
, O
5 B
- I
HT I
turnover O
and O
immuno O
histochemical O
analysis O
of O
neuronal O
activity O
in O
different O
areas O
was O
studied O
. O

VGLUT1 O
immunoreactivity O
was O
markedly O
lower O
in O
the O
DRN O
of O
the O
VGLUT1 O
+ O
/ O
- O
mice O
and O
specifically O
, O
in O
the O
surroundings O
of O
GABA B
and O
5 B
- I
HT I
cell O
bodies O
. O

These O
mice O
showed O
decreased O
induced O
neuronal O
activity O
in O
5 B
- I
HT I
cells O
bodies O
and O
in O
different O
forebrain O
areas O
, O
as O
well O
as O
decreased O
hippocampal O
cell O
proliferation O
and O
5 B
- I
HT I
turnover O
. O

These O
mice O
showed O
decreased O
induced O
neuronal O
activity O
in O
5 B
- I
HT I
cells O
bodies O
and O
in O
different O
forebrain O
areas O
, O
as O
well O
as O
decreased O
hippocampal O
cell O
proliferation O
and O
5 B
- I
HT I
turnover O
. O

This O
study O
shows O
first O
time O
that O
VGLUT1 O
dependent O
glutamate B
innervation O
of O
the O
DRN O
could O
modulate O
5 B
- I
HT I
function O
. O

Pharmacokinetics O
, O
metabolism O
, O
and O
excretion O
of O
the O
antidiabetic O
agent O
ertugliflozin B
( O
PF B
- I
04971729 I
) O
in O
healthy O
male O
subjects O
. O

The O
disposition O
of O
ertugliflozin B
( O
PF B
- I
04971729 I
) O
, O
an O
orally O
active O
selective O
inhibitor O
of O
the O
sodium B
- O
dependent O
glucose B
cotransporter O
2 O
, O
was O
studied O
after O
a O
single O
25 O
- O
mg O
oral O
dose O
of O
[ B
( I
14 I
) I
C I
] I
- I
ertugliflozin I
to O
healthy O
human O
subjects O
. O

The O
role O
of O
cytochrome O
P450 O
- O
dependent O
metabolism O
in O
the O
regulation O
of O
mouse O
hepatic O
growth O
hormone O
signaling O
components O
and O
target O
genes O
by O
3 B
- I
methylcholanthrene I
. O

3 B
- I
Methylcholanthrene I
( O
MC O
) O
is O
a O
readily O
metabolized O
aryl B
hydrocarbon I
receptor O
( O
AHR O
) O
agonist O
. O

Spo0A O
reactivates O
the O
accDA O
operon O
that O
encodes O
the O
carboxylase O
component O
of O
the O
acetyl B
- I
CoA I
carboxylase O
enzyme O
, O
which O
catalyses O
the O
first O
and O
rate O
- O
limiting O
step O
in O
de O
novo O
lipid O
biosynthesis O
, O
malonyl B
- I
CoA I
formation O
. O

Spo0A O
reactivates O
the O
accDA O
operon O
that O
encodes O
the O
carboxylase O
component O
of O
the O
acetyl B
- I
CoA I
carboxylase O
enzyme O
, O
which O
catalyses O
the O
first O
and O
rate O
- O
limiting O
step O
in O
de O
novo O
lipid O
biosynthesis O
, O
malonyl B
- I
CoA I
formation O
. O

Pharmacological O
and O
behavioral O
characterization O
of O
the O
novel O
CRF O
( O
1 O
) O
antagonist O
BMS B
- I
763534 I
. O

BMS B
- I
763534 I
is O
a O
potent O
( O
CRF O
( O
1 O
) O
IC O
( O
50 O
) O
= O
0 O
. O
4 O
nM O
) O
and O
selective O
( O
> O
1000 O
- O
fold O
selectivity O
vs O
. O
all O
other O
sites O
tested O
) O
CRF O
( O
1 O
) O
receptor O
antagonist O
( O
pA2 O
= O
9 O
. O
47 O
vs O
. O
CRF O
( O
1 O
) O
- O
mediated O
cAMP B
production O
in O
Y79 O
cells O
) O
. O

BMS B
- I
763534 I
accelerated O
the O
dissociation O
of O
( B
125 I
) I
I I
- O
o O
- O
CRF O
from O
rat O
frontal O
cortex O
membrane O
CRF O
( O
1 O
) O
receptors O
consistent O
with O
a O
negative O
allosteric O
modulation O
of O
CRF O
binding O
. O

BMS B
- I
763534 I
produced O
dose O
- O
dependent O
increases O
in O
CRF O
( O
1 O
) O
receptor O
occupancy O
and O
anxiolytic O
efficacy O
; O
lowest O
effective O
anxiolytic O
dose O
= O
0 O
. O
56 O
mg O
/ O
kg O
, O
PO O
, O
which O
was O
associated O
with O
71 O
+ O
/ O
- O
5 O
% O
CRF O
( O
1 O
) O
receptor O
occupancy O
of O
frontoparietal O
CRF O
( O
1 O
) O
receptors O
. O

Sedative O
/ O
ataxic O
effects O
of O
BMS B
- I
763534 I
were O
only O
observed O
at O
high O
dose O
multiples O
( O
54 O
- O
179 O
x O
) O
relative O
to O
the O
lowest O
dose O
required O
for O
anxiolytic O
efficacy O
. O

At O
doses O
of O
5 O
- O
to O
18 O
- O
fold O
higher O
than O
the O
lowest O
efficacious O
dose O
in O
the O
anxiety O
assay O
, O
BMS B
- I
763534 I
shared O
subjective O
effects O
with O
the O
benzodiazepine O
chlordiazepoxide B
. O

Interestingly O
BMS B
- I
790318 I
, O
the O
O B
- O
demethylated O
metabolite O
of O
BMS B
- I
763534 I
, O
showed O
weak O
affinity O
for O
the O
TBOB B
site O
of O
the O
GABA B
( O
A O
) O
receptor O
( O
67 O
% O
inhibition O
at O
10 O
mu O
M O
) O
and O
augmented O
GABA B
evoked O
currents O
( O
EC O
( O
50 O
) O
= O
1 O
. O
6 O
mu O
M O
) O
. O

Interestingly O
BMS B
- I
790318 I
, O
the O
O B
- O
demethylated O
metabolite O
of O
BMS B
- I
763534 I
, O
showed O
weak O
affinity O
for O
the O
TBOB B
site O
of O
the O
GABA B
( O
A O
) O
receptor O
( O
67 O
% O
inhibition O
at O
10 O
mu O
M O
) O
and O
augmented O
GABA B
evoked O
currents O
( O
EC O
( O
50 O
) O
= O
1 O
. O
6 O
mu O
M O
) O
. O

Thus O
, O
the O
unanticipated O
signal O
in O
the O
drug O
discrimination O
assay O
may O
have O
resulted O
from O
an O
interaction O
of O
the O
metabolite O
BMS B
- I
790318 I
with O
the O
TBOB B
site O
on O
the O
GABA B
( O
A O
) O
channel O
where O
it O
appears O
to O
behave O
as O
an O
allosteric O
potentiator O
of O
GABA B
evoked O
currents O
. O

The O
transport O
abilities O
were O
examined O
and O
the O
cellular O
accumulation O
of O
rhodamine B
- I
123 I
( O
R B
- I
123 I
) O
was O
also O
measured O
. O

The O
transport O
abilities O
were O
examined O
and O
the O
cellular O
accumulation O
of O
rhodamine B
- I
123 I
( O
R B
- I
123 I
) O
was O
also O
measured O
. O

In O
Caco O
- O
2 O
cells O
, O
emodin O
elevated O
the O
accumulation O
of O
R B
- I
123 I
and O
decreased O
the O
efflux O
ratio O
of O
R B
- I
123 I
, O
which O
indicates O
the O
inhibition O
of O
P O
- O
gp O
function O
. O

In O
Caco O
- O
2 O
cells O
, O
emodin O
elevated O
the O
accumulation O
of O
R B
- I
123 I
and O
decreased O
the O
efflux O
ratio O
of O
R B
- I
123 I
, O
which O
indicates O
the O
inhibition O
of O
P O
- O
gp O
function O
. O

The O
highly O
hydrophobic O
drug O
docetaxel B
( O
DTXL B
) O
was O
physically O
entrapped O
within O
the O
PBS B
/ O
PBDL B
copolyester O
core O
and O
the O
hydrophilic O
drug O
doxorubicin B
hydrochloride I
( O
DOX B
. I
HCl I
) O
was O
chemically O
conjugated O
to O
the O
reactive O
PHPMA B
copolymer O
shell O
via O
hydrazone B
bonding O
that O
allowed O
its O
pH O
- O
sensitive O
release O
. O

We O
studied O
the O
orientations O
and O
magnitudes O
of O
the O
electric O
dipole O
transition O
moments O
( O
EDTMs O
) O
of O
6 B
- I
methyl I
isoxanthopterin I
( O
6 B
- I
MI I
) O
, O
a O
fluorescent O
analogue O
of O
guanine B
that O
has O
been O
particularly O
useful O
in O
biological O
studies O
. O

Our O
results O
indicate O
that O
the O
two O
experimentally O
observed O
lowest O
- O
energy O
transitions O
, O
which O
occur O
at O
29 O
, O
687 O
cm O
( O
- O
1 O
) O
( O
337 O
nm O
) O
and O
34 O
, O
596 O
cm O
( O
- O
1 O
) O
( O
289 O
nm O
) O
, O
are O
each O
polarized O
within O
the O
plane O
of O
the O
6 B
- I
MI I
base O
. O

Based O
on O
these O
results O
, O
we O
constructed O
an O
exciton O
model O
to O
describe O
the O
absorption O
spectra O
of O
a O
6 B
- I
MI I
dinucleotide O
- O
substituted O
double O
- O
stranded O
DNA O
construct O
. O

The O
orientations O
and O
intensities O
of O
the O
low O
- O
energy O
electronic O
transitions O
of O
6 B
- I
MI I
reported O
here O
should O
be O
useful O
for O
studying O
local O
conformations O
of O
DNA O
and O
RNA O
in O
biologically O
important O
complexes O
. O

Sub O
- O
threshold O
doses O
of O
PGE B
( I
2 I
) I
( O
4 O
ng O
/ O
paw O
) O
or O
dopamine B
( O
0 O
. O
4 O
mu O
g O
/ O
paw O
) O
, O
that O
do O
not O
induce O
hyperalgesia O
by O
themselves O
, O
when O
injected O
just O
following O
alpha B
beta I
meATP I
or O
carrageenan O
in O
rats O
treated O
with O
dexamethasone B
induced O
hyperalgesia O
, O
which O
is O
prevented O
by O
A317491 B
or O
treatment O
with O
periganglionar O
( O
DRG O
- O
L5 O
) O
injections O
of O
ODN O
- O
antisense O
, O
against O
P2X3 O
receptor O
. O

Furthermore O
, O
because O
PKC O
epsilon O
translocation O
induces O
an O
increase O
of O
neuronal O
susceptibility O
to O
inflammatory O
mediators O
, O
this O
study O
demonstrates O
that O
alpha B
beta I
meATP I
in O
peripheral O
tissue O
increases O
the O
expression O
of O
PKC O
epsilon O
in O
cell O
membranes O
of O
DRG O
- O
L5 O
, O
and O
in O
contrast O
, O
the O
administration O
of O
PKC O
epsilon O
translocation O
inhibitor O
( O
1 O
mu O
g O
/ O
paw O
) O
in O
peripheral O
tissue O
45 O
min O
before O
alpha B
beta I
meATP I
, O
prevented O
the O
hyperalgesia O
induced O
by O
sub O
- O
threshold O
dose O
of O
PGE B
( I
2 I
) I
( O
4 O
ng O
/ O
paw O
) O
. O

Furthermore O
, O
because O
PKC O
epsilon O
translocation O
induces O
an O
increase O
of O
neuronal O
susceptibility O
to O
inflammatory O
mediators O
, O
this O
study O
demonstrates O
that O
alpha B
beta I
meATP I
in O
peripheral O
tissue O
increases O
the O
expression O
of O
PKC O
epsilon O
in O
cell O
membranes O
of O
DRG O
- O
L5 O
, O
and O
in O
contrast O
, O
the O
administration O
of O
PKC O
epsilon O
translocation O
inhibitor O
( O
1 O
mu O
g O
/ O
paw O
) O
in O
peripheral O
tissue O
45 O
min O
before O
alpha B
beta I
meATP I
, O
prevented O
the O
hyperalgesia O
induced O
by O
sub O
- O
threshold O
dose O
of O
PGE B
( I
2 I
) I
( O
4 O
ng O
/ O
paw O
) O
. O

IR O
and O
NMR O
spectroscopy O
were O
used O
to O
determine O
the O
silanol B
content O
in O
the O
most O
common O
mesoporous O
ordered O
silicas B
: O
MCM B
- I
41 I
, O
MCM B
- I
48 I
, O
SBA B
- I
15 I
and O
SBA B
- I
16 I
. O

IR O
and O
NMR O
spectroscopy O
were O
used O
to O
determine O
the O
silanol B
content O
in O
the O
most O
common O
mesoporous O
ordered O
silicas B
: O
MCM B
- I
41 I
, O
MCM B
- I
48 I
, O
SBA B
- I
15 I
and O
SBA B
- I
16 I
. O

IR O
and O
NMR O
spectroscopy O
were O
used O
to O
determine O
the O
silanol B
content O
in O
the O
most O
common O
mesoporous O
ordered O
silicas B
: O
MCM B
- I
41 I
, O
MCM B
- I
48 I
, O
SBA B
- I
15 I
and O
SBA B
- I
16 I
. O

IR O
and O
NMR O
spectroscopy O
were O
used O
to O
determine O
the O
silanol B
content O
in O
the O
most O
common O
mesoporous O
ordered O
silicas B
: O
MCM B
- I
41 I
, O
MCM B
- I
48 I
, O
SBA B
- I
15 I
and O
SBA B
- I
16 I
. O

In O
addition O
, O
a O
spray O
dried O
MCM B
- I
41 I
and O
an O
ethene B
bridged O
PMO B
are O
investigated O
. O

Effect O
of O
structural O
defects O
and O
chemical O
functionalisation O
on O
the O
intrinsic O
mechanical O
properties O
of O
graphene B
. O

Mangiferin B
is O
a O
plant O
natural O
polyphenol B
of O
C B
- I
glycosylxanthone I
structure O
and O
various O
pharmacological O
activities O
. O

Novel O
block O
copolymers O
comprising O
poly B
( I
ethylene I
glycol I
) I
( O
PEG B
) O
and O
an O
oligo B
( I
tyrosine I
) I
block O
were O
synthesized O
in O
different O
compositions O
by O
N B
- I
carboxyanhydride I
( O
NCA B
) O
polymerization O
. O

2 B
, I
5 I
- I
Dihydroxy I
- I
4 I
- I
methoxybenzophenone I
: O
a O
novel O
major O
in O
vitro O
metabolite O
of O
benzophenone B
- I
3 I
formed O
by O
rat O
and O
human O
liver O
microsomes O
. O

1 O
. O
When O
benzophenone B
- I
3 I
( O
2 B
- I
hydroxy I
- I
4 I
- I
methoxybenzophenone I
; O
BP B
- I
3 I
) O
was O
incubated O
with O
liver O
microsomes O
of O
untreated O
rats O
in O
the O
presence O
of O
NADPH B
, O
the O
5 O
- O
hydroxylated O
metabolite O
, O
2 B
, I
5 I
- I
dihydroxy I
- I
4 I
- I
methoxybenzophenone I
( O
5 B
- I
OH I
- I
BP I
- I
3 I
) O
, O
was O
formed O
as O
a O
major O
novel O
metabolite O
of O
BP B
- I
3 I
. O

1 O
. O
When O
benzophenone B
- I
3 I
( O
2 B
- I
hydroxy I
- I
4 I
- I
methoxybenzophenone I
; O
BP B
- I
3 I
) O
was O
incubated O
with O
liver O
microsomes O
of O
untreated O
rats O
in O
the O
presence O
of O
NADPH B
, O
the O
5 O
- O
hydroxylated O
metabolite O
, O
2 B
, I
5 I
- I
dihydroxy I
- I
4 I
- I
methoxybenzophenone I
( O
5 B
- I
OH I
- I
BP I
- I
3 I
) O
, O
was O
formed O
as O
a O
major O
novel O
metabolite O
of O
BP B
- I
3 I
. O

1 O
. O
When O
benzophenone B
- I
3 I
( O
2 B
- I
hydroxy I
- I
4 I
- I
methoxybenzophenone I
; O
BP B
- I
3 I
) O
was O
incubated O
with O
liver O
microsomes O
of O
untreated O
rats O
in O
the O
presence O
of O
NADPH B
, O
the O
5 O
- O
hydroxylated O
metabolite O
, O
2 B
, I
5 I
- I
dihydroxy I
- I
4 I
- I
methoxybenzophenone I
( O
5 B
- I
OH I
- I
BP I
- I
3 I
) O
, O
was O
formed O
as O
a O
major O
novel O
metabolite O
of O
BP B
- I
3 I
. O

The O
4 O
- O
desmethylated O
metabolite O
, O
2 B
, I
4 I
- I
dihydroxybenzophenon I
( O
2 B
, I
4 I
- I
diOH I
- I
BP I
) O
, O
previously O
reported O
as O
the O
major O
in O
vivo O
metabolite O
of O
BP B
- I
3 I
, O
was O
also O
detected O
. O

The O
oxidase O
activity O
affording O
2 B
, I
4 I
- I
diOH I
- I
BP I
was O
inhibited O
by O
SKF B
525 I
- I
A I
, O
ketoconazole B
and O
alpha B
- I
naphthoflavone I
, O
and O
partly O
by O
sulfaphenazole B
. O

3 O
. O
The O
oxidase O
activity O
affording O
5 B
- I
OH I
- I
BP I
- I
3 I
was O
enhanced O
in O
liver O
microsomes O
of O
dexamethasone B
- O
, O
phenobarbital B
- O
and O
3 B
- I
methylcholanthrene I
- O
treated O
rats O
. O

The O
activity O
affording O
2 B
, I
4 I
- I
diOH I
- I
BP I
was O
enhanced O
in O
liver O
microsomes O
of O
3 B
- I
methylcholanthrene I
- O
and O
phenobarbital B
- O
treated O
rats O
. O

4 O
. O
When O
examined O
recombinant O
rat O
cytochrome O
P450 O
isoforms O
catalyzing O
the O
metabolism O
of O
BP B
- I
3 I
, O
5 O
- O
hydroxylation O
was O
catalyzed O
by O
P450 O
3A2 O
, O
1A1 O
, O
2B1 O
, O
2C6 O
and O
2D1 O
, O
while O
4 O
- O
desmethylation O
was O
catalyzed O
by O
P450 O
2C6 O
and O
1A1 O
. O

We O
observed O
that O
when O
ATDC5 O
cells O
were O
cultured O
on O
functional O
peptide O
nanofibers O
, O
they O
rapidly O
aggregated O
in O
insulin O
- O
free O
medium O
and O
formed O
cartilage O
- O
like O
nodules O
and O
deposited O
sulfated O
glycosaminoglycans O
shown O
by O
Safranin B
- I
O I
staining O
. O

The O
presence O
of O
D B
- I
fagomine I
in O
the O
human O
diet O
from O
buckwheat O
- O
based O
foodstuffs O
. O

Buckwheat O
( O
Fagopyrum O
esculentum O
Moench O
) O
groats O
contain O
the O
iminosugar O
D B
- I
fagomine I
as O
a O
minor O
component O
that O
might O
contribute O
to O
the O
alleged O
health O
benefits O
of O
this O
pseudo O
- O
cereal O
. O

This O
study O
presents O
analysis O
of O
D B
- I
fagomine I
in O
buckwheat O
- O
based O
foodstuffs O
by O
liquid O
chromatography O
coupled O
to O
mass O
spectrometry O
and O
an O
estimation O
of O
its O
presence O
in O
the O
human O
diet O
based O
on O
a O
published O
population O
- O
based O
cross O
- O
sectional O
nutrition O
survey O
. O

D B
- I
fagomine I
is O
present O
in O
common O
buckwheat O
- O
based O
foodstuffs O
in O
amounts O
ranging O
from O
1 O
to O
25 O
mg O
/ O
kg O
or O
mg O
/ O
L O
, O
it O
is O
stable O
during O
boiling O
, O
baking O
, O
frying O
and O
fermentation O
, O
and O
it O
is O
biosynthesised O
upon O
sprouting O
. O

The O
estimated O
total O
intake O
of O
D B
- I
fagomine I
resulting O
from O
a O
diet O
that O
includes O
such O
foodstuffs O
would O
be O
between O
3 O
and O
17 O
mg O
per O
day O
( O
mean O
for O
both O
genders O
; O
range O
from O
P5 O
to O
P95 O
) O
. O

A O
diet O
rich O
in O
buckwheat O
products O
would O
provide O
a O
daily O
amount O
of O
D B
- I
fagomine I
that O
may O
in O
part O
explain O
the O
beneficial O
properties O
traditionally O
attributed O
to O
buckwheat O
consumption O
. O

A O
simple O
multiresidue O
analytical O
method O
is O
developed O
for O
the O
simultaneous O
determination O
of O
carbendazim B
( O
CB O
) O
, O
thiabendazole B
( O
TB O
) O
, O
and O
6 B
- I
benzyl I
aminopurine I
( O
6 B
- I
BA I
) O
in O
bean O
sprouts O
. O

Except O
for O
6 B
- I
BA I
, O
the O
rest O
of O
the O
analytes O
had O
values O
lower O
than O
their O
LOQs O
. O

In O
sum O
, O
carbendazim B
, O
thiabendazole B
, O
and O
6 B
- I
BA I
were O
extracted O
in O
a O
single O
step O
, O
and O
no O
steps O
for O
clean O
- O
up O
or O
concentration O
of O
the O
extracts O
were O
needed O
. O

We O
manipulated O
the O
baseline O
conditions O
of O
this O
task O
and O
also O
systemically O
pre O
- O
administered O
d B
- I
amphetamine I
, O
quinpirole B
, O
dizocilpine B
( O
MK B
- I
801 I
) O
or O
ketanserin B
. O

We O
manipulated O
the O
baseline O
conditions O
of O
this O
task O
and O
also O
systemically O
pre O
- O
administered O
d B
- I
amphetamine I
, O
quinpirole B
, O
dizocilpine B
( O
MK B
- I
801 I
) O
or O
ketanserin B
. O

Only O
D B
- I
amphetamine I
induced O
a O
dose O
- O
dependent O
amelioration O
of O
the O
increased O
perseverative O
responses O
in O
the O
CPF B
group O
. O

GC O
- O
olfactometry O
analysis O
of O
the O
hydrolysates O
of O
ripe O
' O
Hayward O
' O
and O
' O
Hort16A O
' O
revealed O
the O
presence O
of O
2 B
- I
phenylethanol I
, O
beta B
- I
damascenone I
, O
vanillin B
and O
2 B
, I
5 I
- I
dimethyl I
- I
4 I
- I
hydroxy I
- I
3 I
( I
2H I
) I
- I
furanone I
( O
DMHF B
) O
. O

GC O
- O
olfactometry O
analysis O
of O
the O
hydrolysates O
of O
ripe O
' O
Hayward O
' O
and O
' O
Hort16A O
' O
revealed O
the O
presence O
of O
2 B
- I
phenylethanol I
, O
beta B
- I
damascenone I
, O
vanillin B
and O
2 B
, I
5 I
- I
dimethyl I
- I
4 I
- I
hydroxy I
- I
3 I
( I
2H I
) I
- I
furanone I
( O
DMHF B
) O
. O

Proximate O
composition O
, O
fatty B
acid I
profile O
, O
cholesterol B
, O
alpha B
- I
tocoferol I
content O
and O
essential O
( O
K B
, O
Na B
, O
Cl B
, O
S B
, O
Mg B
, O
Ca B
, O
Zn B
, O
Cu B
, O
Fe B
, O
Mn B
, O
and O
Se B
) O
and O
contaminant O
element O
( O
Hg B
/ O
MeHg B
, O
Cd B
, O
Pb B
, O
and O
As B
) O
levels O
in O
silver B
scabbardfish O
( O
Lepidopus O
caudatus O
) O
, O
hake O
( O
Merluccius O
merluccius O
) O
, O
and O
ray O
( O
Raja O
spp O
. O
) O
were O
investigated O
. O

Polyunsaturated B
fatty I
acids I
( O
PUFA B
) O
were O
the O
dominant O
group O
of O
the O
fatty B
acids I
, O
being O
80 O
% O
of O
the O
n O
- O
3 O
family O
. O

The O
discovery O
and O
structure O
- O
activity O
relationships O
of O
4 B
- I
azaindole I
cores O
. O

A O
series O
of O
4 B
- I
azaindole I
oxoacetic I
acid I
piperazine I
benzamides I
was O
synthesized O
and O
evaluated O
in O
an O
effort O
to O
identify O
an O
oral O
HIV O
- O
1 O
attachment O
inhibitor O
with O
the O
potential O
to O
improve O
upon O
the O
pre O
- O
clinical O
profile O
of O
BMS B
- I
378806 I
( O
7 O
) O
, O
an O
initial O
clinical O
compound O
. O

Modifications O
at O
the O
7 O
- O
position O
of O
the O
4 B
- I
azaindole I
core O
modulated O
potency O
significantly O
and O
SAR O
showed O
that O
certain O
compounds O
with O
a O
5 O
- O
membered O
ring O
heteroaryl O
group O
at O
that O
position O
were O
the O
most O
potent O
. O

( B
- I
) I
- I
6 I
- I
( I
7 I
- I
Methoxy I
- I
2 I
- I
( I
trifluoromethyl I
) I
pyrazolo I
[ I
1 I
, I
5 I
- I
a I
] I
pyridin I
- I
4 I
- I
yl I
) I
- I
5 I
- I
methyl I
- I
4 I
, I
5 I
- I
dihydropyridazin I
- I
3 I
( I
2H I
) I
- I
one I
( O
KCA B
- I
1490 I
) O
exhibits O
moderate O
dual O
PDE3 O
/ O
4 O
- O
inhibitory O
activity O
and O
promises O
as O
a O
combined O
bronchodilatory O
/ O
anti O
- O
inflammatory O
agent O
. O

We O
also O
found O
that O
QT O
( O
50 O
mu O
M O
) O
increased O
the O
expressions O
of O
AR O
and O
ER O
- O
alpha O
in O
the O
presence O
of O
a O
sub O
- O
threshold O
level O
of O
cyclic B
- I
AMP I
at O
1h O
culture O
period O
to O
the O
levels O
seen O
with O
maximal O
stimulation O
of O
cyclic B
- I
AMP I
. O

We O
also O
found O
that O
QT O
( O
50 O
mu O
M O
) O
increased O
the O
expressions O
of O
AR O
and O
ER O
- O
alpha O
in O
the O
presence O
of O
a O
sub O
- O
threshold O
level O
of O
cyclic B
- I
AMP I
at O
1h O
culture O
period O
to O
the O
levels O
seen O
with O
maximal O
stimulation O
of O
cyclic B
- I
AMP I
. O

Furthermore O
, O
the O
expressions O
of O
tested O
genes O
were O
unaffected O
by O
cyclic B
- I
AMP I
at O
6h O
when O
the O
stimulatory O
effects O
of O
ATZ B
on O
tested O
genes O
were O
sustained O
. O

These O
findings O
suggest O
that O
ATZ B
may O
stimulate O
the O
expression O
of O
tested O
steroidogenesis O
genes O
in O
ILCs O
via O
a O
mechanism O
independent O
of O
cyclic B
- I
AMP I
which O
was O
partially O
antagonize O
by O
QT O
. O

Cell O
- O
culture O
studies O
showed O
that O
the O
material O
was O
more O
biocompatible O
with O
respect O
to O
the O
control O
Brij B
- I
700 I
( O
R O
) O
. O

The O
aim O
of O
this O
work O
is O
to O
evaluate O
vitamins B
B I
antimutagenic O
effect O
against O
alkylatings O
methyl B
- I
N I
- I
nitro I
- I
N I
- I
nitrosoguanidine I
( O
MNNG B
) O
, O
ethyl B
- I
N I
- I
nitro I
- I
N I
' I
- I
nitrosoguanidine I
( O
ENNG B
) O
, O
frameshift O
mutagens O
2 B
- I
aminoanthracene I
( O
2AA B
) O
and O
2 B
- I
acetyl I
- I
amino I
- I
fluorene I
( O
2AF B
) O
and O
ROS O
- O
generating O
antibiotics O
norfloxacin B
( O
NOR B
) O
and O
nalidixic B
acid I
( O
NLX B
) O
, O
using O

Cardioprotective O
effect O
of O
salvianolic B
acid I
B I
against O
arsenic B
trioxide I
- O
induced O
injury O
in O
cardiac O
H9c2 O
cells O
via O
the O
PI3K O
/ O
Akt O
signal O
pathway O
. O

One O
of O
the O
most O
abundant O
ingredients O
of O
S O
. O
miltiorrhiza O
is O
salvianolic B
acid I
B I
( O
Sal B
B I
) O
. O

Two O
series O
of O
chalcone B
based O
sulfone B
and O
bisulfone B
derivatives O
were O
synthesized O
using O
chalcone B
, O
thiophenol B
and O
sodium B
metal O
at O
room O
temperature O
, O
followed O
by O
oxidation O
of O
chalcone B
sulfides I
with O
m B
- I
CPBA I
at O
0 O
degrees O
C O
in O
a O
novel O
method O
. O

Amphotericin B
- I
B I
and O
Nystatin B
. O

Especially O
, O
8i O
( O
Ar O
= O
4 B
- I
isoquinolyl I
) O
possessed O
an O
MIC O
of O
0 O
. O
064 O
mu O
g O
/ O
mL O
against O
constitutively O
MLS O
( O
B O
) O
- O
resistant O
Streptococcus O
pneumoniae O
, O
and O
MICs O
of O
0 O
. O
032 O
- O
0 O
. O
064 O
mu O
g O
/ O
mL O
against O
methicillin B
- O
resistant O
Staphylococcus O
aureus O
and O
methicillin B
- O
resistant O
Staphylococcus O
hominis O
. O

N B
- I
Acylhydrazone I
moiety O
is O
a O
repeated O
functional O
group O
present O
in O
several O
prototypes O
and O
drug O
candidates O
for O
these O
neglected O
diseases O
. O

The O
protein O
amide O
( B
1 I
) I
H I
( I
N I
) I
chemical O
shift O
temperature O
coefficient O
reflects O
thermal O
expansion O
of O
the O
N B
- I
H I
. O
. O
. O
O B
= I
C I
hydrogen B
bond O
. O

The O
protein O
amide O
( B
1 I
) I
H I
( I
N I
) I
chemical O
shift O
temperature O
coefficient O
reflects O
thermal O
expansion O
of O
the O
N B
- I
H I
. O
. O
. O
O B
= I
C I
hydrogen B
bond O
. O

Effects O
of O
single O
or O
repeated O
silymarin O
administration O
on O
pharmacokinetics O
of O
risperidone B
and O
its O
major O
metabolite O
, O
9 B
- I
hydroxyrisperidone I
in O
rats O
. O

2 O
. O
The O
objective O
of O
this O
article O
is O
to O
examine O
the O
effects O
of O
single O
and O
repeated O
administrations O
of O
silymarin O
on O
pharmacokinetics O
of O
a O
P O
- O
gp O
substrate O
, O
risperidone B
, O
and O
its O
major O
metabolite O
, O
9 B
- I
hydroxyrisperidone I
, O
in O
rats O
. O

3 O
. O
To O
determine O
the O
plasma O
levels O
of O
risperidone B
and O
9 B
- I
hydroxyrisperidone I
in O
rats O
, O
a O
HPLC O
method O
was O
developed O
using O
a O
liquid O
- O
liquid O
acid O
back O
extraction O
. O

When O
risperidone B
( O
6 O
mg O
/ O
kg O
) O
was O
co O
- O
administered O
with O
silymarin O
( O
40 O
mg O
/ O
kg O
) O
to O
rats O
orally O
, O
the O
C O
( O
max O
) O
of O
9 B
- I
hydroxyrisperidone I
was O
significantly O
increased O
to1 O
. O
3 O
- O
fold O
( O
p O
< O
0 O
. O
05 O
) O
, O
while O
the O
other O
pharmacokinetic O
parameters O
did O
not O
show O
any O
significant O
differences O
. O

Expanding O
the O
experiment O
where O
rats O
were O
repeatedly O
administered O
with O
silymarin O
for O
5 O
days O
prior O
to O
giving O
risperidone B
, O
the O
C O
( O
max O
) O
of O
risperidone B
and O
9 B
- I
hydroxyrisperidone I
were O
significantly O
increased O
to O
2 O
. O
4 O
- O
fold O
( O
p O
< O
0 O
. O
001 O
) O
and O
1 O
. O
7 O
- O
fold O
( O
p O
< O
0 O
. O
001 O
) O
, O
respectively O
, O
and O
the O
AUC O
( O
0 O
- O
t O
) O
, O
as O
well O
to O
1 O
. O
7 O
- O
fold O
( O
p O
< O
0 O
. O
05 O
) O
and O
2 O
. O
1 O
- O
fold O
( O
p O
< O
0 O
. O
01 O
) O
, O
respectively O
. O

4 O
. O
The O
repeated O
exposures O
of O
silymarin O
, O
compared O
to O
single O
administration O
of O
silymarin O
, O
increased O
oral O
bioavailability O
and O
affected O
the O
pharmacokinetics O
of O
risperidone B
and O
9 B
- I
hydroxyrisperidone I
, O
by O
inhibiting O
P O
- O
gp O
. O

Diameter O
variations O
are O
associated O
with O
a O
large O
number O
of O
stacking O
faults O
and O
crystallographic O
phase O
changes O
( O
wurtzite B
/ O
zinc B
- I
blende I
) O
; O
also O
the O
axial O
distance O
between O
oscillations O
depends O
on O
the O
indium B
precursor O
flow O
used O
during O
the O
run O
. O

As O
a O
result O
, O
Fe B
( I
3 I
) I
O I
( I
4 I
) I
@ O
Ag B
/ O
SiO B
( I
2 I
) I
/ O
Au B
microspheres O
have O
the O
best O
enhancement O
effect O
in O
the O
Raman O
active O
research O
by O
using O
Rhodamine B
- I
b I
( O
RdB B
) O
as O
a O
probe O
molecule O
. O

Among O
the O
principle O
reaction O
intermediates O
identified O
, O
tri O
- O
and O
tetra O
- O
hydroxylated O
derivatives O
of O
DMP B
, O
as O
well O
as O
hydroxylated B
monomethyl I
phthalates I
and O
hydroxylated B
phthalic I
acid I
were O
reported O
for O
the O
first O
time O
in O
this O
study O
. O

Among O
the O
principle O
reaction O
intermediates O
identified O
, O
tri O
- O
and O
tetra O
- O
hydroxylated O
derivatives O
of O
DMP B
, O
as O
well O
as O
hydroxylated B
monomethyl I
phthalates I
and O
hydroxylated B
phthalic I
acid I
were O
reported O
for O
the O
first O
time O
in O
this O
study O
. O

Total O
synthesis O
of O
the O
polyhydroxy B
caprolactam I
amide I
natural O
product O
, O
bengamide B
E I
, O
is O
accomplished O
starting O
from O
tartaric B
acid I
. O

Upon O
UV O
irradiation O
, O
trans B
- I
ACA I
is O
converted O
to O
cis B
- I
ACA I
, O
and O
in O
turn O
, O
the O
solution O
is O
converted O
to O
its O
EHT O
mode O
( O
i O
. O
e O
. O
, O
it O
loses O
its O
viscoelasticity O
and O
DR O
) O
but O
it O
now O
has O
a O
heat O
- O
transfer O
capability O
comparable O
to O
that O
of O
water O
. O

Upon O
UV O
irradiation O
, O
trans B
- I
ACA I
is O
converted O
to O
cis B
- I
ACA I
, O
and O
in O
turn O
, O
the O
solution O
is O
converted O
to O
its O
EHT O
mode O
( O
i O
. O
e O
. O
, O
it O
loses O
its O
viscoelasticity O
and O
DR O
) O
but O
it O
now O
has O
a O
heat O
- O
transfer O
capability O
comparable O
to O
that O
of O
water O
. O

In O
the O
DR O
mode O
, O
the O
OHAC B
/ O
trans B
- I
ACA I
molecules O
assemble O
into O
long O
threadlike O
micelles O
that O
impart O
viscoelasticity O
and O
DR O
capability O
to O
the O
fluid O
. O

Conversely O
, O
in O
the O
EHT O
mode O
the O
mixture O
of O
OHAC B
and O
cis B
- I
ACA I
forms O
much O
shorter O
cylindrical O
micelles O
that O
contribute O
to O
negligible O
viscoelasticity O
and O
effective O
heat O
transfer O
. O

These O
nanostructural O
changes O
are O
confirmed O
by O
cryo O
- O
transmission O
electron O
microscopy O
( O
cryo O
- O
TEM O
) O
, O
and O
the O
photoisomerization O
of O
trans B
- I
ACA I
and O
cis B
- I
ACA I
is O
verified O
by O
( B
1 I
) I
H I
NMR O
. O

These O
nanostructural O
changes O
are O
confirmed O
by O
cryo O
- O
transmission O
electron O
microscopy O
( O
cryo O
- O
TEM O
) O
, O
and O
the O
photoisomerization O
of O
trans B
- I
ACA I
and O
cis B
- I
ACA I
is O
verified O
by O
( B
1 I
) I
H I
NMR O
. O

However O
, O
only O
one O
of O
them O
, O
CX B
- I
4945 I
, O
has O
recently O
completed O
Phase O
I O
clinical O
trial O
as O
potential O
anticancer O
drug O
. O

LOE O
prevented O
tert B
- I
butyl I
hydroperoxide I
( O
t B
- I
BHP I
) O
- O
induced O
oxidative O
damage O
in O
HepG2 O
cells O
. O

Along O
with O
its O
high O
antioxidant O
potency O
in O
vitro O
, O
our O
animal O
study O
confirmed O
that O
pretreatment O
with O
LOE O
( O
500 O
or O
2000 O
mg O
/ O
kg O
) O
for O
7 O
days O
prior O
to O
a O
single O
dose O
of O
t B
- I
BHP I
( O
i O
. O
p O
. O
: O
0 O
. O
5 O
mmol O
/ O
kg O
) O
significantly O
lowered O
the O
serum O
levels O
of O
alanine B
and O
aspartate B
aminotransferases O
. O

The O
histopathological O
examinations O
of O
rat O
livers O
showed O
that O
LOE O
significantly O
reduced O
the O
incidence O
of O
liver O
lesions O
induced O
by O
t B
- I
BHP I
. O

We O
further O
showed O
that O
central O
administration O
of O
an O
ER O
alpha O
agonist O
, O
propyl B
pyrazole I
triol I
, O
acutely O
increases O
physical O
interaction O
between O
SRC1 O
and O
ER O
alpha O
in O
the O
hypothalamus O
. O

Adsorption O
of O
phenanthrene B
, O
2 B
- I
naphthol I
, O
and O
1 B
- I
naphthylamine I
to O
colloidal O
oxidized O
multiwalled O
carbon B
nanotubes O
: O
effects O
of O
humic O
acid O
and O
surfactant O
modification O
. O

Adsorption O
of O
phenanthrene B
, O
2 B
- I
naphthol I
, O
and O
1 B
- I
naphthylamine I
to O
colloidal O
oxidized O
multiwalled O
carbon B
nanotubes O
: O
effects O
of O
humic O
acid O
and O
surfactant O
modification O
. O

In O
the O
present O
study O
, O
the O
authors O
examined O
the O
adsorption O
of O
phenanthrene B
, O
2 B
- I
naphthol I
, O
and O
1 B
- I
naphthylamine I
to O
three O
colloidal O
CNTs O
, O
including O
a O
stable O
suspension O
of O
oxidized O
multiwalled O
carbon B
nanotubes O
( O
O O
- O
MWNT O
) O
, O
a O
humic O
acid O
( O
HA O
) O
- O
modified O
colloidal O
O O
- O
MWNT O
, O
and O
a O
sodium B
dodecyl I
sulfate I
( O
SDS B
) O
- O
modified O
colloidal O
O O
- O
MWNT O
. O

In O
the O
present O
study O
, O
the O
authors O
examined O
the O
adsorption O
of O
phenanthrene B
, O
2 B
- I
naphthol I
, O
and O
1 B
- I
naphthylamine I
to O
three O
colloidal O
CNTs O
, O
including O
a O
stable O
suspension O
of O
oxidized O
multiwalled O
carbon B
nanotubes O
( O
O O
- O
MWNT O
) O
, O
a O
humic O
acid O
( O
HA O
) O
- O
modified O
colloidal O
O O
- O
MWNT O
, O
and O
a O
sodium B
dodecyl I
sulfate I
( O
SDS B
) O
- O
modified O
colloidal O
O O
- O
MWNT O
. O

In O
the O
present O
study O
, O
the O
authors O
examined O
the O
adsorption O
of O
phenanthrene B
, O
2 B
- I
naphthol I
, O
and O
1 B
- I
naphthylamine I
to O
three O
colloidal O
CNTs O
, O
including O
a O
stable O
suspension O
of O
oxidized O
multiwalled O
carbon B
nanotubes O
( O
O O
- O
MWNT O
) O
, O
a O
humic O
acid O
( O
HA O
) O
- O
modified O
colloidal O
O O
- O
MWNT O
, O
and O
a O
sodium B
dodecyl I
sulfate I
( O
SDS B
) O
- O
modified O
colloidal O
O O
- O
MWNT O
. O

Reduced B
graphene I
oxide I
nanoribbon O
networks O
: O
a O
novel O
approach O
towards O
scalable O
fabrication O
of O
transparent O
conductive O
films O
. O

An O
innovative O
approach O
is O
developed O
for O
the O
high O
- O
throughput O
, O
large O
- O
area O
, O
and O
low O
- O
cost O
fabrication O
of O
reduced B
graphene I
oxide I
( O
RGO B
) O
nanoribbon O
networks O
by O
using O
electrospun O
polymer O
- O
based O
nanowires O
as O
the O
etching O
mask O
. O

Functionalized O
alkynyl B
polyvinyl I
alcohol I
magnetic O
microspheres O
( O
PVA B
MMs O
) O
were O
developed O
for O
the O
specific O
enrichment O
of O
sialic B
acid I
- O
rich O
glycoproteins O
by O
click O
chemistry O
. O

3 B
- I
Hydroxykynurenine I
: O
an O
intriguing O
molecule O
exerting O
dual O
actions O
in O
the O
Central O
Nervous O
System O
. O

3 B
- I
Hydroxykynurenine I
has O
been O
largely O
described O
as O
one O
of O
these O
toxic O
metabolites O
capable O
of O
inducing O
oxidative O
damage O
and O
cell O
death O
; O
consequently O
, O
this O
metabolite O
has O
been O
hypothesized O
to O
play O
a O
pivotal O
role O
in O
different O
neurological O
and O
psychiatric O
disorders O
. O

Supporting O
evidence O
has O
shown O
altered O
3 B
- I
hydroxykynurenine I
levels O
in O
samples O
of O
patients O
from O
several O
disorders O
. O

Through O
this O
collected O
evidence O
, O
we O
provide O
an O
integrative O
hypothesis O
on O
how O
3 B
- I
hydroxykynurenine I
is O
exerting O
its O
dual O
actions O
in O
the O
Central O
Nervous O
System O
and O
what O
will O
be O
the O
course O
of O
investigations O
in O
this O
field O
for O
the O
next O
years O
. O

N B
- I
formyl I
peptide O
receptors O
( O
FPRs O
) O
are O
G O
protein O
- O
coupled O
receptors O
( O
GPCRs O
) O
that O
play O
critical O
roles O
in O
inflammatory O
reactions O
, O
and O
FPR O
- O
specific O
interactions O
can O
possibly O
be O
used O
to O
facilitate O
the O
resolution O
of O
pathological O
inflammatory O
reactions O
. O

This O
study O
investigated O
cytotoxicity O
, O
endocrine O
disruption O
, O
effects O
mediated O
via O
AhR O
, O
lipid O
peroxidation O
and O
effects O
on O
expression O
of O
enzymes O
of O
xenobiotic O
metabolism O
caused O
by O
di B
- I
( I
2 I
- I
ethy I
hexyl I
) I
phthalate I
( O
DEHP B
) O
, O
diethyl B
phthalate I
( O
DEP B
) O
, O
dibutyl B
phthalate I
( O
DBP B
) O
and O
benzyl B
butyl I
phthalate I
( O
BBP B
) O
in O
developing O
fish O
embryos O
. O

Six O
biodegradable O
polymers O
have O
been O
investigated O
as O
drug O
carriers O
using O
molecular O
simulations O
: O
l B
- I
polylactide I
, O
d B
- I
polylactide I
, O
chitosan O
, O
polyglycolic B
acid I
, O
polyethylene B
glycol I
and O
cellulose O
. O

Six O
biodegradable O
polymers O
have O
been O
investigated O
as O
drug O
carriers O
using O
molecular O
simulations O
: O
l B
- I
polylactide I
, O
d B
- I
polylactide I
, O
chitosan O
, O
polyglycolic B
acid I
, O
polyethylene B
glycol I
and O
cellulose O
. O

Hepatic O
metabolism O
of O
sulfur B
amino I
acids I
in O
db O
/ O
db O
mice O
. O

To O
determine O
the O
effect O
of O
type O
- O
2 O
diabetes O
and O
obesity O
on O
the O
hepatic O
metabolism O
of O
sulfur B
amino I
acids I
, O
hepatic O
sulfur B
amino I
acid I
metabolism O
was O
determined O
in O
db O
/ O
db O
mice O
. O

To O
determine O
the O
effect O
of O
type O
- O
2 O
diabetes O
and O
obesity O
on O
the O
hepatic O
metabolism O
of O
sulfur B
amino I
acids I
, O
hepatic O
sulfur B
amino I
acid I
metabolism O
was O
determined O
in O
db O
/ O
db O
mice O
. O

The O
decrease O
in O
hepatic O
methionine B
was O
reflected O
by O
decreased O
sulfur B
- O
containing O
methionine B
metabolites O
, O
including O
S B
- I
adenosylmethionine I
, O
homocysteine B
, O
cysteine B
, O
and O
hypotaurine B
in O
liver O
and O
plasma O
. O

In O
contrast O
, O
S B
- I
adenosylhomocysteine I
, O
putrescine B
, O
and O
spermidine B
were O
increased O
in O
db O
/ O
db O
mice O
. O

The O
hepatic O
level O
and O
activity O
of O
methionine B
adenosyltransferase O
I O
/ O
III O
, O
an O
S B
- I
adenosylmethionine I
synthesizing O
enzyme O
, O
were O
significantly O
increased O
. O

These O
results O
suggest O
that O
increased O
polyamine B
synthesis O
, O
in O
conjunction O
with O
decreased O
hepatic O
methionine B
levels O
, O
is O
partly O
responsible O
for O
the O
reduction O
in O
hepatic O
S B
- I
adenosylmethionine I
. O

Glutathione B
in O
liver O
and O
plasma O
did O
not O
change O
despite O
decreased O
gamma B
- I
glutamylcysteine I
ligase O
activity O
. O

Tetrahydropapaveroli B
( O
THP B
) O
, O
which O
is O
an O
endogenous O
neurotoxin O
, O
has O
been O
suspected O
to O
be O
associated O
with O
dopaminergic O
neurotoxicity O
of O
l B
- I
DOPA I
. O

Ligand O
- O
exchange O
reactions O
of O
copper B
( I
I I
) I
precursors O
( O
[ B
Cu I
( I
CH I
( I
3 I
) I
CN I
) I
( I
4 I
) I
] I
BF I
( I
4 I
) I
, O
CuCl B
) O
with O
a O
panel O
of O
bis B
( I
azolyl I
) I
borates I
or O
poly B
( I
pyrazolyl I
) I
methanes I
and O
a O
tertiary B
monodentate I
phosphine I
( O
PTA B
= O
1 B
, I
3 I
, I
5 I
- I
triaza I
- I
7 I
- I
phosphaadamantane I
, O
PCN B
= O
tris B
( I
cyanoethyl I
) I
phosphine I
) O
produced O
two O
series O
of O
heteroleptic O
, O

We O
present O
an O
ab O
initio O
molecular O
dynamics O
study O
of O
proton O
dynamics O
at O
sulfonic B
- I
acid I
terminated O
surface O
groups O
. O

While O
AT1R O
signaling O
suppresses O
the O
influence O
of O
corticotropin O
on O
the O
generation O
of O
cyclic B
adenosine I
monophosphate I
, O
the O
expression O
of O
the O
AT1R O
and O
its O
associated O
enzyme O
activities O
are O
under O
the O
control O
of O
glucocorticoids O
. O

Isoliquiritigenin B
showed O
strong O
inhibitory O
effects O
towards O
multiple O
UDP B
- O
glucuronosyltransfer O
( O
UGT O
) O
isoform O
- O
catalyzed O
4 B
- I
methylumbelliferone I
( O
4 B
- I
MU I
) O
glucuronidation O
. O

Isoliquiritigenin B
showed O
strong O
inhibitory O
effects O
towards O
multiple O
UDP B
- O
glucuronosyltransfer O
( O
UGT O
) O
isoform O
- O
catalyzed O
4 B
- I
methylumbelliferone I
( O
4 B
- I
MU I
) O
glucuronidation O
. O

The O
recombinant O
UGT O
- O
catalyzed O
4 B
- I
methylumbelliferone I
( O
4 B
- I
MU I
) O
glucuronidation O
was O
used O
as O
probe O
reactions O
. O

The O
recombinant O
UGT O
- O
catalyzed O
4 B
- I
methylumbelliferone I
( O
4 B
- I
MU I
) O
glucuronidation O
was O
used O
as O
probe O
reactions O
. O

In O
this O
study O
, O
we O
undertook O
the O
characterization O
of O
the O
catalytic O
and O
structural O
properties O
of O
MhpEF O
from O
Escherichia O
coli O
, O
an O
ortholog O
of O
DmpFG O
in O
which O
MhpF O
converts O
acetaldehyde B
, O
produced O
by O
the O
cleavage O
of O
4 B
- I
hydroxy I
- I
2 I
- I
ketovalerate I
by O
MhpE O
, O
into O
acetyl B
- I
CoA I
. O

The O
cationic O
polymer O
nanobrush O
was O
synthesized O
on O
a O
gold O
substrate O
by O
AIBN B
photoinitiated O
polymerization O
, O
using O
a O
70 O
: O
30 O
ratio O
of O
2 B
- I
aminoethyl I
methacrylate I
hydrochloride I
( O
AEMA B
) O
: O
N B
- I
isopropylacrylamide I
( O
NIPAAM B
) O
. O

Here O
the O
feasibility O
of O
6 O
clinically O
approved O
CAs O
( O
Gd B
- I
DTPA I
, O
Gd B
- I
BOPTA I
, O
Gd B
- I
DOTA I
, O
Gd B
- I
BT I
- I
DO3A I
, O
Gd B
- I
DTPA I
- I
BMA I
, O
and O
Gd B
- I
HP I
- I
DO3A I
) O
for O
formulation O
into O
TSL O
was O
investigated O
. O

Here O
the O
feasibility O
of O
6 O
clinically O
approved O
CAs O
( O
Gd B
- I
DTPA I
, O
Gd B
- I
BOPTA I
, O
Gd B
- I
DOTA I
, O
Gd B
- I
BT I
- I
DO3A I
, O
Gd B
- I
DTPA I
- I
BMA I
, O
and O
Gd B
- I
HP I
- I
DO3A I
) O
for O
formulation O
into O
TSL O
was O
investigated O
. O

Here O
the O
feasibility O
of O
6 O
clinically O
approved O
CAs O
( O
Gd B
- I
DTPA I
, O
Gd B
- I
BOPTA I
, O
Gd B
- I
DOTA I
, O
Gd B
- I
BT I
- I
DO3A I
, O
Gd B
- I
DTPA I
- I
BMA I
, O
and O
Gd B
- I
HP I
- I
DO3A I
) O
for O
formulation O
into O
TSL O
was O
investigated O
. O

Here O
, O
for O
the O
first O
time O
, O
we O
show O
that O
with O
addition O
of O
a O
biological O
buffer O
, O
4 B
- I
( I
2 I
- I
hydroxyethyl I
) I
piperazine I
- I
1 I
- I
ethanesulfonic I
acid I
( O
HEPES B
) O
, O
into O
aqueous O
solutions O
of O
tetrahydrofuran B
( O
THF B
) O
, O
1 B
, I
3 I
- I
dioxolane I
, I
1 I
, I
4 I
- I
dioxane I
, I
1 I
- I
propanol I
, O
2 B
- I
propanol I
, O
tert B
- I
butanol I
, O
acetonitrile B
, O
or O
acetone B
, O
the O
organic O
solvent O
can O
be O
excluded O
from O
water O
to O
form O
a O
new O
liquid O
phase O
. O

Here O
, O
for O
the O
first O
time O
, O
we O
show O
that O
with O
addition O
of O
a O
biological O
buffer O
, O
4 B
- I
( I
2 I
- I
hydroxyethyl I
) I
piperazine I
- I
1 I
- I
ethanesulfonic I
acid I
( O
HEPES B
) O
, O
into O
aqueous O
solutions O
of O
tetrahydrofuran B
( O
THF B
) O
, O
1 B
, I
3 I
- I
dioxolane I
, I
1 I
, I
4 I
- I
dioxane I
, I
1 I
- I
propanol I
, O
2 B
- I
propanol I
, O
tert B
- I
butanol I
, O
acetonitrile B
, O
or O
acetone B
, O
the O
organic O
solvent O
can O
be O
excluded O
from O
water O
to O
form O
a O
new O
liquid O
phase O
. O

The O
major O
difference O
among O
the O
new O
CO B
- O
RMs O
tested O
was O
that O
three O
compounds O
( O
CORM B
- I
307 I
, O
CORM B
- I
308 I
and O
CORM B
- I
314 I
) O
were O
soluble O
in O
dimethylsulfoxide B
( O
DMSO B
) O
, O
whereas O
a O
fourth O
one O
( O
CORM B
- I
319 I
) O
was O
rendered O
water O
- O
soluble O
by O
reacting O
the O
iron B
- I
carbonyl I
with O
hydrogen B
tetrafluoroborate I
. O

The O
major O
difference O
among O
the O
new O
CO B
- O
RMs O
tested O
was O
that O
three O
compounds O
( O
CORM B
- I
307 I
, O
CORM B
- I
308 I
and O
CORM B
- I
314 I
) O
were O
soluble O
in O
dimethylsulfoxide B
( O
DMSO B
) O
, O
whereas O
a O
fourth O
one O
( O
CORM B
- I
319 I
) O
was O
rendered O
water O
- O
soluble O
by O
reacting O
the O
iron B
- I
carbonyl I
with O
hydrogen B
tetrafluoroborate I
. O

The O
major O
difference O
among O
the O
new O
CO B
- O
RMs O
tested O
was O
that O
three O
compounds O
( O
CORM B
- I
307 I
, O
CORM B
- I
308 I
and O
CORM B
- I
314 I
) O
were O
soluble O
in O
dimethylsulfoxide B
( O
DMSO B
) O
, O
whereas O
a O
fourth O
one O
( O
CORM B
- I
319 I
) O
was O
rendered O
water O
- O
soluble O
by O
reacting O
the O
iron B
- I
carbonyl I
with O
hydrogen B
tetrafluoroborate I
. O

The O
major O
difference O
among O
the O
new O
CO B
- O
RMs O
tested O
was O
that O
three O
compounds O
( O
CORM B
- I
307 I
, O
CORM B
- I
308 I
and O
CORM B
- I
314 I
) O
were O
soluble O
in O
dimethylsulfoxide B
( O
DMSO B
) O
, O
whereas O
a O
fourth O
one O
( O
CORM B
- I
319 I
) O
was O
rendered O
water O
- O
soluble O
by O
reacting O
the O
iron B
- I
carbonyl I
with O
hydrogen B
tetrafluoroborate I
. O

The O
major O
difference O
among O
the O
new O
CO B
- O
RMs O
tested O
was O
that O
three O
compounds O
( O
CORM B
- I
307 I
, O
CORM B
- I
308 I
and O
CORM B
- I
314 I
) O
were O
soluble O
in O
dimethylsulfoxide B
( O
DMSO B
) O
, O
whereas O
a O
fourth O
one O
( O
CORM B
- I
319 I
) O
was O
rendered O
water O
- O
soluble O
by O
reacting O
the O
iron B
- I
carbonyl I
with O
hydrogen B
tetrafluoroborate I
. O

In O
contrast O
, O
CORM B
- I
319 I
that O
is O
soluble O
in O
water O
and O
liberated O
CO B
with O
a O
slower O
rate O
, O
preserved O
smooth O
muscle O
cell O
viability O
, O
relaxed O
aortic O
tissue O
and O
exerted O
a O
significant O
anti O
- O
inflammatory O
effect O
in O
macrophages O
challenged O
with O
endotoxin O
. O

Synthesis O
and O
characterization O
of O
self O
- O
bridged O
silver B
vanadium I
oxide I
/ O
CNTs O
composite O
and O
its O
enhanced O
lithium B
storage O
performance O
. O

We O
designed O
a O
function O
- O
oriented O
hybrid O
material O
consisting O
of O
silver B
vanadium I
oxide I
( O
beta O
- O
AgVO B
( I
3 I
) I
) O
nanowires O
modified O
with O
uniform O
Ag B
nanoparticles O
and O
multi O
- O
walled O
carbon B
nanotubes O
( O
CNTs O
) O
as O
a O
high O
- O
performance O
cathode O
material O
for O
LIBs O
. O

In O
this O
manuscript O
we O
have O
studied O
the O
photophysics O
of O
7 B
- I
( I
N I
, I
N I
' I
- I
diethylamino I
) I
coumarin I
- I
3 I
- I
carboxylic I
acid I
( O
7 B
- I
DCCA I
) O
in O
water O
/ O
AOT B
/ O
isooctane B
reverse O
micelles O
. O

We O
have O
studied O
the O
spectral O
behaviour O
of O
7 B
- I
DCCA I
inside O
the O
water O
/ O
AOT B
/ O
isooctane B
reverse O
micelles O
with O
variation O
of O
excitation O
wavelength O
. O

We O
have O
observed O
the O
excitation O
wavelength O
dependent O
dynamics O
of O
7 B
- I
DCCA I
in O
the O
reverse O
micelles O
. O

The O
fluorescence O
quantum O
yield O
, O
decay O
time O
, O
solvent O
relaxation O
time O
and O
rotational O
relaxation O
time O
of O
7 B
- I
DCCA I
in O
reverse O
micelles O
vary O
with O
the O
excitation O
wavelength O
. O

A O
two O
step O
and O
wobbling O
- O
in O
- O
cone O
model O
was O
used O
to O
interpret O
the O
rotational O
relaxation O
dynamics O
of O
7 B
- I
DCCA I
in O
reverse O
micelles O
. O

The O
effect O
of O
converting O
ammonium B
into O
guanidine B
moieties O
, O
compared O
to O
other O
factors O
such O
as O
molecular O
weight O
or O
hydrophobicity O
, O
on O
the O
antibacterial O
activity O
is O
investigated O
for O
homo O
- O
and O
copolymers O
of O
2 B
- I
aminoethylmethacryla I
in O
solution O
or O
coatings O
. O

The O
electronic O
circular O
dichroism O
( O
CD O
) O
spectra O
of O
a O
methyl B
- I
thiol I
adsorbed O
at O
different O
sites O
on O
an O
icosahedral O
silver B
nanoparticle O
is O
studied O
by O
using O
time O
- O
perturbed O
density O
functional O
theory O
. O

Gene O
expression O
analysis O
showed O
that O
25HC3S B
significantly O
suppressed O
the O
SREBP O
- O
1c O
signaling O
pathway O
that O
was O
associated O
with O
the O
suppression O
of O
the O
key O
enzymes O
involved O
in O
lipogenesis O
: O
fatty B
acid I
synthase O
, O
acetyl B
- I
CoA I
carboxylase O
1 O
, O
and O
glycerol B
- I
3 I
- I
phosphate I
acyltransferase O
. O

Here O
, O
iron B
L O
- O
edge O
X O
- O
ray O
absorption O
spectroscopy O
, O
interpreted O
using O
a O
valence O
bond O
configuration O
interaction O
multiplet O
model O
, O
is O
applied O
to O
directly O
probe O
the O
electronic O
structure O
of O
the O
iron B
in O
the O
biomimetic O
Fe B
- O
O B
( I
2 I
) I
heme B
complex O
[ B
Fe I
( I
pfp I
) I
( I
1 I
- I
MeIm I
) I
O I
( I
2 I
) I
] I
( O
pfp B
( O
" O
picket B
fence I
porphyrin I
" O
) O
= O
meso B
- I
tetra I
( I
alpha I
, I
alpha I
, I
alpha I
, I
alpha I
- I
o I
- I
pivalamidophenyl I
) I
porphyrin I
or O
TpivPP B
) O
. O

The O
L O
- O
edge O
spectrum O
of O
[ B
Fe I
( I
pfp I
) I
( I
1 I
- I
MeIm I
) I
O I
( I
2 I
) I
] I
is O
further O
compared O
to O
those O
of O
[ B
Fe I
( I
II I
) I
( I
pfp I
) I
( I
1 I
- I
MeIm I
) I
( I
2 I
) I
] I
, O
[ B
Fe I
( I
II I
) I
( I
pfp I
) I
] I
, O
and O
[ B
Fe I
( I
III I
) I
( I
tpp I
) I
( I
ImH I
) I
( I
2 I
) I
] I
Cl I
( O
tpp B
= O
meso B
- I
tetraphenylporphyrin I
) O
which O
have O
Fe B
( I
II I
) I
S O
= O
0 O
, O
Fe B
( I
II I
) I
S O
= O
1 O
, O
and O
Fe B
( I
III I
) I
S O

These O
serve O
as O
references O
for O
the O
three O
possible O
contributions O
to O
the O
ground O
state O
of O
oxy B
- I
pfp I
. O

In O
this O
work O
, O
a O
facile O
photoinduced O
one O
- O
step O
method O
was O
first O
developed O
for O
the O
covalent O
immobilization O
of O
ATRP O
initiators O
on O
the O
C B
- I
H I
group O
- O
containing O
substrates O
such O
as O
biaxially O
oriented O
polypropylene B
( O
BOPP O
) O
. O

The O
C B
- I
H I
bonds O
of O
precise O
location O
of O
inert O
polymer O
surfaces O
were O
readily O
transferred O
to O
bromoalkyl B
initiator O
, O
followed O
by O
ATRP O
of O
2 B
- I
( I
dimethylamino I
) I
ethyl I
methacrylate I
( O
DMAEMA B
) O
and O
glycidyl B
methacrylate I
( O
GMA B
) O
, O
respectively O
, O
to O
produce O
the O
resultant O
patterned O
BOPP O
- O
g O
- O
P B
( I
DMAEMA I
) I
and O
BOPP O
- O
g O
- O
P B
( I
GMA I
) I
films O
. O

Disruption O
of O
the O
cell O
- O
cycle O
boxes O
also O
affected O
growth O
in O
a O
DNA O
polymerase O
- O
defective O
strain O
background O
where O
mismatch O
repair O
is O
essential O
, O
particularly O
in O
the O
presence O
of O
the O
DNA O
damaging O
agent O
methyl B
methane I
sulfonate I
( O
MMS B
) O
. O

OlfGST O
pi O
and O
rho O
exhibited O
thiol B
oxidoreductase O
activity O
toward O
2 B
- I
hydroxyethyl I
disulfide I
( O
2 B
- I
HEDS I
) O
and O
conjugated O
4 B
- I
hydroxynonenal I
( O
HNE B
) O
, O
a O
toxic O
aldehyde B
with O
neurodegenerative O
properties O
. O

OlfGST O
pi O
and O
rho O
exhibited O
thiol B
oxidoreductase O
activity O
toward O
2 B
- I
hydroxyethyl I
disulfide I
( O
2 B
- I
HEDS I
) O
and O
conjugated O
4 B
- I
hydroxynonenal I
( O
HNE B
) O
, O
a O
toxic O
aldehyde B
with O
neurodegenerative O
properties O
. O

The O
outcome O
of O
these O
tests O
grouped O
the O
tested O
compounds O
in O
three O
categories O
following O
their O
detoxification O
effect O
( O
benzo B
( I
a I
) I
pyrene I
, O
valproic B
acid I
) O
, O
their O
bio O
- O
activation O
effect O
( O
aflatoxin B
B1 I
) O
and O
their O
specific O
effect O
on O
inhibition O
of O
cell O
proliferation O
( O
cycloheximide B
, O
sodium B
lauryl I
sulphate I
, O
atropine B
sulphate I
monohydrate I
, O
acetylsalicylic B
acid I
) O
. O

The O
outcome O
of O
these O
tests O
grouped O
the O
tested O
compounds O
in O
three O
categories O
following O
their O
detoxification O
effect O
( O
benzo B
( I
a I
) I
pyrene I
, O
valproic B
acid I
) O
, O
their O
bio O
- O
activation O
effect O
( O
aflatoxin B
B1 I
) O
and O
their O
specific O
effect O
on O
inhibition O
of O
cell O
proliferation O
( O
cycloheximide B
, O
sodium B
lauryl I
sulphate I
, O
atropine B
sulphate I
monohydrate I
, O
acetylsalicylic B
acid I
) O
. O

A O
novel O
series O
of O
substituted O
( B
E I
) I
- I
3 I
- I
( I
Benzo I
[ I
d I
] I
thiazol I
- I
2 I
- I
ylamino I
) I
phenylprop I
- I
2 I
- I
en I
- I
1 I
- I
onewere I
synthesized O
starting O
from O
2 B
- I
aminobenzothiazole I
and O
1 B
- I
aryl I
- I
3 I
, I
3 I
- I
bis I
- I
( I
methylsulfanyl I
) I
- I
2 I
- I
propen I
- I
1 I
- I
onesin I
the O
presence O
of O
a O
catalytic O
amount O
of O
sodium B
hydride I
in O
THF B
. O

l B
- I
Glutamate I
( O
30 O
mu O
M O
) O
- O
induced O
inward O
currents O
were O
recorded O
via O
the O
two O
- O
electrode O
voltage O
clamp O
method O
. O

Therefore O
, O
a O
higher O
- O
tier O
experiment O
suitable O
to O
assess O
the O
risk O
for O
soil O
organisms O
was O
conducted O
to O
further O
develop O
the O
TME O
( O
terrestrial O
model O
ecosystems O
) O
methodology O
in O
a O
dose O
- O
response O
design O
with O
the O
persistent O
insecticidal O
model O
compound O
lindane B
( O
gamma B
- I
HCH I
) O
. O

Valacyclovir B
P O
( O
eff O
) O
was O
significantly O
reduced O
by O
the O
dipeptide O
glycylsarcosine B
and O
the O
aminocephalosporin B
cefadroxil I
, O
but O
not O
by O
the O
amino B
acids I
l B
- I
valine I
or O
l B
- I
histidine I
, O
the O
organic O
acid O
p B
- I
aminohippurate I
, O
or O
the O
organic O
base O
tetraethylammonium B
( O
all O
at O
25 O
mM O
) O
. O

Valacyclovir B
P O
( O
eff O
) O
was O
significantly O
reduced O
by O
the O
dipeptide O
glycylsarcosine B
and O
the O
aminocephalosporin B
cefadroxil I
, O
but O
not O
by O
the O
amino B
acids I
l B
- I
valine I
or O
l B
- I
histidine I
, O
the O
organic O
acid O
p B
- I
aminohippurate I
, O
or O
the O
organic O
base O
tetraethylammonium B
( O
all O
at O
25 O
mM O
) O
. O

Valacyclovir B
P O
( O
eff O
) O
was O
significantly O
reduced O
by O
the O
dipeptide O
glycylsarcosine B
and O
the O
aminocephalosporin B
cefadroxil I
, O
but O
not O
by O
the O
amino B
acids I
l B
- I
valine I
or O
l B
- I
histidine I
, O
the O
organic O
acid O
p B
- I
aminohippurate I
, O
or O
the O
organic O
base O
tetraethylammonium B
( O
all O
at O
25 O
mM O
) O
. O

Iron B
- I
sulfur I
( O
Fe B
- I
S I
) O
cluster O
- O
containing O
proteins O
are O
essential O
components O
of O
cells O
. O

Iron B
- I
sulfur I
( O
Fe B
- I
S I
) O
cluster O
- O
containing O
proteins O
are O
essential O
components O
of O
cells O
. O

In O
eukaryotes O
, O
Fe B
- I
S I
clusters O
are O
synthesized O
by O
the O
mitochondrial O
iron B
- I
sulfur I
cluster O
( O
ISC O
) O
machinery O
and O
the O
cytosolic O
iron B
- I
sulfur I
assembly O
( O
CIA O
) O
system O
. O

In O
eukaryotes O
, O
Fe B
- I
S I
clusters O
are O
synthesized O
by O
the O
mitochondrial O
iron B
- I
sulfur I
cluster O
( O
ISC O
) O
machinery O
and O
the O
cytosolic O
iron B
- I
sulfur I
assembly O
( O
CIA O
) O
system O
. O

In O
eukaryotes O
, O
Fe B
- I
S I
clusters O
are O
synthesized O
by O
the O
mitochondrial O
iron B
- I
sulfur I
cluster O
( O
ISC O
) O
machinery O
and O
the O
cytosolic O
iron B
- I
sulfur I
assembly O
( O
CIA O
) O
system O
. O

In O
the O
mammalian O
ISC O
machinery O
, O
preassembly O
of O
the O
Fe B
- I
S I
cluster O
on O
the O
scaffold O
protein O
( O
ISCU O
) O
involves O
a O
cysteine B
desulfurase O
complex O
( O
NFS1 O
/ O
ISD11 O
) O
and O
frataxin O
( O
FXN O
) O
, O
the O
protein O
deficient O
in O
Friedreich O
' O
s O
ataxia O
. O

Furthermore O
, O
we O
show O
for O
the O
first O
time O
that O
in O
the O
presence O
of O
iron B
and O
L B
- I
cysteine I
, O
an O
[ O
Fe B
( I
4 I
) I
S I
( I
4 I
) I
] O
cluster O
is O
formed O
within O
the O
quaternary O
complex O
that O
can O
be O
transferred O
to O
mammalian O
aconitase O
( O
mACO2 O
) O
to O
generate O
an O
active O
enzyme O
. O

In O
the O
absence O
of O
FXN O
, O
although O
the O
ternary O
complex O
can O
assemble O
an O
Fe B
- I
S I
cluster O
, O
the O
cluster O
is O
inefficiently O
transferred O
to O
ACO2 O
. O

Taken O
together O
, O
these O
data O
help O
to O
unravel O
further O
the O
Fe B
- I
S I
cluster O
assembly O
process O
and O
the O
molecular O
basis O
of O
Friedreich O
' O
s O
ataxia O
. O

Auroxanthin O
and O
beta B
- I
cryptoxanthin I
represented O
around O
50 O
% O
of O
total O
carotenoids O
. O

A O
gas O
chromatographic O
method O
for O
the O
determination O
of O
endocrine O
disruptor O
pesticides O
( O
Chlorpyrifos B
, O
Penconazole B
, O
Procymidone B
, O
Iprodione B
, O
Bromopropylate B
and O
Lambda B
- I
Cyhalothrin I
) O
in O
wine O
samples O
is O
described O
. O

We O
have O
isolated O
the O
bacterial O
strain O
SY8519 O
, O
which O
has O
been O
shown O
to O
metabolize O
daidzein B
to O
O B
- I
desmethylangolensin I
and O
to O
produce O
2 B
- I
( I
4 I
- I
hydroxyphenyl I
) I
propionic I
acid I
from O
genistein B
. O

We O
also O
applied O
the O
metabolite O
to O
mouse O
adipocytes O
and O
found O
that O
2 B
- I
HPPA I
was O
less O
effective O
at O
reducing O
leptin O
secretion O
than O
the O
parent O
compound O
genistein B
. O

Our O
results O
suggested O
that O
' O
O B
- I
desmethylangolensin I
- O
production O
' O
attenuates O
the O
effect O
of O
soy O
isoflavonoids B
by O
reducing O
not O
only O
the O
activity O
of O
daidzein B
but O
also O
that O
of O
genistein B
. O

The O
headspace O
volatile O
compounds O
were O
collected O
after O
irradiation O
using O
a O
single O
drop O
of O
n B
- I
heptadecan I
. O

E B
- I
beta I
- I
ocimene I
( O
53 O
. O
81 O
% O
) O
, O
R O
- O
D O
- O
decalactone O
( O
12 O
. O
75 O
% O
) O
, O
alpha B
- I
pinene I
( O
6 O
. O
43 O
% O
) O
, O
n B
- I
heptanol I
( O
6 O
. O
27 O
% O
) O
, O
beta B
- I
phellanderne I
( O
2 O
. O
70 O
% O
) O
and O
linalool B
( O
1 O
. O
89 O
% O
) O
were O
the O
major O
constituents O
. O

E B
- I
beta I
- I
ocimene I
( O
53 O
. O
81 O
% O
) O
, O
R O
- O
D O
- O
decalactone O
( O
12 O
. O
75 O
% O
) O
, O
alpha B
- I
pinene I
( O
6 O
. O
43 O
% O
) O
, O
n B
- I
heptanol I
( O
6 O
. O
27 O
% O
) O
, O
beta B
- I
phellanderne I
( O
2 O
. O
70 O
% O
) O
and O
linalool B
( O
1 O
. O
89 O
% O
) O
were O
the O
major O
constituents O
. O

E B
- I
beta I
- I
ocimene I
( O
53 O
. O
81 O
% O
) O
, O
R O
- O
D O
- O
decalactone O
( O
12 O
. O
75 O
% O
) O
, O
alpha B
- I
pinene I
( O
6 O
. O
43 O
% O
) O
, O
n B
- I
heptanol I
( O
6 O
. O
27 O
% O
) O
, O
beta B
- I
phellanderne I
( O
2 O
. O
70 O
% O
) O
and O
linalool B
( O
1 O
. O
89 O
% O
) O
were O
the O
major O
constituents O
. O

Subsequently O
the O
methods O
were O
applied O
for O
the O
identification O
and O
quantification O
of O
chlorogenic B
acid I
( O
5 B
- I
CQA I
) O
and O
1 B
, I
5 I
- I
dicaffeoylquinic I
acid I
( O
1 B
, I
5 I
- I
DCQA I
) O
as O
main O
compounds O
in O
samples O
. O

The O
total O
phenolic O
content O
of O
samples O
ranged O
from O
3 O
. O
93 O
to O
14 O
. O
13 O
g O
of O
5 B
- I
CQA I
equivalent O
/ O
100g O
dry O
weight O
( O
DW O
) O
. O

There O
was O
a O
significant O
variability O
from O
89 O
to O
571 O
mg O
/ O
100g O
for O
5 B
- I
CQA I
and O
48 O
to O
486 O
mg O
/ O
100g O
for O
1 B
, I
5 I
- I
DCQA I
in O
dry O
material O
. O

The O
use O
of O
diethylaminoethyl B
microspin O
column O
to O
isolate O
spiked O
lunasin O
in O
human O
plasma O
showed O
that O
most O
lunasin O
( O
37 O
. O
8 O
- O
46 O
. O
5 O
% O
) O
bound O
to O
the O
column O
eluted O
with O
Tris B
- I
HCl I
buffer O
, O
pH O
7 O
. O
5 O
with O
a O
yield O
up O
to O
76 O
. O
6 O
% O
. O

Lutein B
content O
of O
wheat O
flour O
ranged O
from O
0 O
. O
10 O
to O
0 O
. O
69 O
mu O
g O
/ O
g O
, O
and O
alpha B
- I
tocopherol I
ranged O
from O
0 O
. O
12 O
to O
0 O
. O
83 O
mu O
g O
/ O
g O
. O

Thus O
, O
determination O
of O
total O
arsenic B
was O
performed O
by O
previous O
degradation O
of O
organo B
- I
arsenic I
species O
, O
followed O
by O
a O
reduction O
. O

By O
the O
methods O
of O
the O
computer O
simulation O
of O
the O
copigmentation O
process O
we O
determined O
the O
sites O
responsible O
for O
the O
stabilization O
of O
a O
cyanidin B
quinoidal I
base I
- O
baicalin B
complex O
. O

Most O
of O
the O
esters B
and O
alcohols B
decreased O
whereas O
13 O
new O
compounds O
appear O
, O
mostly O
furans B
( O
furfural B
, O
2 B
- I
acetylfurane I
, O
5 B
- I
methyl I
furfural I
, O
mesifurane B
) O
and O
aldehydes B
( O
octanal B
, O
nonanal B
, O
decanal B
and O
benzaldeyhde B
) O
. O

Optimization O
of O
ABTS B
radical I
cation I
assay O
specifically O
for O
determination O
of O
antioxidant O
capacity O
of O
intracellular O
extracts O
of O
microalgae O
and O
cyanobacteria O
. O

The O
ease O
of O
synthesis O
of O
phenylacetamido B
- I
polyamines I
, O
coupled O
with O
potent O
nM O
levels O
of O
activity O
towards O
dual O
drug O
resistant O
strains O
of O
P O
. O
falciparum O
makes O
this O
compound O
class O
of O
interest O
in O
the O
development O
of O
new O
antimalarial O
therapeutics O
. O

Lead O
optimization O
of O
a O
dihydropyrrolopyrimi B
inhibitor O
against O
phosphoinositide O
3 O
- O
kinase O
( O
PI3K O
) O
to O
improve O
the O
phenol B
glucuronic I
acid I
conjugation O
. O

High O
- O
throughput O
screening O
resulted O
in O
discovery O
of O
a O
hit O
compound O
( O
ST B
- I
37 I
) O
possessing O
a O
benzimidazole B
core O
which O
led O
to O
a O
potent O
compound O
series O
. O

Ultimately O
, O
lead O
compound O
ST B
- I
193 I
was O
identified O
and O
later O
found O
to O
be O
efficacious O
in O
a O
lethal O
LASV O
guinea O
pig O
model O
showing O
superior O
protection O
compared O
to O
ribavirin O
treatment O
. O

Tri B
- I
and I
diorganotin I
( I
IV I
) I
orotates I
of O
general O
formula O
, O
R B
( I
n I
) I
Sn I
( I
H I
( I
2 I
) I
Or I
) I
( I
m I
) I
[ O
n O
= O
3 O
/ O
2 O
, O
m O
= O
1 O
/ O
2 O
, O
R O
= O
Me B
, O
n B
- I
Bu I
, O
n B
- I
Oct I
and O
Ph B
; O
H B
( I
2 I
) I
Or I
( I
- I
) I
= O
monoanion O
of O
orotic B
acid I
( O
H B
( I
3 I
) I
Or I
) O
] O
( O
n B
- I
Bu I
( I
2 I
) I
Sn I
( I
HOr I
) I
as O
an O
exception O
) O
have O
been O
synthesized O
. O

Tri B
- I
and I
diorganotin I
( I
IV I
) I
orotates I
of O
general O
formula O
, O
R B
( I
n I
) I
Sn I
( I
H I
( I
2 I
) I
Or I
) I
( I
m I
) I
[ O
n O
= O
3 O
/ O
2 O
, O
m O
= O
1 O
/ O
2 O
, O
R O
= O
Me B
, O
n B
- I
Bu I
, O
n B
- I
Oct I
and O
Ph B
; O
H B
( I
2 I
) I
Or I
( I
- I
) I
= O
monoanion O
of O
orotic B
acid I
( O
H B
( I
3 I
) I
Or I
) O
] O
( O
n B
- I
Bu I
( I
2 I
) I
Sn I
( I
HOr I
) I
as O
an O
exception O
) O
have O
been O
synthesized O
. O

Development O
of O
hypoxia O
- O
inducible O
factor O
( O
HIF O
) O
- O
1 O
alpha O
inhibitors O
: O
effect O
of O
ortho B
- I
carborane I
substituents O
on O
HIF O
transcriptional O
activity O
under O
hypoxia O
. O

A O
series O
of O
substituted O
ortho B
- I
carboranylphenoxyace I
were O
synthesized O
and O
evaluated O
for O
their O
ability O
to O
inhibit O
hypoxia O
- O
induced O
HIF O
- O
1 O
transcriptional O
activity O
using O
a O
cell O
- O
based O
reporter O
assay O
in O
HeLa O
cells O
expressing O
the O
HRE O
- O
dependent O
firefly O
luciferase O
reporter O
construct O
( O
HRE O
- O
Luc O
) O
and O
constitutively O
expressing O
CMV O
- O
driven O
Renilla O
luciferase O
reporter O
, O
and O
their O
ability O
to O
inhibit O
cell O
growth O
( O
GI O
( O
50 O
) O
) O
using O
the O
MTT B
assay O
. O

The O
experimental O
C B
= I
O I
stretching O
feature O
of O
cis B
- I
[ I
Pt I
( I
NH I
( I
3 I
) I
) I
( I
2 I
) I
( I
G I
) I
Cl I
] I
( I
+ I
) I
at O
1718 O
cm O
( O
- O
1 O
) O
, O
remarkably O
red O
- O
shifted O
with O
respect O
to O
an O
unperturbed O
C B
= I
O I
stretching O
mode O
, O
is O
indicative O
of O
a O
lengthened O
CO B
bond O
in O
guanine B
, O
a O
signature O
that O
this O
group O
is O
involved O
in O
hydrogen B
bonding O
. O

The O
experimental O
C B
= I
O I
stretching O
feature O
of O
cis B
- I
[ I
Pt I
( I
NH I
( I
3 I
) I
) I
( I
2 I
) I
( I
G I
) I
Cl I
] I
( I
+ I
) I
at O
1718 O
cm O
( O
- O
1 O
) O
, O
remarkably O
red O
- O
shifted O
with O
respect O
to O
an O
unperturbed O
C B
= I
O I
stretching O
mode O
, O
is O
indicative O
of O
a O
lengthened O
CO B
bond O
in O
guanine B
, O
a O
signature O
that O
this O
group O
is O
involved O
in O
hydrogen B
bonding O
. O

6 B
- I
OHDA I
- O
induced O
apoptosis O
and O
mitochondrial O
dysfunction O
are O
mediated O
by O
early O
modulation O
of O
intracellular O
signals O
and O
interaction O
of O
Nrf2 O
and O
NF O
- O
kappa O
B O
factors O
. O

6 B
- I
Hydroxydopamine I
( O
6 B
- I
OHDA I
) O
is O
a O
neurotoxin O
that O
generates O
an O
experimental O
model O
of O
Parkinson O
' O
s O
disease O
in O
rodents O
and O
is O
commonly O
employed O
to O
induce O
a O
lesion O
in O
dopaminergic O
pathways O
. O

6 B
- I
Hydroxydopamine I
( O
6 B
- I
OHDA I
) O
is O
a O
neurotoxin O
that O
generates O
an O
experimental O
model O
of O
Parkinson O
' O
s O
disease O
in O
rodents O
and O
is O
commonly O
employed O
to O
induce O
a O
lesion O
in O
dopaminergic O
pathways O
. O

The O
characterization O
of O
those O
molecular O
mechanisms O
linked O
to O
6 B
- I
OHDA I
- O
induced O
early O
toxicity O
is O
needed O
to O
better O
understand O
the O
cellular O
events O
further O
leading O
to O
neurodegeneration O
. O

The O
present O
work O
explored O
how O
6 B
- I
OHDA I
triggers O
early O
downstream O
signaling O
pathways O
that O
activate O
neurotoxicity O
in O
the O
rat O
striatum O
. O

We O
found O
that O
6 B
- I
OHDA I
initiates O
cell O
damage O
via O
mitochondrial O
complex O
I O
inhibition O
, O
cytochrome O
c O
and O
apoptosis O
- O
inducing O
factor O
( O
AIF O
) O
release O
, O
as O
well O
as O
activation O
of O
caspases O
9 O
and O
3 O
to O
induce O
apoptosis O
, O
kinase O
signaling O
modulation O
and O
NF O
- O
kappa O
B O
- O
mediated O
inflammatory O
responses O
, O
accompanied O
by O
inhibition O
of O
antioxidant O
systems O
regulated O
by O
the O
Nrf2 O
pathway O
. O

Our O
results O
suggest O
that O
kinases O
SAP O
/ O
JNK O
and O
p38 O
up O
- O
regulation O
may O
play O
a O
role O
in O
the O
early O
stages O
of O
6 B
- I
OHDA I
toxicity O
to O
trigger O
intrinsic O
pathways O
for O
apoptosis O
and O
enhanced O
NF O
- O
kappa O
B O
activation O
. O

A O
reamer O
bone O
graft O
alone O
, O
or O
after O
short O
term O
incubation O
in O
a O
dexamethasone B
enriched O
solution O
, O
and O
a O
reamer O
graft O
collected O
using O
beta B
- I
tricalcium I
phosphate I
( O
beta B
- I
TCP I
) O
granules O
in O
the O
filter O
of O
the O
RIA O
collection O
device O
were O
compared O
to O
autologous O
iliac O
wing O
graft O
. O

Reamer O
graft O
collected O
using O
beta B
- I
TCP I
granules O
( O
29 O
. O
2 O
+ O
/ O
- O
1 O
. O
7 O
% O
) O
in O
the O
filter O
produced O
a O
significantly O
higher O
amount O
of O
bone O
in O
comparison O
to O
an O
autologous O
iliac O
wing O
graft O
evaluated O
by O
micro O
- O
CT O
. O

If O
avoidance O
of O
an O
iliac O
wing O
graft O
is O
desirable O
, O
or O
a O
reaming O
procedure O
is O
required O
, O
then O
a O
RIA O
graft O
or O
RIA O
graft O
plus O
beta B
- I
TCP I
granules O
are O
as O
good O
as O
the O
current O
gold O
standard O
for O
this O
model O
. O

Electrical O
stimulation O
, O
ATP B
, O
and O
insulin O
each O
increased O
fluorescent O
2 B
- I
NBD I
- I
Glucose I
( O
2 B
- I
NBDG I
) O
uptake O
in O
primary O
myotubes O
, O
but O
only O
electrical O
stimulation O
and O
ATP B
- O
dependent O
2 B
- I
NBDG I
uptake O
were O
inhibited O
by O
adenosine B
- I
phosphate I
phosphatase O
and O
by O
purinergic O
receptor O
blockade O
( O
suramin B
) O
. O

Electrical O
stimulation O
, O
ATP B
, O
and O
insulin O
each O
increased O
fluorescent O
2 B
- I
NBD I
- I
Glucose I
( O
2 B
- I
NBDG I
) O
uptake O
in O
primary O
myotubes O
, O
but O
only O
electrical O
stimulation O
and O
ATP B
- O
dependent O
2 B
- I
NBDG I
uptake O
were O
inhibited O
by O
adenosine B
- I
phosphate I
phosphatase O
and O
by O
purinergic O
receptor O
blockade O
( O
suramin B
) O
. O

Electrical O
stimulation O
, O
ATP B
, O
and O
insulin O
each O
increased O
fluorescent O
2 B
- I
NBD I
- I
Glucose I
( O
2 B
- I
NBDG I
) O
uptake O
in O
primary O
myotubes O
, O
but O
only O
electrical O
stimulation O
and O
ATP B
- O
dependent O
2 B
- I
NBDG I
uptake O
were O
inhibited O
by O
adenosine B
- I
phosphate I
phosphatase O
and O
by O
purinergic O
receptor O
blockade O
( O
suramin B
) O
. O

Exogenous O
ATP B
transiently O
activated O
Akt O
and O
, O
inhibiting O
phosphatidylinositol O
3 O
- O
kinase O
( O
PI3K O
) O
or O
Akt O
as O
well O
as O
dominant O
- O
negative O
Akt O
mutant O
, O
reduced O
ATP B
- O
dependent O
2 B
- I
NBDG I
uptake O
and O
Akt O
phosphorylation O
. O

ATP B
- O
dependent O
2 B
- I
NBDG I
uptake O
was O
also O
inhibited O
by O
the O
G O
protein O
beta O
gamma O
subunit O
- O
interacting O
peptide O
beta O
ark O
- O
ct O
and O
by O
the O
phosphatidylinositol O
3 O
- O
kinase O
- O
gamma O
( O
PI3K O
gamma O
) O
inhibitor O
AS605240 B
. O

ATP B
stimulated O
2 B
- I
NBDG I
uptake O
in O
normal O
and O
insulin O
- O
resistant O
adult O
muscle O
fibers O
, O
resembling O
the O
reported O
effect O
of O
exercise O
. O

Discriminative O
stimulus O
effects O
of O
the O
GABAB O
receptor O
- O
positive O
modulator O
rac B
- I
BHFF I
: O
comparison O
with O
GABAB O
receptor O
agonists O
and O
drugs O
of O
abuse O
. O

To O
examine O
this O
, O
pigeons O
were O
trained O
to O
discriminate O
the O
GABA B
( O
B O
) O
receptor O
- O
positive O
modulator O
( B
R I
, I
S I
) I
- I
5 I
, I
7 I
- I
di I
- I
tert I
- I
butyl I
- I
3 I
- I
hydroxy I
- I
3 I
- I
trifluoromethyl I
- I
3H I
- I
benzofuran I
- I
2 I
- I
one I
( O
rac B
- I
BHFF I
) O
from O
its O
vehicle O
. O

The O
discriminative O
stimulus O
effects O
of O
rac B
- I
BHFF I
were O
not O
mimicked O
by O
the O
GABA B
( O
B O
) O
receptor O
agonists O
baclofen B
and O
gamma B
- I
hydroxybutyrate I
( O
GHB B
) O
, O
not O
by O
diazepam B
, O
and O
not O
by O
alcohol B
, O
cocaine B
, O
and O
nicotine B
, O
whose O
self O
- O
administration O
has O
been O
reported O
to O
be O
attenuated O
by O
GABA B
( O
B O
) O
receptor O
- O
positive O
modulators O
. O

The O
discriminative O
stimulus O
effects O
of O
rac B
- I
BHFF I
were O
not O
mimicked O
by O
the O
GABA B
( O
B O
) O
receptor O
agonists O
baclofen B
and O
gamma B
- I
hydroxybutyrate I
( O
GHB B
) O
, O
not O
by O
diazepam B
, O
and O
not O
by O
alcohol B
, O
cocaine B
, O
and O
nicotine B
, O
whose O
self O
- O
administration O
has O
been O
reported O
to O
be O
attenuated O
by O
GABA B
( O
B O
) O
receptor O
- O
positive O
modulators O
. O

The O
discriminative O
stimulus O
effects O
of O
rac B
- I
BHFF I
were O
not O
antagonized O
by O
the O
GABA B
( O
B O
) O
receptor O
antagonist O
3 B
- I
aminopropyl I
( I
diethoxymethyl I
) I
phosphinic I
acid I
( O
CGP35348 B
) O
but O
were O
attenuated O
by O
the O
less O
efficacious O
GABA B
( O
B O
) O
receptor O
- O
positive O
modulator O
2 B
, I
6 I
- I
di I
- I
tert I
- I
butyl I
- I
4 I
- I
( I
3 I
- I
hydroxy I
- I
2 I
, I
2 I
- I
dimethylpropyl I
) I
phenol I
( O
CGP7930 B
) O
, O
suggesting O
the O
possibility O
that O
rac B
- I

BHFF I
produces O
its O
discriminative O
stimulus O
effects O
by O
directly O
activating O
GABA B
( O
B2 O
) O
subunits O
of O
GABA B
( O
B O
) O
receptors O
. O

At O
a O
dose O
10 O
- O
fold O
lower O
than O
the O
training O
dose O
, O
rac B
- I
BHFF I
enhanced O
the O
discriminative O
stimulus O
effects O
of O
baclofen B
, O
but O
not O
of O
GHB B
. O

Finally O
, O
the O
finding O
that O
rac B
- I
BHFF I
enhanced O
effects O
of O
baclofen B
but O
not O
of O
GHB B
is O
consistent O
with O
converging O
evidence O
that O
the O
populations O
of O
GABA B
( O
B O
) O
receptors O
mediating O
the O
effects O
of O
baclofen B
and O
GHB B
are O
not O
identical O
. O

p B
- I
Toluenesulfonate I
ion O
- O
complex O
and O
tert B
- I
butoxycarbonyl I
( O
Boc B
) O
protection O
of O
amino B
groups O
were O
found O
to O
effectively O
display O
amino B
groups O
on O
the O
surface O
( O
more O
than O
70 O
pmol O
/ O
cm O
( O
2 O
) O
) O
. O

p B
- I
Toluenesulfonate I
ion O
- O
complex O
and O
tert B
- I
butoxycarbonyl I
( O
Boc B
) O
protection O
of O
amino B
groups O
were O
found O
to O
effectively O
display O
amino B
groups O
on O
the O
surface O
( O
more O
than O
70 O
pmol O
/ O
cm O
( O
2 O
) O
) O
. O

Kinetics O
of O
the O
reaction O
of O
crystal B
violet I
with O
hydroxide B
ion O
in O
the O
critical O
solution O
of O
2 B
- I
butoxyethanol I
+ O
water O
. O

The O
kinetics O
of O
alkaline O
fading O
of O
crystal B
violet I
( O
CV O
) O
has O
been O
studied O
by O
UV O
spectrophotometry O
and O
microcalorimetry O
in O
the O
critical O
binary O
solution O
of O
2 B
- I
butoxyethanol I
+ O
water O
at O
the O
initial O
reaction O
stage O
and O
various O
temperatures O
. O

This O
was O
further O
supported O
by O
the O
inability O
of O
EF O
- O
P O
to O
enhance O
the O
rate O
of O
formation O
of O
fMet B
- I
Lys I
or O
fMet B
- I
Phe I
, O
indicating O
that O
the O
role O
of O
EF O
- O
P O
is O
not O
to O
specifically O
stimulate O
formation O
of O
the O
first O
peptide O
bond O
. O

This O
was O
further O
supported O
by O
the O
inability O
of O
EF O
- O
P O
to O
enhance O
the O
rate O
of O
formation O
of O
fMet B
- I
Lys I
or O
fMet B
- I
Phe I
, O
indicating O
that O
the O
role O
of O
EF O
- O
P O
is O
not O
to O
specifically O
stimulate O
formation O
of O
the O
first O
peptide O
bond O
. O

Biomarkers O
of O
toluene B
exposure O
in O
rats O
: O
mercapturic B
acids I
versus O
traditional O
indicators O
( O
urinary O
hippuric B
acid I
and O
o B
- I
cresol I
and O
blood O
toluene B
) O
. O

The O
aims O
of O
this O
study O
were O
( O
1 O
) O
to O
provide O
data O
on O
MAs B
excretion O
in O
rat O
urine O
following O
TOL B
exposure O
by O
inhalation O
, O
( O
2 O
) O
to O
compare O
them O
to O
data O
from O
traditional O
TOL B
biomarkers O
, O
i O
. O
e O
. O
TOL B
in O
blood O
( O
Tol B
- O
B O
) O
, O
and O
urinary O
hippuric B
acid I
( O
HA O
) O
and O
o B
- I
cresol I
( O
oCre B
) O
and O
( O
3 O
) O
to O
establish O
a O
relationship O
between O
these O
different O
indicators O
and O
the O
airborne O
TOL B
concentration O
( O
Tol B
- O
A O
) O
. O

Chlorophyll B
- I
a I
production O
was O
increased O
only O
in O
G O
. O
spinifera O
exposed O
to O
5 O
mu O
g O
L O
( O
- O
1 O
) O
of O
TBA B
and O
the O
effect O
was O
enhanced O
with O
the O
increase O
of O
temperature O
. O

Aliquots O
of O
the O
sediment O
extracts O
were O
analyzed O
for O
4 B
- I
nonylphenols I
and O
natural O
steroidal B
estrogens I
as O
possible O
candidates O
with O
an O
estrogenic O
potential O
. O

A O
robust O
, O
practical O
synthesis O
of O
( B
20S I
) I
- I
10 I
- I
( I
3 I
- I
aminopropyloxy I
) I
- I
7 I
- I
ethylcamptothecin I
( O
T B
- I
2513 I
, O
5 O
) O
, O
which O
is O
a O
water O
- O
soluble O
analogue O
of O
camptothecin B
, O
has O
been O
developed O
. O

Methods O
: O
A O
total O
of O
113 O
CKD O
patients O
with O
SH O
who O
were O
treated O
with O
L B
- I
thyroxine I
and O
had O
eGFR O
available O
for O
at O
least O
24 O
months O
before O
and O
after O
THRT O
were O
enrolled O
between O
January O
2005 O
and O
December O
2011 O
. O

Two O
[ O
4Fe B
- I
4S I
] O
clusters O
containing O
radical O
SAM O
enzyme O
SkfB O
catalyze O
thioether B
bond O
formation O
during O
the O
maturation O
of O
the O
sporulation O
killing O
factor O
. O

Like O
all O
sactipeptides O
, O
SKF O
contains O
a O
thioether B
bond O
, O
which O
links O
the O
cysteine B
residue O
Cys4 B
with O
the O
alpha B
- I
carbon I
of O
the O
methionine B
residue O
Met12 B
. O

In O
this O
study O
we O
demonstrate O
that O
this O
bond O
is O
generated O
by O
the O
two O
[ O
4Fe B
- I
4S I
] O
clusters O
containing O
radical O
SAM B
enzyme O
SkfB O
, O
which O
is O
encoded O
in O
the O
skf O
operon O
. O

As O
CEs O
hydrolyze O
clinically O
used O
drugs O
, O
the O
ability O
of O
tanshinones O
and O
S O
. O
miltiorrhiza O
root O
extracts O
to O
modulate O
the O
metabolism O
of O
the O
anticancer O
prodrug O
irinotecan B
( O
CPT B
- I
11 I
) O
was O
assessed O
. O

THP O
- O
1 O
cells O
were O
pre O
- O
loaded O
with O
a O
ROS O
sensitive O
fluorescent O
dye O
, O
5 B
- I
( I
and I
6 I
- I
) I
- I
chloromethyl I
- I
2 I
' I
, I
7 I
' I
- I
dichlorodihydrofluor I
diacetate I
, O
acetyl B
ester I
( O
CM B
- I
H2DCFDA I
) O
, O
for O
15min O
, O
then O
incubated O
with O
test O
chemicals O
for O
30min O
. O

Cis B
- I
hinokiresinol I
, O
a O
naturally O
occurring O
phenylpropanoid B
, O
was O
previously O
reported O
to O
possess O
anti O
- O
oxidant O
, O
anti O
- O
inflammatory O
and O
estrogen B
- O
like O
activities O
. O

However O
, O
only O
trans B
- I
hinokiresinol I
significantly O
decreased O
neuronal O
injury O
in O
cultured O
cortical O
neurons O
exposed O
to O
oxygen B
- O
glucose B
deprivation O
( O
75 O
min O
) O
followed O
by O
re O
- O
oxygenation O
( O
9 O
h O
) O
. O

The O
differential O
neuroprotective O
effect O
could O
be O
due O
to O
the O
stereo O
- O
specific O
augmentation O
of O
Cu B
/ O
Zn B
- O
SOD O
activity O
by O
trans B
- I
hinokiresinol I
, O
when O
compared O
with O
cis B
- I
hinokiresinol I
. O

The O
differential O
neuroprotective O
effect O
could O
be O
due O
to O
the O
stereo O
- O
specific O
augmentation O
of O
Cu B
/ O
Zn B
- O
SOD O
activity O
by O
trans B
- I
hinokiresinol I
, O
when O
compared O
with O
cis B
- I
hinokiresinol I
. O

Similarly O
, O
in O
rats O
subjected O
to O
transient O
middle O
cerebral O
artery O
occlusion O
( O
1 O
. O
5 O
h O
) O
followed O
by O
24 O
- O
h O
reperfusion O
, O
pre O
- O
ischemic O
treatment O
with O
trans B
- I
hinokiresinol I
, O
but O
not O
with O
cis O
- O
isomer O
, O
reduced O
cerebral O
infarct O
volume O
. O

When O
administered O
after O
onset O
of O
ischemia O
, O
trans B
- I
hinokiresinol I
, O
but O
not O
its O
cis O
- O
isomer O
reduced O
nitrotyrosine B
immunoreactivity O
in O
ischemic O
regions O
. O

Sunset B
yellow I
FCF I
, O
a O
permitted O
food O
dye O
, O
alters O
functional O
responses O
of O
splenocytes O
at O
non O
- O
cytotoxic O
dose O
. O

Sunset B
yellow I
FCF I
( O
SY O
) O
, O
a O
permitted O
food O
color O
, O
is O
extensively O
used O
in O
various O
food O
preparations O
and O
quite O
often O
exceeds O
the O
permissible O
levels O
( O
100 O
- O
200 O
mg O
/ O
kg O
) O
. O

The O
consecutive O
arrangement O
of O
2 B
' I
- I
deoxy I
- I
6 I
- I
thioguanosines I
( O
s B
( I
6 I
) I
Gs I
) O
and O
4 B
- I
thiothymidines I
( O
s B
( I
4 I
) I
Ts I
) O
in O
antiparallel O
triplex O
- O
forming O
oligonucleotides O
( O
TFOs O
) O
considerably O
stabilized O
the O
resulting O
antiparallel O
triplexes O
with O
high O
base O
recognition O
ability O
by O
the O
strong O
stacking O
effects O
of O
thiocarbonyl B
groups O
. O

Regiospecificity O
and O
stereospecificity O
of O
human O
UDP B
- O
glucuronosyltransfer O
in O
the O
glucuronidation O
of O
estriol B
, O
16 B
- I
epiestriol I
, O
17 B
- I
epiestriol I
, O
and O
13 B
- I
epiestradiol I
. O

Regiospecificity O
and O
stereospecificity O
of O
human O
UDP B
- O
glucuronosyltransfer O
in O
the O
glucuronidation O
of O
estriol B
, O
16 B
- I
epiestriol I
, O
17 B
- I
epiestriol I
, O
and O
13 B
- I
epiestradiol I
. O

Regiospecificity O
and O
stereospecificity O
of O
human O
UDP B
- O
glucuronosyltransfer O
in O
the O
glucuronidation O
of O
estriol B
, O
16 B
- I
epiestriol I
, O
17 B
- I
epiestriol I
, O
and O
13 B
- I
epiestradiol I
. O

The O
glucuronidation O
of O
estriol B
, O
16 B
- I
epiestriol I
, O
and O
17 B
- I
epiestriol I
by O
the O
human O
UDP B
- O
glucuronosyltransfer O
( O
UGTs O
) O
of O
subfamilies O
1A O
, O
2A O
, O
and O
2B O
was O
examined O
. O

The O
glucuronidation O
of O
estriol B
, O
16 B
- I
epiestriol I
, O
and O
17 B
- I
epiestriol I
by O
the O
human O
UDP B
- O
glucuronosyltransfer O
( O
UGTs O
) O
of O
subfamilies O
1A O
, O
2A O
, O
and O
2B O
was O
examined O
. O

UGT1A10 O
is O
highly O
active O
in O
the O
conjugation O
of O
the O
3 B
- I
OH I
in O
all O
these O
estriols B
, O
whereas O
UGT2B7 O
is O
the O
most O
active O
UGT O
toward O
one O
of O
the O
ring O
D O
hydroxyls O
, O
the O
16 B
- I
OH I
in O
estriol B
and O
16 B
- I
epiestriol I
, O
but O
the O
17 B
- I
OH I
in O
17 B
- I
epiestriol I
. O

UGT1A10 O
is O
highly O
active O
in O
the O
conjugation O
of O
the O
3 B
- I
OH I
in O
all O
these O
estriols B
, O
whereas O
UGT2B7 O
is O
the O
most O
active O
UGT O
toward O
one O
of O
the O
ring O
D O
hydroxyls O
, O
the O
16 B
- I
OH I
in O
estriol B
and O
16 B
- I
epiestriol I
, O
but O
the O
17 B
- I
OH I
in O
17 B
- I
epiestriol I
. O

UGT1A10 O
is O
highly O
active O
in O
the O
conjugation O
of O
the O
3 B
- I
OH I
in O
all O
these O
estriols B
, O
whereas O
UGT2B7 O
is O
the O
most O
active O
UGT O
toward O
one O
of O
the O
ring O
D O
hydroxyls O
, O
the O
16 B
- I
OH I
in O
estriol B
and O
16 B
- I
epiestriol I
, O
but O
the O
17 B
- I
OH I
in O
17 B
- I
epiestriol I
. O

UGT1A10 O
is O
highly O
active O
in O
the O
conjugation O
of O
the O
3 B
- I
OH I
in O
all O
these O
estriols B
, O
whereas O
UGT2B7 O
is O
the O
most O
active O
UGT O
toward O
one O
of O
the O
ring O
D O
hydroxyls O
, O
the O
16 B
- I
OH I
in O
estriol B
and O
16 B
- I
epiestriol I
, O
but O
the O
17 B
- I
OH I
in O
17 B
- I
epiestriol I
. O

UGT1A10 O
is O
highly O
active O
in O
the O
conjugation O
of O
the O
3 B
- I
OH I
in O
all O
these O
estriols B
, O
whereas O
UGT2B7 O
is O
the O
most O
active O
UGT O
toward O
one O
of O
the O
ring O
D O
hydroxyls O
, O
the O
16 B
- I
OH I
in O
estriol B
and O
16 B
- I
epiestriol I
, O
but O
the O
17 B
- I
OH I
in O
17 B
- I
epiestriol I
. O

Kinetic O
analyses O
indicated O
that O
the O
17 B
- I
OH I
configuration O
plays O
a O
major O
role O
in O
the O
affinity O
of O
UGT2B7 O
for O
estrogens B
. O

The O
UGT1A10 O
mutant O
1A10 O
- O
F93G O
exhibited O
much O
higher O
V O
( O
max O
) O
values O
than O
UGT1A10 O
in O
estriol B
and O
17 B
- I
epiestriol I
glucuronidation O
, O
but O
a O
significantly O
lower O
value O
in O
16 B
- I
epiestriol I
glucuronidation O
. O

The O
UGT1A10 O
mutant O
1A10 O
- O
F93G O
exhibited O
much O
higher O
V O
( O
max O
) O
values O
than O
UGT1A10 O
in O
estriol B
and O
17 B
- I
epiestriol I
glucuronidation O
, O
but O
a O
significantly O
lower O
value O
in O
16 B
- I
epiestriol I
glucuronidation O
. O

To O
this O
study O
on O
estriol B
glucuronidation O
we O
have O
added O
experiments O
with O
13 B
- I
epiestradiol I
, O
a O
synthetic O
estradiol B
in O
which O
the O
spatial O
arrangement O
of O
the O
methyl B
on O
C18 O
and O
the O
hydroxyl B
on O
C17 O
is O
significantly O
different O
than O
in O
other O
estrogens B
. O

In O
comparison O
with O
estradiol B
glucuronidation O
, O
the O
C13 O
configuration O
change O
decreases O
the O
turnover O
of O
UGTs O
that O
conjugate O
the O
3 B
- I
OH I
, O
but O
increases O
it O
in O
UGTs O
that O
primarily O
conjugate O
the O
17 B
- I
OH I
. O

In O
comparison O
with O
estradiol B
glucuronidation O
, O
the O
C13 O
configuration O
change O
decreases O
the O
turnover O
of O
UGTs O
that O
conjugate O
the O
3 B
- I
OH I
, O
but O
increases O
it O
in O
UGTs O
that O
primarily O
conjugate O
the O
17 B
- I
OH I
. O

Unexpectedly O
, O
UGT2B17 O
exhibited O
similar O
conjugation O
rates O
of O
both O
the O
17 B
- I
OH I
and O
3 B
- I
OH I
of O
13 B
- I
espiestradiol I
. O

Unexpectedly O
, O
UGT2B17 O
exhibited O
similar O
conjugation O
rates O
of O
both O
the O
17 B
- I
OH I
and O
3 B
- I
OH I
of O
13 B
- I
espiestradiol I
. O

Unexpectedly O
, O
UGT2B17 O
exhibited O
similar O
conjugation O
rates O
of O
both O
the O
17 B
- I
OH I
and O
3 B
- I
OH I
of O
13 B
- I
espiestradiol I
. O

The O
combined O
results O
reveal O
the O
strong O
preference O
of O
UGT1A10 O
for O
the O
3 B
- I
OH I
of O
physiologic O
estrogens B
and O
the O
equivalently O
strong O
preference O
of O
UGT2B7 O
and O
UGT2B17 O
for O
the O
hydroxyls B
on O
ring O
D O
of O
such O
steroid B
hormones I
. O

Inhibition O
of O
HIV O
- O
1 O
replication O
by O
a O
tricyclic B
coumarin I
GUT B
- I
70 I
in O
acutely O
and O
chronically O
infected O
cells O
. O

The O
anti O
- O
HIV O
- O
1 O
activity O
of O
GUT B
- I
70 I
, O
a O
natural O
product O
derived O
from O
the O
stem O
bark O
of O
Chlophyllum O
brasiliense O
, O
was O
evaluated O
. O

GUT B
- I
70 I
inhibited O
HIV O
- O
1 O
replication O
in O
both O
acutely O
and O
chronically O
infected O
cells O
through O
suppression O
of O
NF O
- O
kappa O
B O
. O

Our O
results O
strengthen O
the O
idea O
that O
NF O
- O
kappa O
B O
pathway O
is O
one O
of O
the O
potential O
targets O
to O
control O
HIV O
- O
1 O
replication O
and O
that O
GUT B
- I
70 I
could O
serve O
as O
a O
lead O
compound O
to O
develop O
novel O
therapeutic O
agents O
against O
HIV O
- O
1 O
infection O
. O

Cholinesterase O
and O
carboxylesterase O
inhibition O
in O
Planorbarius O
corneus O
exposed O
to O
binary O
mixtures O
of O
azinphos B
- I
methyl I
and O
chlorpyrifos B
. O

The O
present O
investigation O
was O
undertaken O
to O
explore O
the O
in O
vivo O
inhibition O
of O
the O
freshwater O
gastropod O
snail O
Planorbarius O
corneus O
cholinesterase O
( O
ChE O
) O
and O
carboxylesterases O
( O
CES O
) O
activities O
by O
the O
organophosphorus B
pesticides O
azinphos B
- I
methyl I
( O
AZM B
) O
and O
chlorpyrifos B
( O
CPF B
) O
. O

We O
explored O
BRS O
- O
3 O
expression O
in O
skeletal O
muscle O
from O
normal O
, O
obese O
or O
type O
- O
2 O
diabetic O
( O
T2D O
) O
patients O
, O
and O
the O
effect O
of O
[ O
D B
- I
Phe I
( O
6 O
) O
, O
beta B
- I
Ala I
( O
11 O
) O
, O
Phe B
( O
13 O
) O
, O
Nle B
( O
14 O
) O
] O
bombesin B
( O
6 O
- O
14 O
) O
- O
BRS O
- O
3 O
- O
agonist O
- O
peptide O
( O
BRS O
- O
3 O
- O
AP O
) O
- O
on O
glucose B
- O
related O
effects O
, O
before O
or O
after O
BRS O
- O
3 O
gene O
silencing O
. O

We O
explored O
BRS O
- O
3 O
expression O
in O
skeletal O
muscle O
from O
normal O
, O
obese O
or O
type O
- O
2 O
diabetic O
( O
T2D O
) O
patients O
, O
and O
the O
effect O
of O
[ O
D B
- I
Phe I
( O
6 O
) O
, O
beta B
- I
Ala I
( O
11 O
) O
, O
Phe B
( O
13 O
) O
, O
Nle B
( O
14 O
) O
] O
bombesin B
( O
6 O
- O
14 O
) O
- O
BRS O
- O
3 O
- O
agonist O
- O
peptide O
( O
BRS O
- O
3 O
- O
AP O
) O
- O
on O
glucose B
- O
related O
effects O
, O
before O
or O
after O
BRS O
- O
3 O
gene O
silencing O
. O

In O
this O
study O
, O
we O
showed O
that O
another O
potent O
AhR O
agonist O
- O
beta B
- I
naphthoflavone I
( O
BNF B
) O
- O
significantly O
decreased O
light O
- O
induced O
phase O
shifts O
in O
wild O
- O
type O
( O
WT O
) O
mice O
, O
whereas O
AhR O
knockout O
mice O
had O
an O
enhanced O
response O
to O
light O
that O
was O
unaffected O
by O
BNF B
. O

S B
- I
nitrosoglutathione I
covalently O
modifies O
cysteine B
residues O
of O
human O
carbonyl B
reductase O
1 O
and O
affects O
its O
activity O
. O

S B
- I
Nitrosoglutathione I
( O
GSNO B
) O
represents O
the O
newest O
addition O
to O
its O
diverse O
substrate O
spectrum O
, O
which O
includes O
a O
wide O
range O
of O
xenobiotics O
and O
endogenous O
substances O
. O

The O
analysis O
confirmed O
GSNO B
concentration O
- O
dependent O
S B
- I
glutathionylation I
of O
cysteines B
at O
positions O
122 O
, O
150 O
, O
226 O
, O
227 O
which O
was O
2 O
- O
700 O
times O
higher O
compared O
to O
wild O
- O
type O
CBR1 O
( O
WT O
- O
CBR1 O
) O
. O

GSNO B
treatment O
of O
CBR1 O
resulted O
in O
a O
2 O
- O
5 O
- O
fold O
decrease O
in O
kcat O
with O
menadione B
, O
4 B
- I
benzoylpyridine I
, O
2 B
, I
3 I
- I
hexanedione I
, O
daunorubicin B
and O
1 B
, I
4 I
- I
naphthoquinone I
. O

Furthermore O
, O
a O
humanized O
CYP3A4 O
/ O
3A7 O
mouse O
model O
showed O
in O
vivo O
induction O
of O
CYP3A4 O
mRNA O
and O
protein O
by O
[ O
4 B
- I
chloro I
- I
6 I
- I
( I
2 I
, I
3 I
- I
xylidino I
) I
- I
2 I
- I
pyrimidinylthio I
] I
acetic I
acid I
( O
WY14 B
, I
643 I
) O
in O
liver O
but O
not O
in O
intestine O
, O
whereas O
hepatic O
occupancy O
of O
PBRs O
by O
PPAR O
alpha O
was O
ligand O
independent O
. O

Using O
lentiviral O
gene O
knock O
- O
down O
and O
treatment O
with O
WY14 B
, I
643 I
in O
primary O
human O
hepatocytes O
, O
PPAR O
alpha O
was O
further O
shown O
to O
affect O
the O
expression O
of O
a O
distinct O
set O
of O
CYPs O
, O
including O
1A1 O
, O
1A2 O
, O
2B6 O
, O
2C8 O
, O
3A4 O
, O
and O
7A1 O
, O
but O
not O
2C9 O
, O
2C19 O
, O
2D6 O
, O
or O
2E1 O
. O

Interestingly O
, O
the O
common O
phospholipid O
1 B
- I
palmitoyl I
- I
2 I
- I
oleoyl I
- I
sn I
- I
glycerol I
- I
3 I
- I
phosphocholine I
( O
16 O
: O
0 O
/ O
18 O
: O
1 O
- O
PC O
) O
, O
previously O
proposed O
to O
reflect O
nutritional O
status O
and O
shown O
to O
be O
a O
specific O
endogenous O
ligand O
of O
PPAR O
alpha O
, O
induced O
CYP3A4 O
( O
up O
to O
4 O
- O
fold O
) O
and O
other O
biotransformation O
genes O
in O
hepatocytes O
with O
similar O
selectivity O
and O
potency O
as O
WY14 B
, I
643 I
. O

Polymeric B
triamcinolone I
acetonide I
nanoparticles O
as O
a O
new O
alternative O
in O
the O
treatment O
of O
uveitis O
: O
In O
vitro O
and O
in O
vivo O
studies O
. O

Strontium B
doped I
perovskites I
exhibited O
opposite O
temperature O
dependencies O
to O
parent O
materials O
. O

Blocking O
spinal O
5 B
- I
hydroxytryptamine I
- O
7 O
receptors O
with O
( B
2R I
) I
- I
1 I
- I
[ I
( I
3 I
- I
hydroxyphenyl I
) I
sulfonyl I
] I
- I
2 I
- I
[ I
2 I
- I
( I
4 I
- I
methyl I
- I
1 I
- I
piperidinyl I
) I
ethyl I
] I
pyrrolidine I
hydrochloride I
suggested O
that O
the O
effects O
of O
milnacipran B
in O
the O
late O
phase O
were O
partly O
mediated O
by O
these O
receptors O
, O
and O
that O
descending O
serotonergic O
inhibition O
was O
increased O
in O
this O
phase O
. O

Effect O
of O
major O
cations O
( O
Ca B
( I
2 I
+ I
) I
, O
Mg B
( I
2 I
+ I
) I
, O
Na B
( I
+ I
) I
, O
K B
( I
+ I
) I
) O
and O
anions O
( O
SO B
42 I
- I
, O
Cl B
( I
- I
) I
, O
NO B
3 I
- I
) O
on O
Ni B
accumulation O
and O
toxicity O
in O
aquatic O
plant O
( O
Lemna O
minor O
L O
. O
) O
: O
implications O
For O
Ni B
risk O
assessment O
. O

Effect O
of O
major O
cations O
( O
Ca B
( I
2 I
+ I
) I
, O
Mg B
( I
2 I
+ I
) I
, O
Na B
( I
+ I
) I
, O
K B
( I
+ I
) I
) O
and O
anions O
( O
SO B
42 I
- I
, O
Cl B
( I
- I
) I
, O
NO B
3 I
- I
) O
on O
Ni B
accumulation O
and O
toxicity O
in O
aquatic O
plant O
( O
Lemna O
minor O
L O
. O
) O
: O
implications O
For O
Ni B
risk O
assessment O
. O

Crystalline O
alpha B
- I
glucose I
is O
known O
to O
amorphize O
upon O
milling O
at O
- O
15 O
degrees O
C O
while O
it O
remains O
structurally O
invariant O
upon O
milling O
at O
room O
temperature O
. O

The O
results O
indicate O
that O
two O
different O
amorphization O
mechanisms O
occur O
upon O
milling O
: O
an O
amorphization O
at O
the O
surface O
of O
crystallites O
due O
to O
the O
mechanical O
shocks O
and O
a O
spontaneous O
amorphization O
of O
the O
crystallites O
as O
they O
reach O
a O
critical O
size O
, O
which O
is O
close O
to O
200 O
A O
in O
the O
particular O
case O
of O
alpha B
- I
glucose I
. O

Luminol B
as O
in O
situ O
light O
source O
in O
meso B
- I
tetraphenylporphyrin I
- O
mediated O
photodynamic O
therapy O
. O

In O
the O
present O
work O
, O
we O
use O
luminol B
as O
light O
source O
and O
meso B
- I
tetraphenylporphyrin I
as O
the O
photosensitizer O
. O

According O
to O
the O
results O
, O
cells O
incubated O
with O
meso B
- I
tetraphenylporphyrin I
, O
subsequently O
triggered O
by O
luminol B
, O
decreased O
significantly O
in O
assays O
including O
cell O
viability O
and O
cytotoxicity O
, O
while O
the O
other O
groups O
showed O
only O
minor O
differences O
. O

Briefly O
, O
we O
suggest O
that O
luminol B
is O
a O
promising O
light O
source O
in O
meso B
- I
tetraphenylporphyrin I
- O
mediated O
photodynamic O
therapy O
for O
its O
greater O
penetration O
depth O
and O
well O
matched O
emission O
wavelength O
. O

Novel O
P2 O
tris B
- I
tetrahydrofuran I
group O
in O
antiviral O
compound O
1 O
( O
GRL B
- I
0519 I
) O
fills O
the O
S2 O
binding O
pocket O
of O
selected O
mutants O
of O
HIV O
- O
1 O
protease O
. O

Novel O
P2 O
tris B
- I
tetrahydrofuran I
group O
in O
antiviral O
compound O
1 O
( O
GRL B
- I
0519 I
) O
fills O
the O
S2 O
binding O
pocket O
of O
selected O
mutants O
of O
HIV O
- O
1 O
protease O
. O

GRL B
- I
0519 I
( O
1 O
) O
is O
a O
potent O
antiviral O
inhibitor O
of O
HIV O
- O
1 O
protease O
( O
PR O
) O
possessing O
tris B
- I
tetrahydrofuran I
( O
tris B
- I
THF I
) O
at O
P2 O
. O

GRL B
- I
0519 I
( O
1 O
) O
is O
a O
potent O
antiviral O
inhibitor O
of O
HIV O
- O
1 O
protease O
( O
PR O
) O
possessing O
tris B
- I
tetrahydrofuran I
( O
tris B
- I
THF I
) O
at O
P2 O
. O

GRL B
- I
0519 I
( O
1 O
) O
is O
a O
potent O
antiviral O
inhibitor O
of O
HIV O
- O
1 O
protease O
( O
PR O
) O
possessing O
tris B
- I
tetrahydrofuran I
( O
tris B
- I
THF I
) O
at O
P2 O
. O

The O
carbonyl B
oxygen B
of O
Gly48 O
showed O
two O
alternative O
conformations O
in O
all O
structures O
likely O
due O
to O
the O
snug O
fit O
of O
the O
large O
tris B
- I
THF I
group O
in O
the O
S2 O
subsite O
in O
agreement O
with O
high O
antiviral O
efficacy O
of O
1 O
on O
resistant O
virus O
. O

Considering O
the O
strong O
DNA O
minor O
groove O
binding O
observed O
for O
our O
previous O
series O
of O
diaromatic O
symmetric O
and O
asymmetric O
guanidinium B
and O
2 B
- I
aminoimidazolinium I
derivatives O
, O
we O
report O
now O
the O
synthesis O
of O
new O
aminoalkyl B
derivatives O
of O
diaromatic O
guanidines O
with O
potential O
as O
DNA O
minor O
groove O
binders O
and O
antiprotozoal O
activity O
. O

We O
used O
a O
sensitive O
liquid O
chromatography O
- O
mass O
spectrometry O
( O
LC O
/ O
MS O
) O
and O
LC O
/ O
MS O
/ O
MS O
method O
to O
show O
that O
L B
- I
tyrosine I
( O
Tyr B
) O
, O
an O
amino B
acid I
with O
a O
highly O
reactive O
hydroxyl B
group O
, O
readily O
reacts O
with O
cigarette O
smoke O
extract O
( O
CSE O
) O
at O
body O
temperature O
( O
37 O
degrees O
C O
) O
to O
form O
various O
Tyr B
derivatives O
. O

Among O
these O
derivatives O
were O
N B
- I
( I
3 I
- I
oxobutyl I
) I
- I
Tyr I
and O
two O
acetylated O
compounds O
, O
N B
- I
acetyl I
- I
Tyr I
and O
O B
- I
acetyl I
- I
Tyr I
, O
which O
were O
synthesized O
by O
reaction O
of O
Tyr B
with O
methyl B
vinyl I
ketone I
and O
acetic B
anhydride I
, O
respectively O
, O
at O
37 O
degrees O
C O
. O

The O
presence O
of O
methyl B
vinyl I
ketone I
and O
acetic B
anhydride I
in O
CSE O
was O
confirmed O
by O
gas O
chromatography O
- O
mass O
spectrometry O
( O
GC O
/ O
MS O
) O
. O

Tissue O
IDO O
was O
investigated O
using O
quantitative O
RT O
- O
PCR O
and O
Western O
blot O
, O
whereas O
tryptophan B
, O
kynurenine B
, O
and O
5 B
- I
hydroxytryptamine I
( O
5 B
- I
HT I
) O
concentrations O
were O
quantified O
by O
HPLC O
and O
ELISA O
. O

Tissue O
IDO O
was O
investigated O
using O
quantitative O
RT O
- O
PCR O
and O
Western O
blot O
, O
whereas O
tryptophan B
, O
kynurenine B
, O
and O
5 B
- I
hydroxytryptamine I
( O
5 B
- I
HT I
) O
concentrations O
were O
quantified O
by O
HPLC O
and O
ELISA O
. O

L O
. O
johnsonii O
feeding O
resulted O
in O
a O
17 O
% O
reduction O
in O
serum O
kynurenine B
compared O
with O
that O
in O
vehicle O
- O
fed O
controls O
, O
correlating O
with O
a O
1 O
. O
4 O
- O
fold O
elevation O
in O
5 B
- I
HT I
levels O
. O

Dual O
E O
- O
and O
H O
- O
field O
control O
of O
microwave O
performance O
with O
enhanced O
ferromagnetic O
resonance O
( O
FMR O
) O
tunability O
has O
been O
demonstrated O
in O
microwave O
composites O
FeGaB B
/ O
PZN B
- I
PT I
( O
011 O
) O
. O

A O
voltage O
- O
impulse O
- O
induced O
non O
- O
volatile O
magnetization O
switching O
was O
also O
realized O
in O
this O
work O
, O
resulting O
from O
the O
hysteretic O
type O
of O
phase O
transition O
in O
PZN B
- I
PT I
( O
011 O
) O
at O
high O
electric O
fields O
. O

Introducing O
a O
second O
pendant O
group O
- O
- O
biotin B
- O
- O
affords O
an O
unsymmetrical O
bis B
- I
triazole I
- O
scorpionand O
ligand O
that O
interacts O
specifically O
with O
avidin O
. O

Promiscuous O
catalysis O
of O
asymmetric O
Michael O
- O
type O
additions O
of O
linear O
aldehydes B
to O
beta B
- I
nitrostyrene I
by O
the O
proline B
- O
based O
enzyme O
4 B
- I
oxalocrotonate I
tautomerase O
. O

Promiscuous O
catalysis O
of O
asymmetric O
Michael O
- O
type O
additions O
of O
linear O
aldehydes B
to O
beta B
- I
nitrostyrene I
by O
the O
proline B
- O
based O
enzyme O
4 B
- I
oxalocrotonate I
tautomerase O
. O

Exploiting O
catalytic O
promiscuity O
: O
The O
proline B
- O
based O
enzyme O
4 B
- I
oxalocrotonate I
tautomerase O
( O
4 B
- I
OT I
) O
promiscuously O
catalyzes O
asymmetric O
Michael O
- O
type O
additions O
of O
linear O
aldehydes B
- O
- O
ranging O
from O
acetaldehyde B
to O
octanal B
- O
- O
to O
trans B
- I
beta I
- I
nitrostyrene I
in O
aqueous O
solvent O
. O

Exploiting O
catalytic O
promiscuity O
: O
The O
proline B
- O
based O
enzyme O
4 B
- I
oxalocrotonate I
tautomerase O
( O
4 B
- I
OT I
) O
promiscuously O
catalyzes O
asymmetric O
Michael O
- O
type O
additions O
of O
linear O
aldehydes B
- O
- O
ranging O
from O
acetaldehyde B
to O
octanal B
- O
- O
to O
trans B
- I
beta I
- I
nitrostyrene I
in O
aqueous O
solvent O
. O

The O
presence O
of O
1 O
. O
4 O
mol O
% O
of O
4 B
- I
OT I
effected O
formation O
of O
the O
anticipated O
gamma B
- I
nitroaldehydes I
in O
fair O
to O
good O
yields O
with O
dr O
values O
of O
up O
to O
93 O
: O
7 O
and O
ee O
values O
of O
up O
to O
81 O
% O
. O

The O
presence O
of O
1 O
. O
4 O
mol O
% O
of O
4 B
- I
OT I
effected O
formation O
of O
the O
anticipated O
gamma B
- I
nitroaldehydes I
in O
fair O
to O
good O
yields O
with O
dr O
values O
of O
up O
to O
93 O
: O
7 O
and O
ee O
values O
of O
up O
to O
81 O
% O
. O

FTIR O
spectroscopy O
shows O
that O
dissolving O
a O
carboxylic B
acid I
anhydride I
in O
IL O
- O
F O
leads O
to O
the O
formation O
of O
acyl B
fluoride I
. O

Treating O
N B
- I
propylnorglaucine I
with O
90 O
% O
H2SO4 B
yielded O
one O
additional O
product O
, O
an O
11 B
- I
sulfonyl I
- I
1 I
, I
11 I
- I
anhydroaporphine I
. O

Reaction O
of O
N B
- I
formylnorglaucine I
( O
3a O
) O
with O
90 O
% O
H2SO4 B
, O
however O
, O
yielded O
the O
9 B
- I
sulfonyl I
- I
seco I
product O
as O
a O
major O
product O
. O

Firstly O
, O
in O
the O
normal O
human O
renal O
epithelial O
HK O
- O
2 O
cells O
, O
the O
measurement O
of O
the O
expression O
of O
30 O
previously O
reported O
NRF2 O
target O
genes O
in O
response O
to O
NRF2 O
inducers O
( O
sulforaphane B
, O
tert B
- I
butylhydroquinone I
, O
cinnamic B
aldehyde I
, O
and O
hydrogen B
peroxide I
) O
showed O
that O
the O
aldo O
- O
keto O
reductase O
( O
AKR O
) O
1C1 O
is O
highly O
inducible O
by O
all O
treatments O
. O

Decreasing O
PO B
( I
4 I
) I
( I
3 I
- I
) I
and O
increasing O
Cd B
concentrations O
resulted O
in O
higher O
saturated B
fatty I
acid I
( O
SAFA B
) O
and O
monounsaturated B
FA I
( O
MUFA B
) O
concentrations O
. O

Total O
polyunsaturated B
FA I
( O
PUFA B
) O
and O
omega B
3 I
PUFA I
, O
and O
PUFA B
: O
SAFA B
ratios O
were O
higher O
in O
the O
control O
( O
2 O
. O
3 O
x O
10 O
( O
- O
4 O
) O
mol O
L O
( O
- O
1 O
) O
PO B
( I
4 I
) I
( I
3 I
- I
) I
) O
cells O
than O
in O
either O
PO B
( I
4 I
) I
( I
3 I
- I
) I
limitation O
or O
Cd B
stress O
, O
or O
in O
the O
combination O
of O
both O
stresses O
. O

The O
hepatoprotection O
of O
caffeic B
acid I
and O
rosmarinic B
acid I
, O
major O
compounds O
of O
Perilla O
frutescens O
, O
against O
t B
- I
BHP I
- O
induced O
oxidative O
liver O
damage O
. O

Additionally O
, O
all O
doses O
of O
sodium B
metasilicate I
( O
1 O
, O
5 O
, O
10 O
, O
25 O
, O
50 O
, O
and O
100 O
mu O
M O
) O
increased O
mineralized O
nodule O
formation O
at O
14 O
days O
of O
differentiation O
as O
evidenced O
by O
increased O
Alizarin B
Red I
S I
staining O
. O

Herein O
, O
we O
examined O
the O
optical O
properties O
of O
three O
Si B
QDs O
with O
increasing O
sigma O
- O
pi O
conjugation O
length O
: O
octyl B
- O
, O
( B
trimethylsilyl I
) I
vinyl I
- O
, O
and O
2 B
- I
phenylvinyl I
- O
capped O
Si B
QDs O
. O

The O
PL O
photon O
energy O
obtained O
from O
as O
- O
prepared O
samples O
decreased O
by O
0 O
. O
1 O
- O
0 O
. O
3 O
eV O
, O
while O
the O
PL O
excitation O
( O
PLE O
) O
extended O
from O
360 O
nm O
( O
octyl B
- O
capped O
Si B
QDs O
) O
to O
400 O
nm O
( O
2 B
- I
phenylvinyl I
- O
capped O
Si B
QDs O
) O
. O

Hypoxia O
- O
selective O
O6 B
- I
alkylguanine I
- O
DNA O
alkyltransferase O
inhibitors O
: O
design O
, O
synthesis O
, O
and O
evaluation O
of O
6 B
- I
( I
benzyloxy I
) I
- I
2 I
- I
( I
aryldiazenyl I
) I
- I
9H I
- I
purines I
as O
prodrugs O
of O
O6 B
- I
benzylguanine I
. O

Hypoxia O
- O
selective O
O6 B
- I
alkylguanine I
- O
DNA O
alkyltransferase O
inhibitors O
: O
design O
, O
synthesis O
, O
and O
evaluation O
of O
6 B
- I
( I
benzyloxy I
) I
- I
2 I
- I
( I
aryldiazenyl I
) I
- I
9H I
- I
purines I
as O
prodrugs O
of O
O6 B
- I
benzylguanine I
. O

In O
this O
study O
, O
we O
report O
thermosensitive O
hydrogels O
based O
on O
poly B
( I
ethylene I
glycol I
) I
- I
block I
- I
poly I
( I
gamma I
- I
propargyl I
- I
l I
- I
glutamate I
) I
( O
PEG B
- I
PPLG I
) O
. O

The O
presence O
of O
alkynyl B
side O
groups O
in O
the O
PEG B
- I
PPLG I
copolymers O
allowed O
convenient O
further O
functionalization O
with O
azide B
- O
modified O
bioactive O
molecules O
, O
such O
as O
biotin B
and O
galactose B
. O

Of O
these O
, O
the O
newly O
synthesized O
6 B
, I
8 I
- I
diallyl I
- I
5 I
, I
7 I
- I
dihydroxycoumarin I
( O
8a O
) O
was O
produced O
in O
three O
steps O
in O
high O
chemical O
yield O
from O
floroglucinol B
and O
found O
to O
be O
the O
most O
potent O
of O
this O
series O
, O
exhibiting O
activity O
similar O
to O
the O
reference O
coumestan B
LQB B
- I
34 I
. O

However O
, O
other O
steroids B
, O
including O
Delta B
( I
5 I
) I
- I
androstenediol I
, O
5 B
alpha I
- I
androstanediol I
and O
27 B
- I
hydroxycholesterol I
, O
which O
have O
a O
saturated O
A O
ring O
containing O
a O
3 B
beta I
- I
hydroxyl I
and O
a O
C19 O
methyl B
group O
, O
also O
mediate O
physiological O
responses O
through O
binding O
to O
estrogen B
receptor O
- O
alpha O
( O
ER O
alpha O
) O
and O
ER O
beta O
. O

Perturbation O
of O
male O
sexual O
behavior O
in O
mice O
( O
Mus O
musculus O
) O
within O
a O
discrete O
range O
of O
perinatal O
bisphenol B
- I
A I
doses O
in O
the O
context O
of O
a O
high O
- O
or O
low O
- O
phytoestrogen O
diet O
. O

As O
bisphenol B
- I
A I
( O
BPA B
) O
can O
be O
estrogenic O
and O
anti O
- O
androgenic O
, O
we O
examined O
impacts O
of O
perinatal O
exposure O
upon O
adult O
sexual O
behavior O
and O
morphology O
of O
male O
mice O
. O

Diminutive O
effect O
on O
T O
and O
B O
- O
cell O
proliferation O
of O
non O
- O
cytotoxic O
alpha B
- I
santonin I
derived O
1 B
, I
2 I
, I
3 I
- I
triazoles I
: O
a O
report O
. O

alpha B
- I
Santonin I
derived O
new O
series O
of O
1 B
, I
2 I
, I
3 I
- I
triazoles I
synthesized O
through O
Azide B
- I
Alkyne I
Huisgen O
1 O
, O
3 O
- O
dipolar O
cycloaddition O
reaction O
between O
substituted O
aryl B
azide I
and O
a O
propargylated B
alpha I
- I
desmotrosantonin I
were O
bio O
- O
evaluated O
for O
their O
diminutive O
effect O
on O
ConA O
induced O
T O
- O
cell O
and O
LPS O
induced O
B O
- O
cell O
proliferation O
. O

alpha B
- I
Santonin I
derived O
new O
series O
of O
1 B
, I
2 I
, I
3 I
- I
triazoles I
synthesized O
through O
Azide B
- I
Alkyne I
Huisgen O
1 O
, O
3 O
- O
dipolar O
cycloaddition O
reaction O
between O
substituted O
aryl B
azide I
and O
a O
propargylated B
alpha I
- I
desmotrosantonin I
were O
bio O
- O
evaluated O
for O
their O
diminutive O
effect O
on O
ConA O
induced O
T O
- O
cell O
and O
LPS O
induced O
B O
- O
cell O
proliferation O
. O

Interestingly O
, O
most O
of O
the O
synthesized O
compounds O
showed O
better O
immunosuppressant O
activity O
than O
alpha B
- I
santonin I
. O

Dopamine B
levels O
in O
the O
fish O
brains O
increased O
in O
a O
dose O
- O
dependent O
manner O
, O
while O
5 B
- I
hydroxytryptamine I
and O
norepinephrine B
levels O
decreased O
significantly O
in O
the O
TBT B
exposure O
group O
compared O
to O
the O
control O
. O

Although O
the O
levels O
of O
amino B
acid I
neurotransmitters O
, O
including O
glutamate B
, O
did O
not O
show O
marked O
alteration O
, O
the O
expression O
of O
the O
glutamatergic O
signaling O
pathway O
such O
as O
N B
- I
methyl I
- I
D I
- I
aspartate I
receptors O
, O
a B
- I
amino I
- I
3 I
- I
hydroxy I
- I
5 I
- I
methylisoxazole I
- I
4 I
- I
propionic I
acid I
receptor O
, O
calmodulin O
, O
Ca B
( I
2 I
+ I
) I
/ O
calmodulin O
- O
dependent O
protein O
kinases O
- O
II O
and O
cyclic B
adenosine I
monophosphate I
responsive O
element O
binding O
protein O
, O
was O
significantly O
reduced O
by O
TBT B
exposure O

Addition O
of O
LTCC O
opener O
BAY B
K I
8644 I
( O
10 O
( O
- O
7 O
) O
M O
) O
failed O
to O
enhance O
the O
relaxations O
. O

However O
, O
they O
were O
increased O
by O
nearly O
40 O
% O
in O
response O
to O
BAY B
K I
8644 I
( O
10 O
( O
- O
7 O
) O
M O
) O
and O
were O
inhibited O
by O
nifedipine B
( O
10 O
( O
- O
7 O
) O
M O
) O
, O
indicating O
that O
activation O
of O
the O
LTCCs O
was O
essential O
. O

Inositol B
triphosphate I
( O
InsP3 O
) O
receptor O
antagonist O
2 B
- I
APB I
( O
10 O
( O
- O
4 O
) O
M O
) O
significantly O
reduced O
, O
and O
high O
concentration O
of O
caffeine B
( O
20mM O
) O
almost O
totally O
suppressed O
the O
contractions O
. O

Finally O
, O
it O
has O
also O
been O
shown O
that O
SFE O
is O
very O
selective O
towards O
some O
specific O
components O
such O
as O
manoyl B
oxide I
, O
trans B
- I
totarol I
and O
alpha B
- I
acoradiene I
. O

Finally O
, O
it O
has O
also O
been O
shown O
that O
SFE O
is O
very O
selective O
towards O
some O
specific O
components O
such O
as O
manoyl B
oxide I
, O
trans B
- I
totarol I
and O
alpha B
- I
acoradiene I
. O

Lead O
optimization O
of O
a O
pyridine B
- I
carboxamide I
series O
as O
DGAT O
- O
1 O
inhibitors O
. O

The O
structure O
- O
activity O
relationship O
studies O
of O
a O
novel O
series O
of O
carboxylic B
acid I
derivatives O
of O
pyridine B
- I
carboxamides I
as O
DGAT O
- O
1 O
inhibitors O
is O
described O
. O

Ex O
vivo O
samples O
of O
human O
oral O
mucosa O
were O
exposed O
to O
Pb B
or O
BaP B
, O
and O
immunohistochemical O
staining O
was O
performed O
to O
evaluate O
active O
caspase O
- O
3 O
, O
8 B
- I
epi I
- I
prostaglandin I
F2 I
alpha I
( O
8 B
- I
epi I
- I
PGF2a I
) O
, O
and O
3 B
- I
nitrotyrosine I
( O
3 B
- I
NT I
) O
. O

Ex O
vivo O
samples O
of O
human O
oral O
mucosa O
were O
exposed O
to O
Pb B
or O
BaP B
, O
and O
immunohistochemical O
staining O
was O
performed O
to O
evaluate O
active O
caspase O
- O
3 O
, O
8 B
- I
epi I
- I
prostaglandin I
F2 I
alpha I
( O
8 B
- I
epi I
- I
PGF2a I
) O
, O
and O
3 B
- I
nitrotyrosine I
( O
3 B
- I
NT I
) O
. O

Furthermore O
, O
the O
treatments O
induced O
an O
early O
increase O
in O
3 B
- I
NT I
level O
, O
which O
ceased O
with O
longer O
incubation O
times O
. O

To O
investigate O
the O
protective O
effect O
of O
enzymatically O
modified O
isoquercitrin B
( O
EMIQ O
) O
on O
the O
hepatocarcinogenic O
process O
, O
we O
used O
a O
two O
- O
stage O
hepatocarcinogenesis O
model O
in O
N B
- I
diethylnitrosamine I
- O
initiated O
and O
thioacetamide B
( O
TAA B
) O
- O
promoted O
rats O
. O

EMIQ O
increased O
liver O
levels O
of O
thiobarbituric B
acid I
- O
reactive O
substance O
and O
8 B
- I
hydroxydeoxyguanosin I
, O
and O
TUNEL O
( O
+ O
) O
apoptotic O
cells O
, O
death O
receptor O
5 O
( O
DR5 O
) O
( O
+ O
) O
cells O
and O
4 B
- I
hydroxy I
- I
2 I
- I
nonenal I
( O
+ O
) O
cells O
within O
GST O
- O
P O
( O
+ O
) O
foci O
. O

Bioavailability O
and O
intravenous O
toxicokinetic O
parameters O
for O
Pacific O
ciguatoxin B
P O
- O
CTX B
- I
1 I
in O
rats O
. O

In O
this O
study O
, O
we O
determined O
the O
toxicokinetic O
parameters O
of O
the O
Pacific O
ciguatoxin B
P O
- O
CTX B
- I
1 I
in O
rats O
after O
an O
intravenous O
( O
iv O
) O
dose O
of O
0 O
. O
13 O
ng O
P O
- O
CTX B
- I
1 I
per O
g O
of O
body O
weight O
. O

In O
this O
study O
, O
we O
determined O
the O
toxicokinetic O
parameters O
of O
the O
Pacific O
ciguatoxin B
P O
- O
CTX B
- I
1 I
in O
rats O
after O
an O
intravenous O
( O
iv O
) O
dose O
of O
0 O
. O
13 O
ng O
P O
- O
CTX B
- I
1 I
per O
g O
of O
body O
weight O
. O

The O
toxicokinetic O
parameters O
determined O
from O
this O
study O
were O
compared O
to O
data O
previously O
obtained O
after O
oral O
and O
intraperitoneal O
exposure O
of O
rats O
to O
0 O
. O
26 O
ng O
P O
- O
CTX B
- I
1 I
per O
g O
of O
body O
weight O
. O

Maximal O
bioavailability O
was O
determined O
by O
the O
area O
under O
the O
concentration O
curve O
, O
and O
was O
used O
to O
calculate O
the O
absolute O
P O
- O
CTX B
- I
1 I
bioavailabilities O
for O
oral O
and O
intraperitoneal O
routes O
of O
exposures O
of O
39 O
% O
and O
75 O
% O
, O
respectively O
. O

They O
are O
hydrazones B
, O
( B
thio I
) I
semicarbazones I
, O
and O
oximes B
of I
indenoindolones I
, O
and O
indenoindolols B
. O

The O
potent O
topoisomerase O
II O
inhibitor O
indenoindolone B
derivatives O
exhibited O
good O
anticancer O
activities O
compared O
to O
etoposide B
and O
5 B
- I
fluorouracil I
, O
and O
relatively O
low O
toxicity O
to O
normal O
cells O
. O

In O
this O
study O
, O
we O
compared O
the O
effects O
of O
the O
alpha O
7 O
- O
selective O
agonist O
( O
PNU B
- I
282987 I
) O
and O
PAM O
( O
PNU B
- I
120596 I
) O
in O
a O
variety O
of O
behavioral O
tests O
in O
Sprague O
Dawley O
rats O
to O
look O
at O
their O
effects O
on O
learning O
and O
memory O
as O
well O
as O
anxiety O
. O

In O
this O
study O
, O
we O
compared O
the O
effects O
of O
the O
alpha O
7 O
- O
selective O
agonist O
( O
PNU B
- I
282987 I
) O
and O
PAM O
( O
PNU B
- I
120596 I
) O
in O
a O
variety O
of O
behavioral O
tests O
in O
Sprague O
Dawley O
rats O
to O
look O
at O
their O
effects O
on O
learning O
and O
memory O
as O
well O
as O
anxiety O
. O

We O
found O
that O
neither O
PNU B
- I
282987 I
nor O
PNU B
- I
120596 I
improved O
spatial O
- O
learning O
or O
episodic O
memory O
by O
themselves O
. O

We O
found O
that O
neither O
PNU B
- I
282987 I
nor O
PNU B
- I
120596 I
improved O
spatial O
- O
learning O
or O
episodic O
memory O
by O
themselves O
. O

However O
when O
cognitive O
impairment O
was O
induced O
in O
the O
rats O
with O
scopolamine B
( O
1 O
mg O
/ O
kg O
) O
, O
both O
PNU B
- I
120596 I
and O
PNU B
- I
282987 I
were O
able O
to O
reverse O
this O
memory O
impairment O
and O
restore O
it O
back O
to O
normal O
levels O
. O

However O
when O
cognitive O
impairment O
was O
induced O
in O
the O
rats O
with O
scopolamine B
( O
1 O
mg O
/ O
kg O
) O
, O
both O
PNU B
- I
120596 I
and O
PNU B
- I
282987 I
were O
able O
to O
reverse O
this O
memory O
impairment O
and O
restore O
it O
back O
to O
normal O
levels O
. O

While O
PNU B
- I
120596 I
reversed O
the O
scopolamine O
- O
induced O
cognitive O
impairment O
, O
it O
did O
not O
have O
any O
adverse O
effect O
on O
anxiety O
. O

PNU B
- I
282987 I
on O
the O
other O
hand O
displayed O
an O
increase O
in O
anxiety O
- O
like O
behavior O
at O
a O
higher O
dose O
( O
10 O
mg O
/ O
kg O
) O
that O
was O
significantly O
reduced O
by O
the O
serotonin O
5 O
- O
HT1a O
receptor O
antagonist O
WAY B
- I
100135 I
. O

PNU B
- I
282987 I
on O
the O
other O
hand O
displayed O
an O
increase O
in O
anxiety O
- O
like O
behavior O
at O
a O
higher O
dose O
( O
10 O
mg O
/ O
kg O
) O
that O
was O
significantly O
reduced O
by O
the O
serotonin O
5 O
- O
HT1a O
receptor O
antagonist O
WAY B
- I
100135 I
. O

However O
the O
alpha O
7 O
receptor O
antagonist O
methyllycaconitine B
was O
unable O
to O
reverse O
these O
anxiety O
- O
like O
effects O
seen O
with O
PNU B
- I
282987 I
. O

Bioisosterism O
of O
alpha B
- I
amino I
acids I
is O
often O
accomplished O
by O
replacing O
the O
alpha B
- I
carboxylate I
with O
one O
of O
the O
many O
known O
carboxylic B
acid I
bioisosteres O
. O

The O
reported O
bioisosteres O
share O
the O
following O
essential O
structural O
features O
for O
mimicking O
alpha B
- I
amino I
acids I
: O
an O
aromatic O
ring O
system O
joined O
to O
a O
lactam O
ring O
system O
with O
an O
acidic O
feature O
next O
to O
the O
lactam B
carbonyl I
, O
where O
this O
acidic O
feature O
together O
with O
the O
lactam B
carbonyl I
can O
mimic O
the O
alpha O
- O
carboxylate O
, O
and O
the O
lactam O
nitrogen O
together O
with O
the O
aromatic O
ring O
system O
can O
mimic O
the O
alpha B
- I
ammonium I
. O

A O
new O
flavonoid B
with O
6 B
- I
phenyl I
substituent O
from O
Selaginella O
uncinata O
. O

The O
optimal O
nanoparticle O
formulation O
using O
0 O
. O
25 O
% O
( O
w O
/ O
v O
) O
of O
emulsifying O
agent O
( O
Polyvinyl B
- I
alcohol I
, O
PVA B
) O
and O
5 O
min O
of O
sonication O
was O
then O
characterized O
. O

Fasciospyrinadine B
( O
1 O
) O
, O
a O
novel O
sesquiterpene B
pyridine B
alkaloid I
with O
a O
previously O
unreported O
skeleton O
featuring O
a O
monocyclicfarnesane B
moiety O
attached O
to O
a O
3 B
- I
methylenepyridine I
residue O
, O
was O
isolated O
from O
the O
sponge O
Fasciospongia O
sp O
. O
from O
Weizhou O
Island O
, O
Guangxi O
Autonomous O
Region O
. O

Design O
, O
synthesis O
, O
in O
vitro O
MAO O
- O
B O
inhibitory O
evaluation O
, O
and O
computational O
studies O
of O
some O
6 B
- I
nitrobenzothiazole I
- O
derived O
semicarbazones B
. O

A O
series O
of O
6 B
- I
nitrobenzothiazole I
- O
derived O
semicarbazones B
were O
designed O
, O
synthesized O
, O
and O
evaluated O
as O
inhibitors O
of O
the O
rat O
brain O
MAO O
- O
B O
isoenzyme O
. O

Interestingly O
, O
the O
6 B
- I
nitrobenzothiazole I
moiety O
is O
stabilized O
in O
the O
substrate O
cavity O
with O
the O
aryl O
or O
diaryl O
residues O
extending O
up O
into O
the O
entrance O
cavity O
of O
the O
active O
site O
. O

Metabolism O
of O
ABT B
- I
107 I
was O
investigated O
in O
in O
vitro O
hepatic O
systems O
, O
in O
rat O
and O
monkey O
receiving O
[ B
( I
14 I
) I
C I
] I
ABT I
- I
107 I
, O
and O
in O
vivo O
plasma O
in O
rat O
, O
dog O
, O
monkey O
and O
human O
. O

In O
in O
vitro O
hepatic O
systems O
, O
ABT B
- I
107 I
was O
primarily O
cleared O
via O
oxidative O
metabolism O
, O
and O
proceeded O
via O
two O
parallel O
pathways O
. O

Pathway O
1 O
, O
ABT B
- I
107 I
was O
oxidized O
at O
the O
nitrogen B
of O
quinuclidine B
moiety O
to O
form O
M1 O
. O

ABT B
- I
107 I
was O
extensively O
metabolized O
in O
vivo O
in O
rat O
and O
monkey O
. O

Biotransformation O
of O
ABT B
- I
107 I
in O
human O
and O
monkey O
is O
markedly O
different O
from O
that O
in O
dog O
and O
rat O
, O
suggesting O
that O
monkey O
is O
an O
appropriate O
model O
for O
predicting O
human O
biotransformation O
and O
toxicology O
of O
ABT B
- I
107 I
. O

Biotransformation O
of O
ABT B
- I
107 I
in O
human O
and O
monkey O
is O
markedly O
different O
from O
that O
in O
dog O
and O
rat O
, O
suggesting O
that O
monkey O
is O
an O
appropriate O
model O
for O
predicting O
human O
biotransformation O
and O
toxicology O
of O
ABT B
- I
107 I
. O

The O
effects O
of O
solvation O
and O
identity O
of O
the O
varying O
C B
- O
terminal O
residue O
on O
the O
energetics O
, O
structural O
features O
of O
the O
peptide O
planes O
, O
values O
of O
the O
psi O
and O
phi O
dihedrals O
, O
geometry O
around O
the O
alpha B
- I
carbon I
atoms O
and O
theoretically O
predicted O
vibrational O
spectra O
of O
the O
dipeptides B
are O
thoroughly O
analyzed O
. O

Solvation O
effects O
are O
found O
to O
modify O
the O
gas O
phase O
conformation O
of O
the O
dipeptides B
around O
psi O
dihedrals O
while O
the O
identity O
of O
the O
varying O
C B
- O
terminal O
residue O
affect O
the O
values O
of O
phi O
, O
planarity O
of O
the O
peptide O
planes O
and O
geometry O
around O
the O
alpha B
- I
carbon I
atoms O
. O

The O
presence O
or O
absence O
of O
three O
types O
of O
intramolecular O
H B
- O
bonds O
, O
namely O
O B
. O
. O
. O
H B
- I
N I
, O
N B
. O
. O
. O
H B
- I
N I
and O
O B
. O
. O
. O
H B
- I
C I
that O
leave O
noticeable O
signatures O
in O
the O
IR O
spectra O
, O
play O
crucial O
roles O
in O
influencing O
the O
geometry O
of O
the O
peptide O
planes O
and O
in O
determining O
the O
energetics O
of O
the O
dipeptides B
. O

The O
presence O
or O
absence O
of O
three O
types O
of O
intramolecular O
H B
- O
bonds O
, O
namely O
O B
. O
. O
. O
H B
- I
N I
, O
N B
. O
. O
. O
H B
- I
N I
and O
O B
. O
. O
. O
H B
- I
C I
that O
leave O
noticeable O
signatures O
in O
the O
IR O
spectra O
, O
play O
crucial O
roles O
in O
influencing O
the O
geometry O
of O
the O
peptide O
planes O
and O
in O
determining O
the O
energetics O
of O
the O
dipeptides B
. O

The O
presence O
or O
absence O
of O
three O
types O
of O
intramolecular O
H B
- O
bonds O
, O
namely O
O B
. O
. O
. O
H B
- I
N I
, O
N B
. O
. O
. O
H B
- I
N I
and O
O B
. O
. O
. O
H B
- I
C I
that O
leave O
noticeable O
signatures O
in O
the O
IR O
spectra O
, O
play O
crucial O
roles O
in O
influencing O
the O
geometry O
of O
the O
peptide O
planes O
and O
in O
determining O
the O
energetics O
of O
the O
dipeptides B
. O

The O
osteoblast O
cells O
( O
hFOB1 O
. O
19 O
) O
were O
cultured O
in O
a O
medium O
supplemented O
with O
different O
concentrations O
( O
50 O
, O
100 O
, O
and O
200 O
mu O
M O
) O
of O
ferric B
ammonium I
citrate I
as O
a O
donor O
of O
ferric B
ion O
. O

Then O
the O
proposed O
method O
was O
successfully O
applied O
to O
investigate O
the O
possible O
enantioselective O
degradation O
of O
rac B
- I
hexaconazole I
in O
plants O
( O
tomato O
and O
cucumber O
) O
and O
soil O
under O
field O
conditions O
. O

Electron O
transfer O
dissociation O
( O
ETD O
) O
: O
the O
mass O
spectrometric O
breakthrough O
essential O
for O
O B
- I
GlcNAc I
protein O
site O
assignments O
- O
a O
study O
of O
the O
O B
- O
GlcNAcylated O
protein O
host O
cell O
factor O
C1 O
. O

The O
field O
of O
intracellular O
O B
- I
GlcNAc I
( O
O B
- O
linked O
N B
- I
acetylglucosamine I
) O
signaling O
has O
especially O
advanced O
with O
the O
advent O
of O
ETD O
MS O
. O

The O
field O
of O
intracellular O
O B
- I
GlcNAc I
( O
O B
- O
linked O
N B
- I
acetylglucosamine I
) O
signaling O
has O
especially O
advanced O
with O
the O
advent O
of O
ETD O
MS O
. O

Only O
within O
the O
last O
five O
years O
have O
proteomic O
- O
scale O
experiments O
utilizing O
ETD O
allowed O
the O
assignment O
of O
hundreds O
of O
O B
- I
GlcNAc I
sites O
within O
cells O
and O
subcellular O
structures O
. O

Our O
ability O
to O
identify O
and O
unambiguously O
assign O
the O
site O
of O
O B
- I
GlcNAc I
modifications O
using O
ETD O
is O
rapidly O
increasing O
our O
understanding O
of O
this O
regulatory O
glycosylation O
and O
its O
potential O
interaction O
with O
other O
PTMs O
. O

HCF O
- O
1 O
is O
a O
transcriptional O
coregulator O
that O
forms O
a O
stable O
complex O
with O
O B
- I
GlcNAc I
transferase O
and O
controls O
cell O
cycle O
progression O
. O

Twelve O
- O
day O
MC3T3 O
- O
E1 O
osteoblast O
cultures O
with O
added O
ascorbic O
acid O
( O
for O
collagen O
matrix O
assembly O
) O
and O
beta B
- I
glycerophosphate I
( O
a O
source O
of O
phosphate B
for O
mineralization O
) O
were O
treated O
with O
either O
PolyP5 B
or O
PolyP65 B
. O

Importantly O
, O
at O
the O
concentrations O
of O
polyphosphates B
used O
in O
this O
study O
which O
inhibited O
bone O
cell O
culture O
mineralization O
, O
the O
polyphosphates B
competitively O
saturated O
TNAP O
, O
thus O
potentially O
interfering O
with O
its O
ability O
to O
hydrolyze O
mineralization O
- O
inhibiting O
pyrophosphate B
( O
PPi B
) O
and O
mineralizing O
- O
promoting O
beta B
- I
glycerophosphate I
( O
in O
cell O
culture O
) O
. O

Our O
first O
aim O
was O
to O
study O
the O
effects O
of O
d B
- I
amphetamine I
infusions O
into O
the O
shell O
and O
core O
in O
order O
to O
understand O
their O
relative O
importance O
to O
reward O
and O
operant O
responding O
. O

Using O
curve O
- O
shift O
scaling O
, O
we O
measured O
the O
reward O
- O
and O
performance O
- O
enhancing O
effects O
of O
intra O
- O
accumbens O
( O
1 O
- O
20 O
mu O
g O
) O
and O
intra O
- O
habenular O
( O
10 O
- O
40 O
mu O
g O
) O
infusions O
of O
d B
- I
amphetamine I
or O
vehicle O
. O

Conversely O
, O
regardless O
of O
dose O
, O
intra O
- O
habenular O
d B
- I
amphetamine I
did O
not O
alter O
rewarding O
effectiveness O
or O
operant O
rate O
, O
highlighting O
the O
differential O
contribution O
of O
mesoaccumbens O
and O
mesohabenular O
dopamine B
pathways O
to O
intracranial O
self O
- O
stimulation O
. O

Anti O
- O
obesity O
effects O
of O
3 B
- I
hydroxychromone I
derivative O
, O
a O
novel O
small O
- O
molecule O
inhibitor O
of O
glycogen O
synthase O
kinase O
- O
3 O
. O

Compound O
1a O
, O
a O
structure O
based O
on O
3 B
- I
hydroxychromone I
bearing O
isothiazolidine B
- I
1 I
, I
1 I
- I
dione I
, O
was O
identified O
from O
chemical O
library O
as O
a O
highly O
potent O
GSK O
- O
3 O
inhibitor O
. O

Stabilization O
of O
glycogen O
synthase O
and O
beta O
- O
catenin O
, O
which O
are O
direct O
targets O
of O
GSK O
- O
3 O
, O
by O
compound O
1a O
was O
assessed O
in O
comparison O
with O
two O
other O
GSK O
- O
3 O
inhibitors O
: O
LiCl B
and O
SB B
- I
415286 I
. O

Cells O
were O
exposed O
for O
24h O
to O
various O
concentrations O
( O
from O
0 O
. O
1 O
pM O
to O
1 O
mM O
) O
of O
atrazine B
( O
ATR B
) O
, O
diethylstilbestrol B
( O
DES B
) O
, O
para B
- I
nonylphenol I
( O
p B
- I
NP I
) O
, O
resveratrol B
( O
RES B
) O
and O
17 B
beta I
- I
estradiol I
( O
E2 O
) O
and O
assayed O
for O
cell O
viability O
and O
human O
beta O
- O
Chorionic O
Gonadotropin O
( O
beta O
- O
hCG O
) O
secretion O
. O

Cells O
were O
exposed O
for O
24h O
to O
various O
concentrations O
( O
from O
0 O
. O
1 O
pM O
to O
1 O
mM O
) O
of O
atrazine B
( O
ATR B
) O
, O
diethylstilbestrol B
( O
DES B
) O
, O
para B
- I
nonylphenol I
( O
p B
- I
NP I
) O
, O
resveratrol B
( O
RES B
) O
and O
17 B
beta I
- I
estradiol I
( O
E2 O
) O
and O
assayed O
for O
cell O
viability O
and O
human O
beta O
- O
Chorionic O
Gonadotropin O
( O
beta O
- O
hCG O
) O
secretion O
. O

beta O
- O
hCG O
release O
was O
also O
unexpectedly O
inhibited O
by O
ATR B
, O
DES B
, O
p B
- I
NP I
and O
RES B
at O
non O
- O
toxic O
( O
pM O
- O
nM O
) O
concentrations O
. O

We O
demonstrate O
localized O
electrodeposition O
of O
anisotropic O
metal O
nanoobjects O
, O
namely O
Au B
nanorods O
( O
GNR O
) O
, O
on O
indium B
tin I
oxide I
( O
ITO B
) O
using O
scanning O
electrochemical O
microscopy O
( O
SECM O
) O
. O

Metal B
- I
pernitride I
compounds O
belong O
to O
a O
class O
of O
chemical O
systems O
in O
which O
both O
the O
complex O
ions O
and O
the O
non O
- O
bonding O
electrons O
may O
play O
roles O
in O
the O
formation O
of O
their O
modified O
crystalline O
structures O
. O

TOCP B
is O
metabolized O
to O
cresyl B
saligenin I
phosphate I
( O
CBDP B
) O
, O
a O
potent O
irreversible O
inhibitor O
of O
butyrylcholinesteras O
( O
BChE O
) O
, O
a O
natural O
bioscavenger O
present O
in O
the O
bloodstream O
, O
and O
acetylcholinesterase O
( O
AChE O
) O
, O
the O
off O
- O
switch O
at O
cholinergic O
synapses O
. O

This O
study O
evaluates O
the O
influence O
of O
cooking O
and O
handling O
conditions O
on O
the O
quantity O
of O
furanic B
compounds O
( O
furan B
, O
2 B
- I
furfural I
, O
furfuryl B
alcohol I
, O
2 B
- I
pentylfuran I
, O
5 B
- I
hydroxymethylfurfura I
) O
in O
breaded O
fish O
products O
. O

This O
study O
evaluates O
the O
influence O
of O
cooking O
and O
handling O
conditions O
on O
the O
quantity O
of O
furanic B
compounds O
( O
furan B
, O
2 B
- I
furfural I
, O
furfuryl B
alcohol I
, O
2 B
- I
pentylfuran I
, O
5 B
- I
hydroxymethylfurfura I
) O
in O
breaded O
fish O
products O
. O

This O
study O
evaluates O
the O
influence O
of O
cooking O
and O
handling O
conditions O
on O
the O
quantity O
of O
furanic B
compounds O
( O
furan B
, O
2 B
- I
furfural I
, O
furfuryl B
alcohol I
, O
2 B
- I
pentylfuran I
, O
5 B
- I
hydroxymethylfurfura I
) O
in O
breaded O
fish O
products O
. O

The O
increase O
in O
ROS O
formation O
and O
cell O
death O
was O
assayed O
using O
the O
fluorescent O
probe O
2 B
, I
7 I
- I
dichlorofluorescin I
diacetate I
( O
DCFH B
- I
DA I
) O
and O
the O
trypan B
blue I
exclusion O
assay O
. O

A O
complementary O
approach O
that O
combines O
NMR O
measurements O
, O
analysis O
of O
X O
- O
ray O
and O
neutron O
powder O
diffraction O
data O
and O
advanced O
quantum O
mechanical O
calculations O
was O
employed O
to O
study O
the O
alpha O
- O
polymorph O
of O
L B
- I
polylactide I
. O

The O
GIPAW O
method O
was O
used O
to O
compute O
the O
NMR O
shielding O
parameters O
for O
the O
different O
models O
, O
which O
included O
the O
alpha B
- I
PLLA I
structure O
obtained O
by O
2 O
- O
dimensional O
wide O
- O
angle O
X O
- O
ray O
diffraction O
( O
WAXD O
) O
at O
- O
150 O
degrees O
C O
( O
model O
M1 O
) O
and O
at O
25 O
degrees O
C O
( O
model O
M2 O
) O
, O
neutron O
diffraction O
( O
WAND O
) O
measurements O
( O
model O
M3 O
) O
and O
the O
fully O
optimized O
geometry O
of O
the O
PLLA O
chains O
in O
the O
unit O
cell O
with O
defined O
size O
( O
model O
M4 O
) O
. O

The O
essential O
oils O
consisted O
mainly O
of O
monoterpenes B
, O
alpha B
- I
pinene I
( O
27 O
. O
4 O
- O
59 O
. O
2 O
% O
) O
and O
1 B
, I
8 I
- I
cineole I
( O
6 O
. O
1 O
- O
34 O
. O
3 O
% O
) O
being O
the O
major O
components O
. O

Groups O
I O
( O
78 O
% O
of O
the O
samples O
) O
and O
II O
were O
differentiated O
on O
the O
basis O
of O
the O
contents O
of O
alpha B
- I
pinene I
, O
linalool B
, O
and O
linalyl B
acetate I
. O

Subgroups O
IA O
and O
IB O
could O
be O
distinguished O
by O
their O
contents O
of O
alpha B
- I
pinene I
and O
1 B
, I
8 I
- I
cineole I
. O

Organic O
anion O
transporter O
3 O
interacts O
selectively O
with O
lipophilic O
beta B
- I
lactam I
antibiotics O
. O

Some O
beta B
- I
lactam I
antibiotics O
interact O
with O
Oat3 O
, O
and O
penicillin B
G I
exhibits O
a O
strong O
dependence O
on O
Oat3 O
for O
renal O
elimination O
. O

However O
, O
over O
80 O
beta B
- I
lactams I
exist O
, O
and O
many O
have O
not O
been O
assessed O
for O
an O
interaction O
with O
Oat3 O
. O

Moreover O
, O
beta B
- I
lactams I
continue O
to O
receive O
U O
. O
S O
. O

This O
study O
identified O
new O
beta B
- I
lactam I
- O
Oat3 O
interactions O
, O
provided O
a O
head O
- O
to O
- O
head O
comparison O
with O
Oat1 O
, O
and O
characterized O
the O
physicochemical O
determinants O
of O
affinity O
for O
Oat3 O
. O

Of O
26 O
beta B
- I
lactams I
tested O
, O
12 O
were O
clear O
inhibitors O
of O
Oat3 O
, O
and O
14 O
exhibited O
poor O
interactions O
. O

Oat1 O
demonstrated O
a O
poor O
interaction O
with O
most O
beta B
- I
lactams I
. O

These O
findings O
indicate O
that O
Oat3 O
recognizes O
lipophilic O
beta B
- I
lactams I
more O
readily O
. O

Moreover O
, O
this O
study O
has O
potential O
implications O
for O
designing O
beta B
- I
lactams I
to O
avoid O
renal O
accumulation O
or O
brain O
efflux O
via O
Oat3 O
. O

Tissue O
accumulation O
and O
species O
- O
specific O
metabolism O
of O
technical O
pentabrominated B
diphenyl I
ether I
( O
DE B
- I
71 I
) O
in O
two O
predator O
fish O
. O

Tissue O
accumulation O
and O
species O
- O
specific O
metabolism O
of O
technical O
pentabrominated B
diphenyl I
ether I
( O
DE B
- I
71 I
) O
in O
two O
predator O
fish O
. O

The O
tissue O
- O
specific O
accumulation O
and O
species O
- O
specific O
metabolism O
of O
polybrominated B
diphenyl I
ethers I
( O
PBDEs B
) O
in O
two O
predator O
fish O
species O
( O
redtail O
catfish O
and O
oscar O
fish O
) O
feeding O
on O
the O
same O
prey O
( O
tiger O
barb O
) O
that O
was O
exposed O
to O
technical O
pentabrominated B
diphenyl I
ether I
( O
DE B
- I
71 I
) O
in O
the O
laboratory O
were O
investigated O
. O

The O
tissue O
- O
specific O
accumulation O
and O
species O
- O
specific O
metabolism O
of O
polybrominated B
diphenyl I
ethers I
( O
PBDEs B
) O
in O
two O
predator O
fish O
species O
( O
redtail O
catfish O
and O
oscar O
fish O
) O
feeding O
on O
the O
same O
prey O
( O
tiger O
barb O
) O
that O
was O
exposed O
to O
technical O
pentabrominated B
diphenyl I
ether I
( O
DE B
- I
71 I
) O
in O
the O
laboratory O
were O
investigated O
. O

The O
tissue O
- O
specific O
accumulation O
and O
species O
- O
specific O
metabolism O
of O
polybrominated B
diphenyl I
ethers I
( O
PBDEs B
) O
in O
two O
predator O
fish O
species O
( O
redtail O
catfish O
and O
oscar O
fish O
) O
feeding O
on O
the O
same O
prey O
( O
tiger O
barb O
) O
that O
was O
exposed O
to O
technical O
pentabrominated B
diphenyl I
ether I
( O
DE B
- I
71 I
) O
in O
the O
laboratory O
were O
investigated O
. O

Several O
hydroxylated B
PBDEs I
( O
OH B
- I
PBDEs I
) O
were O
detected O
in O
serum O
samples O
from O
the O
two O
fish O
species O
, O
but O
no O
methoxylated O
PBDEs B
were O
found O
. O

The O
similarities O
in O
the O
OH B
- I
PBDE I
congener O
profile O
and O
the O
ratio O
of O
OH B
- I
PBDEs I
to O
total O
PBDEs B
between O
the O
two O
fish O
species O
indicated O
that O
the O
hydroxylation O
of O
PBDEs B
might O
not O
be O
species O
- O
specific O
. O

The O
similarities O
in O
the O
OH B
- I
PBDE I
congener O
profile O
and O
the O
ratio O
of O
OH B
- I
PBDEs I
to O
total O
PBDEs B
between O
the O
two O
fish O
species O
indicated O
that O
the O
hydroxylation O
of O
PBDEs B
might O
not O
be O
species O
- O
specific O
. O

This O
Full O
Paper O
addresses O
the O
electrocatalytic O
hydrogenation O
of O
glucose B
to O
sorbitol B
or O
2 B
- I
deoxysorbitol I
on O
solid O
metal O
electrodes O
in O
neutral O
media O
. O

The O
mechanism O
to O
form O
2 B
- I
deoxysorbitol I
from O
glucose B
and O
/ O
or O
fructose B
is O
discussed O
according O
to O
the O
observed O
reaction O
products O
. O

Phytochemical O
investigation O
of O
the O
methanolic O
extract O
of O
Croton O
tonkinensis O
afforded O
two O
known O
kauranes B
( O
1 O
, O
2 O
) O
, O
eight O
new O
ent B
- I
kauranes I
( O
3 O
- O
10 O
) O
, O
and O
16 O
known O
ent B
- I
kaurane I
- O
type O
diterpenoids B
( O
12 O
- O
27 O
) O
. O

Phytochemical O
investigation O
of O
the O
methanolic O
extract O
of O
Croton O
tonkinensis O
afforded O
two O
known O
kauranes B
( O
1 O
, O
2 O
) O
, O
eight O
new O
ent B
- I
kauranes I
( O
3 O
- O
10 O
) O
, O
and O
16 O
known O
ent B
- I
kaurane I
- O
type O
diterpenoids B
( O
12 O
- O
27 O
) O
. O

Five O
new O
series O
of O
imidazo B
[ I
1 I
, I
2 I
- I
a I
] I
pyridines I
carrying O
biologically O
active O
pyrazoline B
( O
4a O
- O
e O
) O
, O
cyanopyridone B
( O
5a O
, O
b O
) O
, O
cyanopyridine B
( O
6a O
- O
f O
) O
, O
2 B
- I
aminopyrimidine I
( O
7a O
- O
f O
) O
and O
pyrimidine B
- I
2 I
- I
thione I
( O
8a O
- O
d O
) O
systems O
were O
designed O
and O
synthesized O
as O
prominent O
anticonvulsant O
agents O
. O

Compounds O
4b O
, O
5a O
, O
5b O
, O
6a O
, O
7e O
and O
8d O
possessing O
4 B
- I
fluorophenyl I
substituent O
at O
2nd O
position O
of O
imidazo B
[ I
1 I
, I
2 I
- I
a I
] I
pyridine I
ring O
displayed O
potent O
anticonvulsant O
activity O
without O
displaying O
any O
toxicity O
. O

Two O
poly B
( I
styrene I
oxide I
) I
- I
poly I
( I
ethylene I
oxide I
) I
( O
PSO B
- I
PEO I
) O
triblock O
copolymers O
with O
different O
chain O
lengths O
were O
analyzed O
as O
potential O
chemotherapeutic O
nanocarriers O
, O
and O
their O
ability O
to O
inhibit O
the O
P O
- O
glycoprotein O
( O
P O
- O
gp O
) O
efflux O
pump O
in O
a O
multidrug O
resistant O
( O
MDR O
) O
cell O
line O
were O
measured O
in O
order O
to O
establish O
possible O
cell O
- O
responses O
induced O
by O
the O
presence O
of O
the O
copolymer O
molecules O
. O

Hence O
, O
PSO B
- I
PEO I
block O
copolymers O
offer O
interesting O
features O
as O
new O
biological O
response O
modifiers O
to O
be O
used O
in O
the O
design O
of O
efficient O
nanocarriers O
for O
cancer O
chemotherapy O
. O

After O
structure O
- O
based O
drug O
selection O
, O
SGI B
- I
1776 I
, O
ETP B
- I
45299 I
, O
and O
tryptanthrin B
were O
selected O
as O
candidates O
of O
PIM1 O
inhibitors O
that O
act O
as O
radiosensitizers O
. O

After O
structure O
- O
based O
drug O
selection O
, O
SGI B
- I
1776 I
, O
ETP B
- I
45299 I
, O
and O
tryptanthrin B
were O
selected O
as O
candidates O
of O
PIM1 O
inhibitors O
that O
act O
as O
radiosensitizers O
. O

Taken O
together O
, O
our O
findings O
provided O
evidence O
that O
PIM1 O
- O
specific O
inhibitors O
, O
SGI B
- I
1776 I
, O
ETP B
- I
45299 I
, O
and O
tryptanthrin B
, O
can O
act O
as O
novel O
radiosensitizers O
to O
enhance O
the O
efficacy O
of O
radiotherapy O
by O
inhibiting O
irradiation O
- O
induced O
signaling O
pathway O
associated O
with O
radioresistance O
. O

Taken O
together O
, O
our O
findings O
provided O
evidence O
that O
PIM1 O
- O
specific O
inhibitors O
, O
SGI B
- I
1776 I
, O
ETP B
- I
45299 I
, O
and O
tryptanthrin B
, O
can O
act O
as O
novel O
radiosensitizers O
to O
enhance O
the O
efficacy O
of O
radiotherapy O
by O
inhibiting O
irradiation O
- O
induced O
signaling O
pathway O
associated O
with O
radioresistance O
. O

Ceramide B
can O
be O
generated O
by O
exposure O
to O
chemotherapy O
or O
ionizing O
radiation O
, O
or O
it O
can O
be O
administered O
in O
the O
form O
of O
short O
- O
chain O
analogs O
( O
C6 B
- I
ceramide I
) O
. O

Because O
intracellular O
P O
- O
glycoprotein O
( O
P O
- O
gp O
) O
plays O
a O
role O
in O
catalyzing O
the O
conversion O
of O
ceramide B
to O
higher O
sphingolipids B
, O
we O
hypothesized O
that O
administration O
of O
P O
- O
gp O
antagonists O
with O
C6 B
- I
ceramide I
would O
magnify O
cell O
death O
cascades O
. O

The O
addition O
of O
either O
tamoxifen B
, O
VX B
- I
710 I
, O
verapamil B
, O
or O
cyclosporin B
A I
, O
antagonists O
of O
P O
- O
gp O
, O
enhanced O
C6 B
- I
ceramide I
cytotoxicity O
in O
all O
cell O
lines O
. O

The O
addition O
of O
either O
tamoxifen B
, O
VX B
- I
710 I
, O
verapamil B
, O
or O
cyclosporin B
A I
, O
antagonists O
of O
P O
- O
gp O
, O
enhanced O
C6 B
- I
ceramide I
cytotoxicity O
in O
all O
cell O
lines O
. O

In O
depth O
studies O
with O
C6 B
- I
ceramide I
and O
tamoxifen B
in O
LoVo O
cells O
showed O
the O
regimen O
induced O
PARP O
cleavage O
, O
caspase O
- O
dependent O
apoptosis O
, O
mitochondrial O
membrane O
permeabilization O
( O
MMP O
) O
, O
and O
cell O
cycle O
arrest O
at O
G1 O
and O
G2 O
. O

Nanoliposomal O
formulations O
of O
C6 B
- I
ceramide I
and O
tamoxifen B
were O
also O
effective O
, O
yielding O
synergistic O
cell O
kill O
. O

We O
conclude O
that O
tamoxifen B
is O
a O
favorable O
adjuvant O
for O
enhancing O
C6 B
- I
ceramide I
cytotoxicity O
in O
CRC O
, O
and O
demonstrates O
uniquely O
integrated O
effects O
. O

Transmethylation O
is O
an O
important O
reaction O
that O
transfers O
a O
methyl B
group O
in O
S B
- I
adenosylmethionine I
( O
SAM B
) O
to O
substrates O
such O
as O
DNA O
, O
RNA O
, O
and O
proteins O
. O

In O
agreement O
with O
these O
data O
, O
the O
exogenous O
treatment O
of O
SAH B
or O
inhibition O
of O
SAHH O
by O
specific O
siRNA O
or O
another O
type O
of O
inhibitor O
, O
3 B
- I
deazaadenosine I
( O
DAZA B
) O
, O
similarly O
resulted O
in O
antitumorigenic O
responses O
, O
suppressive O
activity O
on O
Src O
, O
the O
alteration O
of O
actin O
cytoskeleton O
, O
and O
a O
change O
of O
the O
colocalization O
pattern O
between O
actin O
and O
Src O
. O

Design O
, O
synthesis O
and O
anticancer O
properties O
of O
5 B
- I
arylbenzoxepins I
as O
conformationally O
restricted O
isocombretastatin B
A I
- I
4 I
analogs O
. O

A O
series O
of O
novel O
benzoxepins B
6 O
was O
designed O
and O
prepared O
as O
rigid O
- O
isoCA B
- I
4 I
analogs O
according O
to O
a O
convergent O
strategy O
using O
the O
coupling O
of O
N B
- I
tosylhydrazones I
with O
aryl B
iodides I
under O
palladium B
catalysis O
. O

A O
series O
of O
novel O
benzoxepins B
6 O
was O
designed O
and O
prepared O
as O
rigid O
- O
isoCA B
- I
4 I
analogs O
according O
to O
a O
convergent O
strategy O
using O
the O
coupling O
of O
N B
- I
tosylhydrazones I
with O
aryl B
iodides I
under O
palladium B
catalysis O
. O

The O
most O
potent O
compound O
6b O
, O
having O
the O
greatest O
resemblance O
to O
CA B
- I
4 I
and O
isoCA B
- I
4 I
displayed O
antiproliferative O
activity O
at O
nanomolar O
concentrations O
against O
various O
cancer O
cell O
lines O
and O
inhibited O
tubulin O
assembly O
at O
a O
micromolar O
range O
. O

The O
most O
potent O
compound O
6b O
, O
having O
the O
greatest O
resemblance O
to O
CA B
- I
4 I
and O
isoCA B
- I
4 I
displayed O
antiproliferative O
activity O
at O
nanomolar O
concentrations O
against O
various O
cancer O
cell O
lines O
and O
inhibited O
tubulin O
assembly O
at O
a O
micromolar O
range O
. O

Docking O
studies O
demonstrated O
that O
benzoxepin B
6b O
adopt O
an O
orientation O
similar O
to O
that O
of O
isoCA B
- I
4 I
at O
the O
colchicine O
binding O
site O
on O
beta O
- O
tubulin O
. O

Cytotoxicity O
of O
lapachol B
, O
beta B
- I
lapachone I
and O
related O
synthetic O
1 B
, I
4 I
- I
naphthoquinones I
against O
oesophageal O
cancer O
cells O
. O

Synthesis O
of O
an O
MIF B
- I
1 I
analogue O
containing O
enantiopure O
( B
S I
) I
- I
alpha I
- I
trifluoromethyl I
- I
proline I
and O
biological O
evaluation O
on O
nociception O
. O

The O
synthesis O
and O
the O
effect O
of O
a O
novel O
MIF B
- I
1 I
analogue O
on O
nociception O
during O
acute O
pain O
in O
rat O
model O
are O
reported O
. O

The O
analgesic O
effect O
of O
the O
CF3 B
- I
( I
MIF I
- I
1 I
) I
2 O
has O
been O
evaluated O
in O
vivo O
on O
rat O
model O
by O
paw O
pressure O
( O
PP O
) O
and O
hot O
plate O
( O
HP O
) O
tests O
and O
compared O
to O
the O
native O
peptide O
MIF B
- I
1 I
. O

The O
results O
are O
in O
favor O
of O
a O
participation O
of O
both O
system O
since O
pretreatment O
, O
20 O
min O
before O
injection O
of O
the O
CF3 B
- I
( I
MIF I
- I
1 I
) I
2 O
, O
with O
the O
non O
- O
competitive O
antagonist O
of O
opiate O
receptors O
naloxone B
, O
the O
nitric B
oxide I
synthase O
( O
NOS O
) O
inhibitor O
l B
- I
N I
( I
G I
) I
- I
nitroarginine I
ester I
( O
l B
- I
NAME I
) O
or O
the O
nitric B
oxide I
( O
NO B
) O
donor O
l B
- I
arginine I
( O
l B
- I
Arg I
) O
significantly O
decreased O
the O
pain O
perception O
in O
PP O
and O
HP O
tests O
. O

The O
results O
are O
in O
favor O
of O
a O
participation O
of O
both O
system O
since O
pretreatment O
, O
20 O
min O
before O
injection O
of O
the O
CF3 B
- I
( I
MIF I
- I
1 I
) I
2 O
, O
with O
the O
non O
- O
competitive O
antagonist O
of O
opiate O
receptors O
naloxone B
, O
the O
nitric B
oxide I
synthase O
( O
NOS O
) O
inhibitor O
l B
- I
N I
( I
G I
) I
- I
nitroarginine I
ester I
( O
l B
- I
NAME I
) O
or O
the O
nitric B
oxide I
( O
NO B
) O
donor O
l B
- I
arginine I
( O
l B
- I
Arg I
) O
significantly O
decreased O
the O
pain O
perception O
in O
PP O
and O
HP O
tests O
. O

The O
results O
are O
in O
favor O
of O
a O
participation O
of O
both O
system O
since O
pretreatment O
, O
20 O
min O
before O
injection O
of O
the O
CF3 B
- I
( I
MIF I
- I
1 I
) I
2 O
, O
with O
the O
non O
- O
competitive O
antagonist O
of O
opiate O
receptors O
naloxone B
, O
the O
nitric B
oxide I
synthase O
( O
NOS O
) O
inhibitor O
l B
- I
N I
( I
G I
) I
- I
nitroarginine I
ester I
( O
l B
- I
NAME I
) O
or O
the O
nitric B
oxide I
( O
NO B
) O
donor O
l B
- I
arginine I
( O
l B
- I
Arg I
) O
significantly O
decreased O
the O
pain O
perception O
in O
PP O
and O
HP O
tests O
. O

Synthesis O
, O
pharmacological O
evaluation O
and O
QSAR O
modeling O
of O
mono O
- O
substituted O
4 B
- I
phenylpiperidines I
and O
4 B
- I
phenylpiperazines I
. O

Synthesis O
, O
pharmacological O
evaluation O
and O
QSAR O
modeling O
of O
mono O
- O
substituted O
4 B
- I
phenylpiperidines I
and O
4 B
- I
phenylpiperazines I
. O

In O
this O
study O
, O
we O
tested O
the O
hypothesis O
that O
encapsulation O
of O
an O
investigational O
anti O
- O
PAH O
molecule O
fasudil B
( O
HA B
- I
1077 I
) O
, O
a O
Rho O
- O
kinase O
inhibitor O
, O
into O
liposomal O
vesicles O
results O
in O
prolonged O
vasodilation O
in O
distal O
pulmonary O
arterioles O
. O

There O
are O
seemingly O
conflicting O
data O
in O
the O
literature O
regarding O
the O
role O
of O
serotonin B
( O
5 B
- I
HT I
) O
5 O
- O
HT2C O
receptors O
in O
the O
mouse O
head O
- O
twitch O
response O
( O
HTR O
) O
elicited O
by O
the O
hallucinogenic O
5 O
- O
HT2A O
/ O
2B O
/ O
2C O
receptor O
agonist O
2 B
, I
5 I
- I
dimethoxy I
- I
4 I
- I
iodoamphetamine I
( O
DOI B
) O
. O

Commercially O
- O
available O
5 O
- O
HT2C O
agonists O
( O
CP B
809101 I
, O
Ro B
60 I
- I
0175 I
, O
WAY B
161503 I
, O
mCPP B
, O
and O
1 B
- I
methylpsilocin I
) O
, O
novel O
4 B
- I
phenyl I
- I
2 I
- I
N I
, I
N I
- I
dimethyl I
- I
aminotetralin I
( O
PAT B
) O
- O
type O
5 O
- O
HT2C O
agonists O
( O
with O
5 O
- O
HT2A O
/ O
2B O
antagonist O
activity O
) O
, O
and O
antagonists O
selective O
for O
5 O
- O
HT2A O
( O
M100907 B
) O
, O
5 O
- O
HT2C O
( O
SB B
- I

The O
5 O
- O
HT2C O
agonists O
and O
M100907 B
decreased O
locomotion O
, O
SB B
- I
242084 I
increased O
locomotion O
, O
SB B
- I
206553 I
resulted O
in O
dose O
- O
dependent O
biphasic O
effects O
on O
locomotion O
, O
and O
the O
PATs O
did O
not O
alter O
locomotion O
. O

The O
5 O
- O
HT2C O
agonists O
and O
M100907 B
decreased O
locomotion O
, O
SB B
- I
242084 I
increased O
locomotion O
, O
SB B
- I
206553 I
resulted O
in O
dose O
- O
dependent O
biphasic O
effects O
on O
locomotion O
, O
and O
the O
PATs O
did O
not O
alter O
locomotion O
. O

Effects O
of O
repeated O
exposure O
to O
MDMA B
on O
5HT1a O
autoreceptor O
function O
: O
behavioral O
and O
neurochemical O
responses O
to O
8 B
- I
OHDPAT I
. O

A O
consistent O
effect O
of O
repeated O
exposure O
to O
3 B
, I
4 I
methylenedioxymetham I
( O
MDMA B
) O
is O
a O
decrease O
in O
the O
tissue O
levels O
of O
serotonin B
( O
5 B
- I
HT I
) O
. O

The O
response O
to O
the O
5 O
- O
HT1a O
agonist O
, O
8 B
- I
OHDPAT I
( O
0 O
. O
003 O
- O
0 O
. O
5 O
mg O
/ O
kg O
, O
SC O
) O
, O
was O
assessed O
using O
lower O
lip O
retraction O
( O
LLR O
) O
, O
hypoactivity O
, O
and O
5 B
- I
hydroxytryptophan I
( O
5 B
- I
HTP I
) O
accumulation O
following O
decarboxylase O
inhibition O
. O

The O
response O
to O
the O
5 O
- O
HT1a O
agonist O
, O
8 B
- I
OHDPAT I
( O
0 O
. O
003 O
- O
0 O
. O
5 O
mg O
/ O
kg O
, O
SC O
) O
, O
was O
assessed O
using O
lower O
lip O
retraction O
( O
LLR O
) O
, O
hypoactivity O
, O
and O
5 B
- I
hydroxytryptophan I
( O
5 B
- I
HTP I
) O
accumulation O
following O
decarboxylase O
inhibition O
. O

The O
response O
to O
the O
5 O
- O
HT1a O
agonist O
, O
8 B
- I
OHDPAT I
( O
0 O
. O
003 O
- O
0 O
. O
5 O
mg O
/ O
kg O
, O
SC O
) O
, O
was O
assessed O
using O
lower O
lip O
retraction O
( O
LLR O
) O
, O
hypoactivity O
, O
and O
5 B
- I
hydroxytryptophan I
( O
5 B
- I
HTP I
) O
accumulation O
following O
decarboxylase O
inhibition O
. O

The O
8 B
- I
OHDPAT I
produced O
a O
dose O
- O
dependent O
increase O
in O
LLR O
and O
hypoactivity O
, O
but O
these O
effects O
were O
comparable O
for O
MDMA B
and O
saline O
pretreated O
groups O
. O

MDMA B
decreased O
tissue O
levels O
of O
5 B
- I
HT I
and O
the O
accumulation O
of O
5 B
- I
HTP I
, O
but O
these O
effects O
were O
not O
reflected O
in O
the O
changes O
in O
autoreceptor O
sensitivity O
. O

MDMA B
decreased O
tissue O
levels O
of O
5 B
- I
HT I
and O
the O
accumulation O
of O
5 B
- I
HTP I
, O
but O
these O
effects O
were O
not O
reflected O
in O
the O
changes O
in O
autoreceptor O
sensitivity O
. O

The O
data O
suggest O
that O
the O
decrease O
in O
tissue O
levels O
of O
5 B
- I
HT I
produced O
by O
MDMA B
is O
accompanied O
by O
a O
decrease O
in O
tryptophan B
hydroxylase O
activity O
but O
cannot O
be O
explained O
by O
supersensitivity O
of O
the O
5 O
- O
HT1a O
autoreceptor O
. O

beta B
- I
Asarone I
induces O
senescence O
in O
colorectal O
cancer O
cells O
by O
inducing O
lamin O
B1 O
expression O
. O

beta B
- I
Asarone I
( O
1 B
- I
propenyl I
- I
2 I
, I
4 I
, I
5 I
- I
methoxybenzol I
) O
is O
a O
compound O
from O
the O
traditional O
medical O
herb O
Acorus O
calamus O
Linn O
. O

This O
study O
tested O
the O
in O
vitro O
and O
in O
vivo O
effects O
of O
beta B
- I
asarone I
on O
colorectal O
cancer O
cells O
by O
testing O
cell O
viability O
using O
human O
colorectal O
cell O
lines O
HT29 O
and O
SW480 O
in O
MTT B
assays O
; O
tumorigenesis O
using O
xenografts O
in O
nude O
mice O
and O
a O
mouse O
model O
of O
colorectal O
cancer O
; O
cell O
senescence O
using O
senescence O
- O
associated O
beta O
- O
galactosidase O
activity O
; O
and O
expression O
of O
cancer O
and O
senescence O
- O
related O
proteins O
, O
specifically O
lamins O
, O
Oct O
- O
1 O
, O
p53 O
, O
p21 O
, O
and O
p15 O
, O
by O
Western O
blot O

beta B
- I
Asarone I
appeared O
to O
increase O
expression O
of O
lamin O
B1 O
, O
p53 O
, O
p21 O
, O
but O
not O
lamin O
A O
/ O
C O
. O

beta B
- I
Asarone I
regulates O
p15 O
expression O
by O
regulation O
of O
Oct O
- O
1 O
binding O
. O

Collectively O
, O
the O
results O
suggested O
that O
beta B
- I
asarone I
inhibits O
colon O
cancer O
formation O
in O
vivo O
and O
in O
vitro O
by O
inducing O
senescence O
. O

Since O
beta B
- I
asarone I
induced O
lamin O
B1 O
expression O
, O
a O
model O
is O
proposed O
in O
which O
beta B
- I
asarone I
inhibits O
colorectal O
cancer O
by O
inducing O
senescence O
through O
lamin O
B1 O
. O

Since O
beta B
- I
asarone I
induced O
lamin O
B1 O
expression O
, O
a O
model O
is O
proposed O
in O
which O
beta B
- I
asarone I
inhibits O
colorectal O
cancer O
by O
inducing O
senescence O
through O
lamin O
B1 O
. O

Four O
new O
lanostane B
triterpenes I
, O
butyl B
lucidenate I
P I
( O
1 O
) O
, O
butyl B
lucidenate I
D I
( I
2 I
) I
( O
2 O
) O
, O
butyl B
lucidenate I
E I
( I
2 I
) I
( O
3 O
) O
and O
butyl B
lucidenate I
Q I
( O
4 O
) O
along O
with O
11 O
known O
compounds O
( O
5 O
- O
15 O
) O
were O
isolated O
from O
the O
fruiting O
bodies O
of O
Ganoderma O
lucidum O
. O

Four O
new O
lanostane B
triterpenes I
, O
butyl B
lucidenate I
P I
( O
1 O
) O
, O
butyl B
lucidenate I
D I
( I
2 I
) I
( O
2 O
) O
, O
butyl B
lucidenate I
E I
( I
2 I
) I
( O
3 O
) O
and O
butyl B
lucidenate I
Q I
( O
4 O
) O
along O
with O
11 O
known O
compounds O
( O
5 O
- O
15 O
) O
were O
isolated O
from O
the O
fruiting O
bodies O
of O
Ganoderma O
lucidum O
. O

We O
found O
that O
three O
out O
of O
the O
twelve O
stemofoline B
derivatives O
including O
OH B
- I
A1 I
, O
NH B
- I
B6 I
and O
NH B
- I
D6 I
showed O
commitment O
efficiency O
to O
increase O
sensitivity O
to O
doxorubicin B
, O
vinblastine B
and O
paclitaxel B
in O
KB O
- O
V1 O
cells O
and O
increase O
sensitivity O
to O
doxorubicin B
, O
and O
paclitaxel B
in O
K562 O
/ O
Adr O
cells O
whereas O
the O
effects O
have O
not O
been O
seen O
in O
their O
parental O
sensitive O
cancer O
cell O
lines O
( O
KB O
- O
3 O
- O
1 O
and O
K562 O
) O
. O

We O
found O
that O
three O
out O
of O
the O
twelve O
stemofoline B
derivatives O
including O
OH B
- I
A1 I
, O
NH B
- I
B6 I
and O
NH B
- I
D6 I
showed O
commitment O
efficiency O
to O
increase O
sensitivity O
to O
doxorubicin B
, O
vinblastine B
and O
paclitaxel B
in O
KB O
- O
V1 O
cells O
and O
increase O
sensitivity O
to O
doxorubicin B
, O
and O
paclitaxel B
in O
K562 O
/ O
Adr O
cells O
whereas O
the O
effects O
have O
not O
been O
seen O
in O
their O
parental O
sensitive O
cancer O
cell O
lines O
( O
KB O
- O
3 O
- O
1 O
and O
K562 O
) O
. O

We O
found O
that O
three O
out O
of O
the O
twelve O
stemofoline B
derivatives O
including O
OH B
- I
A1 I
, O
NH B
- I
B6 I
and O
NH B
- I
D6 I
showed O
commitment O
efficiency O
to O
increase O
sensitivity O
to O
doxorubicin B
, O
vinblastine B
and O
paclitaxel B
in O
KB O
- O
V1 O
cells O
and O
increase O
sensitivity O
to O
doxorubicin B
, O
and O
paclitaxel B
in O
K562 O
/ O
Adr O
cells O
whereas O
the O
effects O
have O
not O
been O
seen O
in O
their O
parental O
sensitive O
cancer O
cell O
lines O
( O
KB O
- O
3 O
- O
1 O
and O
K562 O
) O
. O

As O
the O
results O
of O
structure O
- O
activity O
relationship O
( O
SAR O
) O
study O
of O
the O
series O
, O
the O
compounds O
with O
4 B
- I
methyl I
- I
quinazoline I
- I
2 I
- I
yl I
- I
methyl I
group O
at O
N O
- O
1 O
position O
and O
2 B
- I
aminoethylaminomethy I
group O
gave O
better O
activities O
. O

In O
comparison O
, O
the O
cystodytin B
iminoquinone I
alkaloids I
showed O
lower O
affinity O
for O
DNA O
, O
but O
were O
typically O
just O
as O
active O
as O
styelsamine B
analogues O
at O
inhibiting O
proliferation O
of O
tumor O
cells O
in O
vitro O
. O

Correlation O
was O
observed O
between O
whole O
cell O
activity O
and O
clogP O
, O
with O
the O
most O
potent O
antiproliferative O
activity O
being O
observed O
for O
3 B
- I
phenylpropanamide I
analogues O
37 O
and O
41 O
( O
NCI O
panel O
average O
GI O
( O
50 O
) O
0 O
. O
4 O
mu O
M O
and O
0 O
. O
32 O
mu O
M O
, O
respectively O
) O
with O
clogP O
~ O
4 O
. O
0 O
- O
4 O
. O
5 O
. O

To O
explore O
the O
acceptor O
regioselectivity O
of O
OleD O
- O
catalyzed O
glucosylation O
, O
the O
products O
of O
OleD O
- O
catalyzed O
reactions O
with O
six O
structurally O
diverse O
acceptors O
flavones B
- O
( O
daidzein B
) O
, O
isoflavones B
( O
flavopiridol B
) O
, O
stilbenes B
( O
resveratrol B
) O
, O
indole B
alkaloids I
( O
10 B
- I
hydroxycamptothecin I
) O
, O
and O
steroids B
( O
2 B
- I
methoxyestradiol I
) O
- O
were O
determined O
. O

To O
explore O
the O
acceptor O
regioselectivity O
of O
OleD O
- O
catalyzed O
glucosylation O
, O
the O
products O
of O
OleD O
- O
catalyzed O
reactions O
with O
six O
structurally O
diverse O
acceptors O
flavones B
- O
( O
daidzein B
) O
, O
isoflavones B
( O
flavopiridol B
) O
, O
stilbenes B
( O
resveratrol B
) O
, O
indole B
alkaloids I
( O
10 B
- I
hydroxycamptothecin I
) O
, O
and O
steroids B
( O
2 B
- I
methoxyestradiol I
) O
- O
were O
determined O
. O

We O
measure O
concentration O
- O
dependent O
diffusion O
rates O
for O
n B
- I
hexane I
, O
n B
- I
octane I
, O
n B
- I
decane I
, O
2 B
, I
7 I
- I
dimethyloctane I
, O
and O
cyclodecane B
, O
which O
have O
different O
carbon B
numbers O
and O
geometries O
: O
straight O
chain O
, O
branched O
chain O
, O
and O
cyclic O
. O

We O
measure O
concentration O
- O
dependent O
diffusion O
rates O
for O
n B
- I
hexane I
, O
n B
- I
octane I
, O
n B
- I
decane I
, O
2 B
, I
7 I
- I
dimethyloctane I
, O
and O
cyclodecane B
, O
which O
have O
different O
carbon B
numbers O
and O
geometries O
: O
straight O
chain O
, O
branched O
chain O
, O
and O
cyclic O
. O

We O
measure O
concentration O
- O
dependent O
diffusion O
rates O
for O
n B
- I
hexane I
, O
n B
- I
octane I
, O
n B
- I
decane I
, O
2 B
, I
7 I
- I
dimethyloctane I
, O
and O
cyclodecane B
, O
which O
have O
different O
carbon B
numbers O
and O
geometries O
: O
straight O
chain O
, O
branched O
chain O
, O
and O
cyclic O
. O

Micropore O
diffusion O
is O
determined O
to O
be O
the O
controlling O
mass O
transfer O
resistance O
except O
at O
low O
relative O
saturation O
for O
n B
- I
decane I
, O
where O
an O
external O
mass O
transfer O
resistance O
also O
becomes O
important O
, O
showing O
that O
the O
controlling O
mass O
transfer O
mechanism O
can O
change O
with O
system O
concentration O
. O

By O
screening O
a O
focused O
library O
of O
six O
- O
residue O
cyclic B
D I
, I
L I
- I
alpha I
- I
peptides I
and O
optimizing O
the O
activity O
of O
a O
lead O
peptide O
, O
we O
found O
one O
cyclic B
D I
, I
L I
- I
alpha I
- I
peptide I
( O
CP B
- I
2 I
) O
that O
interacts O
strongly O
with O
A O
beta O
and O
inhibits O
its O
aggregation O
. O

In O
transmission O
electron O
microscopy O
, O
optimized O
thioflavin B
T I
and O
cell O
survival O
assays O
, O
CP B
- I
2 I
inhibits O
the O
formation O
of O
A O
beta O
aggregates O
, O
entirely O
disassembles O
preformed O
aggregated O
and O
fibrillar O
A O
beta O
, O
and O
protects O
rat O
pheochromocytoma O
PC12 O
cells O
from O
A O
beta O
toxicity O
, O
without O
inducing O
any O
toxicity O
by O
itself O
. O

Using O
various O
immunoassays O
, O
circular O
dichroism O
spectroscopy O
, O
photoinduced O
cross O
- O
linking O
of O
unmodified O
proteins O
( O
PICUP O
) O
combined O
with O
SDS B
/ O
PAGE O
, O
and O
NMR O
, O
we O
probed O
the O
mechanisms O
underlying O
CP B
- I
2 I
' O
s O
antiamyloidogenic O
activity O
. O

NMR O
spectroscopy O
indicates O
that O
CP B
- I
2 I
interacts O
with O
A O
beta O
through O
its O
self O
- O
assembled O
conformation O
and O
induces O
weak O
secondary O
structure O
in O
A O
beta O
. O

Upon O
coincubation O
, O
CP B
- I
2 I
changes O
the O
aggregation O
pathway O
of O
A O
beta O
and O
alters O
its O
oligomer O
distribution O
by O
stabilizing O
small O
oligomers O
( O
1 O
- O
3 O
mers O
) O
. O

Our O
results O
support O
studies O
suggesting O
that O
toxic O
early O
oligomeric O
states O
of O
A O
beta O
may O
be O
composed O
of O
antiparallel O
beta O
- O
peptide O
structures O
and O
that O
the O
interaction O
of O
A O
beta O
with O
CP B
- I
2 I
promotes O
formation O
of O
more O
benign O
parallel O
beta O
- O
structures O
. O

These O
include O
trials O
of O
administering O
dichloroacetate B
( O
an O
activator O
of O
pyruvate B
dehydrogenase O
complex O
) O
, O
arginine B
or O
citrulline B
( O
precursors O
of O
nitric B
oxide I
) O
, O
coenzyme B
Q10 I
( O
CoQ10 B
; O
part O
of O
the O
electron O
transport O
chain O
and O
an O
antioxidant O
) O
, O
idebenone B
( O
a O
synthetic O
analogue O
of O
CoQ10 B
) O
, O
EPI B
- I
743 I
( O
a O
novel O
oral O
potent O
2 O
- O
electron O
redox O
cycling O
agent O
) O
, O
creatine B
( O
a O
precursor O
of O
phosphocreatine B
) O
, O
combined O
administration O
( O
of O

creatine B
, O
alpha B
- I
lipoate I
, O
and O
CoQ10 B
) O
, O
and O
exercise O
training O
( O
to O
increase O
muscle O
mitochondria O
) O
. O

Serum O
1 B
, I
25 I
- I
dihydroxyvitamin I
D I
( I
3 I
) I
( O
1 B
, I
25D I
) O
rose O
and O
exceeded O
the O
normal O
range O
. O

Sustained O
elevations O
in O
cFGF23 O
and O
1 B
, I
25D I
were O
observed O
, O
suggesting O
novel O
regulation O
of O
FGF23 O
processing O
and O
1 B
, I
25D I
generation O
. O

Sustained O
elevations O
in O
cFGF23 O
and O
1 B
, I
25D I
were O
observed O
, O
suggesting O
novel O
regulation O
of O
FGF23 O
processing O
and O
1 B
, I
25D I
generation O
. O

Finally O
, O
an O
analysis O
of O
WS O
- O
PM O
fractions O
determined O
the O
presence O
of O
4 O
- O
5 O
polycyclic B
aromatic I
hydrocarbons I
( O
PAHs B
) O
, O
and O
preliminary O
work O
suggests O
a O
potential O
role O
for O
these O
PAHs B
to O
alter O
macrophage O
functions O
. O

The O
length O
of O
FeSe B
filling O
inside O
the O
carbon B
nanofibers O
could O
be O
varied O
by O
controlling O
the O
reaction O
conditions O
while O
the O
diameter O
of O
nanowires O
was O
dependent O
on O
the O
thickness O
of O
Au B
- I
Pd I
coating O
used O
as O
a O
catalyst O
. O

Crystallization O
of O
glycine B
in O
the O
cylindrical O
nanopores O
of O
anodic O
aluminum B
oxide I
( O
AAO B
) O
revealed O
the O
formation O
of O
metastable O
beta B
- I
glycine I
in O
pores O
having O
diameters O
less O
than O
200 O
nm O
. O

Two O
- O
dimensional O
X O
- O
ray O
microdiffraction O
indicated O
that O
the O
[ O
010 O
] O
axis O
of O
the O
embedded O
beta B
- I
glycine I
nanocrystals O
coincided O
with O
the O
pore O
direction O
, O
identical O
to O
behavior O
observed O
previously O
in O
the O
cylindrical O
nanopores O
of O
polymer O
monoliths O
. O

Whereas O
the O
beta B
- I
glycine I
nanocrystals O
were O
stable O
indefinitely O
in O
ambient O
air O
and O
persisted O
upon O
heating O
, O
they O
transformed O
to O
the O
alpha O
polymorph O
upon O
standing O
at O
room O
temperature O
and O
90 O
% O
relative O
humidity O
( O
RH O
) O
. O

The O
alpha B
- I
glycine I
nanocrystals O
were O
oriented O
with O
the O
[ O
010 O
] O
axis O
nearly O
perpendicular O
to O
the O
pore O
direction O
, O
reflecting O
a O
nearly O
90 O
degrees O
rotation O
of O
the O
glycine B
molecules O
during O
the O
transition O
. O

When O
the O
beta B
- I
glycine I
nanocrystals O
were O
formed O
in O
the O
AAO B
cylinders O
in O
the O
presence O
of O
small O
amounts O
of O
racemic O
hydrophobic O
amino B
acid I
auxiliaries O
, O
which O
are O
known O
to O
bind O
selectively O
to O
the O
( O
010 O
) O
and O
( O
010 O
) O
faces O
on O
the O
fast O
- O
growing O
end O
of O
beta B
- I
glycine I
enantiomorphs O
, O
the O
beta O
- O
- O
> O
alpha O
phase O
transition O
at O
90 O
% O
RH O
was O
suppressed O
. O

When O
the O
beta B
- I
glycine I
nanocrystals O
were O
formed O
in O
the O
AAO B
cylinders O
in O
the O
presence O
of O
small O
amounts O
of O
racemic O
hydrophobic O
amino B
acid I
auxiliaries O
, O
which O
are O
known O
to O
bind O
selectively O
to O
the O
( O
010 O
) O
and O
( O
010 O
) O
faces O
on O
the O
fast O
- O
growing O
end O
of O
beta B
- I
glycine I
enantiomorphs O
, O
the O
beta O
- O
- O
> O
alpha O
phase O
transition O
at O
90 O
% O
RH O
was O
suppressed O
. O

In O
contrast O
, O
beta B
- I
glycine I
nanocrystals O
grown O
in O
the O
presence O
of O
an O
enantiopure O
amino B
acid I
auxiliary O
, O
which O
binds O
to O
the O
fast O
- O
growing O
end O
of O
only O
one O
of O
the O
enantiomorphs O
, O
thus O
suppressing O
its O
formation O
and O
leaving O
the O
other O
enantiomorph O
unperturbed O
, O
transformed O
into O
the O
alpha O
polymorph O
under O
the O
same O
conditions O
. O

The O
impact O
of O
functionalization O
on O
the O
stability O
, O
work O
function O
, O
and O
photoluminescence O
of O
reduced B
graphene I
oxide I
. O

Reduced B
graphene I
oxide I
( O
rGO B
) O
is O
a O
promising O
material O
for O
a O
variety O
of O
thin O
- O
film O
optoelectronic O
applications O
. O

However O
, O
these O
substituted O
phenyl B
- I
benzopyrane I
compounds O
have O
been O
reported O
to O
exert O
a O
considerable O
quenching O
effect O
, O
causing O
false O
- O
positive O
results O
in O
the O
commonly O
used O
method O
of O
enzyme O
- O
based O
NA O
inhibition O
assays O
, O
and O
thus O
, O
reliability O
of O
the O
flavonoid B
- O
based O
NAIs O
reported O
in O
the O
literature O
. O

No O
marked O
change O
was O
recorded O
in O
biochemical O
parameters O
( O
plasma O
urea B
, O
creatinine B
, O
lipids O
, O
electrolytes O
, O
bilirubin B
, O
transaminases O
and O
gamma B
- I
glutamyl I
transferase O
) O
. O

TNF O
alpha O
and O
Fas O
/ O
FasL O
pathways O
are O
involved O
in O
9 B
- I
Methoxycamptothecin I
- O
induced O
apoptosis O
in O
cancer O
cells O
with O
oxidative O
stress O
and O
G2 O
/ O
M O
cell O
cycle O
arrest O
. O

9 B
- I
Methoxycamptothecin I
( O
MCPT B
) O
has O
been O
recently O
reported O
to O
have O
a O
strong O
anticancer O
activity O
. O

Synthesis O
and O
biological O
evaluation O
of O
5 B
- I
nitropyrimidine I
analogs O
with O
azabicyclic B
substituents O
as O
GPR119 O
agonists O
. O

5 B
- I
Nitropyrimidine I
analogs O
substituted O
with O
conformationally O
restricted O
azabicyclic B
amines I
and I
alcohols I
were O
prepared O
and O
evaluated O
their O
agonistic O
activity O
against O
human O
GPR119 O
. O

5 B
- I
Nitropyrimidine I
analogs O
with O
( B
2 I
- I
fluoro I
- I
4 I
- I
methylsulfonyl I
) I
phenylamino I
group O
( O
8 O
, O
10 O
, O
12 O
, O
14 O
) O
showed O
more O
potent O
GPR119 O
activation O
activities O
than O
the O
analogs O
without O
fluorine B
in O
all O
cases O
( O
7 O
, O
9 O
, O
11 O
, O
13 O
) O
. O

Characterization O
of O
the O
mouse O
promoter O
region O
of O
the O
acyl B
- I
CoA I
synthetase O
4 O
gene O
: O
role O
of O
Sp1 O
and O
CREB O
. O

Acyl B
- I
CoA I
synthetase O
4 O
( O
Acsl4 O
) O
is O
involved O
in O
several O
cellular O
functions O
including O
steroidogenesis O
, O
synaptic O
development O
and O
cancer O
metastasis O
. O

The O
8 B
- I
oxo I
- I
GDP I
thus O
formed O
can O
be O
converted O
to O
8 B
- I
oxo I
- I
GTP I
because O
nucleoside B
- I
diphosphate I
kinase O
and O
adenylate B
kinase O
, O
both O
of O
which O
catalyze O
the O
conversion O
of O
GDP B
to O
GTP B
, O
do O
not O
discriminate O
8 B
- I
oxo I
- I
GDP I
from O
normal O
GDP B
. O

This O
study O
evaluates O
the O
developmental O
toxicity O
of O
two O
high O
molecular O
weight O
dialkyl B
phthalate I
esters I
, O
diundecyl B
phthalate I
( O
DUDP B
) O
and O
ditridecyl B
phthalate I
( O
DTDP B
) O
. O

There O
is O
now O
a O
large O
body O
of O
published O
data O
showing O
that O
genotype O
for O
certain O
common O
polymorphisms O
in O
the O
genes O
encoding O
the O
target O
vitamin B
K I
epoxide I
reductase O
( O
G O
- O
1639A O
/ O
C1173T O
) O
and O
the O
main O
metabolizing O
enzyme O
CYP2C9 O
( O
CYP2C9 O
* O
2 O
and O
* O
3 O
alleles O
) O
are O
important O
determinants O
of O
the O
individual O
coumarin B
anticoagulant O
dose O
requirement O
. O

Additional O
less O
common O
polymorphisms O
in O
these O
genes O
together O
with O
polymorphisms O
in O
other O
genes O
relevant O
to O
blood O
coagulation O
such O
as O
the O
cytochrome O
P450 O
CYP4F2 O
, O
gamma B
- I
glutamyl I
carboxylase O
, O
calumenin O
and O
cytochrome O
P450 O
oxidoreductase O
may O
also O
be O
significant O
predictors O
of O
dose O
, O
especially O
in O
ethnic O
groups O
such O
as O
Africans O
where O
there O
have O
been O
fewer O
genetic O
studies O
compared O
with O
European O
populations O
. O

The O
autophagy O
inhibitor O
, O
3 B
- I
methyladenine I
, O
salvaged O
the O
final O
apoptosis O
. O

The O
population O
pharmacokinetics O
( O
PPK O
) O
of O
atorvastatin B
and O
its O
principal O
active O
metabolite O
, O
o B
- I
hydroxyatorvastatin I
, O
were O
described O
in O
6 O
- O
17 O
years O
old O
pediatric O
hypercholesterolemia O
patients O
with O
a O
2 O
- O
compartment O
model O
for O
both O
parent O
and O
metabolite O
. O

The O
paramagnetic O
activity O
came O
from O
a O
Gd B
- I
DTPA I
derivative O
that O
was O
grafted O
on O
the O
silica B
surface O
. O

However O
, O
MPT O
was O
prevented O
by O
ANT O
ligands O
ATP B
, O
ADP B
, O
tamoxifen B
and O
4 B
- I
hydroxytamoxifen I
, O
implying O
that O
the O
MPT O
induction O
by O
acitretin O
is O
mediated O
by O
the O
ANT O
. O

Design O
and O
synthesis O
of O
imidazole B
and O
triazole B
derivatives O
as O
Lp O
- O
PLA O
2 O
inhibitors O
and O
the O
unexpected O
discovery O
of O
highly O
potent O
quaternary B
ammonium I
salts I
. O

But O
interestingly O
, O
a O
series O
of O
quaternary B
ammonium I
salts I
that O
were O
isolated O
as O
by O
- O
products O
during O
this O
synthetic O
work O
were O
found O
with O
high O
potency O
. O

The O
compound O
12a O
having O
exo B
- I
cyanoethylidene I
group O
in O
the O
4 O
- O
position O
of O
piperidine B
ring O
was O
found O
to O
be O
two O
to O
threefold O
more O
potent O
than O
the O
linezolid B
against O
penicillin B
- O
resistant O
Staphylococcus O
pneumonia O
and O
Staphylococcus O
agalactiae O
, O
and O
also O
exhibited O
reduced O
MAO O
- O
B O
inhibitory O
activity O
. O

Polymethacrylate B
derivatives O
( O
Eudragit B
( O
R O
) O
RS O
PO O
and O
RL O
PO O
) O
were O
used O
for O
coating O
agents O
, O
and O
polyethylene B
glycol I
6000 I
( O
PEG B
6000 I
) O
, O
triethyl B
citrate I
( O
TEC B
) O
and O
castor O
oil O
were O
as O
plasticizers O
. O

By O
focusing O
on O
SnO B
( I
2 I
) I
, O
the O
hope O
is O
that O
such O
concepts O
and O
strategies O
can O
be O
extended O
to O
other O
potential O
metal B
oxides I
, O
such O
as O
titanium B
dioxide I
or O
iron B
oxides I
, O
thus O
shedding O
some O
light O
on O
the O
future O
development O
of O
high O
- O
performance O
metal B
- I
oxide I
based O
negative O
electrodes O
for O
LIBs O
. O

PCOS O
women O
with O
17 B
- I
hydroxyprogesterone I
( O
17OHP B
) O
basal O
values O
> O
2 O
ng O
/ O
ml O
and O
/ O
or O
post O
- O
ACTH O
> O
10 O
ng O
/ O
ml O
were O
excluded O
. O

Moreover O
, O
17 B
- I
hydroxyprogesterone I
values O
of O
< O
10 O
ng O
/ O
ml O
post O
- O
ACTH O
exclude O
homozygosity O
of O
CYP21A2 O
mutations O
. O

Azaspiracid B
- I
1 I
inhibits O
the O
maturation O
of O
cathepsin O
D O
in O
mammalian O
cells O
. O

Azaspiracid B
- I
1 I
( O
AZA B
- I
1 I
) O
inhibits O
endocytosis O
, O
but O
the O
consequences O
of O
this O
alteration O
on O
cellular O
processes O
are O
unknown O
. O

Azaspiracid B
- I
1 I
( O
AZA B
- I
1 I
) O
inhibits O
endocytosis O
, O
but O
the O
consequences O
of O
this O
alteration O
on O
cellular O
processes O
are O
unknown O
. O

We O
hypothesized O
that O
the O
inhibition O
of O
endocytosis O
is O
a O
key O
step O
of O
the O
mode O
of O
action O
of O
AZA B
- I
1 I
, O
leading O
to O
perturbation O
of O
cellular O
processes O
dependent O
on O
proper O
functioning O
of O
endocytic O
machinery O
. O

We O
tested O
this O
working O
hypothesis O
by O
probing O
whether O
AZA B
- I
1 I
can O
alter O
the O
maturation O
of O
cathepsin O
D O
in O
MCF O
- O
7 O
epithelial O
cells O
, O
as O
a O
model O
system O
. O

We O
found O
that O
cell O
treatment O
with O
AZA B
- I
1 I
inhibited O
the O
conversion O
of O
52 O
kDa O
procathepsin O
D O
into O
the O
mature O
30 O
kDa O
protein O
. O

The O
effects O
induced O
by O
AZA B
- I
1 I
were O
similar O
to O
those O
elicited O
by O
chlorpromazine B
and O
other O
agents O
preventing O
proper O
maturation O
of O
lysosomal O
enzymes O
, O
indicating O
that O
the O
inhibition O
of O
endocytic O
transfer O
of O
proforms O
to O
late O
endosomes O
/ O
lysosomess O
is O
responsible O
for O
the O
effect O
induced O
by O
the O
toxin O
. O

Co O
- O
localization O
of O
cathepsin O
D O
and O
EEA O
- O
1 O
immunoreactivity O
, O
in O
turn O
, O
was O
found O
in O
cells O
exposed O
to O
AZA B
- I
1 I
, O
indicating O
that O
the O
toxin O
blocks O
protein O
maturation O
at O
the O
early O
steps O
of O
endocytosis O
, O
causing O
accumulation O
of O
procathepsin O
D O
in O
early O
endosomes O
. O

The O
molecular O
alteration O
induced O
by O
AZA B
- I
1 I
involved O
both O
secreted O
and O
intracellular O
pools O
of O
procathepsin O
D O
, O
showing O
that O
the O
toxin O
effect O
does O
not O
result O
from O
a O
general O
impairment O
of O
vesicular O
trafficking O
but O
is O
the O
outcome O
of O
a O
perturbed O
centripetal O
process O
. O

Furthermore O
, O
AZA B
- I
1 I
was O
found O
to O
inhibit O
procathepsin O
D O
maturation O
also O
in O
normal O
fibroblasts O
, O
showing O
that O
this O
molecular O
response O
is O
induced O
by O
this O
toxin O
in O
different O
cell O
types O
. O

Four O
new O
germacranes B
[ O
heyneanones B
A I
- I
D I
( O
1 O
- O
4 O
) O
] O
, O
three O
new O
guaianes B
[ O
4 B
, I
10 I
- I
epizedoarondiol I
( O
5 O
) O
, O
15 B
- I
hydroxyprocurcumenol I
( O
6 O
) O
, O
12 B
- I
hydroxycurcumenol I
( O
7 O
) O
] O
, O
and O
two O
new O
spirolactones B
[ O
curcumanolides B
C O
( O
8 O
) O
and O
D O
( O
9 O
) O
] O
were O
isolated O
from O
the O
rhizomes O
of O
Curcuma O
heyneana O
together O
with O
13 O
known O
sesquiterpenes B
and O

Four O
new O
germacranes B
[ O
heyneanones B
A I
- I
D I
( O
1 O
- O
4 O
) O
] O
, O
three O
new O
guaianes B
[ O
4 B
, I
10 I
- I
epizedoarondiol I
( O
5 O
) O
, O
15 B
- I
hydroxyprocurcumenol I
( O
6 O
) O
, O
12 B
- I
hydroxycurcumenol I
( O
7 O
) O
] O
, O
and O
two O
new O
spirolactones B
[ O
curcumanolides B
C O
( O
8 O
) O
and O
D O
( O
9 O
) O
] O
were O
isolated O
from O
the O
rhizomes O
of O
Curcuma O
heyneana O
together O
with O
13 O
known O
sesquiterpenes B
and O

The O
effects O
of O
BMY B
- I
14802 I
against O
L B
- I
DOPA I
- O
and O
dopamine B
agonist O
- O
induced O
dyskinesia O
in O
the O
hemiparkinsonian O
rat O
. O

The O
effects O
of O
BMY B
- I
14802 I
against O
L B
- I
DOPA I
- O
and O
dopamine B
agonist O
- O
induced O
dyskinesia O
in O
the O
hemiparkinsonian O
rat O
. O

RATIONALE O
: O
L B
- I
DOPA I
continues O
to O
be O
the O
primary O
treatment O
for O
patients O
with O
Parkinson O
' O
s O
disease O
; O
however O
, O
the O
benefits O
of O
long O
- O
term O
treatment O
are O
often O
accompanied O
by O
debilitating O
side O
effects O
known O
as O
dyskinesias O
. O

The O
purported O
sigma O
- O
1 O
antagonist O
, O
BMY B
- I
14802 I
has O
been O
previously O
demonstrated O
to O
reduce O
L B
- I
DOPA I
induced O
dyskinesia O
in O
a O
5 O
- O
HT O
( O
1A O
) O
receptor O
dependent O
manner O
. O

The O
purported O
sigma O
- O
1 O
antagonist O
, O
BMY B
- I
14802 I
has O
been O
previously O
demonstrated O
to O
reduce O
L B
- I
DOPA I
induced O
dyskinesia O
in O
a O
5 O
- O
HT O
( O
1A O
) O
receptor O
dependent O
manner O
. O

OBJECTIVE O
: O
In O
the O
present O
study O
, O
we O
extend O
these O
findings O
by O
examining O
the O
anti O
- O
dyskinetic O
potential O
of O
BMY B
- I
14802 I
against O
L B
- I
DOPA I
, O
the O
D O
( O
1 O
) O
receptor O
agonist O
SKF81297 B
and O
the O
D O
( O
2 O
) O
receptor O
agonist O
, O
quinpirole B
, O
in O
the O
hemi O
- O
parkinsonian O
rat O
model O
. O

OBJECTIVE O
: O
In O
the O
present O
study O
, O
we O
extend O
these O
findings O
by O
examining O
the O
anti O
- O
dyskinetic O
potential O
of O
BMY B
- I
14802 I
against O
L B
- I
DOPA I
, O
the O
D O
( O
1 O
) O
receptor O
agonist O
SKF81297 B
and O
the O
D O
( O
2 O
) O
receptor O
agonist O
, O
quinpirole B
, O
in O
the O
hemi O
- O
parkinsonian O
rat O
model O
. O

In O
addition O
, O
the O
receptor O
specificity O
of O
BMY B
- I
14802 I
' O
s O
effects O
was O
evaluated O
using O
WAY B
- I
100635 I
, O
a O
5 O
- O
HT O
( O
1A O
) O
receptor O
antagonist O
. O

In O
addition O
, O
the O
receptor O
specificity O
of O
BMY B
- I
14802 I
' O
s O
effects O
was O
evaluated O
using O
WAY B
- I
100635 I
, O
a O
5 O
- O
HT O
( O
1A O
) O
receptor O
antagonist O
. O

RESULTS O
: O
Results O
confirmed O
the O
dose O
- O
dependent O
( O
20 O
> O
10 O
> O
5 O
mg O
/ O
kg O
) O
anti O
- O
dyskinetic O
effects O
of O
BMY B
- I
14802 I
against O
L B
- I
DOPA I
with O
preservation O
of O
anti O
- O
parkinsonian O
efficacy O
at O
10 O
mg O
/ O
kg O
. O

RESULTS O
: O
Results O
confirmed O
the O
dose O
- O
dependent O
( O
20 O
> O
10 O
> O
5 O
mg O
/ O
kg O
) O
anti O
- O
dyskinetic O
effects O
of O
BMY B
- I
14802 I
against O
L B
- I
DOPA I
with O
preservation O
of O
anti O
- O
parkinsonian O
efficacy O
at O
10 O
mg O
/ O
kg O
. O

BMY B
- I
14802 I
at O
10 O
and O
20 O
mg O
/ O
kg O
also O
reduced O
dyskinesia O
induced O
by O
both O
D O
( O
1 O
) O
and O
D O
( O
2 O
) O
receptor O
agonists O
. O

Additionally O
, O
BMY B
- I
14802 I
' O
s O
anti O
- O
dyskinetic O
effects O
against O
L B
- I
DOPA I
, O
but O
not O
SKF81297 B
or O
quinpirole B
, O
were O
reversed O
by O
WAY B
- I
100635 I
( O
0 O
. O
5 O
mg O
/ O
kg O
) O
. O

Additionally O
, O
BMY B
- I
14802 I
' O
s O
anti O
- O
dyskinetic O
effects O
against O
L B
- I
DOPA I
, O
but O
not O
SKF81297 B
or O
quinpirole B
, O
were O
reversed O
by O
WAY B
- I
100635 I
( O
0 O
. O
5 O
mg O
/ O
kg O
) O
. O

Additionally O
, O
BMY B
- I
14802 I
' O
s O
anti O
- O
dyskinetic O
effects O
against O
L B
- I
DOPA I
, O
but O
not O
SKF81297 B
or O
quinpirole B
, O
were O
reversed O
by O
WAY B
- I
100635 I
( O
0 O
. O
5 O
mg O
/ O
kg O
) O
. O

CONCLUSION O
: O
Collectively O
, O
these O
findings O
demonstrate O
that O
BMY B
- I
14802 I
provides O
anti O
- O
dyskinetic O
relief O
against O
L B
- I
DOPA I
and O
direct O
DA O
agonist O
in O
a O
preclinical O
model O
of O
PD O
, O
acting O
via O
multiple O
receptor O
systems O
and O
supports O
the O
utility O
of O
such O
compounds O
for O
the O
improved O
treatment O
of O
PD O
. O

CONCLUSION O
: O
Collectively O
, O
these O
findings O
demonstrate O
that O
BMY B
- I
14802 I
provides O
anti O
- O
dyskinetic O
relief O
against O
L B
- I
DOPA I
and O
direct O
DA O
agonist O
in O
a O
preclinical O
model O
of O
PD O
, O
acting O
via O
multiple O
receptor O
systems O
and O
supports O
the O
utility O
of O
such O
compounds O
for O
the O
improved O
treatment O
of O
PD O
. O

The O
Ar B
- I
CH2 I
bond O
rotational O
barrier O
for O
encapsulated O
ortho B
- I
substituted I
benzyl I
phosphonium I
guest O
molecules O
is O
sensitive O
to O
the O
size O
and O
shape O
of O
the O
host O
interior O
space O
. O

When O
host O
1 O
is O
dissolved O
in O
organic O
solvents O
with O
large O
solvent O
internal O
pressures O
( O
d O
U O
/ O
d O
V O
) O
T O
, O
we O
find O
that O
the O
free O
energy O
barrier O
to O
Ar B
- I
CH2 I
bond O
rotation O
increases O
by O
1 O
- O
2 O
kcal O
/ O
mol O
, O
compared O
with O
that O
in O
aqueous O
solution O
. O

Effects O
of O
monocarboxylate B
transporter O
inhibition O
on O
the O
oral O
toxicokinetics O
/ O
toxicodynamics O
of O
gamma B
- I
hydroxybutyrate I
and O
gamma B
- I
butyrolactone I
. O

Effects O
of O
monocarboxylate B
transporter O
inhibition O
on O
the O
oral O
toxicokinetics O
/ O
toxicodynamics O
of O
gamma B
- I
hydroxybutyrate I
and O
gamma B
- I
butyrolactone I
. O

Respiratory O
depression O
and O
death O
secondary O
to O
respiratory O
arrest O
have O
occurred O
after O
oral O
overdoses O
of O
gamma B
- I
hydroxybutyrate I
( O
GHB B
) O
and O
its O
precursor O
gamma B
- I
butyrolactone I
( O
GBL B
) O
. O

Respiratory O
depression O
and O
death O
secondary O
to O
respiratory O
arrest O
have O
occurred O
after O
oral O
overdoses O
of O
gamma B
- I
hydroxybutyrate I
( O
GHB B
) O
and O
its O
precursor O
gamma B
- I
butyrolactone I
( O
GBL B
) O
. O

The O
competitive O
MCT O
inhibitor O
l B
- I
lactate I
was O
administered O
by O
intravenous O
infusion O
starting O
1 O
hour O
after O
GHB B
and O
GBL B
administration O
. O

Oral O
administration O
of O
l B
- I
lactate I
and O
the O
MCT O
inhibitor O
luteolin O
was O
also O
evaluated O
. O

Intravenous O
l B
- I
lactate I
, O
but O
not O
oral O
treatments O
, O
significantly O
increased O
GHB B
renal O
and O
/ O
or O
oral O
clearances O
. O

At O
the O
low O
dose O
of O
GHB B
and O
GBL B
, O
i O
. O
v O
. O
l B
- I
lactate I
increased O
GHB B
renal O
clearance O
. O

The O
lack O
of O
effect O
of O
i O
. O
v O
. O
l B
- I
lactate I
on O
renal O
clearance O
after O
a O
high O
oral O
GHB B
dose O
suggests O
possible O
effects O
of O
i O
. O
v O
. O
l B
- I
lactate I
on O
MCT O
- O
mediated O
absorption O
. O

The O
lack O
of O
effect O
of O
i O
. O
v O
. O
l B
- I
lactate I
on O
renal O
clearance O
after O
a O
high O
oral O
GHB B
dose O
suggests O
possible O
effects O
of O
i O
. O
v O
. O
l B
- I
lactate I
on O
MCT O
- O
mediated O
absorption O
. O

Intravenous O
l B
- I
lactate I
also O
reduced O
mortality O
with O
the O
high O
GBL B
dose O
. O

These O
data O
indicate O
i O
. O
v O
. O
l B
- I
lactate I
represents O
a O
potential O
treatment O
strategy O
in O
oral O
overdose O
of O
GHB B
and O
GBL B
. O

5 B
- I
Methoxy I
- I
N I
, I
N I
- I
dimethyltryptamine I
( O
5 B
- I
MeO I
- I
DMT I
or O
street O
name O
" O
5 B
- I
MEO I
" O
) O
is O
a O
newer O
designer O
drug O
belonging O
to O
a O
group O
of O
naturally O
occurring O
indolealkylamines B
. O

One O
- O
pot O
, O
exchange O
- O
free O
, O
room O
- O
temperature O
synthesis O
of O
sub O
- O
10 O
nm O
aqueous O
, O
noninteracting O
, O
and O
stable O
zwitterated B
iron I
oxide I
nanoparticles O
. O

Thymidylate B
kinase O
( O
TMPK O
) O
is O
a O
key O
enzyme O
for O
pyrimidine B
synthesis O
that O
catalyzes O
the O
phosphorylation O
of O
thymidine B
5 I
' I
- I
monophosphate I
( O
dTMP B
) O
in O
the O
presence O
of O
ATP B
and O
Mg B
( I
2 I
+ I
) I
to O
form O
thymidine B
5 I
' I
- I
diphosphate I
( O
dTDP B
) O
, O
which O
is O
then O
converted O
to O
thymidine B
5 I
' I
- I
triphosphate I
( O
dTTP B
) O
by O
nucleoside B
- I
diphosphate I
kinase O
( O
NDK O
) O
. O

Among O
all O
the O
aroma O
compounds O
, O
9 O
key O
ones O
were O
identified O
in O
all O
samples O
, O
including O
ethyl B
2 I
- I
methylbutanoate I
, O
butyl B
acetate I
, O
1 B
- I
butanol I
, O
ethyl B
hexanoate I
, O
1 B
- I
hexanol I
, O
butanoic B
acid I
, O
beta B
- I
damascenone I
, O
hexanoic B
acid I
, O
and O
octanoic B
acid I
. O

Among O
all O
the O
aroma O
compounds O
, O
9 O
key O
ones O
were O
identified O
in O
all O
samples O
, O
including O
ethyl B
2 I
- I
methylbutanoate I
, O
butyl B
acetate I
, O
1 B
- I
butanol I
, O
ethyl B
hexanoate I
, O
1 B
- I
hexanol I
, O
butanoic B
acid I
, O
beta B
- I
damascenone I
, O
hexanoic B
acid I
, O
and O
octanoic B
acid I
. O

Among O
all O
the O
aroma O
compounds O
, O
9 O
key O
ones O
were O
identified O
in O
all O
samples O
, O
including O
ethyl B
2 I
- I
methylbutanoate I
, O
butyl B
acetate I
, O
1 B
- I
butanol I
, O
ethyl B
hexanoate I
, O
1 B
- I
hexanol I
, O
butanoic B
acid I
, O
beta B
- I
damascenone I
, O
hexanoic B
acid I
, O
and O
octanoic B
acid I
. O

Silymarin O
treatment O
was O
associated O
with O
rapid O
repair O
of O
UVB O
- O
induced O
cyclobutane B
pyrimidine I
dimers I
( O
CPDs B
) O
in O
DCs O
and O
silymarin O
treatment O
did O
not O
prevent O
UV O
- O
induced O
immunosuppression O
in O
XPA O
- O
deficient O
mice O
which O
are O
unable O
to O
repair O
UV O
- O
induced O
DNA O
damage O
. O

Such O
degradation O
could O
be O
completely O
rescued O
by O
pretreatment O
of O
MEF O
cells O
with O
the O
proteasomal O
inhibitor O
, O
MG B
- I
132 I
. O

Co O
- O
exposure O
to O
environmental O
polycyclic B
aromatic I
hydrocarbons I
( O
PAHs B
) O
and O
interleukin O
( O
IL O
) O
- O
1 O
beta O
induces O
expression O
of O
the O
tumor O
- O
promoting O
cytokine O
IL O
- O
6 O
in O
cancer O
cells O
. O

We O
identified O
depleted O
PK O
- O
M2 O
( O
M2 O
isoform O
of O
pyruvate B
kinase O
) O
activity O
and O
apoptosis O
of O
NPCs O
revealed O
by O
the O
genomic O
DNA O
fragmentation O
and O
elevated O
PARP O
( O
poly B
ADP I
ribose I
polymerase O
) O
activity O
along O
with O
increased O
Caspase O
activity O
initiated O
by O
severely O
depolarised O
mitochondrial O
membranes O
. O

For O
the O
case O
of O
one O
water O
molecule O
, O
most O
of O
the O
energy O
in O
the O
reactants O
region O
of O
the O
IRC O
is O
used O
for O
structural O
changes O
, O
while O
the O
transition O
state O
region O
encompasses O
the O
majority O
of O
electron O
activity O
, O
except O
for O
the O
formation O
of O
the O
C B
- I
O I
bond O
, O
which O
extends O
well O
into O
the O
products O
region O
. O

Further O
, O
the O
partitioning O
in O
lipid O
bilayer O
systems O
containing O
different O
hydrophobic O
tail O
groups O
( O
DOPC B
( O
1 B
, I
2 I
- I
dioleoyl I
- I
sn I
- I
glycero I
- I
3 I
- I
phosphocholine I
) O
, O
SOPC B
( O
stearoyl B
- I
oleoylphosphatidylch I
) O
, O
DMPC B
( O
1 B
, I
2 I
- I
dimyristoyl I
- I
sn I
- I
glycero I
- I
3 I
- I
phosphocholine I
) O
, O
and O
POPC B
( O
1 B
- I
palmitoyl I
- I
2 I
- I
oleoyl I
- I
sn I
- I

Adsorption O
of O
an O
in O
- O
house O
synthesized O
organic O
- O
inorganic O
Al B
( I
OH I
) I
3 I
- I
PAM I
( O
Al B
- I
PAM I
) O
as O
an O
example O
of O
cationic O
hybrid O
PAM B
and O
a O
commercially O
available O
partially O
hydrolyzed O
polyacrylamide B
( O
MF1011 B
) O
as O
an O
example O
of O
anionic B
PAM I
was O
studied O
. O

In O
contrast O
, O
anionic B
MF1011 I
adsorbed O
strongly O
on O
aluminum B
- I
hydroxy I
basal O
planes O
, O
while O
its O
adsorption O
on O
tetrahedral O
silica B
basal O
planes O
was O
weak O
and O
reversible O
. O

The O
adsorbed O
Al B
- I
PAM I
layer O
was O
able O
to O
release O
trapped O
water O
overtime O
and O
became O
more O
compact O
, O
while O
MF1011 B
film O
became O
more O
dissipative O
as O
backbones O
stretched O
out O
from O
kaolinite B
surface O
with O
minimal O
overlapping O
. O

Gas O
phase O
dissociative O
electron O
attachment O
( O
DEA O
) O
measurements O
with O
methyl B
- I
dialanine I
, O
C B
( I
7 I
) I
H I
( I
14 I
) I
N I
( I
2 I
) I
O I
( I
3 I
) I
, O
are O
performed O
in O
a O
crossed O
electron O
- O
molecular O
beam O
experiment O
at O
high O
energy O
resolution O
( O
~ O
120 O
meV O
) O
. O

Dose O
- O
response O
curves O
were O
also O
constructed O
for O
pre O
- O
incubation O
of O
vascular O
rings O
with O
N B
omega I
- I
nitro I
- I
L I
- I
arginine I
methyl I
ester I
( O
L B
- I
NAME I
) O
( O
a O
non O
- O
specific O
nitric B
oxide I
synthase O
inhibitor O
) O
, O
indomethacin B
( O
an O
unspecific O
cyclooxygenase O
inhibitor O
) O
, O
and O
1H B
- I
[ I
1 I
, I
2 I
, I
4 I
] I
oxadiazolo I
[ I
4 I
, I
3 I
- I
a I
] I
quinoxalin I
- I
1 I
- I
one I
( O
ODQ B
) O
( O
a O
guanylyl O
cyclase O

( B
- I
) I
- I
Cubebin I
was O
found O
to O
exert O
a O
vasorelaxant O
effect O
irrespective O
of O
the O
presence O
of O
endothelium O
, O
which O
was O
abolished O
by O
pretreatment O
with O
L B
- I
NAME I
and O
ODQ B
, O
but O
not O
with O
indomethacin B
. O

Additionally O
, O
on O
day O
11 O
of O
both O
study O
periods O
, O
150 O
mg O
caffeine B
( O
CYP1A2 O
) O
, O
125 O
mg O
tolbutamide B
( O
CYP2C9 O
) O
, O
20 O
mg O
omeprazole B
( O
CYP2C19 O
) O
, O
30 O
mg O
dextromethorphan B
- I
HBr I
( O
CYP2D6 O
) O
, O
and O
2 O
mg O
midazolam B
( O
CYP3A4 O
) O
were O
administered O
orally O
. O

We O
studied O
well O
- O
characterized O
boehmite B
engineered O
NP O
[ O
aluminum B
oxide I
hydroxide I
, O
AlO B
( I
OH I
) I
] O
. O

The O
inhibition O
was O
reversed O
by O
dithioerythritol B
, O
N B
- I
acetylcysteine I
and O
l B
- I
cysteine I
. O

The O
inhibition O
was O
reversed O
by O
dithioerythritol B
, O
N B
- I
acetylcysteine I
and O
l B
- I
cysteine I
. O

Pyrogallol B
- O
related O
chemicals O
and O
tannins B
are O
present O
in O
dietary O
sources O
and O
individually O
produced O
strong O
activity O
: O
pyrogallol B
( O
30 O
x O
) O
, O
3 B
- I
methoxycatechol I
( O
25 O
x O
) O
, O
gallic B
acid I
( O
21 O
x O
) O
, O
and O
1 B
, I
2 I
, I
4 I
- I
benzenetriol I
( O
21 O
x O
) O
. O

Various O
substituted O
indazole B
and O
benzoxazolone B
amino B
acids I
were O
investigated O
as O
d B
- I
tyrosine I
surrogates O
in O
highly O
potent O
CGRP O
receptor O
antagonists O
. O

Compound O
3 O
, O
derived O
from O
the O
7 B
- I
methylindazole I
core O
, O
afforded O
a O
30 O
- O
fold O
increase O
in O
CGRP O
binding O
potency O
compared O
with O
its O
unsubstituted O
indazole B
analog O
1 O
. O

Amongst O
the O
polymers O
tested O
in O
this O
study O
, O
EUDRAGIT B
E I
PO I
was O
found O
to O
have O
the O
greatest O
inhibitory O
effect O
on O
crystallization O
, O
whilst O
PVP B
K30 I
was O
found O
to O
have O
the O
least O
protective O
effect O
; O
presumably O
because O
of O
its O
hygroscopic O
nature O
. O

In O
this O
study O
, O
using O
recombinant O
human O
insulin O
( O
insulin O
) O
as O
a O
model O
, O
we O
investigated O
the O
ability O
of O
several O
excipients O
, O
in O
particular O
triethylenetetramine B
( O
TETA B
) O
, O
reduced B
glutathione I
( O
GSH B
) O
and O
ethylenediamine B
tetraacetic I
acid I
( O
EDTA B
) O
, O
for O
their O
ability O
to O
prevent O
protein O
oxidation O
, O
aggregation O
, O
and O
fragmentation O
. O

The O
increase O
in O
nuclear O
Nrf2 O
levels O
was O
accompanied O
by O
a O
significant O
increase O
in O
heme O
oxygenase O
1 O
( O
HO O
- O
1 O
) O
and O
gamma B
- I
glutamylcysteine I
synthetase O
( O
gamma O
GCS O
) O
mRNA O
and O
protein O
levels O
. O

In O
this O
study O
, O
we O
demonstrated O
that O
treatment O
of O
rat O
primary O
astrocytes O
with O
antofine B
induced O
dose O
- O
dependent O
inhibition O
of O
gap O
junction O
intercellular O
communication O
( O
GJIC O
) O
, O
as O
assessed O
by O
scrape O
- O
loading O
6 B
- I
carboxyfluorescein I
dye O
transfer O
. O

Co O
- O
treatment O
of O
astrocytes O
with O
antofine B
and O
the O
intracellular O
Ca B
( I
2 I
+ I
) I
chelator O
BAPTA B
- I
AM I
prevented O
downregulation O
of O
Cx43 O
and O
inhibition O
of O
GJIC O
. O

Increased O
immunoreactive O
11 B
- I
ketotestosterone I
concentrations O
in O
sheep O
feces O
after O
acth O
challenge O
. O

11 B
- I
Oxoetiocholanolone I
and O
related O
substances O
are O
important O
metabolites O
of O
cortisol B
and O
are O
excreted O
via O
feces O
in O
ruminants O
. O

To O
investigate O
whether O
11 B
- I
ketotestosterone I
( O
11 B
- I
KT I
) O
or O
its O
immunoreactive O
metabolites O
are O
formed O
and O
excreted O
in O
ruminant O
feces O
, O
an O
enzyme O
immunoassay O
( O
EIA O
) O
was O
developed O
and O
validated O
. O

To O
investigate O
whether O
11 B
- I
ketotestosterone I
( O
11 B
- I
KT I
) O
or O
its O
immunoreactive O
metabolites O
are O
formed O
and O
excreted O
in O
ruminant O
feces O
, O
an O
enzyme O
immunoassay O
( O
EIA O
) O
was O
developed O
and O
validated O
. O

Samples O
( O
0 O
. O
5 O
g O
) O
were O
extracted O
using O
80 O
% O
methanol B
and O
immunoreactive O
metabolites O
measured O
using O
the O
11 B
- I
KT I
EIA O
and O
an O
already O
established O
11 B
, I
17 I
- I
dioxoandrostane I
( O
11 B
, I
17 I
- I
DOA I
) O
EIA O
. O

High O
- O
performance O
liquid O
chromatography O
separation O
revealed O
no O
peak O
in O
the O
same O
elution O
position O
as O
authentic O
11 B
- I
KT I
; O
therefore O
, O
reacting O
substances O
were O
referred O
to O
as O
11 B
- I
KT I
equivalents O
. O

High O
- O
performance O
liquid O
chromatography O
separation O
revealed O
no O
peak O
in O
the O
same O
elution O
position O
as O
authentic O
11 B
- I
KT I
; O
therefore O
, O
reacting O
substances O
were O
referred O
to O
as O
11 B
- I
KT I
equivalents O
. O

In O
the O
case O
of O
11 B
- I
KT I
immunoreactive O
substances O
, O
the O
values O
increased O
from O
baseline O
( O
median O
, O
136 O
ng O
/ O
g O
feces O
) O
to O
a O
peak O
concentration O
( O
median O
, O
424 O
ng O
/ O
g O
) O
10 O
to O
14 O
h O
after O
Synacthen O
injection O
and O
declined O
afterwards O
. O

From O
this O
data O
, O
the O
authors O
conclude O
that O
11 B
- I
KT I
- O
like O
substances O
, O
specifically O
C19 B
O3 I
- I
androgens I
with O
a O
17 B
beta I
- I
hydroxy I
group O
, O
were O
present O
in O
the O
feces O
. O

A O
nonionic O
inhibitor O
with O
high O
specificity O
for O
the O
UDP B
- I
Gal I
donor O
binding O
site O
of O
human O
blood O
group O
B O
galactosyltransferas O
: O
design O
, O
synthesis O
, O
and O
characterization O
. O

The O
binding O
epitope O
of O
1 O
demonstrates O
a O
high O
involvement O
of O
the O
arabinityl B
linker O
, O
whereas O
the O
galactose B
residue O
is O
only O
making O
contact O
to O
the O
protein O
via O
its O
C O
- O
2 O
site O
, O
which O
is O
very O
important O
for O
the O
discrimination O
between O
galactose B
and O
N B
- I
acetylgalactosamine I
, O
the O
substrate O
transferred O
by O
GTA O
. O

To O
test O
this O
hypothesis O
, O
constructs O
were O
evaluated O
consisting O
of O
an O
immunophilin O
: O
human O
FK B
- I
506 I
binding O
protein O
12 O
( O
FKBP O
) O
attached O
to O
an O
ELP O
. O

In O
brine O
shrimp O
toxicology O
assays O
, O
profound O
cytotoxicity O
was O
displayed O
by O
ethyl B
acetate I
( O
LD O
( O
50 O
) O
8 O
. O
3 O
mu O
g O
/ O
ml O
) O
and O
chloroform B
( O
LD O
( O
50 O
) O
8 O
. O
8 O
mu O
g O
/ O
ml O
) O
fractions O
, O
followed O
by O
relatively O
weak O
crude O
methanolic O
extract O
of O
H O
. O
strigosum O
( O
LD O
( O
50 O
) O
909 O
mu O
g O
/ O
ml O
) O
and O
n B
- I
hexane I
fraction O
( O
LD O
( O
50 O
) O
1000 O
mu O
g O
/ O
ml O
) O
. O

In O
case O
of O
phytotoxicity O
activity O
against O
Lemna O
acquinoctialis O
, O
highest O
phytotoxic O
effect O
was O
showed O
by O
ethyl B
acetate I
fraction O
( O
LD O
( O
50 O
) O
91 O
. O
0 O
mu O
g O
/ O
ml O
) O
, O
while O
chloroform B
fraction O
, O
plant O
crude O
extract O
and O
n B
- I
hexane I
, O
respectively O
, O
caused O
50 O
% O
, O
30 O
. O
76 O
+ O
/ O
- O
1 O
. O
1 O
% O
and O
30 O
. O
7 O
+ O
/ O
- O
1 O
. O
1 O
% O
inhibitory O
action O
at O
maximum O
concentration O
used O
, O
that O
is O
, O
1000 O
mu O
g O
/ O
ml O
. O

RATIONALE O
: O
The O
head O
- O
twitch O
response O
( O
HTR O
) O
is O
a O
rapid O
side O
- O
to O
- O
side O
rotational O
head O
movement O
that O
occurs O
in O
rats O
and O
mice O
after O
administration O
of O
serotonergic O
hallucinogens O
and O
other O
5 B
- I
HT I
( O
2A O
) O
agonists O
. O

The O
HTR O
is O
widely O
used O
as O
a O
behavioral O
assay O
for O
5 B
- I
HT I
( O
2A O
) O
activation O
and O
to O
probe O
for O
interactions O
between O
the O
5 B
- I
HT I
( O
2A O
) O
receptor O
and O
other O
transmitter O
systems O
. O

The O
HTR O
is O
widely O
used O
as O
a O
behavioral O
assay O
for O
5 B
- I
HT I
( O
2A O
) O
activation O
and O
to O
probe O
for O
interactions O
between O
the O
5 B
- I
HT I
( O
2A O
) O
receptor O
and O
other O
transmitter O
systems O
. O

The O
magnetometer O
coil O
detected O
the O
HTR O
induced O
by O
the O
serotonergic O
hallucinogens O
2 B
, I
5 I
- I
dimethoxy I
- I
4 I
- I
iodoamphetamine I
( O
DOI B
; O
0 O
. O
25 O
, O
0 O
. O
5 O
, O
and O
1 O
. O
0 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
and O
lysergic B
acid I
diethylamide I
( O
LSD B
; O
0 O
. O
05 O
, O
0 O
. O
1 O
, O
0 O
. O
2 O
, O
and O
0 O
. O
4 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
with O
extremely O
high O
sensitivity O
and O
specificity O
. O

In O
2007 O
, O
the O
authors O
measured O
serum O
concentrations O
of O
polybrominated B
diphenyl I
ethers I
( O
PBDEs B
) O
in O
Laizhou O
Bay O
residents O
. O

Compared O
with O
a O
previous O
study O
, O
sum O
8 O
PBDE B
serum O
concentrations O
in O
the O
present O
study O
showed O
no O
change O
in O
order O
of O
magnitude O
, O
but O
the O
relative O
contribution O
of O
BDE B
- I
209 I
to O
sum O
8 O
PBDE B
was O
higher O
. O

All O
compounds O
with O
good O
docking O
scores O
significantly O
inhibited O
FGFR4 O
kinase O
activity O
, O
some O
with O
sub O
- O
micromolar O
( O
most O
potent O
being O
V4 B
- I
015 I
with O
an O
IC O
( O
50 O
) O
of O
0 O
. O
04 O
mu O
M O
) O
. O

The O
most O
potent O
compound O
to O
date O
, O
V4 B
- I
015 I
, O
suppressed O
proliferation O
of O
MDA O
- O
MB453 O
cells O
at O
sub O
- O
micromolar O
concentrations O
, O
activated O
the O
pro O
- O
apoptotic O
caspases O
3 O
/ O
7 O
and O
inhibited O
cellular O
migration O
. O

Protein O
recognition O
of O
the O
S23906 B
- I
1 I
- O
DNA O
adduct O
by O
nuclear O
proteins O
: O
direct O
involvement O
of O
glyceraldehyde B
- I
3 I
- I
phosphate I
dehydrogenase O
( O
GAPDH O
) O
1 O
. O

The O
benzo B
- I
b I
- I
acronycine I
derivative O
S23906 B
- I
1 I
alkylates O
guanine B
nucleobases I
in O
the O
minor O
groove O
of O
the O
DNA O
helix O
and O
presents O
an O
original O
ability O
to O
locally O
open O
the O
double O
helix O
of O
DNA O
, O
which O
appears O
to O
be O
associated O
with O
its O
cytotoxic O
activity O
. O

At O
the O
cellular O
level O
, O
alkylation O
of O
S23906 B
- I
1 I
results O
in O
an O
increase O
in O
the O
binding O
of O
GAPDH O
and O
its O
protein O
partner O
HMG O
( O
high O
- O
mobility O
group O
) O
B1 O
to O
the O
chromatin O
. O

Saturated B
fatty I
acids I
( O
FA O
) O
were O
grafted O
using O
tyrosine B
as O
a O
spacer O
group O
to O
the O
cyclotriphosphazene B
ring O
along O
with O
equimolar O
hydrophilic O
methoxy B
poly I
( I
ethylene I
glycol I
) I
( O
MPEG B
) O
in O
cis O
- O
nongeminal O
way O
. O

Electrochemical O
determination O
of O
Sudan B
I I
in O
food O
samples O
at O
graphene B
modified O
glassy O
carbon B
electrode O
based O
on O
the O
enhancement O
effect O
of O
sodium B
dodecyl I
sulphonate I
. O

This O
paper O
describes O
a O
novel O
electrochemical O
method O
for O
the O
determination O
of O
Sudan B
I I
in O
food O
samples O
based O
on O
the O
electrochemical O
catalytic O
activity O
of O
graphene B
modified O
glassy O
carbon B
electrode O
( O
GMGCE O
) O
and O
the O
enhancement O
effect O
of O
an O
anionic O
surfactant O
: O
sodium B
dodecyl I
sulphonate I
( O
SDS B
) O
. O

In O
general O
, O
C6 B
compounds O
, O
alcohols B
, O
terpenes B
, O
phenols B
and O
C13 B
- I
norisoprenoids I
in O
Syrah O
showed O
a O
decrease O
and O
in O
Chardonnay O
an O
increase O
. O

Ascorbic B
acid I
and O
chlorogenic B
acid I
contents O
were O
determined O
by O
HPLC O
- O
DAD O
, O
total O
anthocyanin B
content O
by O
pH O
- O
differential O
spectrophotometry O
, O
glycoalkaloid B
, O
alpha B
- I
chaconine I
and O
alpha B
- I
solanine I
contents O
by O
HPLC O
- O
ESI O
/ O
MS O
/ O
MS O
. O

Ascorbic B
acid I
and O
chlorogenic B
acid I
contents O
were O
determined O
by O
HPLC O
- O
DAD O
, O
total O
anthocyanin B
content O
by O
pH O
- O
differential O
spectrophotometry O
, O
glycoalkaloid B
, O
alpha B
- I
chaconine I
and O
alpha B
- I
solanine I
contents O
by O
HPLC O
- O
ESI O
/ O
MS O
/ O
MS O
. O

All O
cooking O
treatments O
reduced O
ascorbic B
and I
chlorogenic B
acid I
contents O
, O
total O
glycoalkaloids B
, O
alpha B
- I
chaconine I
and O
alpha B
- I
solanine I
with O
the O
exception O
of O
total O
anthocyanins B
. O

All O
cooking O
treatments O
reduced O
ascorbic B
and I
chlorogenic B
acid I
contents O
, O
total O
glycoalkaloids B
, O
alpha B
- I
chaconine I
and O
alpha B
- I
solanine I
with O
the O
exception O
of O
total O
anthocyanins B
. O

The O
efficiency O
of O
citrate B
- O
buffered O
and O
unbuffered O
method O
in O
liquid O
extraction O
procedure O
was O
compared O
; O
the O
amount O
of O
primary B
secondary I
amine I
( O
PSA B
) O
was O
optimised O
. O

As O
part O
of O
a O
comprehensive O
study O
of O
the O
physiochemical O
and O
biological O
properties O
of O
phytosteryl B
phenolates I
, O
successfully O
synthesized O
chemoenzymatically O
in O
our O
lab O
, O
their O
antioxidant O
activity O
was O
evaluated O
using O
three O
different O
in O
vitro O
model O
systems O
, O
namely O
bulk O
oil O
model O
system O
, O
beta B
- I
carotene I
- O
linoleate B
model O
system O
and O
low O
- O
density O
lipoprotein O
cholesterol B
( O
LDL O
- O
C O
) O
oxidation O
assay O
. O

However O
, O
in O
beta B
- I
carotene I
- O
linoleate B
assay O
, O
an O
emulsion O
model O
system O
, O
phytosteryl B
phenolates I
showed O
enhanced O
antioxidant O
activity O
except O
phytosteryl B
ferulates I
. O

From O
the O
root O
tubers O
of O
Lactuca O
tuberosa O
, O
a O
wild O
edible O
plant O
species O
, O
nine O
phenolic B
compounds O
were O
isolated O
, O
including O
two O
new O
furofuran B
lignan I
glucosides I
, O
named O
lactuberin B
A I
and O
lactuberin B
B I
. O

Losses O
of O
PPO O
activity O
were O
favoured O
by O
the O
presence O
of O
EPI B
in O
model O
solutions O
, O
compared O
with O
CG O
, O
due O
to O
the O
formation O
of O
o B
- I
quinones I
of O
EPI B
( O
QEPI O
) O
lowering O
PPO O
stability O
. O

Results O
also O
confirmed O
that O
AA O
in O
excess O
induced O
a O
fast O
regeneration O
of O
CG O
and O
EPI B
from O
the O
corresponding O
o B
- I
quinones I
formed O
enzymatically O
via O
redox O
chemical O
reactions O
. O

The O
hypocholesterolemic O
and O
antioxidant O
activities O
of O
various O
extracts O
( O
water O
, O
methanol B
, O
ethyl B
acetate I
, O
hexane B
, O
dichloro B
- I
methane I
) O
of O
fenugreek O
seeds O
were O
investigated O
in O
cholesterol B
- O
fed O
rats O
. O

The O
phenolic B
and O
flavono B
i I
d I
contents O
were O
highest O
in O
the O
methanol B
and O
the O
ethyl B
acetate I
extracts O
. O

These O
results O
showed O
that O
the O
ethyl B
acetate I
extract O
of O
the O
fenugreek O
seeds O
had O
a O
significant O
hypocholesterolemic O
effect O
and O
antioxidant O
activity O
in O
cholesterol B
- O
fed O
rats O
, O
whether O
this O
is O
partly O
due O
to O
the O
presence O
of O
flavono B
i I
ds I
in O
the O
extract O
needs O
further O
study O
. O

The O
glucogalactan O
chains O
were O
composed O
of O
( O
1 O
- O
- O
> O
6 O
) O
- O
, O
( O
1 O
- O
- O
> O
5 O
) O
- O
and O
( O
1 O
- O
- O
> O
5 O
, O
6 O
) O
- O
linked O
beta B
- I
Galf I
, O
( O
1 O
- O
- O
> O
4 O
) O
- O
linked O
and O
non O
- O
reducing O
terminal O
beta B
- I
Glcp I
units O
, O
and O
might O
be O
attached O
to O
the O
mannan O
core O
at O
the O
O O
- O
2 O
positions O
of O
alpha B
- I
Manp I
units O
. O

The O
glucogalactan O
chains O
were O
composed O
of O
( O
1 O
- O
- O
> O
6 O
) O
- O
, O
( O
1 O
- O
- O
> O
5 O
) O
- O
and O
( O
1 O
- O
- O
> O
5 O
, O
6 O
) O
- O
linked O
beta B
- I
Galf I
, O
( O
1 O
- O
- O
> O
4 O
) O
- O
linked O
and O
non O
- O
reducing O
terminal O
beta B
- I
Glcp I
units O
, O
and O
might O
be O
attached O
to O
the O
mannan O
core O
at O
the O
O O
- O
2 O
positions O
of O
alpha B
- I
Manp I
units O
. O

The O
glucogalactan O
chains O
were O
composed O
of O
( O
1 O
- O
- O
> O
6 O
) O
- O
, O
( O
1 O
- O
- O
> O
5 O
) O
- O
and O
( O
1 O
- O
- O
> O
5 O
, O
6 O
) O
- O
linked O
beta B
- I
Galf I
, O
( O
1 O
- O
- O
> O
4 O
) O
- O
linked O
and O
non O
- O
reducing O
terminal O
beta B
- I
Glcp I
units O
, O
and O
might O
be O
attached O
to O
the O
mannan O
core O
at O
the O
O O
- O
2 O
positions O
of O
alpha B
- I
Manp I
units O
. O

Isomerisation O
of O
carrot O
beta B
- I
carotene I
in O
presence O
of O
oil O
during O
thermal O
and O
combined O
thermal O
/ O
high O
pressure O
processing O
. O

The O
effect O
of O
thermal O
processing O
( O
85 O
- O
130 O
degrees O
C O
) O
and O
combined O
thermal O
/ O
high O
pressure O
processing O
( O
100 O
degrees O
C O
combined O
with O
0 O
. O
1 O
to O
700 O
MPa O
and O
700 O
MPa O
combined O
with O
85 O
- O
115 O
degrees O
C O
) O
on O
beta B
- I
carotene I
isomerisation O
in O
an O
olive O
oil O
/ O
carrot O
emulsion O
and O
pure O
olive O
oil O
phase O
enriched O
with O
carrot O
beta B
- I
carotene I
was O
investigated O
. O

The O
effect O
of O
thermal O
processing O
( O
85 O
- O
130 O
degrees O
C O
) O
and O
combined O
thermal O
/ O
high O
pressure O
processing O
( O
100 O
degrees O
C O
combined O
with O
0 O
. O
1 O
to O
700 O
MPa O
and O
700 O
MPa O
combined O
with O
85 O
- O
115 O
degrees O
C O
) O
on O
beta B
- I
carotene I
isomerisation O
in O
an O
olive O
oil O
/ O
carrot O
emulsion O
and O
pure O
olive O
oil O
phase O
enriched O
with O
carrot O
beta B
- I
carotene I
was O
investigated O
. O

In O
the O
oil O
/ O
carrot O
emulsion O
, O
less O
beta B
- I
carotene I
isomerisation O
was O
observed O
during O
combined O
thermal O
/ O
high O
pressure O
processing O
compared O
to O
thermal O
processing O
. O

This O
effect O
was O
attributed O
to O
strengthening O
of O
the O
carrot O
cell O
walls O
under O
high O
pressure O
, O
thereby O
hindering O
the O
transfer O
of O
beta B
- I
carotene I
to O
the O
oil O
phase O
and O
lowering O
its O
susceptibility O
to O
isomerisation O
. O

In O
an O
oil O
phase O
enriched O
with O
beta B
- I
carotene I
, O
beta B
- I
carotene I
isomerisation O
was O
not O
influenced O
by O
the O
applied O
pressure O
at O
100 O
degrees O
C O
and O
became O
almost O
temperature O
insensitive O
at O
700 O
MPa O
. O

In O
an O
oil O
phase O
enriched O
with O
beta B
- I
carotene I
, O
beta B
- I
carotene I
isomerisation O
was O
not O
influenced O
by O
the O
applied O
pressure O
at O
100 O
degrees O
C O
and O
became O
almost O
temperature O
insensitive O
at O
700 O
MPa O
. O

These O
K O
( O
i O
) O
values O
are O
nearly O
equal O
to O
that O
of O
histidine B
methyl I
ester I
( O
K O
( O
i O
) O
= O
0 O
. O
46 O
mu O
M O
) O
, O
an O
existing O
substrate O
analogue O
inhibitor O
. O

Skim O
milk O
with O
low O
levels O
of O
added O
beta B
- I
mercaptoethanol I
( O
SM O
- O
ME O
) O
and O
untreated O
skim O
milk O
( O
SM O
) O
were O
heated O
and O
then O
made O
into O
acid O
gels O
. O

Among O
them O
, O
apigenin B
- I
glucuronide I
, O
lucenin B
- I
2 I
and O
lithospermic B
acid I
were O
tentatively O
identified O
for O
the O
first O
time O
. O

Among O
them O
, O
apigenin B
- I
glucuronide I
, O
lucenin B
- I
2 I
and O
lithospermic B
acid I
were O
tentatively O
identified O
for O
the O
first O
time O
. O

D B
/ O
H B
exchange O
in O
C B
- I
H I
bonds O
of O
fatty B
acids I
: O
implication O
for O
geographical O
discrimination O
of O
food O
materials O
. O

Secoisolariciresinol B
, O
lariciresinol B
, O
pinoresinol B
, O
7 B
- I
hydroxymatairesinol I
, O
syringaresinol B
, O
isolariciresinol B
, O
secoisolariciresinol B
diglycoside I
, O
lariciresinol B
monoglycoside I
, O
pinoresinol B
mono I
- I
, I
di I
- I
and I
triglycoside I
, O
sesaminol B
, O
sesaminol B
triglycoside I
, O
sesamolinol B
and O
sesamolinol B
diglycoside I
were O
identified O
. O

An O
inclusion O
complex O
comprising O
BA O
and O
beta B
- I
cyclodextrin I
( O
beta B
- I
CD I
) O
was O
formed O
to O
improve O
the O
dissolution O
of O
BA O
, O
but O
little O
is O
known O
about O
its O
anticancer O
effect O
. O

An O
inclusion O
complex O
comprising O
BA O
and O
beta B
- I
cyclodextrin I
( O
beta B
- I
CD I
) O
was O
formed O
to O
improve O
the O
dissolution O
of O
BA O
, O
but O
little O
is O
known O
about O
its O
anticancer O
effect O
. O

Aiming O
at O
the O
design O
of O
specific O
melanocortin O
- O
1 O
receptor O
( O
MC1R O
) O
targeted O
imaging O
probes O
, O
we O
report O
on O
the O
effect O
of O
different O
azolyl B
- O
ring O
substitution O
patterns O
( O
carboxylate B
at O
the O
4 O
- O
position O
and O
/ O
or O
methyl B
groups O
at O
the O
3 O
, O
5 O
positions O
) O
of O
pyrazolyl B
- I
diamine I
bifunctional O
chelators O
( O
Pz O
( O
2 O
) O
- O
Pz O
( O
4 O
) O
) O
on O
the O
pharmacokinetic O
profile O
of O
the O
( B
99m I
) I
Tc I
( I
CO I
) I
3 I
- O
labeled O
lactam B
bridge O
- O
cyclized B
alpha I
- I

Three O
pyrazolyl B
- I
diamine I
- O
containing O
chelators O
were O
conjugated O
to O
beta B
AlaNleCycMSHhex I
, O
with O
the O
resulting O
peptide O
conjugates O
displaying O
subnanomolar O
MC1R O
binding O
affinity O
. O

Discovery O
of O
novel O
7 B
- I
membered I
cyclic I
amide I
derivatives O
that O
inhibit O
11beta B
- I
hydroxysteroid I
dehydrogenase O
type O
1 O
. O

A O
series O
of O
novel O
5 B
- I
trans I
- I
hydroxyadamantan I
- I
2 I
- I
yl I
- I
5 I
, I
6 I
, I
7 I
, I
8 I
- I
tetrahydropyrazolo I
[ I
4 I
, I
3 I
- I
c I
] I
azepin I
- I
4 I
( I
1H I
) I
- I
ones I
that O
inhibit O
11beta B
- I
hydroxysteroid I
dehydrogenase O
type O
1 O
are O
described O
. O

Here O
we O
show O
for O
the O
first O
time O
a O
3D O
quantitative O
structure O
- O
activity O
relationship O
( O
3D O
- O
QSAR O
) O
for O
a O
series O
of O
aza B
- I
PCU I
- O
derived O
compounds O
with O
activity O
at O
the O
sigma O
- O
1 O
( O
sigma O
1 O
) O
receptor O
. O

Based O
on O
docking O
studies O
we O
evaluated O
in O
a O
[ B
( I
3 I
) I
H I
] I
pentazocine I
binding O
assay O
an O
oxa B
- I
PCU I
, O
NGP1 B
- I
01 I
( O
IC50 O
= O
1 O
. O
78 O
mu O
M O
) O
and O
its O
phenethyl B
derivative O
( O
IC50 O
= O
1 O
. O
54 O
mu O
M O
) O
. O

Based O
on O
docking O
studies O
we O
evaluated O
in O
a O
[ B
( I
3 I
) I
H I
] I
pentazocine I
binding O
assay O
an O
oxa B
- I
PCU I
, O
NGP1 B
- I
01 I
( O
IC50 O
= O
1 O
. O
78 O
mu O
M O
) O
and O
its O
phenethyl B
derivative O
( O
IC50 O
= O
1 O
. O
54 O
mu O
M O
) O
. O

At O
high O
food O
rations O
effects O
were O
only O
observed O
for O
one O
of O
the O
nano O
- O
TiO2 B
, O
P B
- I
25 I
, O
at O
high O
exposure O
levels O
( O
10 O
mg O
/ O
l O
) O
under O
both O
semi O
- O
static O
and O
particle O
re O
- O
suspension O
conditions O
, O
which O
suggest O
that O
P B
- I
25 I
effects O
were O
mediated O
by O
clogging O
the O
gut O
and O
hence O
diminishing O
food O
acquisition O
. O

At O
high O
food O
rations O
effects O
were O
only O
observed O
for O
one O
of O
the O
nano O
- O
TiO2 B
, O
P B
- I
25 I
, O
at O
high O
exposure O
levels O
( O
10 O
mg O
/ O
l O
) O
under O
both O
semi O
- O
static O
and O
particle O
re O
- O
suspension O
conditions O
, O
which O
suggest O
that O
P B
- I
25 I
effects O
were O
mediated O
by O
clogging O
the O
gut O
and O
hence O
diminishing O
food O
acquisition O
. O

In O
comparison O
to O
reference O
fish O
, O
lower O
concentrations O
of O
11 B
- I
ketotestosterone I
were O
measured O
in O
the O
plasma O
of O
male O
fathead O
minnows O
collected O
from O
Demonstration O
Pond O
in O
June O
2006 O
and O
July O
2007 O
. O

Following O
administration O
of O
the O
5 B
- I
HT I
( O
1A O
/ O
7 O
) O
agonist O
8 B
- I
hydroxy I
- I
2 I
- I
( I
di I
- I
n I
- I
propylamino I
) I
tetralin I
( O
8 B
- I
OH I
- I
DPAT I
) O
, O
stereotypical O
head O
weaving O
and O
forepaw O
treading O
were O
increased O
more O
in O
DAT O
- O
KO O
mice O
than O
in O
DAT O
- O
WT O
or O
- O
HET O
mice O
. O

By O
contrast O
, O
head O
twitches O
induced O
by O
treatment O
with O
the O
5 B
- I
HT I
( O
2A O
/ O
2C O
) O
agonist O
( B
+ I
/ I
- I
) I
- I
2 I
, I
5 I
- I
dimethoxy I
- I
4 I
- I
iodophenyl I
- I
2 I
- I
aminopropane I
( O
DOI B
) O
were O
similar O
in O
mice O
of O
all O
three O
DAT O
genotypes O
. O

5 B
- I
HT I
( O
1A O
) O
autoreceptor O
function O
was O
intact O
in O
DAT O
- O
KO O
mice O
. O

Hyperactivity O
, O
stereotypy O
, O
and O
perseverative O
behaviors O
are O
increased O
in O
these O
mice O
, O
with O
brain O
- O
area O
specific O
increases O
in O
serotonin B
levels O
and O
serotonin B
turnover O
, O
and O
marked O
increases O
in O
postsynaptic O
5 B
- I
HT I
( O
1A O
) O
receptor O
- O
mediated O
stereotypic O
responses O
. O

All O
of O
these O
active O
compounds O
possess O
C O
( O
19 O
) O
- O
O B
- I
acyl I
group O
, O
and O
among O
which O
, O
ent B
- I
kaur I
- I
16 I
- I
ene I
- I
13 I
, I
19 I
- I
diol I
19 I
- I
O I
- I
4 I
' I
, I
4 I
' I
, I
4 I
' I
- I
trifluorocrotonate I
( O
14 O
) O
exhibited O
potent O
cytotoxicities O
against O
four O
cell O
lines O
with O
IC O
( O
50 O
) O
values O
in O
the O
range O
of O
1 O
. O
2 O
- O
4 O
. O
1 O
mu O
M O
. O

Optical O
response O
of O
individual O
Au B
- I
Ag I
@ O
SiO B
2 I
heterodimers O
. O

The O
optical O
extinction O
response O
of O
individual O
Au B
- I
Ag I
@ O
SiO2 B
heterodimers O
whose O
individual O
morphologies O
are O
determined O
by O
transmission O
electron O
microscopy O
( O
TEM O
) O
is O
investigated O
using O
spatial O
modulation O
spectroscopy O
. O

Here O
we O
report O
the O
isolation O
and O
structural O
characterization O
of O
a O
thermally O
stable O
compound O
featuring O
a O
Cu B
- I
B I
one O
- O
electron O
bond O
, O
as O
well O
as O
its O
oxidized O
( O
nonbonded O
) O
and O
reduced O
( O
two O
- O
electrons O
- O
bonded O
) O
congeners O
. O

Screening O
of O
transition O
and O
post O
- O
transition O
metals O
to O
incorporate O
into O
copper B
oxide I
and O
copper B
bismuth I
oxide I
for O
photoelectrochemical O
hydrogen B
evolution O
. O

A O
structural O
mapping O
of O
mutations O
causing O
succinyl B
- I
CoA I
: O
3 O
- O
ketoacid O
CoA O
transferase O
( O
SCOT O
) O
deficiency O
. O

Succinyl B
- I
CoA I
: O
3 O
- O
ketoacid O
CoA O
transferase O
( O
SCOT O
) O
deficiency O
is O
a O
rare O
inherited O
metabolic O
disorder O
of O
ketone B
metabolism O
, O
characterized O
by O
ketoacidotic O
episodes O
and O
often O
permanent O
ketosis O
. O

SCOT O
catalyzes O
the O
first O
, O
rate O
- O
limiting O
step O
of O
ketone B
body O
utilization O
in O
peripheral O
tissues O
, O
by O
transferring O
a O
CoA B
moiety O
from O
succinyl B
- I
CoA I
to O
form O
acetoacetyl B
- I
CoA I
, O
for O
entry O
into O
the O
tricarboxylic B
acid I
cycle O
for O
energy O
production O
. O

SCOT O
catalyzes O
the O
first O
, O
rate O
- O
limiting O
step O
of O
ketone B
body O
utilization O
in O
peripheral O
tissues O
, O
by O
transferring O
a O
CoA B
moiety O
from O
succinyl B
- I
CoA I
to O
form O
acetoacetyl B
- I
CoA I
, O
for O
entry O
into O
the O
tricarboxylic B
acid I
cycle O
for O
energy O
production O
. O

The O
amphiphilic O
character O
of O
GNSs O
allows O
the O
water O
solubility O
of O
insoluble O
hydrophobic O
cargos O
such O
as O
a O
perylene B
- I
bisimide I
derivative O
, O
[ B
60 I
] I
fullerene I
, O
or O
the O
anti O
- O
carcinogenic O
drug O
camptothecin B
( O
CPT B
) O
. O

We O
have O
investigated O
the O
adsorption O
and O
organization O
at O
the O
air O
/ O
water O
interface O
of O
catanionic O
molecules O
released O
from O
a O
dispersion O
of O
solid O
- O
like O
catanionic O
vesicles O
composed O
of O
myristic B
acid I
and O
cetyl B
trimethylammonium I
chloride I
at O
the O
2 O
: O
1 O
ratio O
. O

Three O
new O
phenyl B
- I
ethanediols I
from O
the O
fruiting O
bodies O
of O
the O
mushroom O
Fomes O
fomentarius O
. O

Three O
new O
phenyl B
- I
ethanediols I
, O
( B
1R I
) I
- I
( I
3 I
- I
ethenylphenyl I
) I
- I
1 I
, I
2 I
- I
ethanediol I
( O
1 O
) O
, O
( B
1R I
) I
- I
( I
3 I
- I
formylphenyl I
) I
- I
1 I
, I
2 I
- I
ethanediol I
( O
2 O
) O
, O
and O
( B
1R I
) I
- I
( I
3 I
- I
acetophenyl I
) I
- I
1 I
, I
2 I
- I
ethanediol I
( O
3 O
) O
, O
were O
isolated O
from O
the O
fruiting O
bodies O
of O
the O
mushroom O
Fomes O
fomentarius O
, O
together O
with O
two O
related O
known O
compounds O
, O
( B
3 I
- I
ethylphenyl I

Two O
new O
coumarin B
glycosides I
, O
namely O
nitensosides B
A I
- I
B I
( O
1 O
- O
2 O
) O
, O
together O
with O
six O
known O
compounds O
, O
scopolin B
( O
3 O
) O
, O
5 B
, I
6 I
, I
7 I
- I
trimethoxycoumarin I
( O
4 O
) O
, O
d B
- I
calycanthine I
( O
5 O
) O
, O
calycanthoside B
( O
6 O
) O
, O
xeroboside B
( O
7 O
) O
, O
and O
scopoletin B
( O
8 O
) O
, O
were O
isolated O
from O
Chimonanthus O
nitens O
. O

Vibrational O
assignments O
have O
provided O
the O
frequency O
of O
the O
Cu B
- I
C I
stretching O
mode O
, O
nu O
3 O
, O
in O
the O
ground O
and O
all O
three O
excited O
states O
, O
along O
with O
both O
bending O
modes O
, O
nu O
4 O
and O
nu O
5 O
, O
in O
the O
A O
( O
1 O
) O
Sigma O
( O
+ O
) O
and O
B O
( O
1 O
) O
Pi O
states O
, O
and O
the O
Cu B
- I
C I
= I
C I
bending O
mode O
, O
nu O
5 O
, O
in O
the O
ground O
state O
. O

N B
- I
Acetylcysteine I
prevents O
doxorubucine B
- O
induced O
cardiotoxicity O
in O
rats O
. O

This O
study O
is O
designed O
to O
observe O
the O
effects O
of O
N B
- I
acetylcysteine I
( O
NAC B
) O
on O
doxorubucine B
- O
induced O
cardiac O
toxicity O
in O
rats O
both O
histologically O
and O
biochemically O
. O

The O
most O
abundant O
components O
in O
the O
stems O
oil O
included O
carvacrol B
( O
60 O
. O
8 O
% O
) O
, O
alpha B
- I
terpineol I
( O
4 O
. O
7 O
% O
) O
and O
p B
- I
cymene I
( O
2 O
. O
4 O
% O
) O
, O
while O
carvacrol B
( O
33 O
% O
) O
, O
p B
- I
cymene I
( O
25 O
. O
3 O
% O
) O
and O
alpha B
- I
pinene I
( O
11 O
. O
6 O
% O
) O
were O
the O
main O
components O
in O
the O
leaves O
. O

The O
most O
abundant O
components O
in O
the O
stems O
oil O
included O
carvacrol B
( O
60 O
. O
8 O
% O
) O
, O
alpha B
- I
terpineol I
( O
4 O
. O
7 O
% O
) O
and O
p B
- I
cymene I
( O
2 O
. O
4 O
% O
) O
, O
while O
carvacrol B
( O
33 O
% O
) O
, O
p B
- I
cymene I
( O
25 O
. O
3 O
% O
) O
and O
alpha B
- I
pinene I
( O
11 O
. O
6 O
% O
) O
were O
the O
main O
components O
in O
the O
leaves O
. O

The O
most O
abundant O
components O
in O
the O
stems O
oil O
included O
carvacrol B
( O
60 O
. O
8 O
% O
) O
, O
alpha B
- I
terpineol I
( O
4 O
. O
7 O
% O
) O
and O
p B
- I
cymene I
( O
2 O
. O
4 O
% O
) O
, O
while O
carvacrol B
( O
33 O
% O
) O
, O
p B
- I
cymene I
( O
25 O
. O
3 O
% O
) O
and O
alpha B
- I
pinene I
( O
11 O
. O
6 O
% O
) O
were O
the O
main O
components O
in O
the O
leaves O
. O

The O
most O
abundant O
components O
in O
the O
stems O
oil O
included O
carvacrol B
( O
60 O
. O
8 O
% O
) O
, O
alpha B
- I
terpineol I
( O
4 O
. O
7 O
% O
) O
and O
p B
- I
cymene I
( O
2 O
. O
4 O
% O
) O
, O
while O
carvacrol B
( O
33 O
% O
) O
, O
p B
- I
cymene I
( O
25 O
. O
3 O
% O
) O
and O
alpha B
- I
pinene I
( O
11 O
. O
6 O
% O
) O
were O
the O
main O
components O
in O
the O
leaves O
. O

Quantum O
mechanics O
/ O
molecular O
mechanics O
modeling O
of O
fatty B
acid I
amide I
hydrolase O
reactivation O
distinguishes O
substrate O
from O
irreversible O
covalent O
inhibitors O
. O

Carbamate B
and O
urea B
derivatives O
are O
important O
classes O
of O
fatty B
acid I
amide I
hydrolase O
( O
FAAH O
) O
inhibitors O
that O
carbamoylate B
the O
active O
- O
site O
nucleophile O
Ser241 B
. O

This O
is O
consistent O
with O
experimental O
data O
showing O
slowly O
reversible O
FAAH O
inhibition O
for O
the O
N B
- I
piperazinylurea I
inhibitor O
and O
irreversible O
inhibition O
for O
URB597 B
. O

Monolayers O
of O
transition B
metal I
dichalcogenides I
( O
TMDCs B
) O
are O
atomically O
thin O
direct O
- O
gap O
semiconductors O
with O
potential O
applications O
in O
nanoelectronics O
, O
optoelectronics O
, O
and O
electrochemical O
sensing O
. O

Lipophilic O
groups O
with O
different O
steric O
bulk O
were O
introduced O
at O
the O
5 O
- O
position O
of O
the O
bicyclic O
scaffold O
( O
R5 O
= O
Me B
, O
Ph B
, O
CH2Ph B
) O
, O
and O
different O
acyl B
and O
carbamoyl B
moieties O
( O
R7 O
) O
were O
appended O
on O
the O
7 B
- I
amino I
group O
, O
as O
well O
as O
a O
para B
- I
methoxy I
group O
inserted O
on O
the O
2 B
- I
phenyl I
ring O
. O

Lipophilic O
groups O
with O
different O
steric O
bulk O
were O
introduced O
at O
the O
5 O
- O
position O
of O
the O
bicyclic O
scaffold O
( O
R5 O
= O
Me B
, O
Ph B
, O
CH2Ph B
) O
, O
and O
different O
acyl B
and O
carbamoyl B
moieties O
( O
R7 O
) O
were O
appended O
on O
the O
7 B
- I
amino I
group O
, O
as O
well O
as O
a O
para B
- I
methoxy I
group O
inserted O
on O
the O
2 B
- I
phenyl I
ring O
. O

Lipophilic O
groups O
with O
different O
steric O
bulk O
were O
introduced O
at O
the O
5 O
- O
position O
of O
the O
bicyclic O
scaffold O
( O
R5 O
= O
Me B
, O
Ph B
, O
CH2Ph B
) O
, O
and O
different O
acyl B
and O
carbamoyl B
moieties O
( O
R7 O
) O
were O
appended O
on O
the O
7 B
- I
amino I
group O
, O
as O
well O
as O
a O
para B
- I
methoxy I
group O
inserted O
on O
the O
2 B
- I
phenyl I
ring O
. O

In O
fact O
, O
most O
of O
the O
7 B
- I
acylamino I
derivatives O
showed O
low O
nanomolar O
affinity O
( O
Ki O
= O
2 O
. O
5 O
- O
45 O
nM O
) O
and O
high O
selectivity O
toward O
this O
receptor O
. O

In O
this O
article O
, O
we O
present O
a O
one O
- O
step O
hydrogenation O
- O
reduction O
route O
for O
the O
synthesis O
of O
Pt B
- I
Co I
nanoparticles O
( O
NPs O
) O
which O
were O
found O
to O
be O
excellent O
catalysts O
for O
aqueous O
- O
phase O
FTS O
at O
433 O
K O
. O

Coupling O
with O
atomic O
- O
resolution O
scanning O
transmission O
electron O
microscopy O
( O
STEM O
) O
and O
theoretical O
calculations O
, O
the O
outstanding O
activity O
is O
rationalized O
by O
the O
formation O
of O
Co B
overlayer O
structures O
on O
Pt B
NPs O
or O
Pt B
- I
Co I
alloy O
NPs O
. O

A O
fatty B
acid I
amide I
hydrolase O
inhibitor O
, O
phenylmethanesulfony B
fluoride I
reversed O
the O
inhibitory O
effect O
of O
( B
- I
) I
- I
cannabidiol I
on O
anandamide B
- O
induced O
contractions O
. O

Seedlings O
were O
treated O
with O
NO B
donor O
( O
0 O
. O
25 O
mM O
sodium B
nitroprusside I
, O
SNP B
) O
and O
As B
( O
0 O
. O
25 O
and O
0 O
. O
5 O
mM O
Na2HAsO4 B
. I
7H2O I
) O
separately O
and O
/ O
or O
in O
combination O
and O
grown O
for O
72 O
h O
. O

Manganese B
- I
peroxos I
are O
proposed O
as O
key O
intermediates O
in O
a O
number O
of O
important O
biochemical O
and O
synthetic O
transformations O
. O

Strong O
correlations O
between O
structural O
( O
O B
- I
O I
and O
Mn B
. O
. O
. O
N B
( I
py I
, I
quin I
) I
distances O
) O
, O
spectroscopic O
( O
E O
( O
pi O
v O
* O
( O
O B
- I
O I
) O
- O
- O
> O
Mn B
CT O
band O
) O
, O
nu O
( O
O B
- I
O I
) O
) O
, O
and O
kinetic O
( O
Delta O
H O
( O
+ O
+ O
) O
and O
Delta O
S O
( O
+ O
+ O
) O
) O
parameters O
for O
these O
complexes O
provide O
compelling O
evidence O
for O
rate O
- O
limiting O
O B
- I
O I
bond O
cleavage O
. O

Strong O
correlations O
between O
structural O
( O
O B
- I
O I
and O
Mn B
. O
. O
. O
N B
( I
py I
, I
quin I
) I
distances O
) O
, O
spectroscopic O
( O
E O
( O
pi O
v O
* O
( O
O B
- I
O I
) O
- O
- O
> O
Mn B
CT O
band O
) O
, O
nu O
( O
O B
- I
O I
) O
) O
, O
and O
kinetic O
( O
Delta O
H O
( O
+ O
+ O
) O
and O
Delta O
S O
( O
+ O
+ O
) O
) O
parameters O
for O
these O
complexes O
provide O
compelling O
evidence O
for O
rate O
- O
limiting O
O B
- I
O I
bond O
cleavage O
. O

Strong O
correlations O
between O
structural O
( O
O B
- I
O I
and O
Mn B
. O
. O
. O
N B
( I
py I
, I
quin I
) I
distances O
) O
, O
spectroscopic O
( O
E O
( O
pi O
v O
* O
( O
O B
- I
O I
) O
- O
- O
> O
Mn B
CT O
band O
) O
, O
nu O
( O
O B
- I
O I
) O
) O
, O
and O
kinetic O
( O
Delta O
H O
( O
+ O
+ O
) O
and O
Delta O
S O
( O
+ O
+ O
) O
) O
parameters O
for O
these O
complexes O
provide O
compelling O
evidence O
for O
rate O
- O
limiting O
O B
- I
O I
bond O
cleavage O
. O

Strong O
correlations O
between O
structural O
( O
O B
- I
O I
and O
Mn B
. O
. O
. O
N B
( I
py I
, I
quin I
) I
distances O
) O
, O
spectroscopic O
( O
E O
( O
pi O
v O
* O
( O
O B
- I
O I
) O
- O
- O
> O
Mn B
CT O
band O
) O
, O
nu O
( O
O B
- I
O I
) O
) O
, O
and O
kinetic O
( O
Delta O
H O
( O
+ O
+ O
) O
and O
Delta O
S O
( O
+ O
+ O
) O
) O
parameters O
for O
these O
complexes O
provide O
compelling O
evidence O
for O
rate O
- O
limiting O
O B
- I
O I
bond O
cleavage O
. O

Products O
identified O
in O
the O
final O
reaction O
mixtures O
of O
Mn B
( I
III I
) I
- I
OOR I
decay O
are O
consistent O
with O
homolytic O
O B
- I
O I
bond O
scission O
. O

The O
N B
- I
heterocyclic I
amines I
and O
ligand O
backbone O
( O
Et O
vs O
Pr O
) O
are O
found O
to O
modulate O
structural O
and O
reactivity O
properties O
, O
and O
O B
- I
O I
bond O
activation O
is O
shown O
, O
both O
experimentally O
and O
theoretically O
, O
to O
track O
with O
metal O
ion O
Lewis O
acidity O
. O

The O
peroxo B
O I
- I
O I
bond O
is O
shown O
to O
gradually O
become O
more O
activated O
as O
the O
N B
- I
heterocyclic I
amines I
move O
closer O
to O
the O
metal O
ion O
causing O
a O
decrease O
in O
pi O
- O
donation O
from O
the O
peroxo O
pi O
v O
* O
( O
O B
- I
O I
) O
orbital O
. O

This O
low O
- O
temperature O
( O
T O
= O
120 O
degrees O
C O
) O
route O
to O
conformal O
deposition O
of O
crystalline O
Fe3O4 B
or O
alpha B
- I
Fe2O3 I
thin O
films O
is O
determined O
by O
the O
choice O
of O
oxygen B
source O
selected O
for O
the O
second O
surface O
half O
- O
reaction O
. O

The O
approach O
employs O
ozone O
to O
produce O
fully O
oxidized O
alpha B
- I
Fe2O3 I
or O
a O
milder O
oxidant O
, O
H2O2 B
, O
to O
generate O
the O
Fe B
( I
2 I
+ I
) I
/ O
Fe B
( I
3 I
+ I
) I
spinel O
, O
Fe3O4 B
. O

We O
utilized O
this O
process O
to O
prepare O
conformal O
iron B
oxide I
thin O
films O
on O
a O
porous O
framework O
, O
for O
which O
alpha B
- I
Fe2O3 I
is O
active O
for O
photocatalytic O
water O
splitting O
. O

Studies O
on O
an O
( B
S I
) I
- I
2 I
- I
amino I
- I
3 I
- I
( I
3 I
- I
hydroxy I
- I
5 I
- I
methyl I
- I
4 I
- I
isoxazolyl I
) I
propionic I
acid I
( O
AMPA B
) O
receptor O
antagonist O
IKM B
- I
159 I
: O
asymmetric O
synthesis O
, O
neuroactivity O
, O
and O
structural O
characterization O
. O

IKM B
- I
159 I
was O
developed O
and O
identified O
as O
a O
member O
of O
a O
new O
class O
of O
heterotricyclic O
glutamate B
analogues O
that O
act O
as O
AMPA B
receptor O
- O
selective O
antagonists O
. O

However O
, O
it O
was O
not O
known O
which O
enantiomer O
of O
IKM B
- I
159 I
was O
responsible O
for O
its O
pharmacological O
activities O
. O

Here O
, O
we O
report O
in O
vivo O
and O
in O
vitro O
neuronal O
activities O
of O
both O
enantiomers O
of O
IKM B
- I
159 I
prepared O
by O
enantioselective O
asymmetric O
synthesis O
. O

A O
new O
member O
of O
5 B
alpha I
H I
, I
6 I
beta I
H I
, I
7 I
alpha I
H I
, I
11 I
alpha I
H I
- I
guaian I
- I
12 I
, I
6 I
alpha I
- I
olides I
, O
11 B
- I
epi I
- I
8 I
alpha I
- I
hydroxyarborescin I
, O
together O
with O
a O
mixture O
of O
( B
24R I
) I
- I
and I
( I
24S I
) I
- I
cycloart I
- I
25 I
- I
en I
- I
3b I
, I
24 I
- I
diols I
, O
palmitic B
acid I
and O
1 B
- I
octacosanol I
were O
isolated O
from O
the O
leaves O
of O
Artemisia O
roxburghiana O
Bess O
. O

Metabolic O
Activation O
of O
Polycyclic B
Aromatic I
Hydrocarbons I
and O
Aryl B
and I
Heterocyclic I
Amines I
by O
Human O
Cytochromes O
P450 O
2A13 O
and O
2A6 O
. O

Human O
cytochrome O
P450 O
( O
P450 O
) O
2A13 O
was O
found O
to O
interact O
with O
several O
polycyclic B
aromatic I
hydrocarbons I
( O
PAHs B
) O
to O
produce O
Type O
I O
binding O
spectra O
, O
including O
acenaphthene B
, O
acenaphthylene B
, O
benzo B
[ I
c I
] I
phenanthrene I
, O
fluoranthene B
, O
fluoranthene B
- I
2 I
, I
3 I
- I
diol I
, O
and O
1 B
- I
nitropyrene I
. O

Human O
cytochrome O
P450 O
( O
P450 O
) O
2A13 O
was O
found O
to O
interact O
with O
several O
polycyclic B
aromatic I
hydrocarbons I
( O
PAHs B
) O
to O
produce O
Type O
I O
binding O
spectra O
, O
including O
acenaphthene B
, O
acenaphthylene B
, O
benzo B
[ I
c I
] I
phenanthrene I
, O
fluoranthene B
, O
fluoranthene B
- I
2 I
, I
3 I
- I
diol I
, O
and O
1 B
- I
nitropyrene I
. O

P450 O
2A6 O
also O
interacted O
with O
acenaphthene B
and O
acenaphthylene B
, O
but O
not O
with O
fluoranthene B
, O
fluoranthene B
- I
2 I
, I
3 I
- I
diol I
, O
or O
1 B
- I
nitropyrene I
. O

P450 O
1B1 O
is O
well O
- O
known O
to O
oxidize O
many O
carcinogenic O
PAHs B
, O
and O
we O
found O
that O
several O
PAHs B
( O
i O
. O
e O
. O
, O
7 B
, I
12 I
- I
dimethylbenz I
[ I
a I
] I
anthracene I
, O
7 B
, I
12 I
- I
dimethylbenz I
[ I
a I
] I
anthracene I
- I
5 I
, I
6 I
- I
diol I
, O
benzo B
[ I
c I
] I
phenanthrene I
, O
fluoranthene B
, O
fluoranthene B
- I
2 I
, I
3 I
- I
diol I
, O
5 B
- I
methylchrysene I
, O
benz B
[ I
a I
] I
pyrene I
- I
4 I
, I
5 I
- I

diol I
, O
benzo B
[ I
a I
] I
pyrene I
- I
7 I
, I
8 I
- I
diol I
, O
1 B
- I
nitropyrene I
, O
2 B
- I
aminoanthracene I
, O
2 B
- I
aminofluorene I
, O
and O
2 B
- I
acetylaminofluorene I
) O
interacted O
with O
P450 O
1B1 O
, O
producing O
Reverse O
Type O
I O
binding O
spectra O
. O

diol I
, O
benzo B
[ I
a I
] I
pyrene I
- I
7 I
, I
8 I
- I
diol I
, O
1 B
- I
nitropyrene I
, O
2 B
- I
aminoanthracene I
, O
2 B
- I
aminofluorene I
, O
and O
2 B
- I
acetylaminofluorene I
) O
interacted O
with O
P450 O
1B1 O
, O
producing O
Reverse O
Type O
I O
binding O
spectra O
. O

diol I
, O
benzo B
[ I
a I
] I
pyrene I
- I
7 I
, I
8 I
- I
diol I
, O
1 B
- I
nitropyrene I
, O
2 B
- I
aminoanthracene I
, O
2 B
- I
aminofluorene I
, O
and O
2 B
- I
acetylaminofluorene I
) O
interacted O
with O
P450 O
1B1 O
, O
producing O
Reverse O
Type O
I O
binding O
spectra O
. O

diol I
, O
benzo B
[ I
a I
] I
pyrene I
- I
7 I
, I
8 I
- I
diol I
, O
1 B
- I
nitropyrene I
, O
2 B
- I
aminoanthracene I
, O
2 B
- I
aminofluorene I
, O
and O
2 B
- I
acetylaminofluorene I
) O
interacted O
with O
P450 O
1B1 O
, O
producing O
Reverse O
Type O
I O
binding O
spectra O
. O

The O
former O
two O
enzymes O
were O
particularly O
active O
in O
catalyzing O
2 B
- I
aminofluorene I
and O
2 B
- I
aminoanthracene I
activation O
, O
and O
molecular O
docking O
simulations O
supported O
the O
results O
with O
these O
procarcinogens O
, O
in O
terms O
of O
binding O
in O
the O
active O
sites O
of O
P450 O
2A13 O
and O
2A6 O
. O

The O
former O
two O
enzymes O
were O
particularly O
active O
in O
catalyzing O
2 B
- I
aminofluorene I
and O
2 B
- I
aminoanthracene I
activation O
, O
and O
molecular O
docking O
simulations O
supported O
the O
results O
with O
these O
procarcinogens O
, O
in O
terms O
of O
binding O
in O
the O
active O
sites O
of O
P450 O
2A13 O
and O
2A6 O
. O

A O
rapid O
sensitive O
and O
selective O
liquid O
chromatography O
- O
tandem O
mass O
spectrometry O
( O
LC O
- O
MS O
/ O
MS O
) O
method O
was O
developed O
for O
determination O
of O
timosaponin B
AIII I
( O
TA B
- I
III I
) O
in O
rat O
plasma O
, O
using O
ginsenoside B
Re I
as O
an O
internal O
standard O
( O
IS O
) O
. O

TA B
- I
III I
and O
the O
IS O
were O
detected O
in O
MRM O
mode O
with O
a O
negative O
ionization O
electrospray O
mass O
spectrometer O
. O

The O
validated O
method O
was O
successfully O
applied O
to O
monitor O
the O
concentrations O
of O
TA B
- I
III I
in O
rat O
plasma O
after O
intragastric O
administration O
. O

The O
best O
fit O
pharmacokinetic O
model O
to O
estimate O
the O
pharmacokinetic O
parameters O
was O
a O
single O
compartment O
model O
with O
weight O
of O
1 O
/ O
x2 O
for O
oral O
administration O
groups O
of O
rats O
for O
TA B
- I
III I
. O

Furthermore O
, O
knockdown O
of O
OPN O
enhanced O
cell O
death O
caused O
by O
other O
drugs O
, O
including O
paclitaxel B
, O
doxorubicin B
, O
actinomycin B
- I
D I
, O
and O
rapamycin B
, O
which O
are O
also O
P O
- O
gp O
substrates O
. O

Construction O
of O
monophosphoryl B
lipid I
A I
producing O
Escherichia O
coli O
mutants O
and O
comparison O
of O
immuno O
- O
stimulatory O
activities O
of O
their O
lipopolysaccharides O
. O

HW001 O
was O
constructed O
by O
deleting O
lacI O
and O
replacing O
lacZ O
with O
the O
Francisella O
novicida O
lpxE O
gene O
in O
the O
chromosome O
and O
only O
synthesizes O
monophosphoryl B
lipid I
A I
. O

We O
observed O
changes O
in O
FA O
composition O
that O
predominantly O
involved O
increases O
in O
FA B
methyl I
esters I
( O
FAMEs B
) O
, O
mono B
- I
and I
poly I
- I
unsaturated I
FA I
( O
MUFA B
and O
PUFA B
) O
and O
a O
decrease O
in O
n O
- O
3 O
/ O
n O
- O
6 O
PUFA B
ratio O
by O
both O
PFOA B
and O
PFOS B
. O

Luciferase O
reporter O
assays O
showed O
that O
transcription O
of O
FDX1 O
was O
synergistically O
activated O
by O
the O
NR5A O
family O
and O
8Br B
- I
cAMP I
treatment O
through O
two O
SF O
- O
1 O
binding O
sites O
and O
a O
CRE O
- O
like O
sequence O
in O
a O
human O
ovarian O
granulosa O
cell O
line O
, O
KGN O
. O

Surface O
- O
enhanced O
Raman O
scattering O
spectra O
of O
adsorbates O
on O
Cu B
2 I
O I
nanospheres O
: O
charge O
- O
transfer O
and O
electromagnetic O
enhancement O
. O

Surface O
- O
enhanced O
Raman O
scattering O
( O
SERS O
) O
spectra O
of O
4 B
- I
mercaptobenzoic I
acid I
( O
4 B
- I
MBA I
) O
have O
been O
investigated O
on O
the O
surface O
of O
Cu2O B
nanospheres O
. O

The O
coupling O
between O
the O
adsorbates O
and O
the O
semiconductor O
, O
evidenced O
by O
the O
shift O
in O
absorption O
spectrum O
of O
modified O
Cu2O B
and O
the O
enhancement O
of O
non O
- O
totally O
symmetric O
modes O
of O
the O
4 B
- I
MBA I
and O
4 B
- I
mercaptopyridine I
( O
4 B
- I
MPY I
) O
molecules O
, O
were O
invoked O
to O
explain O
the O
experimental O
results O
. O

The O
coupling O
between O
the O
adsorbates O
and O
the O
semiconductor O
, O
evidenced O
by O
the O
shift O
in O
absorption O
spectrum O
of O
modified O
Cu2O B
and O
the O
enhancement O
of O
non O
- O
totally O
symmetric O
modes O
of O
the O
4 B
- I
MBA I
and O
4 B
- I
mercaptopyridine I
( O
4 B
- I
MPY I
) O
molecules O
, O
were O
invoked O
to O
explain O
the O
experimental O
results O
. O

The O
coupling O
between O
the O
adsorbates O
and O
the O
semiconductor O
, O
evidenced O
by O
the O
shift O
in O
absorption O
spectrum O
of O
modified O
Cu2O B
and O
the O
enhancement O
of O
non O
- O
totally O
symmetric O
modes O
of O
the O
4 B
- I
MBA I
and O
4 B
- I
mercaptopyridine I
( O
4 B
- I
MPY I
) O
molecules O
, O
were O
invoked O
to O
explain O
the O
experimental O
results O
. O

The O
study O
objective O
was O
to O
investigate O
the O
potential O
of O
a O
beverage O
containing O
silymarin O
and O
l B
- I
arginine I
to O
alter O
basic O
physiological O
and O
urodynamic O
parameters O
in O
22 O
normal O
healthy O
men O
aged O
38 O
- O
59years O
. O

The O
volunteers O
drank O
500ml O
/ O
day O
beverage O
without O
silymarin O
and O
l B
- I
arginine I
for O
10days O
followed O
, O
after O
a O
7 O
- O
day O
washout O
period O
, O
by O
the O
beverage O
with O
400mg O
silymarin O
and O
295mg O
l B
- I
arginine I
for O
10days O
. O

The O
volunteers O
drank O
500ml O
/ O
day O
beverage O
without O
silymarin O
and O
l B
- I
arginine I
for O
10days O
followed O
, O
after O
a O
7 O
- O
day O
washout O
period O
, O
by O
the O
beverage O
with O
400mg O
silymarin O
and O
295mg O
l B
- I
arginine I
for O
10days O
. O

Moreover O
; O
it O
was O
found O
that O
some O
of O
the O
tested O
compounds O
bearing O
imidazole B
- I
2 I
- I
yl I
moiety O
on O
the O
C11 O
- O
position O
of O
dihydropyridine B
ring O
exhibited O
superior O
antiproliferative O
activity O
in O
comparison O
to O
cis B
- I
platin I
especially O
in O
Jurkat O
cell O
line O
( O
compounds O
29 O
, O
31 O
, O
and O
33 O
) O
. O

The O
equilibrium O
metal O
- O
binding O
constants O
were O
determined O
by O
dilute O
solution O
potentiometric O
titration O
of O
monofunctional O
histidine B
- O
modified O
methoxy B
- I
PEG I
and O
were O
found O
to O
be O
consistent O
with O
binding O
constants O
of O
small O
molecule O
analogs O
previously O
studied O
. O

The O
known O
compounds O
were O
characterised O
as O
n B
- I
tetracosane I
, O
beta B
- I
sitosteryl I
stearate I
, O
eicosanoic B
acid I
, O
stigmasterol B
, O
beta B
- I
sitosterol I
, O
racemosol B
, O
octacosyl B
ferulate I
, O
de B
- I
O I
- I
methyl I
racemosol I
, O
lupeol B
and O
1 B
, I
7 I
, I
8 I
, I
12b I
- I
tetrahydro I
- I
2 I
, I
2 I
, I
4 I
- I
trimethyl I
- I
2H I
- I
benzo I
[ I
6 I
, I
7 I
] I
cyclohepta I
[ I
1 I
, I
2 I
, I
3 I
- I
de I
] I
[ I
1 I
] I

The O
known O
compounds O
were O
characterised O
as O
n B
- I
tetracosane I
, O
beta B
- I
sitosteryl I
stearate I
, O
eicosanoic B
acid I
, O
stigmasterol B
, O
beta B
- I
sitosterol I
, O
racemosol B
, O
octacosyl B
ferulate I
, O
de B
- I
O I
- I
methyl I
racemosol I
, O
lupeol B
and O
1 B
, I
7 I
, I
8 I
, I
12b I
- I
tetrahydro I
- I
2 I
, I
2 I
, I
4 I
- I
trimethyl I
- I
2H I
- I
benzo I
[ I
6 I
, I
7 I
] I
cyclohepta I
[ I
1 I
, I
2 I
, I
3 I
- I
de I
] I
[ I
1 I
] I

We O
have O
characterized O
the O
lysylation O
system O
of O
Plasmodium O
falciparum O
, O
and O
designed O
, O
synthesized O
, O
and O
tested O
a O
set O
of O
inhibitors O
based O
on O
the O
structure O
of O
the O
natural O
substrate O
intermediate O
: O
lysyl B
- I
adenylate I
. O

Ypc1p O
can O
catalyze O
the O
reverse O
reaction O
, O
i O
. O
e O
. O
the O
condensation O
of O
free O
fatty B
acids I
with O
phytosphingosine B
or O
dihydrosphingosine B
and O
overexpression O
of O
YPC1 O
or O
YDC1 O
can O
provide O
enough O
ceramide B
synthesis O
as O
to O
rescue O
the O
viability O
of O
cells O
lacking O
the O
normal O
acyl B
- I
CoA I
- O
dependent O
ceramide O
synthases O
. O

To O
better O
understand O
the O
coexistence O
of O
acyl B
- I
CoA I
dependent O
ceramide B
synthases O
and O
ceramidases B
in O
the O
ER O
we O
investigated O
the O
membrane O
topology O
of O
Ypc1p O
by O
probing O
cysteine B
accessibility O
of O
natural O
and O
substituted O
cysteines B
with O
membrane O
non O
- O
permeating O
mass O
- O
tagged O
probes O
. O

The O
design O
of O
alkylated B
- I
C60 I
is O
selected O
from O
our O
recent O
research O
achievements O
, O
as O
the O
most O
attractive O
example O
of O
such O
alkylated O
- O
pi O
systems O
. O

Discovery O
of O
aromatic O
components O
with O
excellent O
fragrance O
properties O
and O
biological O
activities O
: O
beta B
- I
ionols I
with O
antimelanogenetic O
effects O
and O
their O
asymmetric O
syntheses O
. O

Both O
enantiomers O
of O
dihydro B
- I
beta I
- I
ionol I
and O
beta B
- I
ionol I
, O
contained O
in O
the O
aromatic O
components O
of O
Osmanthus O
flower O
and O
of O
Hakuto O
peach O
, O
were O
obtained O
with O
high O
optical O
purity O
by O
lipase O
- O
catalyzed O
kinetic O
resolution O
of O
the O
racemates O
. O

The O
asymmetric O
synthesis O
of O
( B
R I
) I
- I
dihydro I
- I
beta I
- I
ionol I
, O
one O
of O
the O
most O
valuable O
raw O
materials O
for O
fragrance O
and O
flavor O
, O
was O
performed O
from O
inexpensive O
beta B
- I
ionone I
via O
lipase O
- O
catalyzed O
dynamic O
kinetic O
resolution O
followed O
by O
reduction O
. O

The O
gas O
- O
phase O
reaction O
of O
methane B
sulfonic I
acid I
with O
the O
hydroxyl B
radical O
without O
and O
with O
water O
vapor O
. O

The O
gas O
phase O
reaction O
between O
methane B
sulfonic I
acid I
( O
CH3SO3H B
; O
MSA B
) O
and O
the O
hydroxyl B
radical O
( O
HO B
) O
, O
without O
and O
with O
a O
water O
molecule O
, O
was O
investigated O
with O
DFT O
- O
B3LYP O
and O
CCSD O
( O
T O
) O
- O
F12 O
methods O
. O

Our O
kinetic O
calculations O
show O
that O
99 O
. O
5 O
% O
of O
the O
reaction O
involves O
this O
interchange O
of O
the O
water O
molecule O
and O
, O
consequently O
, O
water O
vapor O
does O
not O
play O
any O
role O
in O
the O
oxidation O
reaction O
of O
methane B
sulfonic I
acid I
by O
the O
hydroxyl B
radical O
. O

Previously O
, O
we O
have O
found O
that O
BRN B
- I
103 I
, O
a O
nicotinamide B
derivative O
, O
inhibits O
vascular O
endothelial O
growth O
factor O
( O
VEGF O
) O
- O
mediated O
angiogenesis O
signaling O
in O
human O
endothelial O
cells O
. O

We O
found O
that O
2 B
- I
{ I
1 I
- I
[ I
1 I
- I
( I
6 I
- I
chloro I
- I
5 I
- I
fluoropyrimidin I
- I
4 I
- I
yl I
) I
ethyl I
] I
piperidin I
- I
4 I
- I
ylamino I
} I
- I
N I
- I
( I
3 I
- I
chlorophenyl I
) I
pyridine I
- I
3 I
- I
carboxamide I
( O
BRN B
- I
250 I
) O
significantly O
inhibited O
human O
umbilical O
vascular O
endothelial O
cells O
( O
HUVECs O
) O
proliferation O
, O
migration O
, O
tube O
formation O
, O
and O
microvessel O
growth O
in O
a O
concentration O
range O
of O
10 O
- O
100 O
nM O
. O

Furthermore O
, O
BRN B
- I
250 I
inhibited O
the O
VEGF O
- O
induced O
phosphorylation O
and O
intracellular O
tyrosine B
kinase O
activity O
of O
VEGF O
receptor O
2 O
( O
VEGFR2 O
) O
and O
the O
activation O
of O
its O
downstream O
AKT O
pathway O
. O

Taken O
together O
, O
these O
findings O
suggest O
that O
BRN B
- I
250 I
be O
considered O
a O
potential O
lead O
compound O
for O
cancer O
therapy O
. O

Analogs O
with O
Z B
= I
Br I
, I
I I
, I
or I
OTs I
were O
weak O
inhibitors O
of O
the O
AChEs O
, O
and O
methyl B
phosphonates I
( O
R B
= I
Me I
) O
were O
more O
potent O
than O
the O
corresponding O
ethyl B
phosphonates I
( O
R B
= I
Et I
) O
. O

Analogs O
with O
Z B
= I
Br I
, I
I I
, I
or I
OTs I
were O
weak O
inhibitors O
of O
the O
AChEs O
, O
and O
methyl B
phosphonates I
( O
R B
= I
Me I
) O
were O
more O
potent O
than O
the O
corresponding O
ethyl B
phosphonates I
( O
R B
= I
Et I
) O
. O

N B
- I
Alkyldeoxynojirimyci I
derivatives O
with O
novel O
terminal O
tertiary B
amide I
substitution O
for O
treatment O
of O
bovine O
viral O
diarrhea O
virus O
( O
BVDV O
) O
, O
Dengue O
, O
and O
Tacaribe O
virus O
infections O
. O

Novel O
N B
- I
alkyldeoxynojirimyci I
( O
NADNJs B
) O
with O
two O
hydrophobic O
groups O
attached O
to O
a O
nitrogen O
linker O
on O
the O
alkyl B
chain O
were O
designed O
. O

Recently O
, O
we O
reported O
on O
the O
ability O
of O
a O
series O
of O
small O
molecule O
, O
cyclic B
polyamine I
disulfides I
to O
condense O
and O
cage O
plasmid O
DNA O
( O
pDNA O
) O
by O
a O
process O
of O
thermodynamically O
controlled O
template O
polymerization O
, O
leading O
to O
a O
series O
of O
corresponding O
pDNA O
- O
polyplex O
nanoparticles O
able O
to O
mediate O
high O
levels O
of O
transfection O
with O
no O
associated O
cytotoxicities O
. O

The O
leading O
cyclic B
polyamine I
disulfide I
was O
shown O
to O
be O
the O
spermine B
tetra I
- I
amine I
disulfide I
( O
TetraN B
- I
3 I
, I
4 I
, I
3 I
) O
. O

Two O
new O
cyclic B
polyamine I
disulfides I
, O
based O
on O
hexa B
- I
and I
octa I
- I
amine I
inserts O
, O
were O
prepared O
and O
their O
transfection O
efficacies O
and O
cytotoxicities O
compared O
with O
our O
previously O
reported O
cyclic B
tri I
- I
and I
tetra I
- I
amine I
disulfides I
. O

Our O
data O
in O
toto O
support O
the O
concept O
of O
shorter O
cyclic B
polyamine I
disulfides I
as O
preferred O
agents O
for O
polycation O
- O
mediated O
controlled O
condensation O
and O
functional O
delivery O
of O
pDNA O
to O
lung O
epithelial O
cells O
in O
vivo O
. O

The O
synthesis O
and O
biochemical O
activities O
of O
novel O
water O
- O
soluble O
beta B
- I
lactam I
analogues O
of O
combretastatin B
A I
- I
4 I
are O
described O
. O

Rational O
design O
, O
synthesis O
and O
QSAR O
study O
of O
vasorelaxant O
active O
3 B
- I
pyridinecarbonitrile I
incorporating O
1H B
- I
benzimidazol I
- I
2 I
- I
yl I
function O
. O

Cereal O
- O
based O
food O
products O
( O
n O
= O
174 O
) O
were O
analysed O
for O
the O
occurrence O
of O
deoxynivalenol B
, O
3 B
- I
acetyldeoxynivalenol I
, O
15 B
- I
acetyldeoxynivalenol I
, O
zearalenone B
, O
alpha B
- I
zearalenol I
, O
beta B
- I
zearalenol I
, O
T B
- I
2 I
- I
toxin I
, O
HT B
- I
2 I
- I
toxin I
, O
and O
their O
respective O
masked O
forms O
, O
including O
, O
deoxynivalenol B
- I
3 I
- I
glucoside I
, O
zearalenone B
- I
4 I
- I
glucoside I
, O
alpha B
- I

Cereal O
- O
based O
food O
products O
( O
n O
= O
174 O
) O
were O
analysed O
for O
the O
occurrence O
of O
deoxynivalenol B
, O
3 B
- I
acetyldeoxynivalenol I
, O
15 B
- I
acetyldeoxynivalenol I
, O
zearalenone B
, O
alpha B
- I
zearalenol I
, O
beta B
- I
zearalenol I
, O
T B
- I
2 I
- I
toxin I
, O
HT B
- I
2 I
- I
toxin I
, O
and O
their O
respective O
masked O
forms O
, O
including O
, O
deoxynivalenol B
- I
3 I
- I
glucoside I
, O
zearalenone B
- I
4 I
- I
glucoside I
, O
alpha B
- I

Cereal O
- O
based O
food O
products O
( O
n O
= O
174 O
) O
were O
analysed O
for O
the O
occurrence O
of O
deoxynivalenol B
, O
3 B
- I
acetyldeoxynivalenol I
, O
15 B
- I
acetyldeoxynivalenol I
, O
zearalenone B
, O
alpha B
- I
zearalenol I
, O
beta B
- I
zearalenol I
, O
T B
- I
2 I
- I
toxin I
, O
HT B
- I
2 I
- I
toxin I
, O
and O
their O
respective O
masked O
forms O
, O
including O
, O
deoxynivalenol B
- I
3 I
- I
glucoside I
, O
zearalenone B
- I
4 I
- I
glucoside I
, O
alpha B
- I

Cereal O
- O
based O
food O
products O
( O
n O
= O
174 O
) O
were O
analysed O
for O
the O
occurrence O
of O
deoxynivalenol B
, O
3 B
- I
acetyldeoxynivalenol I
, O
15 B
- I
acetyldeoxynivalenol I
, O
zearalenone B
, O
alpha B
- I
zearalenol I
, O
beta B
- I
zearalenol I
, O
T B
- I
2 I
- I
toxin I
, O
HT B
- I
2 I
- I
toxin I
, O
and O
their O
respective O
masked O
forms O
, O
including O
, O
deoxynivalenol B
- I
3 I
- I
glucoside I
, O
zearalenone B
- I
4 I
- I
glucoside I
, O
alpha B
- I

The O
suppression O
of O
hematopoiesis O
function O
in O
Balb O
/ O
c O
mice O
induced O
by O
prolonged O
exposure O
of O
microcystin B
- I
LR I
. O

In O
the O
present O
study O
, O
Balb O
/ O
c O
mice O
were O
intraperitoneally O
injected O
with O
microcystin B
- I
LR I
( O
MC B
- I
LR I
) O
at O
the O
doses O
of O
0 O
. O
5 O
, O
2 O
and O
8 O
mu O
g O
/ O
kg O
body O
weight O
( O
bw O
) O
every O
48h O
for O
30d O
. O

In O
the O
present O
study O
, O
Balb O
/ O
c O
mice O
were O
intraperitoneally O
injected O
with O
microcystin B
- I
LR I
( O
MC B
- I
LR I
) O
at O
the O
doses O
of O
0 O
. O
5 O
, O
2 O
and O
8 O
mu O
g O
/ O
kg O
body O
weight O
( O
bw O
) O
every O
48h O
for O
30d O
. O

After O
the O
prolonged O
exposure O
of O
MC B
- I
LR I
, O
significant O
decreases O
of O
red O
blood O
cell O
count O
( O
RBC O
) O
, O
hemoglobin O
( O
Hb O
) O
and O
hematocrit O
( O
Ht O
) O
were O
observed O
in O
2 O
and O
8 O
mu O
g O
/ O
kg O
bw O
groups O
, O
but O
erythrocyte O
mean O
corpuscular O
volume O
( O
MCV O
) O
showed O
no O
significant O
changes O
. O

Significantly O
elevated O
micronucleus O
frequency O
was O
observed O
in O
bone O
marrow O
cells O
( O
BMCs O
) O
in O
all O
MC B
- I
LR I
treatments O
. O

MC B
- I
LR I
exposure O
significantly O
increased O
the O
apoptosis O
rates O
in O
all O
MC B
- I
LR I
treatments O
. O

MC B
- I
LR I
exposure O
significantly O
increased O
the O
apoptosis O
rates O
in O
all O
MC B
- I
LR I
treatments O
. O

The O
present O
study O
indicates O
prolonged O
exposure O
of O
MC B
- I
LR I
induces O
normocytic O
anemia O
, O
and O
the O
disturbed O
hematopoietic O
growth O
factors O
and O
BMCs O
apoptosis O
are O
responsible O
for O
this O
normocytic O
anemia O
. O

No O
significant O
differences O
were O
observed O
between O
mono B
- I
ammonium I
molecular O
coatings O
. O

The O
antiviral O
effect O
of O
7 B
- I
hydroxyisoflavone I
against O
Enterovirus O
71 O
in O
vitro O
. O

In O
screening O
for O
anti O
- O
EV71 O
candidates O
, O
we O
found O
that O
7 B
- I
hydroxyisoflavone I
was O
active O
against O
EV71 O
. O

7 B
- I
Hydroxyisoflavone I
exhibited O
strong O
antiviral O
activity O
against O
three O
different O
EV71 O
strains O
. O

7 B
- I
Hydroxyisoflavone I
could O
reduce O
EV71 O
viral O
RNA O
and O
protein O
synthesis O
in O
a O
dose O
- O
dependent O
manner O
. O

Time O
course O
study O
showed O
that O
treatment O
of O
Vero O
cells O
with O
7 B
- I
hydroxyisoflavone I
at O
indicated O
times O
after O
EV71 O
inoculation O
( O
0 O
- O
6 O
h O
) O
resulted O
in O
significant O
antiviral O
activity O
. O

Results O
showed O
that O
7 B
- I
hydroxyisoflavone I
acted O
at O
an O
early O
step O
of O
EV71 O
replication O
. O

7 B
- I
Hydroxyisoflavone I
also O
exhibited O
strong O
antiviral O
activity O
against O
coxsackievirus O
B2 O
, O
B3 O
, O
and O
B6 O
. O

In O
short O
, O
7 B
- I
hydroxyisoflavone I
may O
be O
used O
as O
a O
lead O
compound O
for O
anti O
- O
EV71 O
drug O
development O
. O

Compound O
1 O
displayed O
the O
protective O
effect O
against O
d B
- I
galactosamine I
- O
induced O
HepG2 O
damage O
and O
reduced O
the O
damage O
from O
58 O
. O
64 O
% O
to O
22 O
. O
26 O
% O
. O

PF B
- I
04859989 I
as O
a O
template O
for O
structure O
- O
based O
drug O
design O
: O
identification O
of O
new O
pyrazole B
series O
of O
irreversible O
KAT O
II O
inhibitors O
with O
improved O
lipophilic O
efficiency O
. O

Mollugin B
treatment O
also O
significantly O
increased O
intracellular O
accumulation O
of O
the O
fluorescently O
- O
tagged O
P O
- O
gp O
substrate O
, O
rhodamine B
- I
123 I
. O

p B
- I
Cresol I
induces O
disruption O
of O
cardiomyocyte O
adherens O
junctions O
. O

Higher O
serum O
levels O
of O
p B
- I
cresol I
in O
chronic O
kidney O
disease O
populations O
have O
been O
associated O
with O
increased O
cardiovascular O
mortality O
. O

However O
, O
studies O
on O
how O
p B
- I
cresol I
affects O
intercellular O
junctions O
between O
cardiomyocytes O
were O
limited O
. O

This O
study O
investigated O
the O
effect O
of O
p B
- I
cresol I
on O
adherens O
junction O
( O
AJ O
) O
of O
neonatal O
cultured O
cardiomyocytes O
and O
its O
underlying O
mechanism O
. O

A O
loss O
of O
N O
- O
cadherin O
and O
p120 O
- O
catenin O
( O
p120ctn O
) O
immunostaining O
from O
cell O
- O
cell O
contact O
sites O
was O
noted O
by O
p B
- I
cresol I
treatment O
. O

In O
addition O
, O
p B
- I
cresol I
disrupted O
AJs O
by O
inducing O
formation O
of O
intercellular O
gaps O
. O

Our O
previous O
study O
has O
revealed O
that O
p B
- I
cresol I
increased O
intracellular O
calcium B
levels O
and O
activated O
protein O
kinase O
C O
alpha O
( O
PKC O
alpha O
) O
by O
phosphorylation O
. O

The O
PKC O
alpha O
activation O
was O
involved O
in O
the O
p B
- I
cresol I
- O
mediated O
AJ O
disassembly O
, O
since O
pharmacological O
inhibition O
of O
PKC O
alpha O
abolished O
the O
above O
- O
mentioned O
p B
- I
cresol I
effect O
. O

The O
PKC O
alpha O
activation O
was O
involved O
in O
the O
p B
- I
cresol I
- O
mediated O
AJ O
disassembly O
, O
since O
pharmacological O
inhibition O
of O
PKC O
alpha O
abolished O
the O
above O
- O
mentioned O
p B
- I
cresol I
effect O
. O

SiRNA O
knockdown O
of O
PKC O
alpha O
prevented O
p B
- I
cresol I
- O
induced O
serine O
dephosphorylation O
of O
p120ctn O
and O
splitting O
of O
AJ O
. O

In O
conclusion O
, O
p B
- I
cresol I
caused O
PKC O
alpha O
- O
dependent O
AJ O
disassembly O
of O
cardiomyocytes O
, O
which O
might O
be O
related O
to O
asychronized O
contraction O
. O

A O
novel O
insulin O
mimetic O
vanadium B
- I
flavonol I
complex O
: O
Synthesis O
, O
characterization O
and O
in O
vivo O
evaluation O
in O
STZ B
- O
induced O
rats O
. O

In O
order O
to O
circumvent O
the O
toxic O
effects O
of O
vanadium B
, O
we O
have O
taken O
up O
a O
combinational O
approach O
wherein O
a O
novel O
vanadium B
- I
flavonol I
complex O
was O
synthesized O
, O
characterized O
and O
its O
toxic O
as O
well O
as O
insulin O
mimetic O
potential O
was O
evaluated O
in O
STZ B
- O
induced O
experimental O
diabetes O
in O
rats O
. O

The O
formation O
from O
D B
- I
glucose I
of O
both O
enantiomers O
of O
2 B
, I
4 I
- I
dideoxy I
- I
2 I
, I
4 I
- I
iminoribonic I
acid I
is O
the O
first O
chemical O
synthesis O
of O
unprotected O
3 B
- I
hydroxyazetidine I
carboxylic I
acids I
. O

An O
N B
- I
methylazetidine I
amide I
derivative O
is O
a O
specific O
inhibitor O
of O
beta O
- O
hexosaminidases O
at O
the O
micromolar O
level O
, O
and O
is O
only O
the O
second O
example O
of O
potent O
inhibition O
of O
any O
glycosidase O
by O
an O
amide B
of O
a O
sugar B
amino I
acid I
related O
to O
an O
iminosugar B
. O

Complementary O
density O
functional O
theory O
calculations O
suggest O
that O
the O
reaction O
is O
most O
likely O
mediated O
by O
a O
monothiolate O
RS B
- I
Au I
complex O
bonded O
to O
the O
gold O
surface O
, O
which O
forms O
a O
trithiolate B
RS B
- I
Au I
- I
( I
SR I
) I
- I
Au I
- I
SR I
complex O
as O
a O
key O
intermediate O
. O

On O
the O
basis O
of O
percent O
edema O
inhibition O
after O
3 O
h O
of O
carrageenin O
injection O
, O
n B
- I
butanol I
fraction O
showed O
promising O
activity O
through O
a O
significant O
( O
p O
< O
0 O
. O
05 O
) O
decrease O
in O
paw O
volume O
by O
85 O
. O
6 O
% O
from O
control O
using O
indomethacin B
as O
reference O
standard O
. O

Moreover O
, O
the O
n B
- I
butanol I
fraction O
significantly O
( O
p O
< O
0 O
. O
05 O
) O
decreased O
PGE2 B
and O
TNF O
- O
alpha O
in O
the O
exudates O
of O
rat O
paw O
edema O
. O

Chemical O
investigation O
of O
n B
- I
butanol I
fraction O
afforded O
alpha B
- I
amyrin I
3 I
- I
O I
- I
glucopyranoside I
( O
1 O
) O
, O
patuletin B
7 I
- I
O I
- I
glucopyranoside I
( O
2 O
) O
, O
myricitrin B
( O
3 O
) O
and O
a O
new O
oleanane B
triterpene I
saponin I
derivative O
( O
4 O
) O
, O
sophradiol B
3 I
- I
O I
- I
alpha I
- I
L I
- I
( I
1 I
) I
C4 I
- I
rhamnopyranosyl I
- I
( I
1 I
' I
' I
' I
- I
- I
> I
4 I
' I
' I
) I
- I
O I
- I
beta I
- I
D I
- I
( I
4 I
) I
C1 I
- I
galactopyranosyl I

Chemical O
investigation O
of O
n B
- I
butanol I
fraction O
afforded O
alpha B
- I
amyrin I
3 I
- I
O I
- I
glucopyranoside I
( O
1 O
) O
, O
patuletin B
7 I
- I
O I
- I
glucopyranoside I
( O
2 O
) O
, O
myricitrin B
( O
3 O
) O
and O
a O
new O
oleanane B
triterpene I
saponin I
derivative O
( O
4 O
) O
, O
sophradiol B
3 I
- I
O I
- I
alpha I
- I
L I
- I
( I
1 I
) I
C4 I
- I
rhamnopyranosyl I
- I
( I
1 I
' I
' I
' I
- I
- I
> I
4 I
' I
' I
) I
- I
O I
- I
beta I
- I
D I
- I
( I
4 I
) I
C1 I
- I
galactopyranosyl I

We O
choose O
AOT B
/ O
Igepal B
- I
520 I
/ O
cyclohexane B
( O
Cy O
) O
mixed O
RM O
as O
a O
model O
system O
which O
exhibits O
synergistic O
water O
solubilization O
behavior O
as O
a O
function O
of O
interfacial O
stoichiometry O
. O

Water O
relaxation O
dynamics O
as O
probed O
by O
time O
- O
resolved O
fluorescence O
spectroscopy O
using O
Coumarin B
- I
500 I
also O
reveals O
an O
overall O
linear O
trend O
with O
no O
characteristic O
feature O
around O
the O
solubilization O
inflation O
point O
. O

Melanoma O
targeting O
property O
of O
a O
Lu B
- I
177 I
- O
labeled O
lactam B
bridge O
- O
cyclized O
alpha O
- O
MSH O
peptide O
. O

The O
present O
study O
determined O
the O
anti O
- O
Mycobacterium O
tuberculosis O
activities O
of O
supercritical O
CO2 B
extracts O
, O
neolignans B
eupomatenoid B
- I
5 I
( O
1 O
) O
, O
conocarpan B
( O
4 O
) O
and O
eupomatenoid B
- I
3 I
( O
7 O
) O
and O
their O
derivatives O
( O
2 O
, O
3 O
, O
5 O
, O
6 O
, O
and O
8 O
) O
from O
Piper O
regnellii O
, O
as O
well O
as O
their O
cytotoxicities O
. O

The O
present O
study O
determined O
the O
anti O
- O
Mycobacterium O
tuberculosis O
activities O
of O
supercritical O
CO2 B
extracts O
, O
neolignans B
eupomatenoid B
- I
5 I
( O
1 O
) O
, O
conocarpan B
( O
4 O
) O
and O
eupomatenoid B
- I
3 I
( O
7 O
) O
and O
their O
derivatives O
( O
2 O
, O
3 O
, O
5 O
, O
6 O
, O
and O
8 O
) O
from O
Piper O
regnellii O
, O
as O
well O
as O
their O
cytotoxicities O
. O

The O
main O
proposed O
metabolic O
pathways O
in O
various O
in O
vitro O
systems O
were O
N B
- O
oxidation O
of O
the O
pyridine B
and O
/ O
or O
pyrimidine B
ring O
and O
conversion O
to O
4 B
- I
pyrimidone I
and O
pyrimidine B
- I
2 I
, I
4 I
- I
dione I
. O

In O
conclusion O
, O
we O
discovered O
an O
unusual O
metabolic O
pathway O
of O
aryl B
- I
pyrimidine I
- O
containing O
compounds O
by O
a O
ring O
- O
opening O
reaction O
followed O
by O
elimination O
of O
a O
carbon B
atom O
and O
a O
ring O
closure O
to O
form O
an O
imidazole B
ring O
. O

The O
antipsychotic O
- O
like O
effects O
of O
the O
mGlu O
group O
III O
orthosteric O
agonist O
, O
LSP1 B
- I
2111 I
, O
involves O
5 O
- O
HT1A O
signalling O
. O

LSP1 B
- I
2111 I
, O
the O
group O
III O
mGlu O
receptor O
orthosteric O
agonist O
, O
with O
a O
high O
affinity O
towards O
mGlu4 O
receptors O
, O
was O
previously O
shown O
to O
exhibit O
antipsychotic O
- O
like O
action O
in O
animal O
models O
displaying O
positive O
symptoms O
of O
schizophrenia O
. O

OBJECTIVES O
: O
Here O
, O
we O
decided O
to O
investigate O
the O
possible O
role O
of O
LSP1 B
- I
2111 I
in O
models O
of O
negative O
( O
social O
interaction O
) O
and O
cognitive O
( O
NOR O
) O
symptoms O
of O
psychosis O
. O

We O
also O
investigated O
the O
involvement O
of O
5 O
- O
HT1A O
receptors O
in O
the O
LSP1 B
- I
2111 I
- O
induced O
antipsychotic O
effects O
. O

Apart O
from O
the O
above O
- O
mentioned O
models O
of O
negative O
and O
cognitive O
symptoms O
, O
MK B
- I
801 I
and O
amphetamine B
- O
induced O
hyperactivity O
tests O
, O
plus O
the O
DOI B
- O
induced O
head O
twitches O
in O
mice O
as O
models O
for O
positive O
symptoms O
of O
psychosis O
, O
were O
used O
in O
this O
part O
of O
the O
investigations O
. O

RESULTS O
: O
LSP1 B
- I
2111 I
( O
0 O
. O
5 O
, O
2 O
, O
and O
5 O
mg O
/ O
kg O
) O
dose O
- O
dependently O
inhibited O
MK B
- I
801 I
- O
induced O
deficits O
in O
social O
interaction O
and O
NOR O
tests O
. O

RESULTS O
: O
LSP1 B
- I
2111 I
( O
0 O
. O
5 O
, O
2 O
, O
and O
5 O
mg O
/ O
kg O
) O
dose O
- O
dependently O
inhibited O
MK B
- I
801 I
- O
induced O
deficits O
in O
social O
interaction O
and O
NOR O
tests O
. O

A O
similar O
inhibition O
of O
LSP1 B
- I
2111 I
- O
induced O
effects O
was O
observed O
in O
models O
of O
positive O
symptoms O
of O
schizophrenia O
. O

Moreover O
, O
the O
concomitant O
administration O
of O
subeffective O
doses O
of O
LSP1 B
- I
2111 I
( O
0 O
. O
3 O
- O
0 O
. O
5 O
mg O
/ O
kg O
) O
with O
a O
subeffective O
dose O
of O
5 O
- O
HT1A O
agonist O
, O
( B
R I
) I
- I
( I
+ I
) I
- I
8 I
- I
Hydroxy I
- I
DPAT I
( O
0 O
. O
01 O
mg O
/ O
kg O
) O
, O
induced O
a O
clear O
antipsychotic O
- O
like O
effect O
in O
all O
of O
the O
procedures O
used O
. O

Discovery O
and O
gram O
- O
scale O
synthesis O
of O
BMS B
- I
593214 I
, O
a O
potent O
, O
selective O
FVIIa O
inhibitor O
. O

A O
6 B
- I
amidinotetrahydroqui I
screening O
hit O
was O
driven O
to O
a O
structurally O
novel O
, O
potent O
, O
and O
selective O
FVIIa O
inhibitor O
through O
a O
combination O
of O
library O
synthesis O
and O
rational O
design O
. O

An O
efficient O
gram O
- O
scale O
synthesis O
of O
the O
active O
enantiomer O
BMS B
- I
593214 I
was O
developed O
, O
which O
required O
significant O
optimization O
of O
the O
key O
Povarov O
annulation O
. O

Importantly O
, O
BMS B
- I
593214 I
showed O
antithrombotic O
efficacy O
in O
a O
rabbit O
arterial O
thrombosis O
model O
. O

A O
crystal O
structure O
of O
BMS B
- I
593214 I
bound O
to O
FVIIa O
highlights O
key O
contacts O
with O
Asp B
189 O
, O
Lys B
192 O
, O
and O
the O
S2 O
pocket O
. O

Rab12 O
regulates O
mTORC1 O
activity O
and O
autophagy O
through O
controlling O
the O
degradation O
of O
amino B
- I
acid I
transporter O
PAT4 O
. O

Here O
, O
we O
report O
small O
GTPase O
Rab12 O
as O
a O
new O
type O
of O
autophagic O
regulator O
that O
controls O
the O
degradation O
of O
an O
amino B
- I
acid I
transporter O
. O

We O
also O
found O
that O
Rab12 O
promotes O
constitutive O
degradation O
of O
PAT4 O
( O
proton O
- O
coupled O
amino B
- I
acid I
transporter O
4 O
) O
, O
whose O
accumulation O
in O
Rab12 O
- O
knockdown O
cells O
modulates O
mTORC1 O
activity O
and O
autophagy O
. O

We O
characterized O
the O
effects O
of O
the O
electrophilic O
arthropod O
defensive O
compound O
para B
- I
benzoquinone I
( O
pBQN B
) O
on O
the O
human O
TRPA1 O
channel O
. O

Two O
mitochondriotropic O
, O
4 B
- I
O I
- I
triphenylphosphonium I
derivatives O
of O
quercetin B
( O
QTA B
- I
3BTPI I
and O
Q B
- I
3BTPI I
) O
were O
compared O
to O
quercetin B
for O
protection O
against O
glyceryl B
trinitrate I
- O
induced O
tolerance O
and O
endothelial O
dysfunction O
of O
isolated O
rat O
aorta O
rings O
. O

Two O
mitochondriotropic O
, O
4 B
- I
O I
- I
triphenylphosphonium I
derivatives O
of O
quercetin B
( O
QTA B
- I
3BTPI I
and O
Q B
- I
3BTPI I
) O
were O
compared O
to O
quercetin B
for O
protection O
against O
glyceryl B
trinitrate I
- O
induced O
tolerance O
and O
endothelial O
dysfunction O
of O
isolated O
rat O
aorta O
rings O
. O

Both O
QTA B
- I
3BTPI I
and O
Q B
- I
3BTPI I
significantly O
counteracted O
the O
reduced O
vascular O
responsiveness O
to O
both O
glyceryl B
trinitrate I
and O
acetylcholine B
caused O
by O
prolonged O
exposure O
of O
the O
vessel O
to O
glyceryl B
trinitrate I
itself O
, O
their O
potency O
being O
much O
greater O
than O
that O
of O
quercetin B
. O

Both O
QTA B
- I
3BTPI I
and O
Q B
- I
3BTPI I
significantly O
counteracted O
the O
reduced O
vascular O
responsiveness O
to O
both O
glyceryl B
trinitrate I
and O
acetylcholine B
caused O
by O
prolonged O
exposure O
of O
the O
vessel O
to O
glyceryl B
trinitrate I
itself O
, O
their O
potency O
being O
much O
greater O
than O
that O
of O
quercetin B
. O

QTA B
- I
3BTPI I
, O
however O
, O
turned O
out O
to O
cause O
endothelial O
dysfunction O
per O
se O
. O

Since O
Q B
- I
3BTPI I
antagonized O
in O
vitro O
nitrate B
tolerance O
and O
endothelial O
dysfunction O
of O
vessels O
, O
this O
encourages O
assessing O
whether O
this O
effect O
is O
displayed O
also O
in O
vivo O
during O
long O
- O
term O
glyceryl B
trinitrate I
treatment O
. O

Here O
, O
we O
determined O
the O
crystal O
structure O
of O
iPSP1 O
from O
H O
. O
thermophilus O
in O
the O
apo O
- O
form O
and O
in O
complex O
with O
its O
substrate O
l B
- I
phosphoserine I
to O
find O
structural O
units O
important O
for O
its O
phosphatase O
activity O
toward O
l B
- I
phosphoserine I
. O

Here O
, O
we O
determined O
the O
crystal O
structure O
of O
iPSP1 O
from O
H O
. O
thermophilus O
in O
the O
apo O
- O
form O
and O
in O
complex O
with O
its O
substrate O
l B
- I
phosphoserine I
to O
find O
structural O
units O
important O
for O
its O
phosphatase O
activity O
toward O
l B
- I
phosphoserine I
. O

Biological O
results O
demonstrated O
that O
the O
introduction O
of O
a O
fluorine B
atom O
at O
the O
ortho O
position O
of O
the O
9 B
- I
benzyl I
group O
generally O
enhanced O
affinity O
toward O
A1 O
subtype O
and O
did O
not O
significantly O
affect O
A2A O
and O
A3 O
affinity O
. O

Very O
interesting O
is O
the O
compound O
bearing O
a O
meta B
- I
fluorophenyl I
substituent O
on O
the O
carbonyl B
carbon I
of O
the O
amide B
group O
, O
which O
shows O
significantly O
high O
A1 O
/ O
A2A O
- O
A3 O
selectivity O
. O

Compounds O
of O
this O
new O
series O
, O
together O
with O
the O
previously O
published O
analogs O
without O
the O
fluorine B
atom O
on O
the O
9 B
- I
benzyl I
group O
, O
constituted O
the O
starting O
dataset O
for O
the O
development O
of O
QSAR O
models O
. O

The O
models O
obtained O
were O
able O
to O
rationally O
describe O
the O
affinity O
trends O
resulting O
from O
biological O
testing O
, O
and O
to O
enable O
investigation O
of O
the O
role O
of O
different O
substituents O
on O
the O
8 B
- I
azapurine I
scaffold O
, O
as O
well O
as O
the O
influence O
of O
the O
newly O
introduced O
fluorine B
atom O
on O
the O
benzyl B
moiety O
. O

Aggregation O
and O
kinetic O
studies O
have O
been O
performed O
to O
understand O
the O
hydrolytic O
potencies O
of O
the O
series O
of O
oxime B
- O
functionalized O
surfactants O
, O
viz O
. O
, O
3 B
- I
hydroxyiminomethyl I
- I
1 I
- I
alkylpyridinium I
bromide I
( O
alkyl B
= O
CnH2n B
+ I
1 I
, O
n O
= O
10 O
, O
12 O
, O
14 O
, O
16 O
, O
18 O
) O
in O
the O
cleavage O
of O
phosphate B
esters I
, O
p B
- I
nitrophenyl I
diphenyl I
phosphate I
( O
PNPDPP B
) O
and O
bis B
( I
2 I
, I
4 I
- I
dinitrophenyl I
) I
phosphate I
( O

Functionalized O
oxime B
- O
based O
surfactants O
were O
proved O
to O
be O
supernucleophiles O
to O
attack O
on O
the O
P B
= I
O I
center O
of O
tri B
- I
and I
diphosphate I
esters I
. O

Oximes B
with O
hexadecyl B
alkyl B
chain O
length O
( O
3 B
- I
C16 I
) O
showed O
maximum O
micellar O
effect O
on O
the O
rate O
constants O
toward O
PNPDPP B
. O

The O
latter O
is O
converted O
to O
functionalised O
diarylamine B
8 O
, O
which O
is O
cyclised O
to O
the O
desired O
carbazole B
1 O
through O
a O
Pd B
- O
promoted O
or O
- O
catalysed O
double O
C B
- I
H I
bond O
activation O
process O
in O
a O
fairly O
good O
overall O
yield O
. O

We O
studied O
the O
equilibrium O
conformations O
of O
a O
zinc B
porphyrin I
tweezer O
composed O
of O
two O
carboxylphenyl B
- O
functionalized O
zinc B
tetraphenyl I
porphyrin I
subunits O
connected O
by O
a O
1 B
, I
4 I
- I
butyndiol I
spacer O
, O
which O
was O
suspended O
inside O
the O
amphiphilic O
regions O
of O
1 B
, I
2 I
- I
distearoyl I
- I
sn I
- I
glycero I
- I
3 I
- I
phosphocholine I
( O
DSPC B
) O
liposomes O
. O

Synthesis O
, O
receptor O
binding O
and O
activity O
of O
iso B
and I
azakainoids I
. O

The O
1 O
, O
3 O
- O
dipolar O
cycloaddition O
of O
diazomethane B
with O
trans B
- I
dibenzyl I
glutaconate I
yields O
a O
1 B
- I
pyrazoline I
, O
which O
may O
be O
reduced O
directly O
to O
the O
pyrazolidine B
. O

An O
unexpected O
trans O
- O
cis O
isomerization O
is O
observed O
during O
Hg B
/ O
Al B
reduction O
of O
the O
1 B
- I
pyrazoline I
NN B
bond O
. O

Alternatively O
, O
when O
TMS B
diazomethane I
is O
used O
as O
the O
dipole O
, O
the O
resulting O
2 B
- I
pyrazoline I
obtained O
after O
desilylation O
may O
be O
reduced O
with O
NaCNBH3 B
to O
provide O
the O
trans B
azakainate I
analog O
exclusively O
. O

A O
scaffold O
bearing O
eight O
terminal O
alkyne B
groups O
was O
synthesized O
from O
sucrose B
, O
and O
copies O
of O
an O
azide B
- O
terminated O
Gd B
- I
DOTA I
complex O
were O
attached O
via O
copper B
( I
I I
) I
- O
catalyzed O
azide B
- I
alkyne I
cycloaddition O
. O

A O
scaffold O
bearing O
eight O
terminal O
alkyne B
groups O
was O
synthesized O
from O
sucrose B
, O
and O
copies O
of O
an O
azide B
- O
terminated O
Gd B
- I
DOTA I
complex O
were O
attached O
via O
copper B
( I
I I
) I
- O
catalyzed O
azide B
- I
alkyne I
cycloaddition O
. O

The O
DSSCs O
based O
on O
the O
G B
- I
TiO2 I
nanocomposites O
improved O
their O
overall O
energy O
conversion O
efficiency O
to O
7 O
. O
1 O
% O
. O

RATIONALE O
: O
Treatment O
with O
a O
carbon B
monoxide I
- O
releasing O
molecule O
( O
tricarbonyldichloror B
( I
II I
) I
dimer O
, O
CORM B
- I
2 I
) O
or O
a O
classical O
heme O
oxygenase O
1 O
inducer O
( O
cobalt B
protoporphyrin I
IX I
, O
CoPP B
) O
has O
potent O
anti O
- O
inflammatory O
effects O
, O
but O
the O
role O
played O
by O
these O
treatments O
in O
the O
antinociceptive O
effects O
of O
morphine B
during O
acute O
and O
chronic O
pain O
was O
not O
evaluated O
. O

RATIONALE O
: O
Treatment O
with O
a O
carbon B
monoxide I
- O
releasing O
molecule O
( O
tricarbonyldichloror B
( I
II I
) I
dimer O
, O
CORM B
- I
2 I
) O
or O
a O
classical O
heme O
oxygenase O
1 O
inducer O
( O
cobalt B
protoporphyrin I
IX I
, O
CoPP B
) O
has O
potent O
anti O
- O
inflammatory O
effects O
, O
but O
the O
role O
played O
by O
these O
treatments O
in O
the O
antinociceptive O
effects O
of O
morphine B
during O
acute O
and O
chronic O
pain O
was O
not O
evaluated O
. O

OBJECTIVES O
: O
In O
wild O
type O
( O
WT O
) O
, O
neuronal O
( O
NOS1 O
- O
KO O
) O
, O
or O
inducible O
( O
NOS2 O
- O
KO O
) O
nitric B
oxide I
synthases O
knockout O
mice O
, O
we O
evaluated O
the O
effects O
of O
CORM B
- I
2 I
and O
CoPP B
treatments O
in O
the O
antinociceptive O
actions O
of O
morphine B
and O
their O
interaction O
with O
nitric B
oxide I
during O
acute O
, O
visceral O
, O
and O
chronic O
inflammatory O
or O
neuropathic O
pain O
. O

Moreover O
, O
while O
CORM B
- I
2 I
or O
CoPP B
treatments O
did O
not O
alter O
or O
reduced O
the O
antinociceptive O
effects O
of O
morphine B
during O
acute O
and O
visceral O
pain O
, O
both O
treatments O
improved O
the O
local O
antiallodynic O
and O
antihyperalgesic O
effects O
of O
morphine B
after O
chronic O
inflammatory O
or O
neuropathic O
pain O
in O
WT O
, O
but O
not O
in O
KO O
mice O
. O

CONCLUSIONS O
: O
CORM B
- I
2 I
and O
CoPP B
treatments O
improved O
the O
local O
antinociceptive O
effects O
of O
morphine B
during O
chronic O
inflammatory O
and O
neuropathic O
pain O
by O
interaction O
with O
nitric B
oxide I
synthetized O
by O
NOS1 O
and O
NOS2 O
isoforms O
. O

Recently O
, O
we O
identified O
1 B
- I
aminoanthracene I
as O
a O
fluorescent O
general O
anesthetic O
. O

To O
investigate O
the O
mechanism O
of O
action O
, O
a O
photoactive O
analogue O
, O
1 B
- I
azidoanthracene I
, O
was O
synthesized O
. O

Administration O
of O
1 B
- I
azidoanthracene I
to O
albino O
stage O
40 O
- O
47 O
tadpoles O
was O
found O
to O
immobilize O
animals O
upon O
near O
- O
UV O
irradiation O
of O
the O
forebrain O
region O
. O

Stage O
40 O
- O
47 O
tadpoles O
were O
also O
incubated O
1 O
h O
with O
microtubule O
stabilizing O
agents O
, O
epothilone B
D I
or O
discodermolide B
, O
followed O
by O
dosing O
with O
1 B
- I
aminoanthracene I
. O

The O
effective O
concentration O
of O
1 B
- I
aminoanthracene I
required O
to O
immobilize O
the O
tadpoles O
was O
significantly O
increased O
in O
the O
presence O
of O
either O
microtubule O
stabilizing O
agent O
. O

Unraveling O
the O
Role O
of O
the O
Protein O
Environment O
for O
[ B
FeFe I
] I
- O
Hydrogenase O
: O
A O
New O
Application O
of O
Coarse O
- O
Graining O
. O

[ B
FeFe I
] I
- O
hydrogenases O
are O
the O
most O
effective O
of O
three O
such O
enzymes O
at O
catalyzing O
H B
( I
+ I
) I
reduction O
. O

In O
this O
study O
, O
we O
develop O
and O
apply O
a O
novel O
combination O
of O
all O
- O
atom O
molecular O
dynamics O
and O
coarse O
- O
grained O
( O
CG O
) O
analysis O
to O
characterize O
two O
important O
steps O
of O
the O
catalytic O
cycle O
of O
[ B
FeFe I
] I
- O
hydrogenase O
. O

Here O
, O
we O
synthesize O
several O
Eudragit B
E I
PO I
( O
n B
- I
butyl I
- O
, O
dimethylaminoethyl B
- O
, O
methyl B
- I
methacrylate I
- O
terpolymer B
) O
analogues O
via O
free O
radical O
polymerization O
. O

Here O
, O
we O
synthesize O
several O
Eudragit B
E I
PO I
( O
n B
- I
butyl I
- O
, O
dimethylaminoethyl B
- O
, O
methyl B
- I
methacrylate I
- O
terpolymer B
) O
analogues O
via O
free O
radical O
polymerization O
. O

Here O
, O
we O
synthesize O
several O
Eudragit B
E I
PO I
( O
n B
- I
butyl I
- O
, O
dimethylaminoethyl B
- O
, O
methyl B
- I
methacrylate I
- O
terpolymer B
) O
analogues O
via O
free O
radical O
polymerization O
. O

Three O
chemical O
modifications O
increased O
the O
glass O
transition O
temperature O
of O
the O
polymer O
: O
( O
a O
) O
substitution O
of O
n B
- I
butyl I
by O
t B
- I
butyl I
groups O
, O
( O
b O
) O
reduction O
of O
the O
dimethylaminoethyl B
methacrylate I
( O
DMAEMA B
) O
content O
, O
and O
( O
c O
) O
incorporation O
of O
a O
bulky O
isobornyl B
repeating O
unit O
. O

Three O
chemical O
modifications O
increased O
the O
glass O
transition O
temperature O
of O
the O
polymer O
: O
( O
a O
) O
substitution O
of O
n B
- I
butyl I
by O
t B
- I
butyl I
groups O
, O
( O
b O
) O
reduction O
of O
the O
dimethylaminoethyl B
methacrylate I
( O
DMAEMA B
) O
content O
, O
and O
( O
c O
) O
incorporation O
of O
a O
bulky O
isobornyl B
repeating O
unit O
. O

Furthermore O
, O
CK O
induced O
activation O
of O
nuclear O
erythroid O
2 O
- O
related O
factor O
2 O
( O
Nrf2 O
) O
- O
mediated O
antioxidant O
enzymes O
such O
as O
gamma B
- I
glutamylcysteine I
synthetase O
( O
gamma O
- O
GCS O
) O
, O
heme B
oxygenase O
- O
1 O
( O
HO O
- O
1 O
) O
, O
NAD B
( I
P I
) I
H I
quinone B
oxidoreductase O
1 O
( O
NQO1 O
) O
, O
and O
glutathione B
- O
S B
- O
transferase O
( O
GST O
) O
in O
HepG2 O
cells O
. O

Migrants O
determination O
and O
bioaccessibility O
study O
of O
ethyl B
lauroyl I
arginate I
( O
LAE B
) O
from O
a O
LAE B
based O
antimicrobial O
food O
packaging O
material O
. O

Ethyl B
lauroyl I
arginate I
( O
LAE B
, O
ethyl B
- I
N I
- I
dodecanoyl I
- I
L I
- I
arginate I
hydrochloride I
) O
is O
a O
strong O
antimicrobial O
agent O
that O
was O
included O
as O
an O
active O
compound O
in O
an O
antimicrobial O
food O
packaging O
material O
. O

Multienzyme O
branched O
- O
chain O
alpha B
- I
ketoacid I
dehydrogenase O
complex O
( O
BCKDH O
) O
catalyzes O
the O
regulatory O
step O
of O
oxidative O
catabolism O
of O
indispensable O
branched O
- O
chain O
amino B
acids I
( O
BCAA O
) O
. O

The O
evidence O
includes O
structures O
with O
Bis B
- I
Tris I
( I
2 I
, I
2 I
- I
bis I
( I
hydroxymethyl I
) I
- I
2 I
, I
2 I
' I
, I
2 I
' I
' I
- I
nitrilotriethanol I
) I
and O
l B
- I
ribose I
in O
the O
site O
and O
kinetic O
binding O
studies O
with O
substituted O
beta O
- O
galactosidases O
. O

Nicotine B
, O
varenicline B
, O
and O
cytisine B
were O
administered O
alone O
, O
in O
combination O
with O
each O
other O
, O
and O
in O
combination O
with O
mecamylamine B
and O
dihydro B
- I
beta I
- I
erythroidine I
( O
DH B
beta I
E I
) O
. O

DH B
beta I
E I
antagonized O
nicotine B
in O
animals O
discriminating O
the O
smallest O
dose O
of O
nicotine B
. O

Evaporation O
- O
Induced O
Coating O
of O
Hydrous B
Ruthenium I
Oxide I
on O
Mesoporous O
Silica B
Nanoparticles O
to O
Develop O
High O
- O
Performance O
Supercapacitors O
. O

Structure O
- O
activity O
relationship O
studies O
were O
performed O
on O
these O
compounds O
, O
and O
various O
modifications O
were O
made O
to O
their O
structures O
involving O
relocation O
of O
the O
halogen B
atom O
, O
introduction O
of O
more O
halogen B
atoms O
, O
replacement O
of O
the O
halogen B
with O
another O
group O
, O
replacement O
of O
the O
methylene B
linker O
with O
a O
difluoromethylene B
linker O
, O
replacement O
of O
the O
para B
- I
cyanophenyl I
ring O
with O
other O
ring O
structures O
, O
and O
replacement O
of O
the O
triazolyl B
group O
with O
an O
imidazolyl B
group O
. O

The O
PU O
derivatives O
having O
amino B
groups O
( O
PU B
- I
Am I
) O
also O
showed O
UCST O
behavior O
. O

In O
this O
study O
, O
we O
modified O
the O
amino B
groups O
of O
the O
polymer O
with O
succinyl B
anhydride I
( O
PU B
- I
Su I
) O
or O
acetyl B
anhydride I
( O
PU B
- I
Ac I
) O
to O
determine O
the O
effects O
of O
these O
ionic O
groups O
on O
the O
UCST O
behavior O
and O
to O
control O
interactions O
between O
the O
PU O
derivatives O
and O
biocomponents O
such O
as O
proteins O
and O
cells O
. O

In O
this O
study O
, O
we O
modified O
the O
amino B
groups O
of O
the O
polymer O
with O
succinyl B
anhydride I
( O
PU B
- I
Su I
) O
or O
acetyl B
anhydride I
( O
PU B
- I
Ac I
) O
to O
determine O
the O
effects O
of O
these O
ionic O
groups O
on O
the O
UCST O
behavior O
and O
to O
control O
interactions O
between O
the O
PU O
derivatives O
and O
biocomponents O
such O
as O
proteins O
and O
cells O
. O

Succinylation O
of O
PU B
- I
Am I
resulted O
in O
a O
significant O
decrease O
in O
phase O
separation O
temperature O
( O
Tp O
) O
, O
whereas O
acetylation O
of O
PU B
- I
Am I
resulted O
in O
an O
increase O
in O
Tp O
. O

Succinylation O
of O
PU B
- I
Am I
resulted O
in O
a O
significant O
decrease O
in O
phase O
separation O
temperature O
( O
Tp O
) O
, O
whereas O
acetylation O
of O
PU B
- I
Am I
resulted O
in O
an O
increase O
in O
Tp O
. O

As O
expected O
, O
the O
Tp O
of O
PU B
- I
Am I
and O
PU B
- I
Su I
changed O
when O
the O
pH O
of O
the O
solution O
was O
changed O
. O

As O
expected O
, O
the O
Tp O
of O
PU B
- I
Am I
and O
PU B
- I
Su I
changed O
when O
the O
pH O
of O
the O
solution O
was O
changed O
. O

The O
Tp O
of O
PU B
- I
Am I
increased O
at O
higher O
pH O
, O
whereas O
that O
of O
PU B
- I
Su I
increased O
at O
lower O
pH O
, O
indicating O
that O
ionic O
charge O
decreases O
Tp O
of O
PU O
derivatives O
by O
increasing O
osmotic O
pressure O
and O
by O
increasing O
hydrophilicity O
of O
the O
polymer O
chains O
. O

The O
Tp O
of O
PU B
- I
Am I
increased O
at O
higher O
pH O
, O
whereas O
that O
of O
PU B
- I
Su I
increased O
at O
lower O
pH O
, O
indicating O
that O
ionic O
charge O
decreases O
Tp O
of O
PU O
derivatives O
by O
increasing O
osmotic O
pressure O
and O
by O
increasing O
hydrophilicity O
of O
the O
polymer O
chains O
. O

Here O
we O
use O
vibrational O
sum O
frequency O
spectroscopy O
( O
SF O
) O
to O
study O
the O
origin O
of O
the O
opposite O
Delta O
V O
signs O
of O
Langmuir O
films O
of O
CH3 B
( I
CH2 I
) I
20COCH2CH3 I
( O
ethyl B
ether I
, O
EE O
) O
and O
CH3 B
( I
CH2 I
) I
20COCH2CF3 I
( O
fluorinated B
ethyl I
ether I
, O
FEE B
) O
. O

Performances O
of O
CN O
- O
columns O
for O
the O
analysis O
of O
gamma B
- I
oryzanol I
and O
its O
p B
- I
coumarate I
and O
caffeate B
derivatives O
by O
normal O
phase O
HPLC O
and O
a O
validated O
method O
of O
quantitation O
. O

Performances O
of O
CN O
- O
columns O
for O
the O
analysis O
of O
gamma B
- I
oryzanol I
and O
its O
p B
- I
coumarate I
and O
caffeate B
derivatives O
by O
normal O
phase O
HPLC O
and O
a O
validated O
method O
of O
quantitation O
. O

gamma B
- I
Oryzanol I
is O
an O
important O
phytochemical O
used O
in O
pharmaceutical O
, O
alimentary O
and O
cosmetic O
preparations O
. O

The O
present O
article O
, O
for O
the O
first O
time O
, O
discloses O
the O
performances O
of O
NP O
- O
HPLC O
in O
separating O
gamma B
- I
oryzanol I
components O
and O
develops O
a O
validated O
method O
for O
its O
routine O
quantification O
. O

The O
method O
allows O
: O
the O
separation O
of O
steryl B
ferulate I
, O
p B
- I
coumarate I
and O
caffeate B
esters I
, O
the O
separation O
of O
cis O
- O
from O
trans B
- I
ferulate I
isomers O
, O
the O
splitting O
of O
steroid B
moieties O
into O
saturated O
and O
unsaturated O
at O
the O
side O
chain O
. O

The O
method O
allows O
: O
the O
separation O
of O
steryl B
ferulate I
, O
p B
- I
coumarate I
and O
caffeate B
esters I
, O
the O
separation O
of O
cis O
- O
from O
trans B
- I
ferulate I
isomers O
, O
the O
splitting O
of O
steroid B
moieties O
into O
saturated O
and O
unsaturated O
at O
the O
side O
chain O
. O

Among O
metabolites O
, O
nutrients O
as O
taurine B
, O
nicotinamide B
and O
beta B
- I
alanine I
, O
were O
found O
. O

In O
transport O
experiments O
, O
the O
transport O
of O
glycyl B
- I
sarcosine I
( O
Gly B
- I
Sar I
, O
a O
model O
molecule O
for O
PEPT1 O
transport O
) O
and O
other O
dipeptides B
( O
Val B
- I
Tyr I
and O
Ile B
- I
Phe I
) O
were O
significantly O
reduced O
( O
P O
< O
0 O
. O
05 O
) O
in O
TFs B
- O
pretreated O
cells O
. O

In O
transport O
experiments O
, O
the O
transport O
of O
glycyl B
- I
sarcosine I
( O
Gly B
- I
Sar I
, O
a O
model O
molecule O
for O
PEPT1 O
transport O
) O
and O
other O
dipeptides B
( O
Val B
- I
Tyr I
and O
Ile B
- I
Phe I
) O
were O
significantly O
reduced O
( O
P O
< O
0 O
. O
05 O
) O
in O
TFs B
- O
pretreated O
cells O
. O

In O
transport O
experiments O
, O
the O
transport O
of O
glycyl B
- I
sarcosine I
( O
Gly B
- I
Sar I
, O
a O
model O
molecule O
for O
PEPT1 O
transport O
) O
and O
other O
dipeptides B
( O
Val B
- I
Tyr I
and O
Ile B
- I
Phe I
) O
were O
significantly O
reduced O
( O
P O
< O
0 O
. O
05 O
) O
in O
TFs B
- O
pretreated O
cells O
. O

In O
transport O
experiments O
, O
the O
transport O
of O
glycyl B
- I
sarcosine I
( O
Gly B
- I
Sar I
, O
a O
model O
molecule O
for O
PEPT1 O
transport O
) O
and O
other O
dipeptides B
( O
Val B
- I
Tyr I
and O
Ile B
- I
Phe I
) O
were O
significantly O
reduced O
( O
P O
< O
0 O
. O
05 O
) O
in O
TFs B
- O
pretreated O
cells O
. O

In O
TF B
3 I
' I
- I
O I
- I
gallate I
- O
pretreated O
cells O
, O
Western O
blot O
analysis O
revealed O
attenuated O
expression O
of O
PEPT1 O
transporter O
and O
Gly B
- I
Sar I
transport O
was O
completely O
ameliorated O
by O
10 O
mu O
M O
Compound B
C I
, O
an O
AMP B
- O
activated O
protein O
kinase O
( O
AMPK O
) O
inhibitor O
. O

Analysing O
chemical O
composition O
of O
the O
extracted O
oil O
by O
GC O
- O
MS O
showed O
that O
the O
content O
of O
unsaturated B
fatty I
acids I
by O
this O
emerging O
method O
( O
91 O
. O
18 O
% O
) O
was O
similar O
to O
that O
by O
conventional O
organic O
solvent O
extraction O
( O
88 O
. O
76 O
% O
) O
. O

The O
formation O
of O
the O
major O
flavour O
compounds O
( O
acetaldehyde B
, O
diacetyl B
, O
acetoin B
, O
and O
2 B
- I
butanone I
) O
followed O
a O
sigmoidal O
trend O
described O
by O
the O
modified O
Gompertz O
model O
. O

In O
this O
study O
, O
gamma B
- I
glutamyl I
transpeptidase O
( O
GGT O
) O
and O
l B
- I
cysteine I
sulphoxide I
lyase O
( O
C O
- O
S O
lyase O
) O
were O
purified O
from O
the O
fruiting O
body O
of O
Lentinula O
edodes O
in O
three O
steps O
and O
then O
characterised O
. O

Also O
, O
products O
resulting O
from O
dehydration O
, O
oxidation O
, O
and O
cleavage O
of O
a O
carbon B
- O
carbon B
bond O
at O
the O
reducing O
end O
of O
the O
corresponding O
non O
- O
modified O
oligosaccharide O
were O
formed O
, O
probably O
promoting O
the O
release O
of O
formaldehyde B
, O
formic B
acid I
, O
glycolaldehyde B
, O
glyoxal B
, O
acetic B
acid I
, O
glycolic B
acid I
, O
glyceraldehyde B
, O
2 B
- I
hydroxypropanedialde I
and O
lactic O
acid O
. O

Thermal O
degradation O
kinetics O
of O
the O
major O
blood O
orange O
xanthophylls O
( O
cis B
- I
violaxanthin I
, O
lutein B
, O
beta B
- I
cryptoxanthin I
, O
zeaxanthin B
and O
cis B
- I
antheraxanthin I
) O
were O
investigated O
at O
45 O
, O
60 O
, O
75 O
, O
and O
90 O
degrees O
C O
in O
real O
juice O
and O
three O
model O
systems O
formulated O
to O
evaluate O
the O
impact O
of O
xanthophyll O
form O
( O
esterified O
or O
free O
) O
and O
pH O
( O
acid O
or O
neutral O
) O
. O

Thermal O
degradation O
kinetics O
of O
the O
major O
blood O
orange O
xanthophylls O
( O
cis B
- I
violaxanthin I
, O
lutein B
, O
beta B
- I
cryptoxanthin I
, O
zeaxanthin B
and O
cis B
- I
antheraxanthin I
) O
were O
investigated O
at O
45 O
, O
60 O
, O
75 O
, O
and O
90 O
degrees O
C O
in O
real O
juice O
and O
three O
model O
systems O
formulated O
to O
evaluate O
the O
impact O
of O
xanthophyll O
form O
( O
esterified O
or O
free O
) O
and O
pH O
( O
acid O
or O
neutral O
) O
. O

Thermal O
degradation O
kinetics O
of O
the O
major O
blood O
orange O
xanthophylls O
( O
cis B
- I
violaxanthin I
, O
lutein B
, O
beta B
- I
cryptoxanthin I
, O
zeaxanthin B
and O
cis B
- I
antheraxanthin I
) O
were O
investigated O
at O
45 O
, O
60 O
, O
75 O
, O
and O
90 O
degrees O
C O
in O
real O
juice O
and O
three O
model O
systems O
formulated O
to O
evaluate O
the O
impact O
of O
xanthophyll O
form O
( O
esterified O
or O
free O
) O
and O
pH O
( O
acid O
or O
neutral O
) O
. O

In O
all O
acidic O
media O
, O
beta B
- I
cryptoxanthin I
exhibited O
the O
lowest O
degradation O
rates O
followed O
by O
lutein B
and O
zeaxanthin B
. O

In O
comparison O
, O
the O
epoxy B
carotenoids O
cis B
- I
violaxanthin I
and O
cis B
- I
antheraxanthin I
degraded O
around O
3 O
- O
fold O
faster O
in O
their O
esterified O
form O
. O

In O
comparison O
, O
the O
epoxy B
carotenoids O
cis B
- I
violaxanthin I
and O
cis B
- I
antheraxanthin I
degraded O
around O
3 O
- O
fold O
faster O
in O
their O
esterified O
form O
. O

In O
their O
free O
form O
, O
cis B
- I
antheraxanthin I
degraded O
30 O
- O
fold O
faster O
while O
cis B
- I
violaxanthin I
instantaneously O
disappeared O
because O
of O
the O
isomerisation O
of O
its O
5 B
, I
6 I
- I
epoxy I
groups O
into O
5 B
, I
8 I
- I
epoxy I
. O

In O
their O
free O
form O
, O
cis B
- I
antheraxanthin I
degraded O
30 O
- O
fold O
faster O
while O
cis B
- I
violaxanthin I
instantaneously O
disappeared O
because O
of O
the O
isomerisation O
of O
its O
5 B
, I
6 I
- I
epoxy I
groups O
into O
5 B
, I
8 I
- I
epoxy I
. O

By O
contrast O
, O
in O
neutral O
medium O
, O
free O
epoxy B
- O
xanthophylls O
were O
about O
2 O
- O
fold O
more O
stable O
than O
were O
the O
free O
hydroxy B
xanthophylls O
lutein B
, O
zeaxanthin B
and O
beta B
- I
cryptoxanthin I
. O

Ang O
II O
stimulated O
cell O
proliferation O
and O
the O
effect O
was O
antagonized O
by O
the O
KCa3 O
. O
1 O
blocker O
TRAM B
- I
34 I
and O
siRNA O
targeting O
KCa3 O
. O
1 O
. O

The O
lowest O
levels O
of O
peroxide B
value O
( O
PV O
) O
, O
thiobarbituric B
acid I
reactive O
substances O
( O
TBARs O
) O
, O
cholesterol B
oxidation O
products O
( O
COPs O
) O
and O
the O
highest O
level O
of O
polyunsaturated B
fatty I
acids I
( O
PUFAs B
) O
content O
, O
especially O
PUFA B
n I
- I
3 I
, O
were O
found O
in O
the O
untreated O
sardines O
( O
time O
zero O
) O
. O

EROD O
activity O
induction O
in O
peripheral O
blood O
lymphocytes O
, O
liver O
and O
brain O
tissues O
of O
rats O
orally O
exposed O
to O
polycyclic B
aromatic I
hydrocarbons I
. O

OBJECTIVES O
: O
To O
investigate O
the O
ability O
of O
naltrexone B
and O
beta B
- I
funaltrexamine I
, O
an O
irreversible O
mu O
- O
opioid O
specific O
antagonist O
, O
to O
inhibit O
ethanol B
- O
stimulated O
and O
morphine B
- O
stimulated O
mesolimbic O
dopamine B
release O
, O
and O
to O
determine O
whether O
opioid O
receptors O
on O
mesolimbic O
neurons O
contribute O
to O
these O
mechanisms O
. O

RESULTS O
: O
Administration O
of O
naltrexone B
( O
intravenously O
) O
and O
beta B
- I
funaltrexamine I
( O
subcutaneously O
) O
, O
as O
well O
as O
intracranial O
injection O
of O
naltrexone B
into O
the O
VTA O
did O
not O
prevent O
the O
initiation O
of O
dopamine B
release O
by O
intravenous O
ethanol B
administration O
, O
but O
prevented O
it O
from O
being O
as O
prolonged O
. O

They O
are O
immersed O
in O
a O
sodium B
dodecyl I
sulfate I
( O
SDS B
) O
solution O
, O
and O
the O
SDS B
molecules O
selectively O
adsorb O
onto O
m O
- O
SWNTs O
. O

Structural O
Basis O
for O
Enzyme O
I O
Inhibition O
by O
alpha B
- I
Ketoglutarate I
. O

Recently O
, O
alpha B
- I
ketoglutarate I
( O
alpha B
KG I
) O
, O
the O
carbon B
substrate O
for O
ammonia B
assimilation O
, O
has O
been O
observed O
to O
inhibit O
Escherichia O
coli O
enzyme O
I O
( O
EI O
) O
, O
the O
first O
component O
of O
the O
bacterial O
phosphotransferase O
system O
( O
PTS O
) O
, O
thereby O
providing O
a O
direct O
biochemical O
link O
between O
central O
carbon B
and O
nitrogen B
metabolism O
. O

An O
enriched O
fraction O
of O
n B
- I
butanol I
was O
obtained O
, O
after O
partition O
. O

The O
applicability O
of O
this O
protocol O
is O
demonstrated O
experimentally O
by O
assessing O
the O
performance O
of O
diamond B
- O
like O
carbon B
- O
coated O
and O
silicon B
- I
nitride I
- O
coated O
silicon B
probes O
scanned O
over O
ultrananocrystalline O
diamond B
substrates O
in O
repulsive O
mode O
AM O
- O
AFM O
. O

Transition O
to O
Reinforced O
State O
by O
Percolating O
Domains O
of O
Intercalated O
Brush O
- O
Modified O
Cellulose O
Nanocrystals O
and O
Poly B
( I
butadiene I
) I
in O
Cross O
- O
Linked O
Composites O
Based O
on O
Thiol B
- I
ene I
Click O
Chemistry O
. O

Composite O
films O
with O
0 O
- O
80 O
wt O
% O
of O
such O
modified O
CNCs O
( O
mCNCs O
) O
within O
a O
poly B
( I
butadiene I
) I
( O
PBD B
) O
rubber O
matrix O
were O
prepared O
via O
cross O
- O
linking O
by O
UV O
- O
light O
initiated O
thiol B
- I
ene I
click O
reaction O
. O

Biomarkers O
of O
prolonged O
exposure O
to O
microcystin B
- I
LR I
in O
mice O
. O

The O
aim O
of O
this O
work O
is O
to O
determine O
, O
based O
on O
an O
animal O
model O
of O
prolonged O
exposure O
to O
successive O
i O
. O
p O
. O
doses O
of O
25 O
mu O
g O
MC B
- I
LR I
/ O
kg O
body O
weight O
, O
several O
plasma O
parameters O
which O
could O
be O
useful O
as O
exposure O
biomarkers O
. O

We O
also O
studied O
plasma O
levels O
of O
hydroperoxides B
( O
ROOHs B
) O
, O
alpha B
- I
tocopherol I
, O
glutathione B
and O
lipid O
profile O
as O
well O
as O
superoxide B
dismutase O
( O
SOD O
) O
and O
catalase O
( O
CAT O
) O
erythrocyte O
activities O
. O

In O
addition O
, O
the O
determination O
of O
MC B
- I
LR I
levels O
in O
liver O
, O
kidney O
, O
plasma O
, O
urine O
and O
feces O
of O
treated O
mice O
was O
carried O
out O
. O

We O
found O
that O
alteration O
in O
MetHb O
, O
ROOHs B
, O
glutathione B
, O
alpha B
- I
tocopherol I
levels O
, O
SOD O
activity O
and O
plasma O
lipid O
profile O
, O
correlates O
with O
those O
expected O
if O
the O
alteration O
derived O
from O
hepatic O
damage O
. O

The O
alterated O
plasma O
paramenters O
together O
with O
MC B
- I
LR I
determination O
could O
be O
used O
as O
biomarkers O
, O
helpful O
tools O
in O
screening O
and O
epidemiological O
studies O
. O

Hop O
extract O
is O
a O
long O
used O
medicinal O
product O
and O
, O
regarding O
hormonal O
activities O
, O
in O
1999 O
a O
number O
of O
prenylflavanones B
have O
been O
identified O
as O
its O
major O
constituents O
with O
8 B
- I
prenylnaringenin I
( O
8 B
- I
PN I
) O
being O
the O
main O
active O
estrogenic O
compound O
. O

Hop O
extract O
is O
a O
long O
used O
medicinal O
product O
and O
, O
regarding O
hormonal O
activities O
, O
in O
1999 O
a O
number O
of O
prenylflavanones B
have O
been O
identified O
as O
its O
major O
constituents O
with O
8 B
- I
prenylnaringenin I
( O
8 B
- I
PN I
) O
being O
the O
main O
active O
estrogenic O
compound O
. O

There O
have O
been O
several O
in O
vivo O
studies O
performed O
that O
demonstrate O
the O
potential O
of O
hop O
extract O
and O
the O
single O
compound O
8 B
- I
PN I
to O
alleviate O
climacteric O
symptoms O
like O
osteoporosis O
, O
vasomotoric O
complaints O
, O
and O
sexual O
motivation O
. O

Despite O
preferentially O
activating O
estrogen B
receptor O
alpha O
, O
8 B
- I
PN I
is O
only O
slightly O
uterotrophic O
, O
but O
it O
also O
elucidates O
estrogenic O
effects O
on O
the O
mammary O
gland O
. O

In O
conclusion O
, O
although O
hop O
extract O
and O
especially O
8 B
- I
PN I
are O
promising O
candidates O
as O
a O
relief O
for O
climacteric O
symptoms O
, O
data O
on O
the O
safety O
and O
efficacy O
is O
still O
scarce O
. O

Cardamonin B
increased O
the O
2 B
- I
deoxyglucose I
uptake O
and O
glycogen O
concentration O
, O
which O
was O
reduced O
by O
insulin O
resistance O
. O

The O
Aryl B
Hydrocarbon I
Receptor O
( O
AhR O
) O
is O
a O
ligand O
mediated O
basic O
helix O
- O
loop O
- O
helix O
transcription O
factor O
of O
Per O
/ O
Arnt O
/ O
Sim O
family O
that O
regulates O
adaptive O
and O
toxic O
responses O
to O
variety O
of O
chemical O
pollutants O
including O
polycyclic B
aromatic I
hydrocarbons I
( O
PAH B
) O
and O
halogenated B
aromatic I
hydrocarbons I
, O
most O
notably O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
tetrachlorodibenzo I
- I
p I
- I
dioxin I
( O
TCDD B
) O
. O

The O
Aryl B
Hydrocarbon I
Receptor O
( O
AhR O
) O
is O
a O
ligand O
mediated O
basic O
helix O
- O
loop O
- O
helix O
transcription O
factor O
of O
Per O
/ O
Arnt O
/ O
Sim O
family O
that O
regulates O
adaptive O
and O
toxic O
responses O
to O
variety O
of O
chemical O
pollutants O
including O
polycyclic B
aromatic I
hydrocarbons I
( O
PAH B
) O
and O
halogenated B
aromatic I
hydrocarbons I
, O
most O
notably O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
tetrachlorodibenzo I
- I
p I
- I
dioxin I
( O
TCDD B
) O
. O

Stereoselective O
Potencies O
and O
Relative O
Toxicities O
of O
gamma B
- I
Coniceine I
and O
N B
- I
Methylconiine I
Enantiomers O
. O

Stereoselective O
Potencies O
and O
Relative O
Toxicities O
of O
gamma B
- I
Coniceine I
and O
N B
- I
Methylconiine I
Enantiomers O
. O

gamma B
- I
Coniceine I
, O
coniine B
, O
and O
N B
- I
methylconiine I
are O
toxic O
alkaloids O
present O
in O
poison O
hemlock O
( O
Conium O
maculatum O
) O
. O

gamma B
- I
Coniceine I
, O
coniine B
, O
and O
N B
- I
methylconiine I
are O
toxic O
alkaloids O
present O
in O
poison O
hemlock O
( O
Conium O
maculatum O
) O
. O

In O
this O
study O
, O
we O
synthesized O
gamma B
- I
coniceine I
and O
the O
enantiomers O
of O
N B
- I
methylconiine I
and O
determined O
the O
biological O
activity O
of O
gamma B
- I
coniceine I
and O
each O
of O
the O
N B
- I
methylconiine I
enantiomers O
in O
vitro O
and O
in O
vivo O
. O

In O
this O
study O
, O
we O
synthesized O
gamma B
- I
coniceine I
and O
the O
enantiomers O
of O
N B
- I
methylconiine I
and O
determined O
the O
biological O
activity O
of O
gamma B
- I
coniceine I
and O
each O
of O
the O
N B
- I
methylconiine I
enantiomers O
in O
vitro O
and O
in O
vivo O
. O

In O
this O
study O
, O
we O
synthesized O
gamma B
- I
coniceine I
and O
the O
enantiomers O
of O
N B
- I
methylconiine I
and O
determined O
the O
biological O
activity O
of O
gamma B
- I
coniceine I
and O
each O
of O
the O
N B
- I
methylconiine I
enantiomers O
in O
vitro O
and O
in O
vivo O
. O

In O
this O
study O
, O
we O
synthesized O
gamma B
- I
coniceine I
and O
the O
enantiomers O
of O
N B
- I
methylconiine I
and O
determined O
the O
biological O
activity O
of O
gamma B
- I
coniceine I
and O
each O
of O
the O
N B
- I
methylconiine I
enantiomers O
in O
vitro O
and O
in O
vivo O
. O

The O
relative O
potencies O
of O
these O
piperidine B
alkaloids I
on O
cells O
expressing O
human O
fetal O
muscle O
- O
type O
nicotinic O
acetylcholine B
receptors O
had O
the O
rank O
order O
of O
gamma B
- I
coniceine I
> O
( B
- I
) I
- I
N I
- I
methylconiine I
> O
( B
+ I
/ I
- I
) I
- I
N I
- I
methylconiine I
> O
( B
+ I
) I
- I
N I
- I
methylconiine I
. O

The O
relative O
lethalities O
of O
gamma B
- I
coniceine I
and O
( B
- I
) I
- I
, I
( I
+ I
/ I
- I
) I
- I
, I
and I
( I
+ I
) I
- I
N I
- I
methylconiine I
in O
vivo O
using O
a O
mouse O
bioassay O
were O
4 O
. O
4 O
, O
16 O
. O
1 O
, O
17 O
. O
8 O
, O
and O
19 O
. O
2 O
mg O
/ O
kg O
, O
respectively O
. O

The O
results O
from O
this O
study O
suggest O
gamma B
- I
coniceine I
is O
a O
more O
potent O
agonist O
than O
the O
enantiomers O
of O
N B
- I
methylconiine I
and O
that O
there O
is O
a O
stereoselective O
difference O
in O
the O
in O
vitro O
potencies O
of O
the O
enantiomers O
of O
N B
- I
methylconiine I
that O
correlates O
with O
the O
relative O
toxicities O
of O
the O
enantiomers O
in O
vivo O
. O

The O
results O
from O
this O
study O
suggest O
gamma B
- I
coniceine I
is O
a O
more O
potent O
agonist O
than O
the O
enantiomers O
of O
N B
- I
methylconiine I
and O
that O
there O
is O
a O
stereoselective O
difference O
in O
the O
in O
vitro O
potencies O
of O
the O
enantiomers O
of O
N B
- I
methylconiine I
that O
correlates O
with O
the O
relative O
toxicities O
of O
the O
enantiomers O
in O
vivo O
. O

The O
results O
from O
this O
study O
suggest O
gamma B
- I
coniceine I
is O
a O
more O
potent O
agonist O
than O
the O
enantiomers O
of O
N B
- I
methylconiine I
and O
that O
there O
is O
a O
stereoselective O
difference O
in O
the O
in O
vitro O
potencies O
of O
the O
enantiomers O
of O
N B
- I
methylconiine I
that O
correlates O
with O
the O
relative O
toxicities O
of O
the O
enantiomers O
in O
vivo O
. O

Herein O
we O
report O
the O
electrical O
transport O
properties O
of O
a O
series O
of O
ordered O
mesoporous O
ceria B
- I
zirconia I
( O
CexZr1 B
- I
xO2 I
, O
referred O
to O
as O
mp O
- O
CZO B
) O
thin O
films O
with O
both O
a O
cubic O
structure O
of O
( O
17 O
+ O
/ O
- O
2 O
) O
nm O
diameter O
pores O
and O
nanocrystalline O
walls O
. O

Herein O
we O
report O
the O
electrical O
transport O
properties O
of O
a O
series O
of O
ordered O
mesoporous O
ceria B
- I
zirconia I
( O
CexZr1 B
- I
xO2 I
, O
referred O
to O
as O
mp O
- O
CZO B
) O
thin O
films O
with O
both O
a O
cubic O
structure O
of O
( O
17 O
+ O
/ O
- O
2 O
) O
nm O
diameter O
pores O
and O
nanocrystalline O
walls O
. O

The O
results O
showed O
that O
OTA B
exposure O
elevated O
intracellular O
ROS O
production O
, O
which O
directly O
induced O
DNA O
damage O
and O
increased O
the O
levels O
of O
8 B
- I
OHdG I
and O
DNA O
double O
- O
strand O
breaks O
( O
DSBs O
) O
. O

7 B
- I
hydroxymitragynine I
( O
7 B
- I
OH I
- I
MG I
) O
, O
and O
several O
synthetic O
analogues O
of O
these O
natural O
products O
display O
centrally O
mediated O
( O
supraspinal O
and O
spinal O
) O
antinociceptive O
( O
analgesic O
) O
activity O
in O
various O
pain O
models O
. O

The O
design O
, O
modeling O
, O
synthesis O
and O
biological O
activity O
evaluation O
of O
two O
hybrid O
agents O
formed O
by O
7 B
- I
oxyiminomethylcampto I
derivatives O
and O
diaminedichloro B
- I
platinum I
( I
II I
) I
complex O
are O
reported O
. O

Chemical O
characterization O
of O
domestic O
oral O
tobacco O
products O
: O
Total O
nicotine B
, O
pH O
, O
unprotonated O
nicotine B
and O
tobacco O
- O
specific O
N B
- I
nitrosamines I
. O

In O
this O
study O
, O
we O
measured O
pH O
, O
moisture O
, O
nicotine B
( O
total O
and O
unprotonated O
) O
, O
and O
tobacco O
- O
specific O
N B
- I
nitrosamines I
( O
TSNAs O
) O
for O
other O
established O
( O
twist O
, O
loose O
leaf O
, O
plug O
, O
and O
dry O
snuff O
without O
pouch O
) O
and O
emerging O
oral O
tobacco O
products O
( O
dry O
snuff O
pouch O
, O
US O
- O
made O
snus O
, O
and O
dissolvable O
tobacco O
) O
. O

Experimental O
evidence O
for O
surface O
freezing O
in O
supercooled O
n B
- I
alkane I
nanodroplets O
. O

Intermediate O
chain O
length O
( O
16 O
< O
= O
i O
< O
= O
50 O
) O
n B
- I
alkanes I
are O
known O
to O
surface O
freeze O
at O
temperatures O
that O
are O
up O
to O
three O
degrees O
higher O
than O
the O
equilibrium O
melting O
point O
[ O
B O
. O
M O
. O
Ocko O
et O
al O
. O
, O
Phys O
. O
Rev O
. O
E O
, O
1997 O
, O
55 O
, O
3164 O
- O
3182 O
] O
. O

Our O
recent O
experimental O
results O
suggest O
that O
highly O
supercooled O
nanodroplets O
of O
n B
- I
octane I
and O
n B
- I
nonane I
also O
surface O
freeze O
, O
and O
subsequently O
bulk O
crystallization O
occurs O
. O

Our O
recent O
experimental O
results O
suggest O
that O
highly O
supercooled O
nanodroplets O
of O
n B
- I
octane I
and O
n B
- I
nonane I
also O
surface O
freeze O
, O
and O
subsequently O
bulk O
crystallization O
occurs O
. O

Molecular O
dynamics O
simulations O
at O
the O
united O
atom O
level O
were O
used O
to O
follow O
the O
freezing O
of O
a O
supercooled O
n B
- I
octane I
drop O
and O
show O
that O
an O
ordered O
monolayer O
develops O
on O
the O
surface O
of O
the O
droplet O
almost O
immediately O
, O
and O
the O
rest O
of O
the O
droplet O
then O
freezes O
in O
a O
layer O
- O
by O
- O
layer O
manner O
. O

Au B
- I
Au I
homodimer O
and O
Au B
- I
Ag I
heterodimer O
arrays O
produced O
using O
electron O
- O
beam O
lithography O
were O
investigated O
using O
confocal O
nonlinear O
optical O
imaging O
and O
spectroscopy O
. O

Au B
- I
Au I
homodimer O
and O
Au B
- I
Ag I
heterodimer O
arrays O
produced O
using O
electron O
- O
beam O
lithography O
were O
investigated O
using O
confocal O
nonlinear O
optical O
imaging O
and O
spectroscopy O
. O

Compared O
to O
the O
Au B
- I
Au I
homodimers O
, O
the O
Au B
- I
Ag I
dimers O
showed O
slightly O
broadened O
two O
- O
photon O
photoluminescence O
near O
the O
X O
symmetry O
point O
at O
the O
first O
Brillouin O
zone O
of O
Au B
, O
whilst O
that O
from O
the O
L O
symmetry O
point O
stayed O
the O
same O
. O

Compared O
to O
the O
Au B
- I
Au I
homodimers O
, O
the O
Au B
- I
Ag I
dimers O
showed O
slightly O
broadened O
two O
- O
photon O
photoluminescence O
near O
the O
X O
symmetry O
point O
at O
the O
first O
Brillouin O
zone O
of O
Au B
, O
whilst O
that O
from O
the O
L O
symmetry O
point O
stayed O
the O
same O
. O

Additionally O
, O
weakly O
coupled O
Au B
- I
Ag I
heterodimers O
generated O
strong O
second O
harmonic O
signals O
which O
were O
invisible O
in O
the O
Au B
- I
Au I
homodimers O
. O

Additionally O
, O
weakly O
coupled O
Au B
- I
Ag I
heterodimers O
generated O
strong O
second O
harmonic O
signals O
which O
were O
invisible O
in O
the O
Au B
- I
Au I
homodimers O
. O

Coupling O
this O
computational O
technique O
with O
a O
high O
- O
quality O
low O
- O
throughput O
screen O
identified O
5 B
- I
( I
4 I
- I
piperidyl I
) I
- I
3 I
- I
isoxazolol I
( O
4 B
- I
PIOL I
) O
as O
a O
potent O
plasminogen O
binding O
inhibitor O
with O
the O
potential O
for O
the O
treatment O
of O
various O
bleeding O
disorders O
. O

Remarkably O
, O
4 B
- I
PIOL I
was O
found O
to O
be O
more O
than O
four O
times O
as O
potent O
as O
the O
drug O
TXA B
. O

The O
results O
showed O
that O
PL O
significantly O
reduced O
tacrine B
- O
induced O
ROS O
production O
, O
disruption O
of O
Delta O
Psi O
m O
, O
8 B
- I
OHdG I
formation O
in O
mitochondrial O
DNA O
, O
and O
cytotoxicity O
in O
HepG2 O
cells O
. O

GLPG0492 B
was O
tested O
in O
the O
exercised O
mdx O
mouse O
model O
of O
DMD O
in O
a O
4 O
- O
week O
trial O
at O
a O
single O
high O
dose O
( O
30mg O
/ O
kg O
, O
6 O
day O
/ O
week O
s O
. O
c O
. O
) O
, O
and O
the O
results O
were O
compared O
with O
those O
from O
the O
administration O
of O
alpha B
- I
methylprednisolone I
( O
PDN B
; O
1mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
and O
nandrolone B
( O
NAND B
, O
5mg O
/ O
kg O
, O
s O
. O
c O
. O
) O
. O

Finally O
, O
we O
found O
that O
trifluoperazine B
, O
a O
calmodulin O
inhibitor O
, O
and O
pyrrolidine B
dithiocarbamic I
acid I
, O
an O
NF O
- O
kappa O
B O
inhibitor O
, O
attenuated O
the O
AVM B
- O
induced O
expression O
of O
P O
- O
gp O
, O
suggesting O
that O
AVM B
induces O
P O
- O
gp O
protein O
expression O
via O
the O
calmodulin O
/ O
Relish O
( O
NF O
- O
kappa O
B O
) O
signaling O
pathway O
. O

High O
electrochemical O
cycling O
stability O
, O
chloride B
( O
Cl B
( I
- I
) I
) O
tolerance O
and O
good O
selectivity O
are O
also O
obtained O
for O
the O
Pt B
NP O
@ O
PPy B
NF O
structure O
, O
as O
the O
electrode O
showed O
no O
obvious O
response O
to O
the O
common O
interfering O
agents O
, O
such O
as O
ascorbic B
acid I
( O
AA O
) O
, O
uric B
acid I
( O
UA O
) O
, O
and O
4 B
- I
acetamidophenol I
( O
AP O
) O
. O

Biocomposites O
of O
pHEMA B
with O
HA O
/ O
beta B
- I
TCP I
( O
60 O
/ O
40 O
) O
for O
bone O
tissue O
engineering O
: O
Swelling O
, O
hydrolytic O
degradation O
, O
and O
in O
vitro O
behavior O
. O

The O
pre O
- O
clinical O
absorption O
, O
distribution O
, O
metabolism O
and O
excretion O
properties O
of O
IPI B
- I
926 I
, O
an O
orally O
bioavailable O
antagonist O
of O
the O
hedgehog O
signal O
transduction O
pathway O
. O

IPI B
- I
926 I
is O
a O
novel O
semisynthetic O
cyclopamine B
derivative O
that O
is O
a O
potent O
and O
selective O
Smoothened O
inhibitor O
that O
blocks O
the O
hedgehog O
signal O
transduction O
pathway O
. O

The O
in O
vivo O
clearance O
of O
IPI B
- I
926 I
is O
low O
in O
mouse O
and O
dog O
and O
moderate O
in O
monkey O
. O

IPI B
- I
926 I
is O
highly O
bound O
to O
plasma O
proteins O
and O
has O
minimal O
interaction O
with O
human O
alpha O
- O
1 O
- O
acid O
glycoprotein O
. O

IPI B
- I
926 I
is O
not O
a O
potent O
reversible O
inhibitor O
of O
CYP1A2 O
, O
2C8 O
, O
2C9 O
or O
3A4 O
( O
testosterone B
) O
. O

IPI B
- I
926 I
is O
a O
moderate O
inhibitor O
of O
CYP2C19 O
, O
2D6 O
and O
3A4 O
( O
midazolam B
) O
with O
KI O
values O
of O
19 O
, O
16 O
and O
4 O
. O
5 O
micro O
M O
, O
respectively O
. O

IPI B
- I
926 I
is O
both O
a O
substrate O
and O
inhibitor O
( O
IC50 O
= O
1 O
. O
9 O
micro O
M O
) O
of O
P O
- O
glycoprotein O
. O

In O
summary O
, O
IPI B
- I
926 I
has O
desirable O
pre O
- O
clinical O
absorption O
, O
distribution O
, O
metabolism O
and O
excretion O
properties O
. O

This O
is O
demonstrated O
in O
calculations O
for O
2 B
- I
pyridone I
and O
chlorophyll O
dimers O
. O

Docking O
study O
of O
the O
synthesized O
compound O
8a O
into O
the O
active O
site O
of O
COX O
- O
2 O
revealed O
a O
similar O
binding O
mode O
to O
SC B
- I
558 I
, O
a O
selective O
COX O
- O
2 O
inhibitor O
. O

Glycyrrhizic B
acid I
( O
GA O
, O
also O
known O
as O
Glycyrrhizin B
) O
, O
a O
triterpenoid B
saponin I
glycoside I
, O
is O
considered O
to O
be O
a O
bioactive O
component O
in O
Licorice O
and O
is O
beneficial O
to O
diabetic O
vascular O
complications O
. O

The O
superoxide B
dismutase O
( O
SOD O
) O
activity O
and O
malondialdehyde B
( O
MDA B
) O
level O
in O
cell O
supernatant O
were O
detected O
by O
kits O
while O
the O
intracellular O
reactive O
oxygen B
species O
( O
ROS O
) O
generation O
was O
determined O
by O
2 B
, I
7 I
- I
dichlorodihydrofluor I
diacetate I
( O
DCFH B
- I
DA I
) O
kit O
. O

The O
tested O
liposomes O
caused O
no O
or O
only O
mild O
( O
30 O
% O
) O
activation O
of O
C O
except O
for O
one O
formulation O
wherein O
the O
PEG2000 B
was O
anchored O
to O
cholesterol B
( O
CHOL B
- I
PEG2000 I
) O
. O

While O
the O
relative O
safety O
of O
weak O
C O
activator O
liposomes O
remains O
to O
be O
confirmed O
in O
vivo O
, O
the O
unique O
, O
non O
- O
charge O
and O
non O
- O
antibody O
- O
mediated O
direct O
conversion O
of O
C3 O
by O
CHOL B
- I
PEG2000 I
liposomes O
( O
although O
argues O
against O
the O
clinical O
development O
of O
these O
vesicles O
) O
opens O
new O
opportunities O
to O
understand O
liposomal O
C O
activation O
at O
the O
molecular O
level O
. O

Both O
types O
of O
granules O
contain O
catechol B
oxidase O
that O
catalyzes O
oxidative O
cross O
- O
linking O
of O
L B
- I
DOPA I
. O

The O
noncellular O
reduction O
of O
MTT B
tetrazolium I
salt I
by O
TiO2 B
nanoparticles O
and O
its O
implications O
for O
cytotoxicity O
assays O
. O

This O
study O
describes O
the O
use O
of O
the O
pyrrolidinium B
nitrate I
( O
[ B
Pyrr I
] I
[ I
NO3 I
] I
) O
protic O
ionic O
liquid O
( O
PIL O
) O
in O
a O
mixture O
with O
gamma B
butyrolactone I
( O
gamma B
- I
BL I
) O
as O
an O
electrolyte O
for O
carbon B
- O
based O
supercapacitors O
with O
an O
operating O
voltage O
of O
2 O
. O
0 O
V O
and O
at O
very O
low O
temperature O
. O

The O
evolution O
of O
conductivity O
with O
the O
addition O
of O
gamma B
- I
BL I
rendered O
it O
possible O
to O
determine O
the O
optimal O
composition O
for O
electrochemical O
application O
, O
with O
a O
molar O
fraction O
of O
gamma B
- I
BL I
of O
0 O
. O
6 O
. O

The O
evolution O
of O
conductivity O
with O
the O
addition O
of O
gamma B
- I
BL I
rendered O
it O
possible O
to O
determine O
the O
optimal O
composition O
for O
electrochemical O
application O
, O
with O
a O
molar O
fraction O
of O
gamma B
- I
BL I
of O
0 O
. O
6 O
. O

A O
Novel O
Automethylation O
Reaction O
in O
the O
Aspergillus O
nidulans O
LaeA O
Protein O
Generates O
S B
- I
Methylmethionine I
. O

These O
findings O
not O
only O
indicate O
LaeA O
may O
perform O
novel O
chemistry O
with O
S B
- I
adenosylmethionine I
, O
but O
also O
provide O
new O
insights O
into O
the O
physiological O
function O
of O
LaeA O
. O

By O
using O
the O
novel O
phosphorescent O
dye O
EuLH O
and O
BHQ B
- I
10 I
as O
a O
donor O
- O
acceptor O
pair O
, O
the O
FRET O
efficiency O
increases O
to O
> O
99 O
. O
5 O
% O
, O
leading O
to O
significantly O
improved O
signal O
- O
to O
- O
background O
ratio O
, O
precision O
and O
linear O
range O
. O

Synthesis O
and O
structure O
- O
activity O
relationship O
of O
pyripyropene B
A I
derivatives O
as O
potent O
and O
selective O
acyl B
- I
CoA I
: O
cholesterol B
acyltransferase O
2 O
( O
ACAT2 O
) O
inhibitors O
: O
Part O
2 O
. O

The O
extent O
of O
saturation O
and O
the O
signature O
of O
polyenic B
fatty I
acids I
varied O
according O
to O
the O
specific O
species O
of O
the O
Stichaeidae O
family O
under O
study O
. O

Intra O
- O
dorsal O
hippocampus O
( O
DH O
) O
injections O
of O
8 B
- I
hydroxy I
- I
2 I
- I
( I
di I
- I
n I
- I
propylamino I
) I
tetralin I
( O
8 B
- I
OH I
- I
DPAT I
) O
, O
a O
serotonin B
- O
1A O
( O
5 B
- I
hydroxytryptamine I
( O
5 B
- I
HT I
) O
- O
1A O
) O
receptor O
agonist O
, O
were O
previously O
shown O
to O
inhibit O
the O
expression O
of O
contextual O
fear O
when O
administered O
six O
hours O
after O
conditioning O
. O

Intra O
- O
dorsal O
hippocampus O
( O
DH O
) O
injections O
of O
8 B
- I
hydroxy I
- I
2 I
- I
( I
di I
- I
n I
- I
propylamino I
) I
tetralin I
( O
8 B
- I
OH I
- I
DPAT I
) O
, O
a O
serotonin B
- O
1A O
( O
5 B
- I
hydroxytryptamine I
( O
5 B
- I
HT I
) O
- O
1A O
) O
receptor O
agonist O
, O
were O
previously O
shown O
to O
inhibit O
the O
expression O
of O
contextual O
fear O
when O
administered O
six O
hours O
after O
conditioning O
. O

The O
present O
findings O
, O
together O
with O
previous O
data O
, O
indicate O
that O
in O
contrast O
to O
5 B
- I
HT I
, O
which O
appears O
to O
play O
a O
role O
during O
the O
early O
phases O
of O
contextual O
aversive O
memory O
consolidation O
, O
longer O
- O
lasting O
GABA B
- O
mediated O
mechanisms O
are O
recruited O
during O
the O
expression O
of O
contextual O
fear O
memories O
. O

2 B
- I
Amino I
- I
9H I
- I
pyrido I
[ I
2 I
, I
3 I
- I
b I
] I
indole I
( O
A O
alpha O
C O
) O
is O
an O
abundant O
heterocyclic B
aromatic I
amine I
present O
in O
tobacco O
smoke O
. O

However O
, O
content O
of O
omega B
- I
3 I
was O
diminished O
in O
DBP B
- O
treated O
groups O
. O

Biotransformation O
of O
2 B
, I
2 I
' I
, I
4 I
, I
4 I
' I
- I
Tetrabromodiphenyl I
Ether I
( O
BDE B
- I
47 I
) O
by O
Human O
Liver O
Microsomes O
: O
Identification O
of O
Cytochrome O
P450 O
2B6 O
as O
the O
Major O
Enzyme O
Involved O
. O

Polybrominated B
diphenyl I
ethers I
( O
PBDEs B
) O
were O
widely O
used O
flame O
retardants O
that O
have O
become O
persistent O
environmental O
pollutants O
. O

In O
the O
present O
study O
, O
we O
investigated O
the O
in O
vitro O
oxidative O
metabolism O
of O
2 B
, I
2 I
' I
, I
4 I
, I
4 I
' I
- I
tetrabromodiphenyl I
ether I
( O
BDE B
- I
47 I
) O
, O
a O
major O
PBDE B
detected O
in O
human O
tissue O
and O
environmental O
samples O
. O

Biotransformation O
of O
BDE B
- I
47 I
by O
pooled O
and O
individual O
human O
liver O
microsomes O
and O
by O
human O
recombinant O
cytochrome O
P450 O
( O
P450 O
) O
enzymes O
was O
assessed O
using O
a O
liquid O
chromatography O
/ O
tandem O
mass O
spectrometry O
- O
based O
method O
. O

Of O
the O
nine O
hydroxylated O
metabolites O
of O
BDE B
- I
47 I
produced O
by O
human O
liver O
microsomes O
, O
seven O
metabolites O
were O
identified O
using O
authentic O
standards O
. O

Among O
the O
human O
recombinant O
P450 O
enzymes O
tested O
, O
P450 O
2B6 O
was O
the O
most O
active O
enzyme O
in O
the O
formation O
of O
the O
hydroxylated O
metabolites O
of O
BDE B
- I
47 I
. O

Moreover O
, O
the O
formation O
of O
all O
metabolites O
of O
BDE B
- I
47 I
by O
pooled O
human O
liver O
microsomes O
was O
inhibited O
by O
a O
P450 O
2B6 O
- O
specific O
antibody O
and O
was O
highly O
correlated O
with O
P450 O
2B6 O
- O
mediated O
activity O
in O
single O
donor O
liver O
microsomes O
indicating O
that O
P450 O
2B6 O
was O
the O
major O
P450 O
responsible O
for O
the O
biotransformation O
of O
BDE B
- I
47 I
. O

Moreover O
, O
the O
formation O
of O
all O
metabolites O
of O
BDE B
- I
47 I
by O
pooled O
human O
liver O
microsomes O
was O
inhibited O
by O
a O
P450 O
2B6 O
- O
specific O
antibody O
and O
was O
highly O
correlated O
with O
P450 O
2B6 O
- O
mediated O
activity O
in O
single O
donor O
liver O
microsomes O
indicating O
that O
P450 O
2B6 O
was O
the O
major O
P450 O
responsible O
for O
the O
biotransformation O
of O
BDE B
- I
47 I
. O

Additional O
experiments O
involving O
the O
incubation O
of O
liver O
microsomes O
with O
individual O
monohydroxy B
- O
tetrabrominated O
metabolites O
in O
place O
of O
BDE B
- I
47 I
demonstrated O
that O
2 B
, I
4 I
- I
dibromophenol I
was O
a O
product O
of O
BDE B
- I
47 I
and O
several O
primary O
metabolites O
, O
but O
the O
dihydroxy B
- O
tetrabrominated O
metabolite O
was O
not O
formed O
by O
sequential O
hydroxylation O
of O
any O
of O
the O
monohydroxy B
- O
tetrabrominated O
metabolites O
tested O
. O

Additional O
experiments O
involving O
the O
incubation O
of O
liver O
microsomes O
with O
individual O
monohydroxy B
- O
tetrabrominated O
metabolites O
in O
place O
of O
BDE B
- I
47 I
demonstrated O
that O
2 B
, I
4 I
- I
dibromophenol I
was O
a O
product O
of O
BDE B
- I
47 I
and O
several O
primary O
metabolites O
, O
but O
the O
dihydroxy B
- O
tetrabrominated O
metabolite O
was O
not O
formed O
by O
sequential O
hydroxylation O
of O
any O
of O
the O
monohydroxy B
- O
tetrabrominated O
metabolites O
tested O
. O

The O
present O
study O
provides O
a O
comprehensive O
characterization O
of O
the O
oxidative O
metabolism O
of O
BDE B
- I
47 I
by O
human O
liver O
microsomes O
and O
P450 O
2B6 O
. O

In O
addition O
, O
major O
metabolites O
were O
identified O
and O
measurements O
of O
OH B
- I
PAHs I
( O
1 B
- I
naphthol I
, O
9 B
- I
phenantrol I
, O
9 B
- I
fluorenol I
, O
1 B
- I
pyrenol I
, O
1OH B
- I
BaP I
and O
3OH B
- I
BaP I
) O
and O
alkylphenols B
( O
4 B
- I
n I
- I
nonylphenol I
( O
4 B
- I
n I
- I
NP I
) O
and O
4 B
- I
tertoctylphenol I
( O
4 B
- I
tert I
- I
OP I
) O
) O
in O
the O
same O
fish O
bile O
extracts O
were O
taken O
by O
gas O
chromatography O
- O
mass O
spectrometry O
in O
electron O

In O
addition O
, O
major O
metabolites O
were O
identified O
and O
measurements O
of O
OH B
- I
PAHs I
( O
1 B
- I
naphthol I
, O
9 B
- I
phenantrol I
, O
9 B
- I
fluorenol I
, O
1 B
- I
pyrenol I
, O
1OH B
- I
BaP I
and O
3OH B
- I
BaP I
) O
and O
alkylphenols B
( O
4 B
- I
n I
- I
nonylphenol I
( O
4 B
- I
n I
- I
NP I
) O
and O
4 B
- I
tertoctylphenol I
( O
4 B
- I
tert I
- I
OP I
) O
) O
in O
the O
same O
fish O
bile O
extracts O
were O
taken O
by O
gas O
chromatography O
- O
mass O
spectrometry O
in O
electron O

In O
addition O
, O
major O
metabolites O
were O
identified O
and O
measurements O
of O
OH B
- I
PAHs I
( O
1 B
- I
naphthol I
, O
9 B
- I
phenantrol I
, O
9 B
- I
fluorenol I
, O
1 B
- I
pyrenol I
, O
1OH B
- I
BaP I
and O
3OH B
- I
BaP I
) O
and O
alkylphenols B
( O
4 B
- I
n I
- I
nonylphenol I
( O
4 B
- I
n I
- I
NP I
) O
and O
4 B
- I
tertoctylphenol I
( O
4 B
- I
tert I
- I
OP I
) O
) O
in O
the O
same O
fish O
bile O
extracts O
were O
taken O
by O
gas O
chromatography O
- O
mass O
spectrometry O
in O
electron O

In O
addition O
, O
major O
metabolites O
were O
identified O
and O
measurements O
of O
OH B
- I
PAHs I
( O
1 B
- I
naphthol I
, O
9 B
- I
phenantrol I
, O
9 B
- I
fluorenol I
, O
1 B
- I
pyrenol I
, O
1OH B
- I
BaP I
and O
3OH B
- I
BaP I
) O
and O
alkylphenols B
( O
4 B
- I
n I
- I
nonylphenol I
( O
4 B
- I
n I
- I
NP I
) O
and O
4 B
- I
tertoctylphenol I
( O
4 B
- I
tert I
- I
OP I
) O
) O
in O
the O
same O
fish O
bile O
extracts O
were O
taken O
by O
gas O
chromatography O
- O
mass O
spectrometry O
in O
electron O

In O
addition O
, O
major O
metabolites O
were O
identified O
and O
measurements O
of O
OH B
- I
PAHs I
( O
1 B
- I
naphthol I
, O
9 B
- I
phenantrol I
, O
9 B
- I
fluorenol I
, O
1 B
- I
pyrenol I
, O
1OH B
- I
BaP I
and O
3OH B
- I
BaP I
) O
and O
alkylphenols B
( O
4 B
- I
n I
- I
nonylphenol I
( O
4 B
- I
n I
- I
NP I
) O
and O
4 B
- I
tertoctylphenol I
( O
4 B
- I
tert I
- I
OP I
) O
) O
in O
the O
same O
fish O
bile O
extracts O
were O
taken O
by O
gas O
chromatography O
- O
mass O
spectrometry O
in O
electron O

In O
addition O
, O
major O
metabolites O
were O
identified O
and O
measurements O
of O
OH B
- I
PAHs I
( O
1 B
- I
naphthol I
, O
9 B
- I
phenantrol I
, O
9 B
- I
fluorenol I
, O
1 B
- I
pyrenol I
, O
1OH B
- I
BaP I
and O
3OH B
- I
BaP I
) O
and O
alkylphenols B
( O
4 B
- I
n I
- I
nonylphenol I
( O
4 B
- I
n I
- I
NP I
) O
and O
4 B
- I
tertoctylphenol I
( O
4 B
- I
tert I
- I
OP I
) O
) O
in O
the O
same O
fish O
bile O
extracts O
were O
taken O
by O
gas O
chromatography O
- O
mass O
spectrometry O
in O
electron O

In O
addition O
, O
major O
metabolites O
were O
identified O
and O
measurements O
of O
OH B
- I
PAHs I
( O
1 B
- I
naphthol I
, O
9 B
- I
phenantrol I
, O
9 B
- I
fluorenol I
, O
1 B
- I
pyrenol I
, O
1OH B
- I
BaP I
and O
3OH B
- I
BaP I
) O
and O
alkylphenols B
( O
4 B
- I
n I
- I
nonylphenol I
( O
4 B
- I
n I
- I
NP I
) O
and O
4 B
- I
tertoctylphenol I
( O
4 B
- I
tert I
- I
OP I
) O
) O
in O
the O
same O
fish O
bile O
extracts O
were O
taken O
by O
gas O
chromatography O
- O
mass O
spectrometry O
in O
electron O

In O
addition O
, O
major O
metabolites O
were O
identified O
and O
measurements O
of O
OH B
- I
PAHs I
( O
1 B
- I
naphthol I
, O
9 B
- I
phenantrol I
, O
9 B
- I
fluorenol I
, O
1 B
- I
pyrenol I
, O
1OH B
- I
BaP I
and O
3OH B
- I
BaP I
) O
and O
alkylphenols B
( O
4 B
- I
n I
- I
nonylphenol I
( O
4 B
- I
n I
- I
NP I
) O
and O
4 B
- I
tertoctylphenol I
( O
4 B
- I
tert I
- I
OP I
) O
) O
in O
the O
same O
fish O
bile O
extracts O
were O
taken O
by O
gas O
chromatography O
- O
mass O
spectrometry O
in O
electron O

The O
highest O
biliary O
concentrations O
of O
1 B
- I
pyrenol I
, O
9 B
- I
fluorenol I
and O
4 B
- I
n I
- I
NP I
were O
found O
in O
fish O
from O
Barcelona O
and O
from O
the O
Mar O
Menor O
coastal O
lagoon O
. O

The O
highest O
biliary O
concentrations O
of O
1 B
- I
pyrenol I
, O
9 B
- I
fluorenol I
and O
4 B
- I
n I
- I
NP I
were O
found O
in O
fish O
from O
Barcelona O
and O
from O
the O
Mar O
Menor O
coastal O
lagoon O
. O

The O
contribution O
of O
1 B
- I
pyrenol I
, O
4 B
- I
n I
- I
NP I
and O
4 B
- I
tert I
- I
OP I
to O
the O
total O
estrogenic O
potency O
measured O
in O
male O
fish O
bile O
was O
found O
to O
be O
negligible O
, O
indicating O
the O
presence O
of O
other O
estrogenic O
compounds O
in O
red O
mullet O
bile O
. O

The O
identified O
Treg O
- O
promoting O
drugs O
include O
those O
previously O
known O
to O
induce O
Treg O
( O
rapamycin B
and O
retinoic B
acid I
) I
, O
statins O
, O
glucocorticoids O
and O
drugs O
in O
many O
other O
categories O
. O

In O
this O
study O
we O
investigated O
the O
relationship O
between O
several O
selected O
commercially O
available O
essential O
oils O
and O
beta B
- I
lactam I
antibiotics O
on O
their O
antibacterial O
effect O
against O
multidrug O
resistant O
bacteria O
. O

Reduced O
usage O
of O
antibiotics O
could O
be O
employed O
as O
a O
treatment O
strategy O
to O
decrease O
the O
adverse O
effects O
and O
possibly O
to O
reverse O
the O
beta B
- I
lactam I
antibiotic O
resistance O
. O

The O
conjugation O
of O
microcystin B
- I
RR I
by O
human O
recombinant O
GSTs O
and O
hepatic O
cytosol O
. O

MC B
- I
RR I
differs O
from O
MC B
- I
LR I
, O
the O
most O
studied O
congener O
only O
for O
one O
residue O
( O
arginine B
vs O
leucine B
) O
, O
resulting O
in O
a O
ten O
- O
fold O
difference O
in O
the O
acute O
toxicity O
in O
mice O
. O

MC B
- I
RR I
differs O
from O
MC B
- I
LR I
, O
the O
most O
studied O
congener O
only O
for O
one O
residue O
( O
arginine B
vs O
leucine B
) O
, O
resulting O
in O
a O
ten O
- O
fold O
difference O
in O
the O
acute O
toxicity O
in O
mice O
. O

The O
accepted O
pathway O
for O
MC O
detoxication O
is O
GSH B
conjugation O
: O
here O
the O
MC B
- I
RR I
conjugation O
with O
GSH B
catalyzed O
by O
5 O
recombinant O
human O
GSTs O
and O
human O
liver O
cytosol O
( O
HLC O
) O
has O
been O
characterized O
and O
appeared O
to O
be O
more O
efficient O
than O
MC B
- I
LR I
conjugation O
. O

The O
accepted O
pathway O
for O
MC O
detoxication O
is O
GSH B
conjugation O
: O
here O
the O
MC B
- I
RR I
conjugation O
with O
GSH B
catalyzed O
by O
5 O
recombinant O
human O
GSTs O
and O
human O
liver O
cytosol O
( O
HLC O
) O
has O
been O
characterized O
and O
appeared O
to O
be O
more O
efficient O
than O
MC B
- I
LR I
conjugation O
. O

However O
, O
at O
low O
MC B
- I
RR I
concentrations O
, O
representative O
of O
repeated O
oral O
exposure O
, O
and O
low O
GSH B
content O
( O
down O
to O
0 O
. O
05mM O
) O
, O
possibly O
associated O
to O
exposure O
to O
drugs O
or O
in O
patients O
affected O
by O
several O
pathologies O
, O
the O
relevance O
of O
the O
enzymatic O
reaction O
progressively O
increases O
, O
providing O
the O
predominant O
contribution O
to O
MC B
- I
RR I
detoxication O
. O

However O
, O
at O
low O
MC B
- I
RR I
concentrations O
, O
representative O
of O
repeated O
oral O
exposure O
, O
and O
low O
GSH B
content O
( O
down O
to O
0 O
. O
05mM O
) O
, O
possibly O
associated O
to O
exposure O
to O
drugs O
or O
in O
patients O
affected O
by O
several O
pathologies O
, O
the O
relevance O
of O
the O
enzymatic O
reaction O
progressively O
increases O
, O
providing O
the O
predominant O
contribution O
to O
MC B
- I
RR I
detoxication O
. O

The O
reported O
compounds O
herein O
are O
: O
4 B
- I
aminothienopyrimidin I
derivatives O
4a O
, O
b O
and O
their O
4 B
- I
substituted I
phenylamino I
analogues O
8a O
, O
b O
; O
4 B
- I
thienopyrimidin I
- I
4 I
- I
ones I
5a O
, O
b O
; O
N B
- I
alkyl I
thienopyrimidin I
- I
4 I
- I
ones I
6a O
- O
g O
; O
4 B
- I
chlorothienopyrimidi I
7a O
, O
b O
; O
and O
thienopyrimidoquinaz B
9a O
, O
b O
which O
are O
the O
structural O
mimics O
of O
8a O
, O
b O
. O

The O
reported O
compounds O
herein O
are O
: O
4 B
- I
aminothienopyrimidin I
derivatives O
4a O
, O
b O
and O
their O
4 B
- I
substituted I
phenylamino I
analogues O
8a O
, O
b O
; O
4 B
- I
thienopyrimidin I
- I
4 I
- I
ones I
5a O
, O
b O
; O
N B
- I
alkyl I
thienopyrimidin I
- I
4 I
- I
ones I
6a O
- O
g O
; O
4 B
- I
chlorothienopyrimidi I
7a O
, O
b O
; O
and O
thienopyrimidoquinaz B
9a O
, O
b O
which O
are O
the O
structural O
mimics O
of O
8a O
, O
b O
. O

Chemical O
Stability O
of O
the O
Lipid O
Phase O
in O
Concentrated O
Beverage O
Emulsions O
Colored O
with O
Natural O
beta B
- I
Carotene I
. O

The O
aim O
of O
this O
study O
was O
to O
examine O
the O
oxidation O
of O
selected O
plant O
oils O
in O
concentrated O
beverage O
emulsions O
colored O
with O
natural O
beta B
- I
carotene I
. O

In O
vitro O
, O
lipid O
transfers O
were O
evaluated O
by O
incubation O
of O
plasma O
samples O
( O
37 O
degrees O
C O
, O
1h O
) O
with O
a O
donor O
lipid O
nanoemulsion O
labeled O
with O
3H B
- I
triglycerides I
( O
TG O
) O
and O
14C B
- O
unesterified O
cholesterol B
( O
UC O
) O
or O
with O
3H B
- I
cholesteryl I
ester I
( O
EC O
) O
and O
14C B
- O
phospholipids O
( O
PL O
) O
. O

Most O
of O
the O
compounds O
, O
especially O
26 O
and O
22 O
, O
bearing O
a O
3 B
- I
isopropyl I
and O
3 B
- I
iodine I
group O
, O
respectively O
, O
exhibited O
highly O
potent O
activity O
against O
wild O
- O
type O
HIV O
- O
1 O
strains O
and O
those O
resistant O
to O
reverse O
transcriptase O
inhibitors O
( O
RTIs O
) O
. O

Most O
of O
the O
compounds O
, O
especially O
26 O
and O
22 O
, O
bearing O
a O
3 B
- I
isopropyl I
and O
3 B
- I
iodine I
group O
, O
respectively O
, O
exhibited O
highly O
potent O
activity O
against O
wild O
- O
type O
HIV O
- O
1 O
strains O
and O
those O
resistant O
to O
reverse O
transcriptase O
inhibitors O
( O
RTIs O
) O
. O

Pine O
particulate O
activated O
TRPA1 O
in O
mouse O
trigeminal O
neurons O
and O
A549 O
cells O
in O
a O
concentration O
- O
dependent O
manner O
, O
which O
was O
inhibited O
by O
the O
TRPA1 O
antagonist O
HC B
- I
030031 I
. O

After O
the O
last O
dose O
of O
amitraz B
, O
NE O
, O
DA O
and O
5 B
- I
HT I
and O
its O
metabolites O
levels O
were O
determined O
in O
the O
brain O
regions O
hypothalamus O
, O
midbrain O
, O
prefrontal O
cortex O
, O
striatum O
and O
hippocampus O
by O
HPLC O
. O

Amitraz O
caused O
changes O
in O
the O
NE O
, O
DA O
and O
5 B
- I
HT I
and O
their O
metabolite O
levels O
in O
a O
brain O
regional O
- O
, O
dose O
- O
and O
age O
- O
related O
manner O
. O

In O
the O
brain O
regions O
studied O
, O
amitraz O
induced O
a O
statistically O
significant O
increase O
in O
5 B
- I
HT I
, O
NE O
and O
DA O
content O
with O
age O
interaction O
, O
but O
the O
NE O
increases O
in O
prefrontal O
cortex O
and O
hippocampus O
was O
without O
age O
interaction O
. O

Moreover O
, O
in O
the O
brain O
regions O
studied O
, O
amitraz B
induced O
a O
statistically O
significant O
decrease O
in O
the O
metabolite O
5 B
- I
HIAA I
, O
MHPG B
, O
DOPAC B
and O
HVA B
levels O
displaying O
an O
age O
interaction O
, O
excepting O
the O
5 B
- I
HIAA I
decrease O
in O
midbrain O
and O
the O
DOPAC B
decrease O
in O
hypothalamus O
and O
striatum O
which O
were O
without O
age O
interaction O
. O

Moreover O
, O
in O
the O
brain O
regions O
studied O
, O
amitraz B
induced O
a O
statistically O
significant O
decrease O
in O
the O
metabolite O
5 B
- I
HIAA I
, O
MHPG B
, O
DOPAC B
and O
HVA B
levels O
displaying O
an O
age O
interaction O
, O
excepting O
the O
5 B
- I
HIAA I
decrease O
in O
midbrain O
and O
the O
DOPAC B
decrease O
in O
hypothalamus O
and O
striatum O
which O
were O
without O
age O
interaction O
. O

Furthermore O
, O
amitraz B
evoked O
a O
statistically O
significant O
decrease O
in O
5 B
- I
HT I
, O
NE O
and O
DA O
turnover O
in O
the O
brain O
regions O
studied O
. O

In O
order O
to O
improve O
on O
cellular O
selectivity O
to O
lower O
post O
- O
treatment O
photosensitivity O
bile B
acid I
porphyrin I
bioconjugates O
have O
been O
prepared O
and O
investigated O
in O
esophageal O
cancer O
cells O
. O

Synthesis O
of O
the O
conjugates O
was O
achieved O
via O
selective O
nucleophilic O
monofunctionalizatio O
of O
5 B
, I
10 I
, I
15 I
, I
20 I
- I
tetrahydroxyphenylpo I
with O
propargyl B
bromide I
followed O
by O
Cu B
( I
I I
) I
mediated O
cycloaddition O
with O
bile B
acid I
azides I
in O
good O
yields O
. O

Oligomeric O
ureas B
of O
m B
- I
phenylenediamine I
target O
anionic O
DMPG B
( O
dimyristoylphosphati B
) O
and O
possess O
promise O
as O
antimicrobial O
agents O
. O

PEG B
mediated O
synthesis O
and O
pharmacological O
evaluation O
of O
some O
fluoro B
substituted I
pyrazoline I
derivatives O
as O
antiinflammatory O
and O
analgesic O
agents O
. O

A O
new O
series O
of O
fluoro B
substituted I
pyrazoline I
derivatives O
5a O
- O
g O
and O
6a O
- O
g O
were O
synthesized O
in O
good O
to O
excellent O
yield O
from O
the O
corresponding O
pyrazole B
chalcones I
, O
4a O
- O
g O
, O
by O
using O
polyethylene B
glycol I
- I
400 I
( O
PEG B
- I
400 I
) O
as O
an O
alternative O
reaction O
medium O
. O

A O
new O
series O
of O
fluoro B
substituted I
pyrazoline I
derivatives O
5a O
- O
g O
and O
6a O
- O
g O
were O
synthesized O
in O
good O
to O
excellent O
yield O
from O
the O
corresponding O
pyrazole B
chalcones I
, O
4a O
- O
g O
, O
by O
using O
polyethylene B
glycol I
- I
400 I
( O
PEG B
- I
400 I
) O
as O
an O
alternative O
reaction O
medium O
. O

To O
further O
investigate O
the O
structure O
- O
activity O
relationship O
( O
SAR O
) O
of O
the O
5 B
- I
hydroxytryptamine I
type O
6 O
( O
5 O
- O
HT6 O
) O
receptor O
agonist O
5 B
- I
chloro I
- I
2 I
- I
methyl I
- I
3 I
- I
( I
1 I
, I
2 I
, I
3 I
, I
6 I
- I
tetrahydropyridin I
- I
4 I
- I
yl I
) I
- I
1H I
- I
indole I
( O
EMD386088 B
, O
6 O
) O
, O
a O
series O
of O
2 B
- I
methyl I
- I
3 I
- I
( I
1 I
, I
2 I
, I
3 I
, I
6 I
- I
tetrahydropyridin I
- I
4 I
- I
yl I
) I
- I
1H I
- I
indoles I

In O
order O
for O
a O
compound O
to O
demonstrate O
potent O
5 O
- O
HT6 O
receptor O
agonist O
properties O
, O
the O
indole B
N O
( O
1 O
) O
should O
be O
unsubstituted O
, O
an O
alkyl B
group O
such O
as O
2 B
- I
methyl I
is O
needed O
and O
finally O
halogen B
substituents O
in O
the O
indole B
5 O
- O
position O
( O
fluoro B
, O
chloro B
or O
, O
bromo B
) O
were O
essential O
requirements O
. O

A O
few O
compounds O
within O
the O
2 B
- I
methyl I
- I
3 I
- I
( I
1 I
, I
2 I
, I
3 I
, I
6 I
- I
tetrahydropyridin I
- I
4 I
- I
yl I
) I
- I
1H I
- I
indoles I
were O
also O
screened O
for O
off O
- O
targets O
and O
generally O
they O
displayed O
low O
affinity O
for O
other O
5 B
- I
HT I
subtypes O
and O
serotonin B
transporter O
protein O
( O
SERT O
) O
. O

Induction O
of O
G2 O
/ O
M O
arrest O
, O
caspase O
activation O
and O
apoptosis O
by O
alpha B
- I
santonin I
derivatives O
in O
HL O
- O
60 O
cells O
. O

Previously O
, O
we O
demonstrated O
the O
cytotoxic O
effects O
of O
three O
new O
alpha B
- I
santonin I
derivatives O
on O
different O
tumor O
cell O
lines O
with O
low O
toxic O
effects O
upon O
peripheral O
human O
leukocytes O
. O

Tail O
Tip O
Proteins O
Related O
to O
Bacteriophage O
lambda O
gpL O
Coordinate O
an O
Iron B
- I
Sulfur I
Cluster O
. O

The O
C B
- O
terminal O
domain O
was O
demonstrated O
to O
coordinate O
an O
iron B
- I
sulfur I
cluster O
, O
providing O
the O
first O
example O
of O
a O
viral O
structural O
protein O
binding O
to O
this O
type O
of O
metal O
group O
. O

We O
characterized O
the O
iron B
- I
sulfur I
cluster O
using O
inductively O
coupled O
plasma O
- O
atomic O
emission O
spectroscopy O
, O
absorbance O
spectroscopy O
, O
and O
electron O
paramagnetic O
resonance O
spectroscopy O
and O
found O
that O
it O
is O
an O
oxygen B
- O
sensitive O
[ B
4Fe I
- I
4S I
] I
( I
2 I
+ I
) I
cluster O
. O

Four O
highly O
conserved O
cysteine B
residues O
were O
shown O
to O
be O
required O
for O
coordinating O
the O
iron B
- I
sulfur I
cluster O
, O
and O
substitution O
of O
any O
of O
these O
Cys B
residues O
with O
Ser B
or O
Ala B
within O
the O
context O
of O
lambda O
gpL O
abolished O
biological O
activity O
. O

These O
data O
imply O
that O
the O
intact O
iron B
- I
sulfur I
cluster O
is O
required O
for O
function O
. O

The O
presence O
of O
four O
conserved O
Cys B
residues O
in O
the O
C B
- O
terminal O
regions O
of O
very O
diverse O
gpL O
homologues O
suggest O
that O
utilization O
of O
an O
iron B
- I
sulfur I
cluster O
is O
a O
widespread O
feature O
of O
non O
- O
contractile O
tailed O
phages O
that O
infect O
Gram O
- O
negative O
bacteria O
. O

In O
addition O
, O
this O
is O
the O
first O
example O
of O
a O
viral O
structural O
protein O
that O
binds O
an O
iron B
- I
sulfur I
cluster O
. O

Global O
and O
MGMT O
promoter O
hypomethylation O
independently O
associated O
with O
genomic O
instability O
of O
lymphocytes O
in O
subjects O
exposed O
to O
high O
- O
dose O
polycyclic B
aromatic I
hydrocarbon I
. O

To O
date O
, O
few O
studies O
have O
examined O
the O
aberrant O
DNA O
methylation O
patterns O
in O
coke O
oven O
workers O
, O
who O
are O
highly O
at O
risk O
of O
lung O
cancer O
by O
occupational O
exposure O
to O
polycyclic B
aromatic I
hydrocarbons I
( O
PAHs B
) O
. O

We O
recruited O
82 O
PAH B
- O
exposed O
workers O
and O
62 O
unexposed O
controls O
, O
assessed O
exposure O
levels O
by O
urinary O
1 B
- I
hydroxypyrene I
, O
and O
measured O
genetic O
damages O
by O
comet O
assay O
, O
bleomycin B
sensitivity O
, O
and O
micronucleus O
assay O
. O

LINE O
- O
1 O
, O
MGMT O
, O
and O
its O
hot O
CpG B
site O
- O
specific O
methylation O
were O
negatively O
correlated O
with O
urinary O
1 B
- I
hydroxypyrene I
levels O
( O
r O
= O
- O
0 O
. O
329 O
, O
p O
< O
0 O
. O
001 O
; O
r O
= O
- O
0 O
. O
164 O
, O
p O
= O
0 O
. O
049 O
and O
r O
= O
- O
0 O
. O
176 O
, O
p O
= O
0 O
. O
034 O
, O
respectively O
) O
. O

Memory O
impairment O
was O
induced O
by O
scopolamine B
, O
a O
muscarinic O
receptor O
antagonist O
, O
or O
MK B
- I
801 I
, O
an O
N B
- I
methyl I
- I
D I
- I
aspartate I
receptor O
antagonist O
. O

Sensorimotor O
gating O
deficits O
were O
induced O
by O
MK B
- I
801 I
and O
measured O
by O
prepulse O
inhibition O
( O
PPI O
) O
of O
the O
acoustic O
startle O
response O
task O
. O

DMPC B
treatment O
( O
20 O
mg O
/ O
kg O
) O
significantly O
attenuated O
scopolamine B
- O
or O
MK B
- I
801 I
- O
induced O
memory O
impairment O
and O
it O
even O
enhanced O
cognitive O
performance O
of O
normal O
animals O
. O

Furthermore O
, O
DMPC B
significantly O
ameliorated O
MK B
- I
801 I
- O
induced O
PPI O
deficits O
in O
the O
acoustic O
startle O
response O
task O
. O

Ionic O
conductivities O
and O
dielectric O
constants O
of O
0 O
. O
0055 O
mol O
. O
L O
( O
- O
1 O
) O
tetrabutylammonium B
trifluoromethanesulf I
in O
2 B
- I
pentanone I
, O
2 B
- I
hexanone I
, O
2 B
- I
heptanone I
, O
2 B
- I
octanone I
, O
2 B
- I
nonanone I
, O
and O
2 B
- I
decanone I
were O
also O
measured O
. O

Ionic O
conductivities O
and O
dielectric O
constants O
of O
0 O
. O
0055 O
mol O
. O
L O
( O
- O
1 O
) O
tetrabutylammonium B
trifluoromethanesulf I
in O
2 B
- I
pentanone I
, O
2 B
- I
hexanone I
, O
2 B
- I
heptanone I
, O
2 B
- I
octanone I
, O
2 B
- I
nonanone I
, O
and O
2 B
- I
decanone I
were O
also O
measured O
. O

Ionic O
conductivities O
and O
dielectric O
constants O
of O
0 O
. O
0055 O
mol O
. O
L O
( O
- O
1 O
) O
tetrabutylammonium B
trifluoromethanesulf I
in O
2 B
- I
pentanone I
, O
2 B
- I
hexanone I
, O
2 B
- I
heptanone I
, O
2 B
- I
octanone I
, O
2 B
- I
nonanone I
, O
and O
2 B
- I
decanone I
were O
also O
measured O
. O

Ionic O
conductivities O
and O
dielectric O
constants O
of O
0 O
. O
0055 O
mol O
. O
L O
( O
- O
1 O
) O
tetrabutylammonium B
trifluoromethanesulf I
in O
2 B
- I
pentanone I
, O
2 B
- I
hexanone I
, O
2 B
- I
heptanone I
, O
2 B
- I
octanone I
, O
2 B
- I
nonanone I
, O
and O
2 B
- I
decanone I
were O
also O
measured O
. O

Ionic O
conductivities O
and O
dielectric O
constants O
of O
0 O
. O
0055 O
mol O
. O
L O
( O
- O
1 O
) O
tetrabutylammonium B
trifluoromethanesulf I
in O
2 B
- I
pentanone I
, O
2 B
- I
hexanone I
, O
2 B
- I
heptanone I
, O
2 B
- I
octanone I
, O
2 B
- I
nonanone I
, O
and O
2 B
- I
decanone I
were O
also O
measured O
. O

Ionic O
conductivities O
and O
dielectric O
constants O
of O
0 O
. O
0055 O
mol O
. O
L O
( O
- O
1 O
) O
tetrabutylammonium B
trifluoromethanesulf I
in O
2 B
- I
pentanone I
, O
2 B
- I
hexanone I
, O
2 B
- I
heptanone I
, O
2 B
- I
octanone I
, O
2 B
- I
nonanone I
, O
and O
2 B
- I
decanone I
were O
also O
measured O
. O

Catalytic O
Asymmetric O
Synthesis O
of O
gamma B
- I
Butenolides I
by O
Direct O
Vinylogous O
Reactions O
. O

The O
gamma B
- I
butenolide I
structural O
motif O
is O
a O
prominent O
feature O
in O
many O
bioactive O
natural O
products O
and O
drugs O
. O

This O
short O
review O
summarizes O
catalytic O
asymmetric O
synthesis O
of O
gamma B
- I
butenolides I
through O
direct O
vinylogous O
reactions O
by O
metal O
complexes O
and O
organocatalysts O
. O

Enzymatically O
catalyzed O
polycondensation O
of O
p B
- I
xylylenediamine I
and O
diethyl B
sebacate I
resulted O
in O
oligo B
( I
p I
- I
xylylene I
sebacamide I
) I
with O
high O
melting O
temperatures O
( O
223 O
- O
230 O
degrees O
C O
) O
and O
the O
enzymatic O
polycondensation O
of O
dimethyl B
terephthalate I
and O
1 B
, I
8 I
- I
diaminooctane I
leads O
to O
oligo B
( I
octamethylene I
terephthalamide I
) I
with O
two O
melting O
temperatures O
at O
186 O
and O
218 O
degrees O
C O
. O

No O
oligoamides O
, O
but O
products O
1 O
and O
2 O
, O
were O
formed O
from O
the O
enzymatic O
reaction O
of O
dimethyl B
terephthalate I
and O
p B
- I
xylylenediamine I
. O

Results O
and O
discussion O
: O
Lyophilized O
microparticles O
exhibited O
vanishment O
of O
crystallinity O
of O
drug O
in O
XRPD O
analysis O
, O
the O
enfeeblement O
of O
carbonyl B
( O
C B
= I
O I
) O
stretching O
bands O
of O
carboxyl B
group O
in O
BDS B
in O
FT O
- O
IR O
spectra O
and O
the O
disappearance O
of O
endothermic O
peak O
of O
drug O
in O
the O
results O
of O
DSC O
study O
. O

Serotonin B
( O
5 B
- I
HT I
) O
in O
the O
Regulation O
of O
Depression O
- O
Related O
Emotionality O
: O
Insight O
from O
5 B
- I
HT I
Transporter O
and O
Tryptophan B
Hydroxylase O
- O
2 O
Knockout O
Mouse O
Models O
. O

Serotonin B
( O
5 B
- I
HT I
) O
in O
the O
Regulation O
of O
Depression O
- O
Related O
Emotionality O
: O
Insight O
from O
5 B
- I
HT I
Transporter O
and O
Tryptophan B
Hydroxylase O
- O
2 O
Knockout O
Mouse O
Models O
. O

Accumulating O
evidence O
suggests O
involvement O
of O
serotonin B
( O
5 B
- I
HT I
) O
in O
the O
regulation O
of O
emotion O
. O

Over O
the O
last O
decade O
, O
research O
on O
mice O
with O
a O
targeted O
inactivation O
of O
the O
5 B
- I
HT I
transporter O
( O
5 O
- O
Htt O
, O
Sert O
, O
Slc6a4 O
) O
has O
considerably O
advanced O
our O
knowledge O
about O
functions O
that O
the O
5 O
- O
HTT O
plays O
in O
the O
context O
of O
emotion O
related O
to O
depression O
. O

Moreover O
, O
the O
recent O
advent O
of O
knockout O
( O
KO O
) O
mice O
for O
tryptophan B
hydroxylase O
2 O
( O
Tph2 O
KO O
) O
, O
which O
lacks O
the O
rate O
- O
limiting O
enzyme O
for O
5 B
- I
HT I
synthesis O
in O
the O
brain O
, O
has O
further O
provided O
insight O
to O
the O
brain O
serotonergic O
system O
and O
its O
role O
in O
emotion O
dysregulation O
. O

Here O
, O
we O
first O
highlight O
basic O
characteristics O
of O
the O
serotonergic O
system O
including O
the O
biosynthesis O
of O
5 B
- I
HT I
as O
well O
as O
the O
anatomy O
and O
firing O
activity O
of O
serotonergic O
neurons O
. O

A O
Coupling O
of O
Benzamides B
and O
Donor O
/ O
Acceptor O
Diazo B
Compounds O
To O
Form O
gamma B
- I
Lactams I
via O
Rh B
( I
III I
) I
- O
Catalyzed O
C B
- I
H I
Activation O
. O

A O
Coupling O
of O
Benzamides B
and O
Donor O
/ O
Acceptor O
Diazo B
Compounds O
To O
Form O
gamma B
- I
Lactams I
via O
Rh B
( I
III I
) I
- O
Catalyzed O
C B
- I
H I
Activation O
. O

Mechanistic O
experiments O
suggested O
that O
C B
- I
H I
activation O
is O
turnover O
- O
limiting O
and O
irreversible O
and O
that O
insertion O
of O
the O
diazo B
compound O
favors O
electron O
- O
deficient O
substrates O
. O

Comparison O
of O
X O
- O
ray O
reflectivity O
data O
for O
strongly O
hydrated O
alkali B
- I
metal I
ions O
( O
Li B
( I
+ I
) I
and O
Na B
( I
+ I
) I
) O
, O
for O
which O
ion O
pairing O
to O
TPFB B
( I
- I
) I
ions O
across O
the O
interface O
is O
not O
expected O
, O
to O
data O
for O
weakly O
hydrated O
alkali B
- I
metal I
ions O
( O
Rb B
( I
+ I
) I
and O
Cs B
( I
+ I
) I
) O
indicates O
that O
the O
Gibbs O
energy O
of O
adsorption O
due O
to O
ion O
pairing O
at O
the O
interface O
must O
be O
small O
( O
< O
1 O
kBT O
per O
ion O
pair O
) O
for O
both O
the O
CsCl B
and O
RbCl B
samples O
. O

Comparison O
of O
X O
- O
ray O
reflectivity O
data O
for O
strongly O
hydrated O
alkali B
- I
metal I
ions O
( O
Li B
( I
+ I
) I
and O
Na B
( I
+ I
) I
) O
, O
for O
which O
ion O
pairing O
to O
TPFB B
( I
- I
) I
ions O
across O
the O
interface O
is O
not O
expected O
, O
to O
data O
for O
weakly O
hydrated O
alkali B
- I
metal I
ions O
( O
Rb B
( I
+ I
) I
and O
Cs B
( I
+ I
) I
) O
indicates O
that O
the O
Gibbs O
energy O
of O
adsorption O
due O
to O
ion O
pairing O
at O
the O
interface O
must O
be O
small O
( O
< O
1 O
kBT O
per O
ion O
pair O
) O
for O
both O
the O
CsCl B
and O
RbCl B
samples O
. O

Here O
we O
demonstrate O
that O
the O
boron B
nitride I
nanomesh O
, O
a O
corrugated O
single O
layer O
of O
hexagonal O
boron B
nitride I
( O
h B
- I
BN I
) O
with O
a O
3 O
. O
2 O
nm O
honeycomb O
superstructure O
formed O
on O
a O
Rh B
( I
111 I
) I
surface O
, O
can O
trap O
individual O
argon B
atoms O
at O
distinct O
subsurface O
sites O
at O
room O
temperature O
. O

A O
kinetic O
energy O
window O
for O
implantation O
is O
identified O
where O
the O
argon B
ions O
can O
penetrate O
the O
h B
- I
BN I
layer O
but O
not O
enter O
the O
Rh B
lattice O
. O

Annealing O
of O
implanted O
structures O
to O
900 O
K O
induces O
the O
formation O
of O
highly O
regular O
holes O
of O
2 O
nm O
diameter O
in O
the O
h B
- I
BN I
layer O
with O
adjacent O
flakes O
of O
the O
same O
size O
found O
on O
top O
of O
the O
layer O
. O

We O
explain O
this O
" O
can O
- O
opener O
" O
effect O
by O
the O
presence O
of O
a O
vacancy O
defect O
, O
generated O
during O
the O
penetration O
of O
the O
Ar B
ion O
through O
the O
h B
- I
BN I
lattice O
, O
and O
propagating O
along O
the O
rim O
of O
a O
nanomesh O
pore O
where O
the O
h B
- I
BN I
lattice O
is O
highly O
bent O
. O

We O
explain O
this O
" O
can O
- O
opener O
" O
effect O
by O
the O
presence O
of O
a O
vacancy O
defect O
, O
generated O
during O
the O
penetration O
of O
the O
Ar B
ion O
through O
the O
h B
- I
BN I
lattice O
, O
and O
propagating O
along O
the O
rim O
of O
a O
nanomesh O
pore O
where O
the O
h B
- I
BN I
lattice O
is O
highly O
bent O
. O

Regarding O
urease O
inhibition O
, O
n B
- I
butanol I
was O
the O
most O
potent O
fraction O
( O
IC50 O
: O
97 O
micro O
g O
/ O
mL O
) O
. O

Both O
R B
- I
and I
S I
- I
lorazepam I
were O
glucuronidated O
by O
UGT O
2B4 O
, O
2B7 O
, O
and O
2B15 O
, O
while O
R B
- I
lorazepam I
was O
additionally O
metabolized O
by O
the O
extra O
- O
hepatic O
enzymes O
UGT O
1A7 O
and O
1A10 O
. O

Posaconazole B
- I
d4 I
was O
used O
as O
internal O
standard O
. O

This O
work O
addresses O
structural O
and O
nonequilibrium O
effects O
of O
the O
interactions O
between O
well O
- O
defined O
cationic O
poly B
( I
amidoamine I
) I
PAMAM B
dendrimers O
of O
generations O
4 O
and O
8 O
and O
the O
anionic O
surfactant O
sodium B
dodecyl I
sulfate I
( O
SDS B
) O
at O
the O
hydrophilic O
silica B
- O
water O
interface O
. O

The O
following O
surfactants O
were O
used O
in O
the O
experiments O
: O
cationic O
dodecyltrimethylammo B
bromide I
( O
DTAB B
) O
, O
anionic O
sodium B
dodecyl I
sulfate I
( O
SDS B
) O
, O
anionic O
Pantene O
shampoo O
which O
primarily O
contains O
sodium B
lauryl I
sulfate I
, O
nonionic O
tetraethylene B
glycol I
monooctyl I
ether I
( O
C8E4 B
) O
, O
and O
nonionic O
Pluronic B
( I
P I
- I
123 I
) I
surfactants O
at O
different O
concentrations O
. O

The O
following O
surfactants O
were O
used O
in O
the O
experiments O
: O
cationic O
dodecyltrimethylammo B
bromide I
( O
DTAB B
) O
, O
anionic O
sodium B
dodecyl I
sulfate I
( O
SDS B
) O
, O
anionic O
Pantene O
shampoo O
which O
primarily O
contains O
sodium B
lauryl I
sulfate I
, O
nonionic O
tetraethylene B
glycol I
monooctyl I
ether I
( O
C8E4 B
) O
, O
and O
nonionic O
Pluronic B
( I
P I
- I
123 I
) I
surfactants O
at O
different O
concentrations O
. O

Determination O
of O
Specific O
Binding O
Interactions O
at O
l B
- I
Cystine I
Crystal O
Surfaces O
with O
Chemical O
Force O
Microscopy O
. O

The O
pathogenesis O
of O
l B
- I
cystine I
kidney O
stones O
involves O
four O
critical O
steps O
: O
nucleation O
, O
crystal O
growth O
, O
crystal O
aggregation O
, O
and O
crystal O
adhesion O
to O
cells O
. O

Although O
inhibition O
of O
crystal O
growth O
by O
l B
- I
cystine I
" O
imposters O
" O
at O
l B
- I
cystine I
crystal O
surfaces O
has O
been O
suggested O
as O
a O
plausible O
route O
for O
the O
suppression O
of O
stones O
, O
understanding O
the O
factors O
that O
govern O
crystal O
- O
crystal O
aggregation O
and O
adhesion O
of O
crystals O
to O
epithelial O
cells O
also O
is O
essential O
for O
devising O
strategies O
to O
mitigate O
l B
- I
cystine I
stone O
formation O
. O

Although O
inhibition O
of O
crystal O
growth O
by O
l B
- I
cystine I
" O
imposters O
" O
at O
l B
- I
cystine I
crystal O
surfaces O
has O
been O
suggested O
as O
a O
plausible O
route O
for O
the O
suppression O
of O
stones O
, O
understanding O
the O
factors O
that O
govern O
crystal O
- O
crystal O
aggregation O
and O
adhesion O
of O
crystals O
to O
epithelial O
cells O
also O
is O
essential O
for O
devising O
strategies O
to O
mitigate O
l B
- I
cystine I
stone O
formation O
. O

Although O
inhibition O
of O
crystal O
growth O
by O
l B
- I
cystine I
" O
imposters O
" O
at O
l B
- I
cystine I
crystal O
surfaces O
has O
been O
suggested O
as O
a O
plausible O
route O
for O
the O
suppression O
of O
stones O
, O
understanding O
the O
factors O
that O
govern O
crystal O
- O
crystal O
aggregation O
and O
adhesion O
of O
crystals O
to O
epithelial O
cells O
also O
is O
essential O
for O
devising O
strategies O
to O
mitigate O
l B
- I
cystine I
stone O
formation O
. O

Chemical O
force O
microscopy O
performed O
with O
atomic O
force O
microscope O
tips O
decorated O
with O
functional O
groups O
commonly O
found O
in O
urinary O
constituents O
that O
likely O
mediate O
aggregation O
and O
attachment O
( O
e O
. O
g O
. O
, O
COOH B
, O
NH2 B
, O
SH B
, O
CH3 B
, O
OH B
) O
revealed O
signatures O
that O
reflect O
differences O
in O
the O
chemical O
affinity O
of O
these O
groups O
for O
the O
( O
001 O
) O
and O
{ O
100 O
} O
faces O
of O
the O
naturally O
occurring O
hexagonal O
form O
of O
l B
- I
cystine I
single O
crystals O
and O
the O
{ O
110 O
} O
faces O
of O
the O
non O
- O
native O
tetragonal O
form O
. O

A O
novel O
series O
of O
histamine B
H4 O
receptor O
antagonists O
based O
on O
the O
pyrido B
[ I
3 I
, I
2 I
- I
d I
] I
pyrimidine I
scaffold O
: O
Comparison O
of O
hERG O
binding O
and O
target O
residence O
time O
with O
PF B
- I
3893787 I
. O

The O
pyrido B
[ I
3 I
, I
2 I
- I
d I
] I
pyrimidine I
ligands O
have O
significantly O
reduced O
hERG O
binding O
compared O
to O
clinical O
stage O
compound O
PF B
- I
3893787 I
while O
showing O
good O
affinities O
at O
the O
human O
and O
rodent O
histamine B
receptors O
. O

The O
receptor O
residence O
time O
of O
several O
of O
these O
new O
compounds O
was O
determined O
for O
the O
human O
H4R O
and O
compared O
with O
JNJ7777120 B
and O
PF B
- I
3893787 I
. O

The O
pyrido B
[ I
3 I
, I
2 I
- I
d I
] I
pyrimidines I
showed O
residence O
times O
lower O
than O
JNJ7777120 B
but O
comparable O
to O
the O
residence O
time O
of O
PF B
- I
3893787 I
. O

Either O
the O
Li B
metal O
or O
Li B
ions O
( O
by O
the O
formation O
LixC6 B
or O
Li4 B
+ I
xTi5O12 I
) O
was O
harvested O
from O
waste O
Li B
ion O
source O
materials O
such O
as O
a O
waste O
anode O
( O
LixC6 B
) O
, O
cathode O
( O
LixFePO4 B
) O
, O
and O
electrolyte O
( O
LiPF6 B
in O
EC O
: O
DEC O
) O
by O
charging O
the O
cell O
, O
which O
then O
discharged O
with O
the O
waste O
products O
in O
the O
liquid O
cathode O
solution O
to O
produce O
electric O
energy O
. O

The O
ethyl B
acetate I
and O
methanol B
bark O
extracts O
of O
Melicope O
glabra O
were O
evaluated O
for O
their O
antioxidant O
capacities O
by O
1 B
, I
1 I
- I
diphenyl I
- I
2 I
- I
picrylhydrazyl I
( O
DPPH B
) O
free O
radical O
scavenging O
activity O
and O
beta B
- I
carotene I
bleaching O
/ O
linoleic B
acid I
system O
. O

Both O
extracts O
exhibited O
strong O
inhibition O
against O
the O
DPPH B
radical O
( O
IC50 O
values O
of O
24 O
. O
81 O
and O
13 O
. O
01 O
mu O
gml O
( O
- O
1 O
) O
, O
respectively O
) O
and O
strong O
antioxidant O
activity O
in O
beta B
- I
carotene I
bleaching O
assay O
. O

However O
, O
in O
beta B
- I
carotene I
bleaching O
assay O
, O
sesamin B
( O
4 O
) O
showed O
higher O
inhibitory O
activity O
( O
1mgml O
( O
- O
1 O
) O
, O
95 O
% O
) O
than O
glabranin B
( O
1 O
) O
( O
1mgml O
( O
- O
1 O
) O
, O
74 O
% O
) O
, O
whilst O
umbelliferone B
( O
2 O
) O
and O
scopoletin B
( O
3 O
) O
were O
slightly O
pro O
- O
oxidant O
. O

The O
SPME O
device O
, O
which O
was O
wetted O
with O
1 B
- I
octanol I
, O
was O
placed O
in O
a O
stirred O
apple O
samples O
to O
extract O
target O
analytes O
. O

A O
new O
molecularly O
imprinted O
polymer O
( O
MIP O
) O
, O
selective O
for O
major O
metabolites O
of O
quinoxaline B
- I
1 I
, I
4 I
- I
dioxides I
, O
was O
prepared O
through O
bulk O
polymerisation O
using O
quinoxaline B
- I
2 I
- I
carboxylic I
acid I
( O
QCA B
) O
as O
template O
, O
diethylaminoethylmet B
as O
functional O
monomer O
and O
ethylene B
glycol I
dimethacrylate I
as O
cross O
- O
linker O
in O
tetrahydrofuran B
. O

The O
present O
study O
confirms O
that O
triterpenoids B
present O
in O
apple O
peel O
and O
beta B
- I
damascone I
may O
be O
implicated O
in O
the O
anti O
- O
inflammatory O
properties O
of O
apple O
constituents O
, O
suggesting O
that O
these O
substances O
might O
be O
helpful O
in O
the O
treatment O
of O
IBD O
as O
nutrient O
supplements O
. O

The O
results O
showed O
that O
saturated B
fatty I
acids I
( O
C16 B
: I
0 I
and O
C18 B
: I
0 I
) O
were O
released O
faster O
than O
unsaturated B
fatty I
acids I
( O
C18 B
: I
1n9 I
, O
C18 B
: I
2n6 I
and O
C18 B
: I
3n3 I
) O
from O
soya O
bean O
oil O
emulsions O
; O
short O
chain O
fatty B
acids I
were O
released O
faster O
than O
long O
chain O
fatty B
acids I
from O
milk O
fat O
emulsions O
; O
long O
chain O
polyunsaturated B
fatty I
acids I
, O
such O
as O
eicosapentaenoic B
acid I
and O
docosahexaenoic B
acid I
, O
were O
released O
more O
slowly O
than O
other O
fatty B
acids I
from O
fish O
oil O
emulsions O
. O

The O
results O
showed O
that O
saturated B
fatty I
acids I
( O
C16 B
: I
0 I
and O
C18 B
: I
0 I
) O
were O
released O
faster O
than O
unsaturated B
fatty I
acids I
( O
C18 B
: I
1n9 I
, O
C18 B
: I
2n6 I
and O
C18 B
: I
3n3 I
) O
from O
soya O
bean O
oil O
emulsions O
; O
short O
chain O
fatty B
acids I
were O
released O
faster O
than O
long O
chain O
fatty B
acids I
from O
milk O
fat O
emulsions O
; O
long O
chain O
polyunsaturated B
fatty I
acids I
, O
such O
as O
eicosapentaenoic B
acid I
and O
docosahexaenoic B
acid I
, O
were O
released O
more O
slowly O
than O
other O
fatty B
acids I
from O
fish O
oil O
emulsions O
. O

The O
results O
showed O
that O
saturated B
fatty I
acids I
( O
C16 B
: I
0 I
and O
C18 B
: I
0 I
) O
were O
released O
faster O
than O
unsaturated B
fatty I
acids I
( O
C18 B
: I
1n9 I
, O
C18 B
: I
2n6 I
and O
C18 B
: I
3n3 I
) O
from O
soya O
bean O
oil O
emulsions O
; O
short O
chain O
fatty B
acids I
were O
released O
faster O
than O
long O
chain O
fatty B
acids I
from O
milk O
fat O
emulsions O
; O
long O
chain O
polyunsaturated B
fatty I
acids I
, O
such O
as O
eicosapentaenoic B
acid I
and O
docosahexaenoic B
acid I
, O
were O
released O
more O
slowly O
than O
other O
fatty B
acids I
from O
fish O
oil O
emulsions O
. O

The O
results O
showed O
that O
saturated B
fatty I
acids I
( O
C16 B
: I
0 I
and O
C18 B
: I
0 I
) O
were O
released O
faster O
than O
unsaturated B
fatty I
acids I
( O
C18 B
: I
1n9 I
, O
C18 B
: I
2n6 I
and O
C18 B
: I
3n3 I
) O
from O
soya O
bean O
oil O
emulsions O
; O
short O
chain O
fatty B
acids I
were O
released O
faster O
than O
long O
chain O
fatty B
acids I
from O
milk O
fat O
emulsions O
; O
long O
chain O
polyunsaturated B
fatty I
acids I
, O
such O
as O
eicosapentaenoic B
acid I
and O
docosahexaenoic B
acid I
, O
were O
released O
more O
slowly O
than O
other O
fatty B
acids I
from O
fish O
oil O
emulsions O
. O

The O
results O
showed O
that O
saturated B
fatty I
acids I
( O
C16 B
: I
0 I
and O
C18 B
: I
0 I
) O
were O
released O
faster O
than O
unsaturated B
fatty I
acids I
( O
C18 B
: I
1n9 I
, O
C18 B
: I
2n6 I
and O
C18 B
: I
3n3 I
) O
from O
soya O
bean O
oil O
emulsions O
; O
short O
chain O
fatty B
acids I
were O
released O
faster O
than O
long O
chain O
fatty B
acids I
from O
milk O
fat O
emulsions O
; O
long O
chain O
polyunsaturated B
fatty I
acids I
, O
such O
as O
eicosapentaenoic B
acid I
and O
docosahexaenoic B
acid I
, O
were O
released O
more O
slowly O
than O
other O
fatty B
acids I
from O
fish O
oil O
emulsions O
. O

The O
results O
showed O
that O
saturated B
fatty I
acids I
( O
C16 B
: I
0 I
and O
C18 B
: I
0 I
) O
were O
released O
faster O
than O
unsaturated B
fatty I
acids I
( O
C18 B
: I
1n9 I
, O
C18 B
: I
2n6 I
and O
C18 B
: I
3n3 I
) O
from O
soya O
bean O
oil O
emulsions O
; O
short O
chain O
fatty B
acids I
were O
released O
faster O
than O
long O
chain O
fatty B
acids I
from O
milk O
fat O
emulsions O
; O
long O
chain O
polyunsaturated B
fatty I
acids I
, O
such O
as O
eicosapentaenoic B
acid I
and O
docosahexaenoic B
acid I
, O
were O
released O
more O
slowly O
than O
other O
fatty B
acids I
from O
fish O
oil O
emulsions O
. O

The O
results O
showed O
that O
saturated B
fatty I
acids I
( O
C16 B
: I
0 I
and O
C18 B
: I
0 I
) O
were O
released O
faster O
than O
unsaturated B
fatty I
acids I
( O
C18 B
: I
1n9 I
, O
C18 B
: I
2n6 I
and O
C18 B
: I
3n3 I
) O
from O
soya O
bean O
oil O
emulsions O
; O
short O
chain O
fatty B
acids I
were O
released O
faster O
than O
long O
chain O
fatty B
acids I
from O
milk O
fat O
emulsions O
; O
long O
chain O
polyunsaturated B
fatty I
acids I
, O
such O
as O
eicosapentaenoic B
acid I
and O
docosahexaenoic B
acid I
, O
were O
released O
more O
slowly O
than O
other O
fatty B
acids I
from O
fish O
oil O
emulsions O
. O

The O
results O
showed O
that O
saturated B
fatty I
acids I
( O
C16 B
: I
0 I
and O
C18 B
: I
0 I
) O
were O
released O
faster O
than O
unsaturated B
fatty I
acids I
( O
C18 B
: I
1n9 I
, O
C18 B
: I
2n6 I
and O
C18 B
: I
3n3 I
) O
from O
soya O
bean O
oil O
emulsions O
; O
short O
chain O
fatty B
acids I
were O
released O
faster O
than O
long O
chain O
fatty B
acids I
from O
milk O
fat O
emulsions O
; O
long O
chain O
polyunsaturated B
fatty I
acids I
, O
such O
as O
eicosapentaenoic B
acid I
and O
docosahexaenoic B
acid I
, O
were O
released O
more O
slowly O
than O
other O
fatty B
acids I
from O
fish O
oil O
emulsions O
. O

malonylglucoside I
, O
luteolin B
7 I
- I
O I
- I
6 I
' I
malonylglucoside I
, O
luteolin B
7 I
- I
O I
- I
malonylglucoside I
, O
myricetin B
3 I
- I
O I
- I
galactoside I
, O
and O
naringenin B
tri I
glycoside I
. O

JG O
milk O
was O
associated O
with O
both O
favourable O
traits O
for O
human O
health O
, O
such O
as O
the O
higher O
total O
protein O
, O
total O
casein O
, O
alpha O
- O
casein O
, O
beta O
- O
casein O
, O
kappa O
- O
casein O
and O
alpha B
- I
tocopherol I
contents O
, O
and O
unfavourable O
traits O
, O
such O
as O
the O
higher O
concentrations O
of O
saturated O
fat O
, O
C12 O
: O
0 O
, O
C14 O
: O
0 O
and O
lower O
concentrations O
of O
monounsaturated B
fatty I
acids I
. O

JG O
milk O
was O
associated O
with O
both O
favourable O
traits O
for O
human O
health O
, O
such O
as O
the O
higher O
total O
protein O
, O
total O
casein O
, O
alpha O
- O
casein O
, O
beta O
- O
casein O
, O
kappa O
- O
casein O
and O
alpha B
- I
tocopherol I
contents O
, O
and O
unfavourable O
traits O
, O
such O
as O
the O
higher O
concentrations O
of O
saturated O
fat O
, O
C12 O
: O
0 O
, O
C14 O
: O
0 O
and O
lower O
concentrations O
of O
monounsaturated B
fatty I
acids I
. O

Also O
, O
the O
relative O
increase O
in O
omega B
- I
3 I
fatty I
acids I
and O
alpha B
- I
tocopherol I
, O
from O
winter O
to O
summer O
, O
was O
greater O
in O
JG O
milk O
. O

Ethyl B
acetate I
- O
n B
- I
butanol I
- O
water O
( O
1 O
: O
2 O
: O
3 O
, O
v O
/ O
v O
/ O
v O
) O
was O
selected O
as O
the O
optimum O
solvent O
system O
to O
purify O
geniposidic B
acid I
. O

Amino B
acid I
analysis O
showed O
that O
the O
vicilin O
had O
high O
contents O
of O
acidic B
amino I
acids I
and O
a O
low O
lysine B
/ O
arginine B
ratio O
. O

In O
addition O
, O
gallic B
, I
vanilic I
and I
syringic I
acids I
, O
siringaldehyde B
, O
coniferaldehyde B
, O
sinapaldehyde B
, O
vanillin B
, O
5 B
- I
hydroxymethylfurfura I
and O
furfural B
were O
identified O
and O
quantified O
. O

The O
volatile O
compounds O
of O
wines O
made O
from O
three O
grape O
varieties O
( O
Monastrell O
, O
Cabernet O
Sauvignon O
and O
Syrah O
) O
using O
three O
pre O
- O
fermentation O
techniques O
( O
grape O
freezing O
, O
dry B
- I
ice I
and O
cold O
maceration O
) O
and O
a O
control O
treatment O
were O
measured O
. O

Among O
them O
, O
three O
isomers O
of O
feruloyl B
- I
sucrose I
were O
firmly O
identified O
and O
another O
was O
strongly O
supposed O
to O
be O
a O
sinapoyl B
- I
diglycoside I
. O

Among O
them O
, O
three O
isomers O
of O
feruloyl B
- I
sucrose I
were O
firmly O
identified O
and O
another O
was O
strongly O
supposed O
to O
be O
a O
sinapoyl B
- I
diglycoside I
. O

Forty O
- O
nine O
animals O
were O
divided O
into O
7 O
groups O
( O
n O
= O
7 O
) O
and O
received O
by O
oral O
gavage O
30 O
% O
glucose B
plus O
0 O
. O
55g O
/ O
kg O
body O
mass O
of O
the O
following O
WPH O
components O
: O
( O
a O
) O
control O
; O
( O
b O
) O
WPH O
; O
( O
c O
) O
l B
- I
isoleucine I
; O
( O
d O
) O
l B
- I
leucine I
; O
( O
e O
) O
l B
- I
leucine I
plus O
l B
- I
isoleucine I
; O
( O
f O
) O
l B
- I
isoleucyl I
- I
l I
- I
leucine I
dipeptide I
; O
( O
g O
) O
l B
- I
leucyl I
- I
l I
- I
isoleucine I
dipeptide I
. O

Forty O
- O
nine O
animals O
were O
divided O
into O
7 O
groups O
( O
n O
= O
7 O
) O
and O
received O
by O
oral O
gavage O
30 O
% O
glucose B
plus O
0 O
. O
55g O
/ O
kg O
body O
mass O
of O
the O
following O
WPH O
components O
: O
( O
a O
) O
control O
; O
( O
b O
) O
WPH O
; O
( O
c O
) O
l B
- I
isoleucine I
; O
( O
d O
) O
l B
- I
leucine I
; O
( O
e O
) O
l B
- I
leucine I
plus O
l B
- I
isoleucine I
; O
( O
f O
) O
l B
- I
isoleucyl I
- I
l I
- I
leucine I
dipeptide I
; O
( O
g O
) O
l B
- I
leucyl I
- I
l I
- I
isoleucine I
dipeptide I
. O

Forty O
- O
nine O
animals O
were O
divided O
into O
7 O
groups O
( O
n O
= O
7 O
) O
and O
received O
by O
oral O
gavage O
30 O
% O
glucose B
plus O
0 O
. O
55g O
/ O
kg O
body O
mass O
of O
the O
following O
WPH O
components O
: O
( O
a O
) O
control O
; O
( O
b O
) O
WPH O
; O
( O
c O
) O
l B
- I
isoleucine I
; O
( O
d O
) O
l B
- I
leucine I
; O
( O
e O
) O
l B
- I
leucine I
plus O
l B
- I
isoleucine I
; O
( O
f O
) O
l B
- I
isoleucyl I
- I
l I
- I
leucine I
dipeptide I
; O
( O
g O
) O
l B
- I
leucyl I
- I
l I
- I
isoleucine I
dipeptide I
. O

Forty O
- O
nine O
animals O
were O
divided O
into O
7 O
groups O
( O
n O
= O
7 O
) O
and O
received O
by O
oral O
gavage O
30 O
% O
glucose B
plus O
0 O
. O
55g O
/ O
kg O
body O
mass O
of O
the O
following O
WPH O
components O
: O
( O
a O
) O
control O
; O
( O
b O
) O
WPH O
; O
( O
c O
) O
l B
- I
isoleucine I
; O
( O
d O
) O
l B
- I
leucine I
; O
( O
e O
) O
l B
- I
leucine I
plus O
l B
- I
isoleucine I
; O
( O
f O
) O
l B
- I
isoleucyl I
- I
l I
- I
leucine I
dipeptide I
; O
( O
g O
) O
l B
- I
leucyl I
- I
l I
- I
isoleucine I
dipeptide I
. O

Of O
the O
WPH O
components O
tested O
, O
the O
amino O
acid O
l B
- I
isoleucine I
and O
the O
peptide O
l B
- I
leucyl I
- I
l I
- I
isoleucine I
showed O
greater O
efficiency O
in O
translocating O
GLUT O
- O
4 O
to O
the O
PM O
and O
of O
increasing O
glucose B
capture O
by O
skeletal O
muscle O
. O

Major O
Se B
species O
( O
selenium B
methionine I
and O
oxidized B
selenium I
methionine I
) O
from O
dialyzate O
were O
identified O
and O
characterized O
by O
HPLC O
coupled O
to O
mass O
spectrometry O
( O
HPLC O
- O
MS O
) O
. O

Similar O
bioavailability O
percentages O
was O
achieved O
for O
total O
selenium B
as O
a O
sum O
of O
selenium B
species O
( O
selenocystine B
plus O
oxidized B
selenium I
methionine I
and O
selenium B
methionine I
, O
mainly O
) O
. O

Polycyclic B
aromatic I
hydrocarbons I
( O
PAH B
) O
and O
phenolic B
substances O
in O
meat O
products O
smoked O
with O
different O
types O
of O
wood O
and O
smoking O
spices O
. O

The O
contents O
of O
polycyclic B
aromatic I
hydrocarbons I
( O
15 O
+ O
1 O
EU O
PAH B
) O
and O
phenolic B
substances O
( O
guaiacol B
, O
4 B
- I
methylguaiacol I
, O
syringol B
, O
eugenol B
, O
and O
trans B
- I
isoeugenol I
) O
were O
investigated O
in O
smouldering O
- O
smoked O
Frankfurters O
and O
mini O
- O
salamis O
. O

The O
contents O
of O
polycyclic B
aromatic I
hydrocarbons I
( O
15 O
+ O
1 O
EU O
PAH B
) O
and O
phenolic B
substances O
( O
guaiacol B
, O
4 B
- I
methylguaiacol I
, O
syringol B
, O
eugenol B
, O
and O
trans B
- I
isoeugenol I
) O
were O
investigated O
in O
smouldering O
- O
smoked O
Frankfurters O
and O
mini O
- O
salamis O
. O

The O
contents O
of O
polycyclic B
aromatic I
hydrocarbons I
( O
15 O
+ O
1 O
EU O
PAH B
) O
and O
phenolic B
substances O
( O
guaiacol B
, O
4 B
- I
methylguaiacol I
, O
syringol B
, O
eugenol B
, O
and O
trans B
- I
isoeugenol I
) O
were O
investigated O
in O
smouldering O
- O
smoked O
Frankfurters O
and O
mini O
- O
salamis O
. O

The O
results O
showed O
that O
WFI O
inhibited O
the O
mutagenicity O
of O
2 B
- I
aminoanthracene I
( O
2 B
- I
AA I
) O
, O
an O
indirect O
mutagen O
; O
and O
4 B
- I
nitroquinoline I
- I
N I
- I
oxide I
( O
4 B
- I
NQO I
) O
, O
a O
direct O
mutagen O
toward O
Salmonella O
typhimurium O
TA O
98 O
and O
TA O
100 O
. O

The O
results O
showed O
that O
WFI O
inhibited O
the O
mutagenicity O
of O
2 B
- I
aminoanthracene I
( O
2 B
- I
AA I
) O
, O
an O
indirect O
mutagen O
; O
and O
4 B
- I
nitroquinoline I
- I
N I
- I
oxide I
( O
4 B
- I
NQO I
) O
, O
a O
direct O
mutagen O
toward O
Salmonella O
typhimurium O
TA O
98 O
and O
TA O
100 O
. O

The O
results O
showed O
that O
WFI O
inhibited O
the O
mutagenicity O
of O
2 B
- I
aminoanthracene I
( O
2 B
- I
AA I
) O
, O
an O
indirect O
mutagen O
; O
and O
4 B
- I
nitroquinoline I
- I
N I
- I
oxide I
( O
4 B
- I
NQO I
) O
, O
a O
direct O
mutagen O
toward O
Salmonella O
typhimurium O
TA O
98 O
and O
TA O
100 O
. O

Influence O
of O
pH O
, O
metal O
chelator O
, O
free O
radical O
scavenger O
and O
interfacial O
characteristics O
on O
the O
oxidative O
stability O
of O
beta B
- I
carotene I
in O
conjugated O
whey O
protein O
- O
pectin O
stabilised O
emulsion O
. O

The O
influence O
of O
whey O
protein O
isolate O
( O
WPI O
) O
- O
beet O
pectin O
conjugates O
formed O
by O
dry O
- O
heating O
on O
the O
oxidative O
stability O
of O
beta B
- I
carotene I
in O
O O
/ O
W O
emulsions O
was O
studied O
. O

It O
was O
mainly O
focused O
on O
the O
influence O
of O
pH O
, O
metal O
chelator O
, O
free O
radical O
scavenger O
and O
interfacial O
characteristics O
on O
the O
degradation O
of O
beta B
- I
carotene I
in O
the O
emulsion O
stabilised O
by O
conjugate O
. O

The O
conjugate O
increased O
the O
oxidative O
stability O
of O
beta B
- I
carotene I
in O
the O
emulsion O
as O
compared O
to O
their O
unconjugated O
mixture O
at O
pH O
7 O
. O
0 O
. O

The O
desferoxamine B
retarded O
beta B
- I
carotene I
degradation O
at O
pH O
4 O
. O
0 O
more O
effectively O
than O
pH O
7 O
. O
0 O
and O
more O
effectively O
in O
the O
emulsion O
with O
the O
conjugate O
than O
the O
unconjugated O
mixture O
( O
p O
< O
0 O
. O
05 O
) O
. O

The O
addition O
of O
200mg O
/ O
kg O
alpha B
- I
tocopherol I
significantly O
improved O
the O
stability O
of O
beta B
- I
carotene I
in O
the O
conjugate O
stabilised O
emulsion O
. O

The O
addition O
of O
200mg O
/ O
kg O
alpha B
- I
tocopherol I
significantly O
improved O
the O
stability O
of O
beta B
- I
carotene I
in O
the O
conjugate O
stabilised O
emulsion O
. O

The O
emulsions O
were O
washed O
to O
remove O
conjugate O
not O
absorbed O
to O
the O
emulsion O
droplet O
interface O
, O
indicating O
that O
unabsorbed O
emulsifiers O
could O
protect O
beta B
- I
carotene I
. O

Conformational O
restriction O
approach O
to O
BACE1 O
inhibitors O
II O
: O
SAR O
study O
of O
the O
isocytosine B
derivatives O
fixed O
with O
a O
cis B
- I
cyclopropane I
ring O
. O

Evn B
- I
50 I
is O
a O
lignan B
compounds O
mixture O
extracted O
from O
Vitex O
negundo O
, O
a O
widely O
used O
herb O
in O
traditional O
Chinese O
medicine O
. O

This O
study O
is O
aimed O
to O
define O
the O
spectrum O
of O
cytotoxic O
activity O
of O
EVn B
- I
50 I
, O
and O
also O
to O
investigate O
mechanisms O
underlying O
the O
anticancer O
actions O
via O
assessing O
the O
influence O
on O
cell O
cycle O
using O
EVn B
- I
50 I
, O
and O
the O
lignan B
compound O
VB1 B
purified O
from O
EVn B
- I
50 I
. O

This O
study O
is O
aimed O
to O
define O
the O
spectrum O
of O
cytotoxic O
activity O
of O
EVn B
- I
50 I
, O
and O
also O
to O
investigate O
mechanisms O
underlying O
the O
anticancer O
actions O
via O
assessing O
the O
influence O
on O
cell O
cycle O
using O
EVn B
- I
50 I
, O
and O
the O
lignan B
compound O
VB1 B
purified O
from O
EVn B
- I
50 I
. O

This O
study O
is O
aimed O
to O
define O
the O
spectrum O
of O
cytotoxic O
activity O
of O
EVn B
- I
50 I
, O
and O
also O
to O
investigate O
mechanisms O
underlying O
the O
anticancer O
actions O
via O
assessing O
the O
influence O
on O
cell O
cycle O
using O
EVn B
- I
50 I
, O
and O
the O
lignan B
compound O
VB1 B
purified O
from O
EVn B
- I
50 I
. O

The O
cytotoxic O
effect O
of O
EVn B
- I
50 I
and O
VB1 B
was O
determined O
with O
SRB O
assay O
using O
a O
panel O
of O
cancer O
cell O
lines O
. O

Breast O
cancer O
cell O
line O
MDA O
- O
MB O
- O
435 O
and O
liver O
cancer O
cell O
line O
SMMC O
- O
7721 O
were O
selected O
for O
further O
evaluating O
the O
effect O
of O
EVn B
- I
50 I
or O
VB1 B
on O
cell O
cycle O
by O
flow O
cytometric O
analysis O
. O

Apoptosis O
exerted O
by O
EVn B
- I
50 I
or O
VB1 B
was O
measured O
by O
TUNEL O
assay O
and O
DAPI O
staining O
, O
and O
Western O
blot O
analysis O
was O
utilized O
to O
assess O
the O
influence O
on O
expression O
and O
phosphorylation O
of O
proteins O
which O
are O
closely O
related O
to O
cell O
cycle O
and O
apoptosis O
. O

EVn B
- I
50 I
possessed O
a O
broad O
spectrum O
of O
in O
vitro O
anticancer O
activity O
for O
those O
tested O
cancer O
cells O
, O
especially O
sensitive O
to O
MDA O
- O
MB O
- O
435 O
, O
SKOV O
- O
3 O
, O
BXPC O
- O
3 O
, O
SMMC O
- O
7721 O
, O
MCF O
- O
7 O
, O
HO O
- O
8910 O
, O
SGC O
- O
7901 O
, O
BEL O
- O
7402 O
, O
HCT O
- O
116 O
, O
and O
786 O
- O
O O
, O
with O
the O
respective O
IC50 O
below O
10 O
mu O
g O
/ O
ml O
. O

Treatment O
with O
EVn B
- I
50 I
or O
VB1 B
resulted O
in O
arresting O
the O
MDA O
- O
MB O
- O
435 O
and O
SMMC O
- O
7721 O
cells O
at O
G2 O
/ O
M O
phase O
, O
which O
was O
further O
supported O
by O
observations O
of O
increased O
phosphorylation O
of O
Histone O
3 O
at O
Ser10 B
, O
phosphorylation O
of O
Cdk1 O
at O
Tyr15 B
, O
expression O
of O
cyclin O
B1 O
, O
and O
decreased O
expression O
of O
Cdc25c O
. O

Moreover O
, O
we O
found O
that O
exposure O
of O
MDA O
- O
MB O
- O
435 O
cells O
to O
EVn B
- I
50 I
or O
VB1 B
caused O
obvious O
apoptosis O
of O
MDA O
- O
MB O
- O
435 O
cells O
. O

Our O
data O
show O
that O
EVn B
- I
50 I
, O
lignan B
compounds O
extracted O
from O
Vitex O
negundo O
, O
possesses O
a O
broad O
spectrum O
cytotoxic O
effect O
via O
arresting O
cancer O
cells O
at O
G2 O
/ O
M O
phase O
cell O
cycle O
and O
subsequently O
inducing O
apoptosis O
. O

2 B
- I
Hydroxychalcone I
and O
xanthohumol B
inhibit O
invasion O
of O
triple O
negative O
breast O
cancer O
cells O
. O

Here O
, O
we O
showed O
that O
treatment O
with O
chalcone B
, O
2 B
- I
hydroxychalcone I
, O
and O
xanthohumol B
for O
24h O
inhibited O
the O
growth O
of O
MDA O
- O
MB O
- O
231cells O
with O
IC50 O
values O
of O
18 O
. O
1 O
, O
4 O
. O
6 O
, O
and O
6 O
. O
7 O
mu O
M O
, O
respectively O
. O

Similarly O
, O
Chalcone B
, O
2 B
- I
hydroxychalcone I
, O
and O
xanthohumol B
also O
exerted O
cytotoxicity O
in O
another O
TNBC O
cell O
line O
, O
Hs578T O
. O

Neohesperidin B
dihydrochalcone I
, O
4 B
- I
methoxychalcone I
, O
and O
hesperidin B
methylchalcone I
did O
not O
show O
the O
cytotoxicity O
on O
the O
MDA O
- O
MB O
- O
231cells O
. O

Xanthohumol B
and O
2 B
- I
hydroxychalcone I
induced O
apoptosis O
by O
Bcl O
- O
2 O
downregulation O
. O

Importantly O
, O
2 B
- I
hydroxychalcone I
and O
xanthohumol B
exerted O
more O
potent O
inhibitory O
effects O
on O
the O
proliferation O
, O
MMP O
- O
9 O
expression O
and O
invasive O
phenotype O
of O
MDA O
- O
MB O
- O
231 O
than O
chalcone B
. O

The O
formulation O
of O
the O
extrudate O
had O
an O
AUC O
( O
0 O
- O
t O
) O
and O
Cmax O
similar O
to O
those O
of O
ITZ B
and O
also O
OH B
- I
ITZ I
compared O
with O
the O
commercial O
capsule O
( O
Sporanox B
( O
R O
) O
) O
. O

In O
addition O
, O
MK B
- I
571 I
, O
an O
inhibitor O
of O
multidrug O
resistance O
- O
associated O
protein O
2 O
( O
MRP2 O
) O
, O
exhibited O
the O
same O
trend O
but O
to O
a O
lesser O
extent O
. O

Metabolic O
response O
demonstrated O
by O
18F B
- I
FDG I
- O
PET O
/ O
CT O
in O
metastatic O
medullary O
thyroid O
carcinoma O
under O
sorafenib B
therapy O
. O

To O
evaluate O
the O
metabolic O
activity O
of O
these O
lesions O
, O
18F B
- I
fluorodeoxiglucose I
positron O
emission O
tomography O
- O
CT O
( O
FDG B
- O
PET O
/ O
CT O
) O
scan O
was O
requested O
. O

Microsomal O
epoxide B
hydrolase O
( O
mEH O
, O
EPHX1 O
) O
is O
a O
critical O
xenobiotic O
- O
metabolizing O
enzyme O
, O
catalyzing O
both O
detoxification O
and O
bioactivation O
reactions O
that O
direct O
the O
disposition O
of O
chemical O
epoxides B
, O
including O
the O
carcinogenic O
metabolites O
of O
several O
polycyclic B
aromatic I
hydrocarbons I
. O

Confirmation O
of O
the O
structure O
of O
MC B
- I
RY I
( O
9 O
) O
facilitated O
detailed O
analysis O
of O
its O
MS O
( O
2 O
) O
spectrum O
, O
thereby O
supporting O
the O
structures O
of O
related O
analogues O
tentatively O
established O
on O
the O
basis O
of O
MS O
analyses O
. O

The O
in O
vitro O
experiment O
results O
showed O
that O
the O
amine B
salts I
of O
TEF B
and O
LOX B
, O
especially O
TEF B
- I
TEtA I
and O
LOX B
- I
TEtA I
, O
enhanced O
the O
skin O
permeation O
of O
TEF B
and O
LOX B
from O
the O
transdermal O
patch O
system O
. O

The O
in O
vitro O
experiment O
results O
showed O
that O
the O
amine B
salts I
of O
TEF B
and O
LOX B
, O
especially O
TEF B
- I
TEtA I
and O
LOX B
- I
TEtA I
, O
enhanced O
the O
skin O
permeation O
of O
TEF B
and O
LOX B
from O
the O
transdermal O
patch O
system O
. O

The O
optimal O
formulation O
successfully O
displayed O
isochronous O
permeation O
rates O
for O
TEF B
and O
LOX B
across O
rabbit O
skin O
, O
and O
was O
defined O
with O
5 O
% O
of O
TEF B
- I
TEtA I
, O
10 O
% O
of O
LOX B
- I
TEtA I
and O
15 O
% O
of O
azone O
. O

The O
optimal O
formulation O
successfully O
displayed O
isochronous O
permeation O
rates O
for O
TEF B
and O
LOX B
across O
rabbit O
skin O
, O
and O
was O
defined O
with O
5 O
% O
of O
TEF B
- I
TEtA I
, O
10 O
% O
of O
LOX B
- I
TEtA I
and O
15 O
% O
of O
azone O
. O

The O
cyclin O
D1 O
( O
CCND1 O
) O
rs9344 O
G O
> O
A O
polymorphism O
predicts O
clinical O
outcome O
in O
colon O
cancer O
patients O
treated O
with O
adjuvant O
5 B
- I
FU I
- O
based O
chemotherapy O
. O

Patients O
treated O
with O
5 B
- I
fluorouracil I
- O
based O
chemotherapy O
, O
carrying O
the O
CCND1 O
rs9344 O
A O
/ O
A O
genotype O
had O
significantly O
decreased O
time O
- O
to O
- O
tumor O
recurrence O
( O
TTR O
) O
in O
univariate O
analysis O
and O
multivariate O
analysis O
( O
hazard O
ratio O
( O
HR O
) O
2 O
. O
47 O
; O
95 O
% O
confidence O
interval O
( O
CI O
) O
1 O
. O
16 O
- O
5 O
. O
29 O
; O
P O
= O
0 O
. O
019 O
) O
. O

We O
solved O
the O
crystal O
structures O
of O
tau O
55 O
- O
HPD O
and O
its O
closely O
related O
paralogue O
Huf O
and O
used O
in O
silico O
docking O
methods O
to O
identify O
phospho B
- I
serine I
and O
phospho B
- I
tyrosine I
containing O
peptides O
as O
possible O
substrates O
that O
were O
subsequently O
validated O
using O
in O
vitro O
phosphatase O
assays O
. O

We O
solved O
the O
crystal O
structures O
of O
tau O
55 O
- O
HPD O
and O
its O
closely O
related O
paralogue O
Huf O
and O
used O
in O
silico O
docking O
methods O
to O
identify O
phospho B
- I
serine I
and O
phospho B
- I
tyrosine I
containing O
peptides O
as O
possible O
substrates O
that O
were O
subsequently O
validated O
using O
in O
vitro O
phosphatase O
assays O
. O

Ultrasonic O
synthesis O
, O
characterization O
of O
beta B
- I
aminoketones I
by O
bismuth B
( I
III I
) I
triflate I
and O
determination O
of O
antigenotoxic O
properties O
. O

Direct O
- O
type O
catalytic O
Mannich O
reaction O
for O
the O
synthesis O
of O
beta B
- I
aminoketones I
from O
cyclohexanone B
, O
substituted O
aromatic B
amines I
and I
aromatic I
or I
hetero I
- I
aromatic I
aldehydes I
has O
been O
applied O
in O
water O
with O
bismuth B
triflate I
under O
ultrasound O
. O

Good O
yields O
of O
the O
expected O
beta B
- I
aminoketones I
were O
obtained O
from O
available O
substrates O
, O
at O
room O
temperature O
in O
1 O
- O
2 O
hours O
. O

This O
study O
was O
designed O
to O
evaluate O
the O
mutagenic O
and O
antimutagenic O
potential O
of O
synthesized O
beta B
- I
aminoketones I
compounds O
using O
Ames O
/ O
Salmonella O
and O
Escherichia O
coli O
WP2 O
bacterial O
reverse O
mutation O
assay O
systems O
. O

Methods O
: O
2 B
- I
iminothiolane I
was O
covalently O
attached O
to O
a O
chitosan O
backbone O
. O

This O
expands O
the O
number O
of O
known O
solvents O
which O
can O
support O
amphiphilic O
self O
- O
assembly O
to O
ethanol B
, O
acetone B
, O
tetrahydrofuran B
, O
N B
- I
dimethylformamide I
, O
N B
- I
cyclohexyl I
- I
2 I
- I
pyrrolidone I
, O
and O
a O
number O
of O
other O
organic O
solvents O
, O
many O
of O
which O
were O
not O
known O
to O
afford O
solvophobic O
self O
- O
assembly O
prior O
to O
this O
report O
. O

Helicity O
as O
a O
Steric O
Force O
: O
Stabilization O
and O
Helicity O
- O
Dependent O
Reversion O
of O
Colored O
o B
- I
Quinonoid I
Intermediates O
of O
Helical O
Chromenes O
. O

Aazahelical O
chromenes O
3 O
and O
4 O
with O
varying O
magnitudes O
of O
helicity O
were O
designed O
in O
pursuit O
of O
o B
- I
quinonoid I
intermediates O
with O
graded O
activation O
barriers O
. O

Detection O
of O
Nitrogen B
- O
Protonated B
Nitrous I
Oxide I
( O
HNNO B
( I
+ I
) I
) O
by O
Rotational O
Spectroscopy O
. O

The O
rotational O
spectrum O
of O
nitrogen B
- O
protonated B
nitrous I
oxide I
( O
HNNO B
( I
+ I
) I
) O
, O
an O
isomer O
whose O
existence O
was O
first O
inferred O
from O
kinetic O
studies O
more O
than O
30 O
years O
ago O
, O
has O
now O
been O
detected O
by O
Fourier O
transform O
microwave O
spectroscopy O
, O
guided O
by O
new O
high O
- O
level O
coupled O
- O
cluster O
calculations O
of O
its O
molecular O
structure O
. O

The O
chi O
aa O
( O
N B
) O
values O
for O
the O
two O
isomers O
of O
protonated B
nitrous I
oxide I
are O
qualitatively O
consistent O
with O
the O
valence O
bond O
description O
of O
H B
- I
N I
= I
N I
( I
+ I
) I
= I
O I
for O
the O
electronic O
structure O
of O
the O
nitrogen B
- O
protonated O
form O
and O
N B
= I
N I
( I
+ I
) I
- I
O I
- I
H I
for O
the O
oxygen B
- O
protonated O
form O
. O

Twelve O
alkyl B
analogues O
( O
1 O
- O
12 O
) O
of O
the O
high O
- O
affinity O
serotonin B
transporter O
( O
SERT O
) O
inhibitor O
6 B
- I
nitroquipazine I
( O
6 B
- I
NQ I
) O
were O
synthesized O
and O
studied O
using O
in O
vitro O
radioligand O
competition O
binding O
assays O
to O
determine O
their O
binding O
affinity O
( O
Ki O
) O
. O

Twelve O
alkyl B
analogues O
( O
1 O
- O
12 O
) O
of O
the O
high O
- O
affinity O
serotonin B
transporter O
( O
SERT O
) O
inhibitor O
6 B
- I
nitroquipazine I
( O
6 B
- I
NQ I
) O
were O
synthesized O
and O
studied O
using O
in O
vitro O
radioligand O
competition O
binding O
assays O
to O
determine O
their O
binding O
affinity O
( O
Ki O
) O
. O

Our O
results O
showed O
that O
several O
of O
the O
6 B
- I
NQ I
analogues O
are O
high O
- O
affinity O
SERT O
inhibitors O
and O
indicated O
that O
the O
octyl B
( O
8 O
) O
, O
decyl B
( O
10 O
) O
and O
dodecyl B
( O
12 O
) O
6 B
- I
NQ I
analogues O
exhibit O
moderate O
antidepressant O
activity O
. O

Our O
results O
showed O
that O
several O
of O
the O
6 B
- I
NQ I
analogues O
are O
high O
- O
affinity O
SERT O
inhibitors O
and O
indicated O
that O
the O
octyl B
( O
8 O
) O
, O
decyl B
( O
10 O
) O
and O
dodecyl B
( O
12 O
) O
6 B
- I
NQ I
analogues O
exhibit O
moderate O
antidepressant O
activity O
. O

Different O
concentrations O
of O
sodium B
pentaborate I
pentahydrate I
( O
NaB B
) O
were O
prepared O
for O
the O
analysis O
of O
cell O
toxicity O
and O
differentiation O
evaluations O
. O

Profile O
hidden O
Markov O
models O
( O
HMMs O
) O
were O
used O
to O
predict O
the O
configuration O
of O
secondary B
alcohols I
and O
alpha B
- I
methyl I
branches O
of O
modular O
polyketides O
. O

Additional O
studies O
suggest O
the O
possibility O
that O
TBAF B
chelation O
by O
neighboring O
acyl B
groups O
may O
account O
for O
the O
unexpected O
regioselectivity O
at O
the O
secondary B
alcohol I
esters I
that O
is O
observed O
in O
the O
TBAF B
deacylation O
of O
cellulose O
esters B
. O

As O
of O
early O
2013 O
, O
over O
200 O
natural O
products O
are O
known O
to O
contain O
a O
nitrogen B
- O
nitrogen B
( O
N B
- I
N I
) O
bond O
. O

Glutathione B
conjugation O
attenuates O
biological O
activities O
of O
6 B
- I
dehydroshogaol I
from O
ginger O
. O

6 B
- I
Dehydroshogaol I
( O
6 B
- I
DHSG I
) O
is O
a O
bioactive O
alpha B
, I
beta I
- I
unsaturated I
carbonyl I
compound O
isolated O
from O
fresh O
ginger O
with O
anti O
- O
inflammatory O
and O
phase O
II O
enzyme O
inducing O
activities O
. O

6 B
- I
Dehydroshogaol I
( O
6 B
- I
DHSG I
) O
is O
a O
bioactive O
alpha B
, I
beta I
- I
unsaturated I
carbonyl I
compound O
isolated O
from O
fresh O
ginger O
with O
anti O
- O
inflammatory O
and O
phase O
II O
enzyme O
inducing O
activities O
. O

Here O
we O
describe O
the O
glutathione B
( O
GSH B
) O
- O
dependent O
metabolism O
and O
the O
effect O
of O
this O
metabolic O
transformation O
on O
the O
biological O
activities O
of O
6 B
- I
DHSG I
. O

Compared O
with O
other O
ginger O
compounds O
, O
such O
as O
6 B
- I
gingerol I
and O
6 B
- I
shogaol I
, O
6 B
- I
DHSG I
showed O
the O
most O
potent O
anti O
- O
inflammatory O
effect O
in O
lipopolysaccharide O
( O
LPS O
) O
- O
stimulated O
RAW O
264 O
. O
7 O
cells O
. O

Compared O
with O
other O
ginger O
compounds O
, O
such O
as O
6 B
- I
gingerol I
and O
6 B
- I
shogaol I
, O
6 B
- I
DHSG I
showed O
the O
most O
potent O
anti O
- O
inflammatory O
effect O
in O
lipopolysaccharide O
( O
LPS O
) O
- O
stimulated O
RAW O
264 O
. O
7 O
cells O
. O

Compared O
with O
other O
ginger O
compounds O
, O
such O
as O
6 B
- I
gingerol I
and O
6 B
- I
shogaol I
, O
6 B
- I
DHSG I
showed O
the O
most O
potent O
anti O
- O
inflammatory O
effect O
in O
lipopolysaccharide O
( O
LPS O
) O
- O
stimulated O
RAW O
264 O
. O
7 O
cells O
. O

The O
biological O
activities O
of O
6 B
- I
DHSG I
were O
attenuated O
by O
sulfhydryl B
antioxidants O
such O
as O
glutathione B
( O
GSH B
) O
or O
N B
- I
acetyl I
cysteine I
( O
NAC B
) O
, O
but O
not O
ascorbic B
acid I
( O
ASC B
) O
. O

6 B
- I
DHSG I
was O
metabolised O
by O
GSH B
to O
form O
a O
GSH B
conjugate O
( O
GS B
- I
6 I
- I
DHSG I
) O
in O
RAW O
264 O
. O
7 O
cells O
, O
via O
a O
potential O
mechanism O
involving O
the O
catalytic O
activity O
of O
glutathione B
- O
S B
- O
transferase O
( O
GST O
) O
. O

GS B
- I
6 I
- I
DHSG I
showed O
reduced O
biological O
activities O
compared O
with O
6 B
- I
DHSG I
in O
multiple O
biological O
assays O
. O

Together O
, O
these O
results O
indicate O
that O
GSH B
conjugation O
attenuates O
the O
biological O
activities O
of O
6 B
- I
DHSG I
and O
other O
alpha B
, I
beta I
- I
unsaturated I
carbonyl I
compounds O
. O

The O
addition O
of O
sodium B
sulphite I
or O
sodium B
dodecyl I
sulphate I
also O
inhibited O
precipitate O
formation O
after O
freeze O
- O
thawing O
, O
resulting O
in O
no O
fractionation O
. O

Prooxidative O
and O
antioxidative O
properties O
of O
beta B
- I
carotene I
in O
chlorophyll B
and O
riboflavin B
photosensitized O
oil O
- O
in O
- O
water O
emulsions O
. O

Effects O
of O
beta B
- I
carotene I
on O
the O
oxidative O
stability O
of O
chlorophyll B
or O
riboflavin B
photosensitized O
oil O
- O
in O
- O
water O
( O
O O
/ O
W O
) O
emulsions O
were O
determined O
by O
analysing O
the O
depleted O
headspace O
oxygen B
content O
, O
lipid O
hydroperoxides B
, O
fluorescence O
intensity O
, O
and O
headspace O
volatiles O
. O

As O
the O
concentration O
of O
beta B
- I
carotene I
increased O
from O
0 O
to O
10 O
, O
100 O
, O
and O
1000 O
mu O
M O
, O
the O
oxidative O
stability O
of O
samples O
containing O
chlorophylls B
decreased O
in O
a O
concentration O
- O
dependent O
manner O
under O
light O
, O
indicating O
that O
beta B
- I
carotene I
acted O
as O
a O
prooxidant O
. O

As O
the O
concentration O
of O
beta B
- I
carotene I
increased O
from O
0 O
to O
10 O
, O
100 O
, O
and O
1000 O
mu O
M O
, O
the O
oxidative O
stability O
of O
samples O
containing O
chlorophylls B
decreased O
in O
a O
concentration O
- O
dependent O
manner O
under O
light O
, O
indicating O
that O
beta B
- I
carotene I
acted O
as O
a O
prooxidant O
. O

However O
, O
in O
riboflavin B
photosensitized O
O O
/ O
W O
emulsions O
, O
100 O
and O
1000 O
mu O
M O
beta B
- I
carotene I
inhibited O
lipid O
oxidation O
. O

Although O
beta B
- I
carotene I
protected O
both O
photosensitisers O
in O
O O
/ O
W O
emulsions O
, O
beta B
- I
carotene I
displayed O
antioxidative O
or O
prooxidative O
properties O
, O
which O
depended O
on O
the O
polarity O
of O
the O
photosensitisers O
. O

Although O
beta B
- I
carotene I
protected O
both O
photosensitisers O
in O
O O
/ O
W O
emulsions O
, O
beta B
- I
carotene I
displayed O
antioxidative O
or O
prooxidative O
properties O
, O
which O
depended O
on O
the O
polarity O
of O
the O
photosensitisers O
. O

The O
development O
of O
t B
- I
2 I
- I
heptenal I
and O
1 B
- I
octen I
- I
3 I
- I
ol I
increased O
greatly O
in O
chlorophyll B
sensitised O
O O
/ O
W O
emulsions O
with O
an O
increase O
in O
beta B
- I
carotene I
concentration O
, O
implying O
that O
more O
singlet O
oxygen B
oxidation O
occurred O
due O
to O
the O
higher O
levels O
of O
remaining O
chlorophylls B
. O

However O
, O
the O
content O
of O
t B
- I
2 I
- I
heptenal I
and O
1 B
- I
octen I
- I
3 I
- I
ol I
in O
the O
riboflavin B
sensitised O
O O
/ O
W O
emulsions O
was O
not O
significantly O
correlated O
with O
the O
beta B
- I
carotene I
concentration O
, O
which O
indicates O
that O
beta B
- I
carotene I
in O
the O
lipid O
particles O
effectively O
quenched O
singlet O
oxygen B
. O

However O
, O
the O
content O
of O
t B
- I
2 I
- I
heptenal I
and O
1 B
- I
octen I
- I
3 I
- I
ol I
in O
the O
riboflavin B
sensitised O
O O
/ O
W O
emulsions O
was O
not O
significantly O
correlated O
with O
the O
beta B
- I
carotene I
concentration O
, O
which O
indicates O
that O
beta B
- I
carotene I
in O
the O
lipid O
particles O
effectively O
quenched O
singlet O
oxygen B
. O

derivative O
, O
one O
alkaloid O
, O
three O
benzenoids B
, O
and O
two O
steroids B
. O

Synthesis O
and O
evaluation O
of O
carbamoylmethylene B
linked O
prodrugs O
of O
BMS B
- I
582949 I
, O
a O
clinical O
p38 O
alpha O
inhibitor O
. O

A O
series O
of O
carbamoylmethylene B
linked O
prodrugs O
of O
1 O
( O
BMS B
- I
582949 I
) O
, O
a O
clinical O
p38 O
alpha O
inhibitor O
, O
were O
synthesized O
and O
evaluated O
. O

The O
specific O
impact O
of O
enhanced O
2 B
- I
arachidonoylglycerol I
signaling O
on O
corticosterone B
plasma O
levels O
, O
however O
, O
was O
not O
investigated O
so O
far O
. O

Moreover O
, O
exposure O
to O
the O
OP O
pesticides O
resulted O
in O
increased O
7 B
- I
methylguanine I
, O
ribothymidine B
, O
cholic B
acid I
, O
4 B
- I
pyridoxic I
acid I
, O
kynurenine B
and O
indoxyl B
sulfate I
levels O
, O
as O
well O
as O
decreased O
hippuric B
acid I
, O
creatinine B
, O
uric B
acid I
, O
gentisic B
acid I
, O
C18 B
- I
dihydrosphingosine I
, O
phytosphingosine B
, O
suberic B
acid I
and O
citric B
acid I
. O

Moreover O
, O
exposure O
to O
the O
OP O
pesticides O
resulted O
in O
increased O
7 B
- I
methylguanine I
, O
ribothymidine B
, O
cholic B
acid I
, O
4 B
- I
pyridoxic I
acid I
, O
kynurenine B
and O
indoxyl B
sulfate I
levels O
, O
as O
well O
as O
decreased O
hippuric B
acid I
, O
creatinine B
, O
uric B
acid I
, O
gentisic B
acid I
, O
C18 B
- I
dihydrosphingosine I
, O
phytosphingosine B
, O
suberic B
acid I
and O
citric B
acid I
. O

Six O
compounds O
were O
isolated O
and O
identified O
from O
this O
plant O
: O
three O
phenolic B
compounds O
( O
kampferol B
, O
kampferol B
- I
3 I
- I
glucoside I
and O
kampferol B
- I
3 I
- I
galactoside I
) O
in O
addition O
to O
three O
steroidal O
compounds O
( O
1 B
- I
ethoxypentacosane I
, O
heptacosan B
- I
1 I
- I
ol I
and O
beta B
- I
sitosterol I
) O
. O

Six O
compounds O
were O
isolated O
and O
identified O
from O
this O
plant O
: O
three O
phenolic B
compounds O
( O
kampferol B
, O
kampferol B
- I
3 I
- I
glucoside I
and O
kampferol B
- I
3 I
- I
galactoside I
) O
in O
addition O
to O
three O
steroidal O
compounds O
( O
1 B
- I
ethoxypentacosane I
, O
heptacosan B
- I
1 I
- I
ol I
and O
beta B
- I
sitosterol I
) O
. O

Three O
compounds O
( O
heptacosan B
- I
1 I
- I
ol I
, O
beta B
- I
sitosterol I
and O
kampferol B
- I
3 I
- I
galactoside I
) O
were O
found O
to O
be O
responsible O
for O
the O
anti O
- O
UC O
activity O
of O
E O
. O
granuleta O
extract O
. O

Inhibitors O
of O
galectin O
- O
3 O
function O
( O
beta B
- I
lactose I
, O
a O
dominant O
- O
negative O
form O
of O
galectin O
- O
3 O
, O
Gal O
- O
3C O
, O
and O
anti O
- O
galectin O
- O
3 O
antibody O
M3 O
/ O
38 O
) O
or O
collagen O
receptor O
- O
mediated O
platelet O
adhesion O
( O
revacept O
, O
a O
dimeric O
collagen O
receptor O
GPVI O
- O
Fc O
) O
prevented O
aberrant O
COX O
- O
2 O
expression O
. O

Solvent O
effect O
studies O
revealed O
that O
in O
good O
solvents O
such O
as O
n B
- I
hexane I
, O
benzene B
, O
and O
1 B
, I
4 I
- I
dioxane I
, O
the O
profile O
of O
the O
fluorescence O
emission O
of O
the O
compound O
is O
characterized O
by O
pyrene B
monomer O
emission O
, O
but O
in O
poor O
solvent O
such O
as O
water O
, O
the O
emission O
is O
dominated O
by O
pyrene O
excimer O
emission O
. O

Quantitatively O
speaking O
, O
the O
ratio O
of O
the O
excimer O
emission O
to O
monomer O
emission O
changes O
from O
50 O
to O
0 O
when O
ECPS O
is O
dissolved O
in O
water O
and O
n B
- I
hexane I
, O
respectively O
. O

Spin O
- O
cast O
films O
of O
dyes O
( O
donor O
- O
pi O
- O
donor O
, O
donor O
- O
pi O
- O
acceptor O
, O
and O
acceptor O
- O
pi O
- O
acceptor O
type O
, O
where O
the O
donor O
is O
Ph2N B
- O
, O
the O
acceptor O
is O
2 B
- I
benzothiazoyl I
, O
and O
the O
pi O
- O
linker O
is O
9 B
, I
9 I
- I
diethylfluorene I
) O
blended O
with O
nonconjugated O
bisphthalimides B
were O
prepared O
. O

In O
fact O
, O
we O
demonstrated O
a O
significant O
stimulation O
of O
Nox4 O
activity O
by O
4 O
quinone B
derivatives O
( O
AA B
- I
861 I
, O
tBuBHQ B
, O
tBuBQ B
, O
and O
duroquinone B
) O
observed O
in O
3 O
different O
cellular O
models O
, O
HEK293E O
, O
T O
- O
REx O
( O
TM O
) O
, O
and O
chondrocyte O
cell O
lines O
. O

Simonols B
A I
and I
B I
, O
two O
novel O
sesqui B
- I
neolignans I
from O
the O
fruits O
of O
Illicium O
simonsii O
. O

Two O
new O
sesqui B
- I
neolignans I
with O
novel O
conjugation O
way O
, O
simonol B
A I
( O
1 O
) O
, O
featuring O
a O
unique O
motif O
of O
a O
5 B
, I
5 I
- I
dihydro I
- I
pyran I
with O
a O
hemiketal B
carbon I
, O
while O
simonol B
B I
( O
2 O
) O
possessing O
two O
dihydronfuran B
rings O
in O
the O
same O
direction O
, O
were O
isolated O
from O
the O
ethanol B
extract O
of O
the O
fruits O
of O
Illicium O
simonii O
. O

The O
two O
isolates O
were O
evaluated O
for O
their O
inhibitory O
activities O
against O
the O
growth O
of O
four O
lines O
of O
human O
cancer O
cells O
( O
NCI O
- O
H460 O
, O
SMMC O
- O
7721 O
, O
MCF O
- O
7 O
, O
BGC O
- O
823 O
) O
: O
1 O
showed O
strong O
activities O
comparable O
to O
5 B
- I
Fluorouracil I
, O
and O
2 O
to O
a O
less O
content O
. O

Thermal O
stability O
of O
oligodeoxynucleotide O
duplexes O
containing O
l B
- I
deoxynucleotide I
at O
termini O
. O

The O
effects O
of O
substituting O
l B
- I
deoxynucleotide I
for O
d B
- I
deoxynucleotide I
at O
duplex O
termini O
were O
evaluated O
and O
the O
terminal O
substitutions O
were O
found O
to O
show O
much O
less O
effects O
on O
duplex O
destabilization O
and O
to O
show O
a O
similar O
tendency O
in O
base O
pairing O
selectivity O
, O
compared O
with O
internal O
chiral O
substitutions O
. O

The O
effects O
of O
substituting O
l B
- I
deoxynucleotide I
for O
d B
- I
deoxynucleotide I
at O
duplex O
termini O
were O
evaluated O
and O
the O
terminal O
substitutions O
were O
found O
to O
show O
much O
less O
effects O
on O
duplex O
destabilization O
and O
to O
show O
a O
similar O
tendency O
in O
base O
pairing O
selectivity O
, O
compared O
with O
internal O
chiral O
substitutions O
. O

Agonistic O
activity O
of O
ICI B
182 I
780 I
on O
activation O
of O
GSK O
3 O
beta O
/ O
AKT O
pathway O
in O
the O
rat O
uterus O
during O
the O
estrous O
cycle O
. O

MATERIALS O
AND O
METHODS O
: O
In O
this O
study O
, O
we O
examined O
the O
proposed O
penetration O
enhancing O
properties O
of O
spilanthol B
, O
an O
N B
- I
alkylamide I
abundantly O
present O
in O
several O
Asteraceae O
plants O
like O
Spilanthes O
acmella O
L O
. O
, O
on O
three O
model O
drugs O
( O
caffeine B
, O
testosterone B
and O
ibuprofen B
) O
. O

Next O
to O
its O
beneficial O
applicability O
to O
increase O
local O
as O
well O
as O
systemic O
pharmacological O
effects O
of O
dermally O
co O
- O
administrated O
drug O
, O
this O
N B
- I
alkylamide I
negatively O
influences O
human O
health O
risk O
if O
spilanthol B
containing O
formulations O
are O
polluted O
with O
mycotoxins O
: O
the O
presence O
of O
spilanthol B
( O
0 O
. O
3w O
/ O
V O
% O
) O
induced O
a O
significant O
increase O
of O
permeability O
coefficient O
Kp O
of O
five O
investigated O
mycotoxins O
, O
with O
ER O
values O
ranging O
between O
1 O
. O
57 O
and O
6 O
. O
37 O
. O

Copper B
( I
II I
) I
complexes O
[ B
Cu I
( I
Fc I
- I
aa I
) I
( I
cur I
) I
] I
( O
1 O
- O
3 O
) O
of O
curcumin B
( O
Hcur B
) O
and O
N B
- I
ferrocenylmethyl I
- I
l I
- I
amino I
acids I
( O
Fc B
- I
aa I
) O
, O
viz O
. O
, O
ferrocenylmethyl B
- I
l I
- I
tyrosine I
( O
Fc B
- I
TyrH I
) O
, O
ferrocenylmethyl B
- I
l I
- I
tryptophan I
( O
Fc B
- I
TrpH I
) O
and O
ferrocenylmethyl B
- I
l I
- I
methionine I

Copper B
( I
II I
) I
complexes O
[ B
Cu I
( I
Fc I
- I
aa I
) I
( I
cur I
) I
] I
( O
1 O
- O
3 O
) O
of O
curcumin B
( O
Hcur B
) O
and O
N B
- I
ferrocenylmethyl I
- I
l I
- I
amino I
acids I
( O
Fc B
- I
aa I
) O
, O
viz O
. O
, O
ferrocenylmethyl B
- I
l I
- I
tyrosine I
( O
Fc B
- I
TyrH I
) O
, O
ferrocenylmethyl B
- I
l I
- I
tryptophan I
( O
Fc B
- I
TrpH I
) O
and O
ferrocenylmethyl B
- I
l I
- I
methionine I

Copper B
( I
II I
) I
complexes O
[ B
Cu I
( I
Fc I
- I
aa I
) I
( I
cur I
) I
] I
( O
1 O
- O
3 O
) O
of O
curcumin B
( O
Hcur B
) O
and O
N B
- I
ferrocenylmethyl I
- I
l I
- I
amino I
acids I
( O
Fc B
- I
aa I
) O
, O
viz O
. O
, O
ferrocenylmethyl B
- I
l I
- I
tyrosine I
( O
Fc B
- I
TyrH I
) O
, O
ferrocenylmethyl B
- I
l I
- I
tryptophan I
( O
Fc B
- I
TrpH I
) O
and O
ferrocenylmethyl B
- I
l I
- I
methionine I

tert B
- I
Butylhydroquinone I
reduces O
lipid O
accumulation O
in O
C57BL O
/ O
6 O
mice O
with O
lower O
body O
weight O
gain O
. O

tert B
- I
Butylhydroquinone I
( O
tBHQ B
) O
is O
a O
commonly O
used O
antioxidant O
additive O
that O
is O
approved O
for O
human O
use O
by O
both O
the O
Food O
and O
Agriculture O
Organization O
and O
the O
World O
Health O
Organization O
( O
FAO O
/ O
WHO O
) O
. O

In O
this O
paper O
, O
ultrastable O
aqueous O
foam O
stabilized O
by O
a O
kind O
of O
flexible O
connecting O
bipolar O
- O
headed O
surfactant O
alkyl B
polyoxyethylene I
sulfate I
( O
AE3S B
) O
with O
coexisting O
Mg B
( I
2 I
+ I
) I
was O
reported O
. O

Detailed O
molecular O
behaviors O
of O
AE3S B
in O
foam O
film O
with O
coexisting O
divalent O
cationic O
Ca B
( I
2 I
+ I
) I
or O
Mg B
( I
2 I
+ I
) I
were O
investigated O
by O
molecular O
dynamic O
simulation O
, O
comparing O
with O
the O
traditional O
surfactant O
sodium B
dodecyl I
sulfate I
( O
SDS B
) O
, O
to O
find O
out O
how O
the O
microcharacter O
and O
array O
behavior O
of O
molecules O
in O
the O
foam O
film O
determined O
by O
molecular O
interaction O
effect O
the O
foam O
stability O
. O

A O
selective O
KOR O
agonist O
( O
U69593 B
, O
1 O
mu O
M O
) O
diminished O
evoked O
GABAergic O
inhibitory O
postsynaptic O
currents O
( O
IPSCs O
) O
by O
18 O
% O
( O
n O
= O
10 O
) O
in O
the O
CeA O
, O
whereas O
blockade O
of O
KORs O
with O
a O
selective O
antagonist O
( O
nor B
- I
binaltorphimine I
, O
1 O
mu O
M O
) O
augmented O
the O
baseline O
evoked O
GABAergic O
IPSCs O
by O
14 O
% O
( O
p O
< O
0 O
. O
01 O
; O
n O
= O
34 O
) O
, O
suggesting O
that O
the O
KOR O
system O
contributes O
to O
tonic O
inhibition O
of O
GABAergic O
neurotransmission O
in O
the O
CeA O
. O

The O
fraction O
of O
proximal O
renal O
cells O
with O
elevated O
8 B
- I
oxodeoxyguanosine I
( O
8 B
- I
OH I
- I
dG I
) O
was O
only O
increased O
at O
the O
high O
dose O
and O
did O
not O
differ O
by O
sex O
. O

MAO O
Inhibitory O
Activity O
of O
2 B
- I
Arylbenzofurans I
versus O
3 B
- I
Arylcoumarins I
: O
Synthesis O
, O
in O
vitro O
Study O
, O
and O
Docking O
Calculations O
. O

MAO O
Inhibitory O
Activity O
of O
2 B
- I
Arylbenzofurans I
versus O
3 B
- I
Arylcoumarins I
: O
Synthesis O
, O
in O
vitro O
Study O
, O
and O
Docking O
Calculations O
. O

Several O
3 B
- I
arylcoumarin I
derivatives O
were O
previously O
described O
as O
interesting O
selective O
MAO O
- O
B O
inhibitors O
. O

Preserving O
the O
trans B
- I
stilbene I
structure O
, O
a O
series O
of O
2 B
- I
arylbenzofuran I
and O
corresponding O
3 B
- I
arylcoumarin I
derivatives O
were O
synthesized O
and O
evaluated O
as O
inhibitors O
of O
both O
MAO O
isoforms O
, O
MAO O
- O
A O
and O
MAO O
- O
B O
. O

Preserving O
the O
trans B
- I
stilbene I
structure O
, O
a O
series O
of O
2 B
- I
arylbenzofuran I
and O
corresponding O
3 B
- I
arylcoumarin I
derivatives O
were O
synthesized O
and O
evaluated O
as O
inhibitors O
of O
both O
MAO O
isoforms O
, O
MAO O
- O
A O
and O
MAO O
- O
B O
. O

Preserving O
the O
trans B
- I
stilbene I
structure O
, O
a O
series O
of O
2 B
- I
arylbenzofuran I
and O
corresponding O
3 B
- I
arylcoumarin I
derivatives O
were O
synthesized O
and O
evaluated O
as O
inhibitors O
of O
both O
MAO O
isoforms O
, O
MAO O
- O
A O
and O
MAO O
- O
B O
. O

However O
, O
3 B
- I
phenylcoumarin I
14 O
showed O
activity O
in O
the O
same O
range O
( O
IC50 O
= O
6 O
nM O
) O
, O
is O
reversible O
, O
and O
also O
severalfold O
more O
selective O
than O
compound O
15 O
. O

Docking O
experiments O
for O
the O
most O
active O
compounds O
into O
the O
MAO O
- O
B O
and O
MAO O
- O
A O
binding O
pockets O
highlighted O
different O
interactions O
between O
the O
derivative O
classes O
( O
2 B
- I
arylbenzofurans I
and O
3 B
- I
arylcoumarins I
) O
, O
and O
provided O
new O
information O
about O
the O
enzyme O
- O
inhibitor O
interaction O
and O
the O
potential O
therapeutic O
application O
of O
these O
scaffolds O
. O

Docking O
experiments O
for O
the O
most O
active O
compounds O
into O
the O
MAO O
- O
B O
and O
MAO O
- O
A O
binding O
pockets O
highlighted O
different O
interactions O
between O
the O
derivative O
classes O
( O
2 B
- I
arylbenzofurans I
and O
3 B
- I
arylcoumarins I
) O
, O
and O
provided O
new O
information O
about O
the O
enzyme O
- O
inhibitor O
interaction O
and O
the O
potential O
therapeutic O
application O
of O
these O
scaffolds O
. O

Determination O
of O
urinary O
6 B
- I
mercaptopurine I
and O
three O
of O
its O
metabolites O
by O
HPLC O
- O
UV O
coupled O
with O
the O
iodine B
- O
azide B
reaction O
. O

Background O
: O
The O
presented O
method O
is O
able O
to O
determine O
6 B
- I
mercaptopurine I
( O
6 B
- I
MP I
) O
, O
6 B
- I
thioguanine I
, O
6 B
- I
mercaptopurine I
riboside I
and O
6 B
- I
thioguanine I
riboside I
in O
urine O
, O
and O
is O
thereby O
dedicated O
to O
control O
of O
thiopurine B
therapy O
of O
children O
with O
acute O
lymphoblastic O
leukemia O
. O

Background O
: O
The O
presented O
method O
is O
able O
to O
determine O
6 B
- I
mercaptopurine I
( O
6 B
- I
MP I
) O
, O
6 B
- I
thioguanine I
, O
6 B
- I
mercaptopurine I
riboside I
and O
6 B
- I
thioguanine I
riboside I
in O
urine O
, O
and O
is O
thereby O
dedicated O
to O
control O
of O
thiopurine B
therapy O
of O
children O
with O
acute O
lymphoblastic O
leukemia O
. O

Background O
: O
The O
presented O
method O
is O
able O
to O
determine O
6 B
- I
mercaptopurine I
( O
6 B
- I
MP I
) O
, O
6 B
- I
thioguanine I
, O
6 B
- I
mercaptopurine I
riboside I
and O
6 B
- I
thioguanine I
riboside I
in O
urine O
, O
and O
is O
thereby O
dedicated O
to O
control O
of O
thiopurine B
therapy O
of O
children O
with O
acute O
lymphoblastic O
leukemia O
. O

Good O
separation O
of O
the O
mentioned O
compounds O
was O
achieved O
on O
a O
C18 O
stationary O
phase O
with O
a O
sodium B
azide I
and O
sodium B
heptane I
sulfonate I
solution O
, O
acetonitrile B
and O
water O
at O
ratio O
of O
50 O
: O
1 O
: O
49 O
( O
v O
/ O
v O
/ O
v O
) O
. O

LOD O
and O
LOQ O
are O
0 O
. O
3 O
, O
0 O
. O
4 O
, O
0 O
. O
3 O
, O
0 O
. O
8 O
and O
0 O
. O
4 O
, O
0 O
. O
6 O
, O
0 O
. O
5 O
and O
0 O
. O
9 O
nmol O
/ O
ml O
of O
urine O
for O
6 B
- I
MP I
, O
6 B
- I
thioguanine I
, O
6 B
- I
mercaptopurine I
riboside I
and O
6 B
- I
thioguanine I
riboside I
, O
respectively O
. O

LOD O
and O
LOQ O
are O
0 O
. O
3 O
, O
0 O
. O
4 O
, O
0 O
. O
3 O
, O
0 O
. O
8 O
and O
0 O
. O
4 O
, O
0 O
. O
6 O
, O
0 O
. O
5 O
and O
0 O
. O
9 O
nmol O
/ O
ml O
of O
urine O
for O
6 B
- I
MP I
, O
6 B
- I
thioguanine I
, O
6 B
- I
mercaptopurine I
riboside I
and O
6 B
- I
thioguanine I
riboside I
, O
respectively O
. O

Conclusion O
: O
The O
elaborated O
method O
was O
successfully O
applied O
for O
detection O
and O
quantitation O
of O
6 B
- I
MP I
and O
its O
selected O
metabolites O
in O
patients O
' O
urine O
samples O
. O

Polyelectrolyte O
- O
Surfactant O
Complexes O
of O
Poly B
[ I
3 I
, I
5 I
- I
bis I
( I
dimethylaminomethyl I
) I
- I
4 I
- I
hydroxystyrene I
] I
- I
block I
- I
poly I
( I
ethylene I
oxide I
) I
and O
Sodium B
Dodecyl I
Sulfate I
: O
Anomalous O
Self O
- O
Assembly O
Behavior O
. O

Polyelectrolyte O
- O
surfactant O
complexes O
( O
PE O
- O
S O
) O
formed O
by O
double O
hydrophilic O
cationic O
polyelectrolyte O
poly B
[ I
3 I
, I
5 I
- I
bis I
( I
dimethylaminomethyl I
) I
- I
4 I
- I
hydroxystyrene I
] I
- I
block I
- I
poly I
( I
ethylene I
oxide I
) I
( O
NPHOS B
- I
PEO I
) O
and O
anionic O
surfactant O
sodium B
dodecyl I
sulfate I
( O
SDS B
) O
in O
acidic O
aqueous O
solutions O
were O
studied O
by O
light O
scattering O
, O
SAXS O
, O
and O
scanning O
transmission O
electron O
microcopy O
in O
the O
environmental O
mode O
( O

Polyelectrolyte O
- O
surfactant O
complexes O
( O
PE O
- O
S O
) O
formed O
by O
double O
hydrophilic O
cationic O
polyelectrolyte O
poly B
[ I
3 I
, I
5 I
- I
bis I
( I
dimethylaminomethyl I
) I
- I
4 I
- I
hydroxystyrene I
] I
- I
block I
- I
poly I
( I
ethylene I
oxide I
) I
( O
NPHOS B
- I
PEO I
) O
and O
anionic O
surfactant O
sodium B
dodecyl I
sulfate I
( O
SDS B
) O
in O
acidic O
aqueous O
solutions O
were O
studied O
by O
light O
scattering O
, O
SAXS O
, O
and O
scanning O
transmission O
electron O
microcopy O
in O
the O
environmental O
mode O
( O

The O
obtained O
results O
show O
that O
the O
NPHOS B
- I
PEO I
/ O
SDS B
system O
behaves O
differently O
from O
other O
systems O
of O
double O
hydrophilic O
block O
polyelectrolyte O
and O
oppositely O
charged O
ionic O
surfactant O
because O
it O
forms O
water O
- O
insoluble O
PE O
- O
S O
for O
compositions O
close O
to O
the O
zero O
net O
charge O
of O
the O
complex O
. O

SAXS O
measurements O
indicate O
that O
although O
the O
NPHOS B
- I
PEO I
/ O
SDS B
system O
does O
not O
form O
the O
core O
- O
shell O
particles O
with O
the O
NPHOS B
/ O
SDS B
core O
and O
the O
PEO B
shell O
as O
other O
PE O
- O
S O
of O
double O
hydrophilic O
polyelectrolytes O
, O
the O
aggregates O
contain O
domains O
of O
closely O
packed O
surfactant O
micelles O
which O
bind O
to O
both O
NPHOS B
polyelectrolyte O
blocks O
and O
PEO B
blocks O
. O

pH O
- O
Responsive O
Aggregation O
States O
of O
Chiral O
Polymerizable O
Amphiphiles O
from O
l B
- I
Tyrosine I
and O
l B
- I
Phenyl I
Alanine I
in O
Water O
. O

The O
induced O
' O
ischemic O
depression O
' O
was O
lasting O
and O
sensitive O
to O
an O
acute O
administration O
of O
brain O
- O
derived O
neurotrophic O
factor O
or O
bryostatin B
- I
1 I
, O
a O
relatively O
selective O
activator O
of O
protein O
kinase O
C O
epsilon O
, O
during O
the O
induction O
phase O
. O

Chronic O
treatment O
with O
bryostatin B
- I
1 I
( O
5 O
weeks O
) O
after O
the O
induction O
of O
depressive O
behavior O
reversed O
the O
depressive O
immobility O
and O
produced O
a O
lasting O
therapeutic O
effect O
, O
which O
remained O
effective O
3 O
weeks O
after O
discontinuation O
of O
the O
treatment O
. O

The O
results O
strongly O
suggest O
that O
cerebral O
ischemia O
has O
a O
direct O
role O
in O
shaping O
the O
sensitivity O
of O
an O
individual O
to O
depressogenic O
events O
and O
that O
bryostatin B
- I
1 I
- O
like O
agents O
may O
be O
developed O
as O
therapeutics O
for O
treating O
ischemic O
depression O
in O
humans O
. O

Antimalarial O
Activity O
of O
Axidjiferosides B
, O
New O
beta B
- I
Galactosylceramides I
from O
the O
African O
Sponge O
Axinyssa O
djiferi O
. O

They O
were O
identified O
as O
homologous O
beta B
- I
galactopyranosylcera I
composed O
of O
2 B
- I
amino I
- I
( I
6E I
) I
- I
octadec I
- I
6 I
- I
en I
- I
1 I
, I
3 I
, I
4 I
- I
triol I
, O
and O
the O
major O
one O
, O
axidjiferoside B
- I
A I
( O
around O
60 O
% O
) O
, O
contained O
2 B
- I
hydroxytetracosanoic I
acid I
. O

They O
were O
identified O
as O
homologous O
beta B
- I
galactopyranosylcera I
composed O
of O
2 B
- I
amino I
- I
( I
6E I
) I
- I
octadec I
- I
6 I
- I
en I
- I
1 I
, I
3 I
, I
4 I
- I
triol I
, O
and O
the O
major O
one O
, O
axidjiferoside B
- I
A I
( O
around O
60 O
% O
) O
, O
contained O
2 B
- I
hydroxytetracosanoic I
acid I
. O

The O
metabolism O
of O
nitrooxybutyl B
- I
esters I
of O
flurbiprofen B
and O
ferulic B
- I
acid I
, O
a O
class O
of O
organic O
nitrates B
with O
potential O
therapeutic O
implication O
in O
variety O
of O
different O
conditions O
, O
was O
investigated O
in O
comparison O
with O
glyceryl B
trinitrate I
( O
GTN B
) O
in O
human O
liver O
by O
a O
multiple O
approach O
, O
using O
a O
spontaneous O
metabolism O
- O
independent O
NO B
donor O
( O
NOC B
- I
5 I
) O
as O
a O
reference O
tool O
. O

The O
metabolism O
of O
nitrooxybutyl B
- I
esters I
of O
flurbiprofen B
and O
ferulic B
- I
acid I
, O
a O
class O
of O
organic O
nitrates B
with O
potential O
therapeutic O
implication O
in O
variety O
of O
different O
conditions O
, O
was O
investigated O
in O
comparison O
with O
glyceryl B
trinitrate I
( O
GTN B
) O
in O
human O
liver O
by O
a O
multiple O
approach O
, O
using O
a O
spontaneous O
metabolism O
- O
independent O
NO B
donor O
( O
NOC B
- I
5 I
) O
as O
a O
reference O
tool O
. O

The O
metabolism O
of O
nitrooxybutyl B
- I
esters I
of O
flurbiprofen B
and O
ferulic B
- I
acid I
, O
a O
class O
of O
organic O
nitrates B
with O
potential O
therapeutic O
implication O
in O
variety O
of O
different O
conditions O
, O
was O
investigated O
in O
comparison O
with O
glyceryl B
trinitrate I
( O
GTN B
) O
in O
human O
liver O
by O
a O
multiple O
approach O
, O
using O
a O
spontaneous O
metabolism O
- O
independent O
NO B
donor O
( O
NOC B
- I
5 I
) O
as O
a O
reference O
tool O
. O

Nitrooxybutyl B
- I
esters I
were O
rapidly O
and O
quantitatively O
metabolized O
to O
their O
respective O
parent O
compounds O
and O
the O
organic O
nitrate B
moiety O
nitrooxybutyl B
- I
alcohol I
( O
NOBA B
) O
. O

Nitrooxybutyl B
- I
esters I
were O
rapidly O
and O
quantitatively O
metabolized O
to O
their O
respective O
parent O
compounds O
and O
the O
organic O
nitrate B
moiety O
nitrooxybutyl B
- I
alcohol I
( O
NOBA B
) O
. O

In O
contrast O
to O
the O
spontaneous O
NO B
donor O
NOC B
- I
5 I
, O
NOBA B
and O
GTN B
did O
not O
generate O
detectable O
NO B
and O
failed O
to O
suppress O
the O
activity O
of O
cytochromeP450 O
; O
an O
enzyme O
known O
to O
be O
inhibited O
by O
NO B
. O

The O
direct O
identification O
of O
NOBA B
following O
liver O
metabolism O
targets O
this O
compound O
as O
the O
functional O
organic O
nitrate B
metabolite O
of O
nitrooxybutyl B
- I
esters I
. O

We O
assessed O
nociception O
, O
endocannabinoids O
and O
the O
therapeutic O
efficacy O
of O
R B
- I
flurbiprofen I
in O
young O
and O
aged O
mice O
in O
the O
spared O
nerve O
injury O
model O
of O
neuropathic O
pain O
. O

R B
- I
flurbiprofen I
was O
used O
because O
it O
is O
able O
to O
reduce O
neuropathic O
pain O
in O
young O
mice O
in O
part O
by O
increasing O
anandamide B
. O

In O
aged O
mice O
, O
R B
- I
flurbiprofen I
had O
only O
weak O
antinociceptive O
efficacy O
and O
it O
failed O
to O
restore O
normal O
anandamide B
levels O
after O
nerve O
injury O
. O

This O
may O
overwhelm O
the O
capacity O
of O
R B
- I
flurbiprofen I
to O
restore O
anandamide B
homeostasis O
and O
may O
contribute O
to O
the O
heightened O
risk O
for O
neuropathic O
pain O
at O
old O
age O
. O

This O
study O
determined O
the O
effects O
of O
MDPV B
, O
alongside O
those O
of O
the O
better O
studied O
stimulant O
d B
- I
methamphetamine I
( O
METH B
) O
, O
using O
rodent O
models O
of O
intravenous O
self O
- O
administration O
( O
IVSA O
) O
, O
thermoregulation O
and O
locomotor O
activity O
. O

The O
reaction O
kinetics O
between O
CO2 B
and O
trihexyl B
( I
tetradecyl I
) I
phosphonium I
( O
[ B
P66614 I
] I
) O
- O
based O
ionic O
liquids O
( O
ILs O
) O
with O
prolinate B
( O
[ B
Pro I
] I
) O
, O
2 B
- I
cyanopyrrolide I
( O
[ B
2 I
- I
CNpyr I
] I
) O
, O
and O
3 B
- I
( I
trifluoromethyl I
) I
pyrazolide I
( O
[ B
3 I
- I
CF3pyra I
] I
) O
anions O
are O
studied O
at O
temperatures O
from O
22 O
- O
60 O
degrees O
C O
. O

The O
reaction O
kinetics O
between O
CO2 B
and O
trihexyl B
( I
tetradecyl I
) I
phosphonium I
( O
[ B
P66614 I
] I
) O
- O
based O
ionic O
liquids O
( O
ILs O
) O
with O
prolinate B
( O
[ B
Pro I
] I
) O
, O
2 B
- I
cyanopyrrolide I
( O
[ B
2 I
- I
CNpyr I
] I
) O
, O
and O
3 B
- I
( I
trifluoromethyl I
) I
pyrazolide I
( O
[ B
3 I
- I
CF3pyra I
] I
) O
anions O
are O
studied O
at O
temperatures O
from O
22 O
- O
60 O
degrees O
C O
. O

The O
reaction O
kinetics O
between O
CO2 B
and O
trihexyl B
( I
tetradecyl I
) I
phosphonium I
( O
[ B
P66614 I
] I
) O
- O
based O
ionic O
liquids O
( O
ILs O
) O
with O
prolinate B
( O
[ B
Pro I
] I
) O
, O
2 B
- I
cyanopyrrolide I
( O
[ B
2 I
- I
CNpyr I
] I
) O
, O
and O
3 B
- I
( I
trifluoromethyl I
) I
pyrazolide I
( O
[ B
3 I
- I
CF3pyra I
] I
) O
anions O
are O
studied O
at O
temperatures O
from O
22 O
- O
60 O
degrees O
C O
. O

A O
highly O
selective O
P450 O
1B1 O
inhibitor O
5 B
- I
hydroxy I
- I
4 I
' I
- I
propargyloxyflavone I
( O
5H4 B
' I
FPE I
) O
was O
discovered O
. O

alpha B
- I
Naphthoflavone I
- O
like O
and O
5 B
- I
hydroxyflavone I
derivatives O
preferentially O
inhibited O
P450 O
1A2 O
, O
while O
beta B
- I
naphthoflavone I
- O
like O
flavone B
derivatives O
showed O
selective O
inhibition O
of O
P450 O
1A1 O
. O

alpha B
- I
Naphthoflavone I
- O
like O
and O
5 B
- I
hydroxyflavone I
derivatives O
preferentially O
inhibited O
P450 O
1A2 O
, O
while O
beta B
- I
naphthoflavone I
- O
like O
flavone B
derivatives O
showed O
selective O
inhibition O
of O
P450 O
1A1 O
. O

alpha B
- I
Naphthoflavone I
- O
like O
and O
5 B
- I
hydroxyflavone I
derivatives O
preferentially O
inhibited O
P450 O
1A2 O
, O
while O
beta B
- I
naphthoflavone I
- O
like O
flavone B
derivatives O
showed O
selective O
inhibition O
of O
P450 O
1A1 O
. O

Trans B
fatty I
acids I
in O
a O
range O
of O
UK O
processed O
foods O
. O

A O
survey O
to O
determine O
the O
trans B
fatty I
acid I
content O
of O
a O
range O
of O
processed O
foods O
was O
carried O
out O
in O
response O
to O
recent O
reformulation O
work O
by O
the O
food O
industry O
to O
lower O
the O
artificial O
trans B
fatty I
acid I
content O
of O
processed O
products O
. O

A O
survey O
to O
determine O
the O
trans B
fatty I
acid I
content O
of O
a O
range O
of O
processed O
foods O
was O
carried O
out O
in O
response O
to O
recent O
reformulation O
work O
by O
the O
food O
industry O
to O
lower O
the O
artificial O
trans B
fatty I
acid I
content O
of O
processed O
products O
. O

Levels O
of O
trans B
fatty I
acids I
were O
reduced O
considerably O
compared O
with O
previous O
UK O
analyses O
of O
similar O
foods O
where O
comparisons O
are O
possible O
. O

Concentrations O
of O
trans B
elaidic I
acid I
( O
t9 B
- I
C18 I
: I
1 I
) O
from O
hydrogenated O
oils O
in O
all O
samples O
were O
< O
0 O
. O
2g O
/ O
100g O
food O
. O

But O
pork O
meat O
also O
contributes O
to O
the O
intake O
of O
fat O
, O
saturated B
fatty I
acids I
, O
cholesterol B
, O
and O
other O
substances O
that O
, O
in O
inappropriate O
amounts O
, O
may O
result O
in O
negative O
physiologically O
effects O
. O

Also O
the O
composition O
in O
fatty B
acids I
of O
triacylglycerols B
is O
very O
sensitive O
to O
the O
contents O
of O
cereals O
in O
the O
feed O
; O
for O
instance O
, O
polyunsaturated B
fatty I
acids I
may O
range O
from O
10 O
% O
to O
22 O
% O
in O
pork O
meat O
. O

In O
order O
to O
develop O
new O
iodinated O
and O
fluorinated O
matched O
- O
pair O
radiotracers O
for O
Single O
- O
Photon O
Emission O
Computed O
Tomography O
( O
SPECT O
) O
/ O
Positron O
Emission O
Tomography O
( O
PET O
) O
imaging O
and O
targeted O
radionuclide O
therapy O
of O
melanoma O
, O
we O
successfully O
synthesized O
and O
radiolabelled O
with O
iodine B
- I
125 I
seven O
new O
derivatives O
, O
starting O
from O
our O
previously O
described O
lead O
structure O
3 O
. O

These O
results O
make O
compounds O
39 O
- O
42 O
suitable O
candidates O
for O
( O
i O
) O
PET O
imaging O
of O
melanoma O
after O
labelling O
with O
fluorine B
- I
18 I
and O
( O
ii O
) O
targeted O
radionuclide O
therapy O
of O
disseminated O
melanoma O
after O
labelling O
with O
iodine B
- I
131 I
. O

These O
results O
make O
compounds O
39 O
- O
42 O
suitable O
candidates O
for O
( O
i O
) O
PET O
imaging O
of O
melanoma O
after O
labelling O
with O
fluorine B
- I
18 I
and O
( O
ii O
) O
targeted O
radionuclide O
therapy O
of O
disseminated O
melanoma O
after O
labelling O
with O
iodine B
- I
131 I
. O

Short O
- O
term O
toxicity O
of O
hexavalent B
- I
chromium I
to O
epipsammic O
diatoms O
of O
a O
microtidal O
estuary O
( O
R O
i O
o O
de O
la O
Plata O
) O
: O
Responses O
from O
the O
individual O
cell O
to O
the O
community O
structure O
. O

Furthermore O
, O
gold B
- I
thioglucose I
- O
induced O
hypothalamic O
lesions O
, O
including O
the O
VMH O
and O
the O
arcuate O
nucleus O
, O
abolished O
the O
anorexigenic O
effects O
of O
ECS O
, O
indicating O
the O
requirement O
for O
the O
activation O
of O
the O
hypothalamus O
. O

hexachlorobiphenyl I
( O
PCB B
- I
153 I
) O
, O
hexachlorobenzene B
( O
HCB B
) O
, O
hexabromocyclododeca B
( O
HBCD B
) O
, O
2 B
, I
2 I
' I
, I
4 I
, I
4 I
' I
- I
tetrabrominated I
diphenyl I
ether I
( O
BDE B
- I
47 I
) O
, O
perfluorinated B
octyl I
acid I
( O
PFOA B
) O
and O
perfluorinated B
octyl I
sulfonate I
( O
PFOS B
) O
. O

hexachlorobiphenyl I
( O
PCB B
- I
153 I
) O
, O
hexachlorobenzene B
( O
HCB B
) O
, O
hexabromocyclododeca B
( O
HBCD B
) O
, O
2 B
, I
2 I
' I
, I
4 I
, I
4 I
' I
- I
tetrabrominated I
diphenyl I
ether I
( O
BDE B
- I
47 I
) O
, O
perfluorinated B
octyl I
acid I
( O
PFOA B
) O
and O
perfluorinated B
octyl I
sulfonate I
( O
PFOS B
) O
. O

hexachlorobiphenyl I
( O
PCB B
- I
153 I
) O
, O
hexachlorobenzene B
( O
HCB B
) O
, O
hexabromocyclododeca B
( O
HBCD B
) O
, O
2 B
, I
2 I
' I
, I
4 I
, I
4 I
' I
- I
tetrabrominated I
diphenyl I
ether I
( O
BDE B
- I
47 I
) O
, O
perfluorinated B
octyl I
acid I
( O
PFOA B
) O
and O
perfluorinated B
octyl I
sulfonate I
( O
PFOS B
) O
. O

A O
modest O
decrease O
in O
global O
DNA O
methylation O
was O
observed O
in O
N2A O
cells O
exposed O
to O
10 O
mu O
M O
DES B
, O
BPA B
, O
TCDD B
, O
BDE B
- I
47 I
, O
PCB B
- I
153 I
and O
1 O
mu O
M O
HCB B
, O
but O
no O
changes O
were O
found O
in O
the O
human O
SK O
- O
N O
- O
AS O
cells O
. O

A O
modest O
decrease O
in O
global O
DNA O
methylation O
was O
observed O
in O
N2A O
cells O
exposed O
to O
10 O
mu O
M O
DES B
, O
BPA B
, O
TCDD B
, O
BDE B
- I
47 I
, O
PCB B
- I
153 I
and O
1 O
mu O
M O
HCB B
, O
but O
no O
changes O
were O
found O
in O
the O
human O
SK O
- O
N O
- O
AS O
cells O
. O

We O
reveal O
for O
the O
first O
time O
that O
BDE B
- I
47 I
increases O
adipocyte O
differentiation O
in O
a O
dose O
- O
dependent O
manner O
( O
2 O
. O
5 O
- O
25 O
mu O
M O
) O
. O

The O
other O
chemicals O
showed O
either O
modest O
or O
no O
effects O
on O
adipocyte O
differentiation O
at O
the O
concentrations O
tested O
( O
PFOA B
, O
PFOS B
and O
HBCD B
at O
10 O
mu O
M O
; O
PCB B
- I
153 I
, O
3 O
. O
4 O
mu O
M O
and O
HCB B
, O
1 O
mu O
M O
) O
. O

In O
the O
present O
study O
, O
the O
anti O
- O
inflammatory O
effect O
of O
salicylideneamino B
- I
2 I
- I
thiophenol I
( O
SAL B
- I
2 I
) O
, O
a O
derivative O
of O
salicylate B
, O
on O
a O
potent O
oxidant O
4 B
- I
hydroxynonenal I
( O
HNE B
) O
- O
induced O
oxidative O
stress O
was O
investigated O
using O
rat O
prostate O
endothelial O
( O
YPEN O
- O
1 O
) O
cells O
. O

In O
the O
present O
study O
, O
the O
anti O
- O
inflammatory O
effect O
of O
salicylideneamino B
- I
2 I
- I
thiophenol I
( O
SAL B
- I
2 I
) O
, O
a O
derivative O
of O
salicylate B
, O
on O
a O
potent O
oxidant O
4 B
- I
hydroxynonenal I
( O
HNE B
) O
- O
induced O
oxidative O
stress O
was O
investigated O
using O
rat O
prostate O
endothelial O
( O
YPEN O
- O
1 O
) O
cells O
. O

We O
focused O
on O
anti O
- O
inflammatory O
activity O
of O
SAL B
- I
2 I
which O
was O
determined O
by O
its O
ability O
to O
suppress O
COX O
- O
2 O
and O
iNOS O
gene O
expression O
through O
suppression O
of O
NF O
- O
kappa O
B O
and O
redox O
regulation O
. O

We O
found O
that O
SAL B
- I
2 I
effectively O
inhibited O
HNE B
- O
induced O
reactive O
species O
generation O
, O
while O
upregulated O
GSH B
/ O
GSSG B
ratio O
. O

Prostagrandin O
( B
PG I
) I
E2 I
production O
stimulated O
by O
arachidonic B
acid I
was O
suppressed O
by O
SAL B
- I
2 I
. O

SAL B
- I
2 I
also O
downregulated O
COX O
- O
2 O
and O
iNOS O
expression O
induced O
by O
HNE B
, O
but O
salicylate B
did O
not O
. O

We O
found O
that O
SAL B
- I
2 I
inhibited O
HNE B
- O
mediated O
IKK O
phosphorylation O
, O
I O
kappa O
B O
alpha O
degradation O
and O
nuclear O
translocation O
of O
p65 O
which O
are O
linked O
to O
NF O
- O
kappa O
B O
activation O
. O

Furthermore O
, O
SAL B
- I
2 I
inhibited O
HNE B
- O
induced O
activation O
of O
mitogen O
- O
activated O
protein O
kinases O
. O

Collectively O
, O
SAL B
- I
2 I
inhibited O
COX O
- O
2 O
and O
iNOS O
gene O
expression O
through O
suppression O
of O
NF O
- O
kappa O
B O
leading O
to O
the O
inhibition O
of O
PGE2 B
synthesis O
. O

Based O
on O
these O
data O
, O
we O
propose O
that O
with O
its O
combined O
effect O
on O
strong O
anti O
- O
oxidant O
and O
anti O
- O
inflammatory O
action O
, O
SAL B
- I
2 I
can O
be O
a O
potent O
anti O
- O
inflammatory O
agent O
for O
treatment O
of O
inflammatory O
- O
related O
diseases O
. O

Bicyclic O
Derivatives O
of O
L B
- I
Idonojirimycin I
as O
Pharmacological O
Chaperones O
for O
Neuronopathic O
Forms O
of O
Gaucher O
Disease O
. O

15 B
- I
deoxy I
- I
delta12 I
, I
14 I
- I
prostaglandin I
J2 I
( O
15d B
- I
PGJ2 I
) O
is O
an O
endogenous O
anti O
- O
inflammatory O
lipid O
derived O
from O
PGD2 B
. O

In O
order O
to O
identify O
the O
candidate O
target O
proteins O
covalently O
modified O
by O
15d B
- I
PGJ2 I
in O
human O
aortic O
endothelial O
cell O
( O
EC O
) O
, O
EC O
were O
treated O
with O
biotinylated B
- I
15d I
- I
PGJ2 I
, O
the O
modified O
proteins O
extracted O
by O
Neutravidin O
affinity O
- O
purification O
and O
the O
proteins O
identified O
by O
LTQ O
Orbitrap O
mass O
spectrometer O
. O

This O
protein O
data O
set O
highlights O
the O
potential O
for O
15d B
- I
PGJ2 I
to O
covalently O
modify O
cellular O
proteins O
and O
provides O
a O
source O
of O
data O
that O
will O
aid O
further O
studies O
on O
the O
mechanism O
of O
action O
of O
this O
endogenous O
regulator O
of O
inflammation O
. O

The O
structural O
information O
of O
the O
first O
shell O
around O
a O
Co B
ion O
was O
expressed O
in O
terms O
of O
the O
hydration O
number O
, O
Co B
- I
O I
distance O
and O
Debye O
- O
Waller O
factor O
. O

The O
actual O
coordination O
number O
and O
the O
interatomic O
distance O
of O
Co B
- I
O I
for O
the O
dissolved O
species O
were O
remarkably O
reduced O
compared O
to O
the O
bulk O
aqueous O
solution O
indicating O
the O
dehydration O
of O
water O
molecules O
from O
Co B
ions O
and O
a O
compact O
hydrated O
structure O
in O
the O
micropore O
of O
SWNTs O
. O

Two O
new O
bis B
( I
trialkoxysilyl I
) I
derivatives O
of O
Gd B
( I
III I
) I
diethylenetriamine I
pentaacetate I
( O
Gd B
- I
DTPA I
) O
containing O
disulfide B
linkages O
are O
synthesized O
and O
used O
to O
form O
biodegradable O
Gd B
- I
PSQ I
particles O
by O
base O
- O
catalyzed O
condensation O
reactions O
in O
reverse O
microemulsions O
. O

Two O
new O
bis B
( I
trialkoxysilyl I
) I
derivatives O
of O
Gd B
( I
III I
) I
diethylenetriamine I
pentaacetate I
( O
Gd B
- I
DTPA I
) O
containing O
disulfide B
linkages O
are O
synthesized O
and O
used O
to O
form O
biodegradable O
Gd B
- I
PSQ I
particles O
by O
base O
- O
catalyzed O
condensation O
reactions O
in O
reverse O
microemulsions O
. O

The O
Gd B
- I
PSQ I
particles O
, O
PSQ O
- O
1 O
and O
PSQ O
- O
2 O
, O
carry O
53 O
. O
8 O
wt O
% O
and O
49 O
. O
3 O
wt O
% O
of O
Gd B
- I
DTPA I
derivatives O
, O
respectively O
. O

The O
Gd B
- I
PSQ I
particles O
, O
PSQ O
- O
1 O
and O
PSQ O
- O
2 O
, O
carry O
53 O
. O
8 O
wt O
% O
and O
49 O
. O
3 O
wt O
% O
of O
Gd B
- I
DTPA I
derivatives O
, O
respectively O
. O

The O
Gd B
- I
PSQ I
particles O
are O
readily O
degradable O
to O
release O
the O
constituent O
Gd B
( I
III I
) I
chelates O
in O
the O
presence O
of O
endogenous O
reducing O
agents O
such O
as O
cysteine B
and O
glutathione B
. O

The O
MR O
relaxivities O
of O
the O
Gd B
- I
PSQ I
particles O
are O
determined O
using O
a O
3T O
MR O
scanner O
, O
with O
r1 O
values O
ranging O
from O
5 O
. O
9 O
to O
17 O
. O
8 O
mMs O
( O
- O
1 O
) O
on O
a O
per O
- O
Gd B
basis O
. O

Finally O
, O
the O
high O
sensitivity O
of O
the O
Gd B
- I
PSQ I
particles O
as O
T1 O
- O
weighted O
MR O
contrast O
agents O
is O
demonstrated O
with O
in O
vitro O
MR O
imaging O
of O
human O
lung O
and O
pancreatic O
cancer O
cells O
. O

A O
new O
ent B
- I
kaurane I
diterpenoid B
glycoside I
from O
Isodon O
japonica O
var O
. O
glaucocalyx O
. O

A O
new O
ent B
- I
kaurane I
diterpenoid B
glycoside I
( O
1 O
) O
, O
named O
glaucocalyxin B
G I
, O
has O
been O
isolated O
from O
the O
n B
- I
butanol I
- O
soluble O
fraction O
of O
the O
dried O
whole O
plants O
of O
Isodon O
japonica O
var O
. O
glaucocalyx O
along O
with O
two O
known O
compounds O
, O
namely O
arjunglucoside B
( O
2 O
) O
and O
kaempferol B
- I
3 I
- I
O I
- I
rutinoside I
( O
3 O
) O
. O

A O
new O
ent B
- I
kaurane I
diterpenoid B
glycoside I
( O
1 O
) O
, O
named O
glaucocalyxin B
G I
, O
has O
been O
isolated O
from O
the O
n B
- I
butanol I
- O
soluble O
fraction O
of O
the O
dried O
whole O
plants O
of O
Isodon O
japonica O
var O
. O
glaucocalyx O
along O
with O
two O
known O
compounds O
, O
namely O
arjunglucoside B
( O
2 O
) O
and O
kaempferol B
- I
3 I
- I
O I
- I
rutinoside I
( O
3 O
) O
. O

Metabolomics O
of O
brain O
homogenate O
and O
cerebrospinal O
fluid O
revealed O
a O
significant O
up O
- O
regulation O
of O
L B
- I
carnitine I
, O
acetyl B
- I
L I
- I
carnitine I
, O
pantothenic B
acid I
, O
2 B
' I
- I
deoxycytidine I
diphosphate I
( O
dCDP B
) O
, O
anandamide B
, O
N B
- I
acetylglucosaminylam I
and O
a O
down O
- O
regulation O
of O
stearoyl B
- I
L I
- I
carnitine I
in O
Tg O
- O
2D6 O
mice O
compared O
with O
WT O
mice O
. O

Metabolomics O
of O
brain O
homogenate O
and O
cerebrospinal O
fluid O
revealed O
a O
significant O
up O
- O
regulation O
of O
L B
- I
carnitine I
, O
acetyl B
- I
L I
- I
carnitine I
, O
pantothenic B
acid I
, O
2 B
' I
- I
deoxycytidine I
diphosphate I
( O
dCDP B
) O
, O
anandamide B
, O
N B
- I
acetylglucosaminylam I
and O
a O
down O
- O
regulation O
of O
stearoyl B
- I
L I
- I
carnitine I
in O
Tg O
- O
2D6 O
mice O
compared O
with O
WT O
mice O
. O

Co O
- O
treating O
TW2 O
. O
6 O
cells O
with O
CAPE B
and O
5 B
- I
fluorouracil I
, O
a O
commonly O
used O
chemotherapeutic O
drug O
for O
oral O
cancers O
, O
exhibited O
additive O
cell O
proliferation O
inhibition O
. O

Locked O
nucleic O
acid O
( O
LNA O
) O
is O
a O
chemical O
modification O
which O
introduces O
a O
- O
O B
- I
CH2 I
- O
linkage O
in O
the O
furanose B
sugar I
of O
nucleic O
acids O
and O
blocks O
its O
conformation O
in O
a O
particular O
state O
. O

A O
combination O
of O
two O
factors O
, O
namely O
, O
nature O
of O
the O
- O
O B
- I
CH2 I
- O
linkage O
in O
the O
LNAs O
vs O
their O
absence O
in O
the O
pure O
duplexes O
and O
similar O
conformations O
of O
the O
sugar O
rings O
in O
DNA O
and O
alpha O
- O
LNA O
vs O
the O
other O
two O
, O
is O
suggested O
to O
contribute O
to O
the O
stark O
differences O
among O
the O
four O
duplexes O
studied O
here O
in O
terms O
of O
their O
structural O
, O
dynamic O
, O
and O
energetic O
properties O
. O

In O
contrast O
to O
the O
reduced O
activity O
of O
the O
unsubstituted O
E O
- O
ring O
derivatives O
, O
hydrophobic O
and O
relatively O
non O
- O
polar O
substituents O
approach O
or O
match O
the O
chloro B
substituted I
vancomycin I
and O
was O
insensitive O
to O
the O
electronic O
character O
of O
the O
substituent O
( O
e O
. O
g O
. O
Cl B
vs O
CN B
or O
OMe B
) O
, O
whereas O
highly O
polar O
substituents O
fail O
to O
provide O
the O
enhancements O
. O

The O
robust O
borylation O
reaction O
also O
enabled O
the O
selective O
functionalization O
of O
a O
minimally O
protected O
vancomycin B
aglycon O
( O
N B
- I
Boc I
vancomycin B
aglycon O
) O
, O
and O
provides O
a O
direct O
method O
for O
the O
preparation O
of O
previously O
inaccessible O
analogues O
. O

AIM O
OF O
THE O
STUDY O
: O
To O
explore O
the O
effectiveness O
and O
the O
material O
basis O
of O
XXD O
in O
trinitrobenzene B
sulfonic I
acid I
( O
TNBS B
) O
- O
induced O
UC O
rats O
. O

An O
increase O
in O
intracellular O
reactive O
oxygen B
species O
( O
ROS O
) O
was O
observed O
in O
AC O
- O
treated O
cells O
, O
whereas O
the O
antioxidant O
N B
- I
acetylcysteine I
( O
NAC B
) O
prevented O
AC O
- O
induced O
cell O
death O
, O
HER O
- O
2 O
/ O
neu O
depletion O
, O
PI3K O
/ O
Akt O
inactivation O
, O
and O
Bcl O
- O
2 O
/ O
Bax O
dysregulation O
, O
indicating O
that O
AC O
- O
induced O
cell O
death O
was O
mediated O
by O
ROS O
generation O
. O

Interestingly O
, O
we O
showed O
that O
rapamycin B
shares O
all O
the O
proteasome O
targeting O
properties O
not O
only O
with O
other O
two O
- O
domain O
, O
closed O
- O
ring O
analogs O
( O
rapalogs O
) O
, O
but O
also O
with O
its O
single O
domain O
mimics O
, O
and O
with O
seco B
- I
rapamycin I
. O

The O
sensor O
is O
a O
planar O
crystalline O
silicon B
waveguide O
, O
which O
is O
highly O
transparent O
, O
between O
lambda O
= O
1 O
. O
3 O
and O
6 O
. O
5 O
mu O
m O
, O
so O
that O
its O
operational O
spectral O
range O
covers O
most O
characteristic O
chemical O
absorption O
bands O
due O
to O
bonds O
such O
as O
C B
- I
H I
, O
N B
- I
H I
, O
O B
- I
H I
, O
C B
- I
C I
, O
N B
- I
O I
, O
C B
[ O
double O
bond O
, O
length O
as O
m O
- O
dash O
] O
O B
, O
and O
C B
[ O
triple O
bond O
, O
length O
as O
m O
- O
dash O
] O
N B
, O
as O
opposed O
to O
conventional O
UV O
, O
Vis O
, O
Near O
- O
IR O
sensors O
, O
which O
use O
weaker O
overtones O
of O
these O
fundamental O
bands O
. O

The O
sensor O
is O
a O
planar O
crystalline O
silicon B
waveguide O
, O
which O
is O
highly O
transparent O
, O
between O
lambda O
= O
1 O
. O
3 O
and O
6 O
. O
5 O
mu O
m O
, O
so O
that O
its O
operational O
spectral O
range O
covers O
most O
characteristic O
chemical O
absorption O
bands O
due O
to O
bonds O
such O
as O
C B
- I
H I
, O
N B
- I
H I
, O
O B
- I
H I
, O
C B
- I
C I
, O
N B
- I
O I
, O
C B
[ O
double O
bond O
, O
length O
as O
m O
- O
dash O
] O
O B
, O
and O
C B
[ O
triple O
bond O
, O
length O
as O
m O
- O
dash O
] O
N B
, O
as O
opposed O
to O
conventional O
UV O
, O
Vis O
, O
Near O
- O
IR O
sensors O
, O
which O
use O
weaker O
overtones O
of O
these O
fundamental O
bands O
. O

The O
sensor O
is O
a O
planar O
crystalline O
silicon B
waveguide O
, O
which O
is O
highly O
transparent O
, O
between O
lambda O
= O
1 O
. O
3 O
and O
6 O
. O
5 O
mu O
m O
, O
so O
that O
its O
operational O
spectral O
range O
covers O
most O
characteristic O
chemical O
absorption O
bands O
due O
to O
bonds O
such O
as O
C B
- I
H I
, O
N B
- I
H I
, O
O B
- I
H I
, O
C B
- I
C I
, O
N B
- I
O I
, O
C B
[ O
double O
bond O
, O
length O
as O
m O
- O
dash O
] O
O B
, O
and O
C B
[ O
triple O
bond O
, O
length O
as O
m O
- O
dash O
] O
N B
, O
as O
opposed O
to O
conventional O
UV O
, O
Vis O
, O
Near O
- O
IR O
sensors O
, O
which O
use O
weaker O
overtones O
of O
these O
fundamental O
bands O
. O

The O
sensor O
is O
a O
planar O
crystalline O
silicon B
waveguide O
, O
which O
is O
highly O
transparent O
, O
between O
lambda O
= O
1 O
. O
3 O
and O
6 O
. O
5 O
mu O
m O
, O
so O
that O
its O
operational O
spectral O
range O
covers O
most O
characteristic O
chemical O
absorption O
bands O
due O
to O
bonds O
such O
as O
C B
- I
H I
, O
N B
- I
H I
, O
O B
- I
H I
, O
C B
- I
C I
, O
N B
- I
O I
, O
C B
[ O
double O
bond O
, O
length O
as O
m O
- O
dash O
] O
O B
, O
and O
C B
[ O
triple O
bond O
, O
length O
as O
m O
- O
dash O
] O
N B
, O
as O
opposed O
to O
conventional O
UV O
, O
Vis O
, O
Near O
- O
IR O
sensors O
, O
which O
use O
weaker O
overtones O
of O
these O
fundamental O
bands O
. O

The O
sensor O
is O
a O
planar O
crystalline O
silicon B
waveguide O
, O
which O
is O
highly O
transparent O
, O
between O
lambda O
= O
1 O
. O
3 O
and O
6 O
. O
5 O
mu O
m O
, O
so O
that O
its O
operational O
spectral O
range O
covers O
most O
characteristic O
chemical O
absorption O
bands O
due O
to O
bonds O
such O
as O
C B
- I
H I
, O
N B
- I
H I
, O
O B
- I
H I
, O
C B
- I
C I
, O
N B
- I
O I
, O
C B
[ O
double O
bond O
, O
length O
as O
m O
- O
dash O
] O
O B
, O
and O
C B
[ O
triple O
bond O
, O
length O
as O
m O
- O
dash O
] O
N B
, O
as O
opposed O
to O
conventional O
UV O
, O
Vis O
, O
Near O
- O
IR O
sensors O
, O
which O
use O
weaker O
overtones O
of O
these O
fundamental O
bands O
. O

For O
instance O
, O
we O
show O
that O
when O
testing O
at O
lambda O
= O
3 O
. O
55 O
mu O
m O
, O
the O
Mid O
- O
IR O
sensor O
can O
distinguish O
hexane B
from O
the O
rest O
of O
the O
tested O
analytes O
( O
methanol B
, O
toluene B
, O
carbon B
tetrachloride I
, O
ethanol B
and O
acetone B
) O
, O
since O
hexane B
has O
a O
strong O
absorption O
from O
the O
aliphatic O
C B
- I
H I
stretch O
at O
lambda O
= O
3 O
. O
55 O
mu O
m O
. O

Analogously O
, O
applying O
the O
same O
technique O
at O
lambda O
= O
3 O
. O
3 O
mu O
m O
, O
the O
Mid O
- O
IR O
sensor O
is O
able O
to O
determine O
the O
concentration O
of O
toluene B
dissolved O
in O
carbon B
tetrachloride I
, O
because O
toluene B
has O
a O
strong O
absorption O
at O
lambda O
= O
3 O
. O
3 O
mu O
m O
from O
the O
aromatic O
C B
- I
H I
stretch O
. O

The O
Effect O
of O
BCRP O
, O
MDR1 O
and O
OATP1B3 O
on O
the O
Antitumor O
Efficacy O
of O
the O
Lipophilic O
Camptothecin B
AR B
- I
67 I
In O
Vitro O
. O

AR B
- I
67 I
is O
a O
lipophilic O
camptothecin B
analogue O
, O
currently O
under O
early O
stage O
clinical O
trials O
. O

Therefore O
, O
the O
interplay O
between O
the O
BCRP O
, O
MDR1 O
and O
OATP1B1 O
/ O
OATP1B3 O
transporters O
and O
AR B
- I
67 I
and O
their O
impact O
on O
the O
toxicity O
profile O
of O
AR B
- I
67 I
was O
investigated O
. O

Therefore O
, O
the O
interplay O
between O
the O
BCRP O
, O
MDR1 O
and O
OATP1B1 O
/ O
OATP1B3 O
transporters O
and O
AR B
- I
67 I
and O
their O
impact O
on O
the O
toxicity O
profile O
of O
AR B
- I
67 I
was O
investigated O
. O

Using O
cell O
lines O
expressing O
the O
aforementioned O
transporters O
, O
we O
showed O
that O
the O
lipophilic O
AR B
- I
67 I
lactone B
form O
is O
a O
substrate O
for O
efflux O
transporters O
BCRP O
and O
MDR1 O
. O

Additionally O
, O
OATP1B1 O
and O
OATP1B3 O
facilitated O
the O
uptake O
of O
AR B
- I
67 I
carboxylate B
in O
SLCO1B1 O
and O
SLCO1B3 O
- O
transfected O
cell O
systems O
compared O
to O
the O
mock O
- O
transfected O
ones O
. O

Notably O
, O
both O
BCRPand O
MDR1 O
, O
conferred O
resistance O
to O
AR B
- I
67 I
lactone B
. O

Prompted O
by O
recent O
studies O
showing O
increased O
OATP1B3 O
expression O
in O
certain O
cancer O
types O
, O
we O
investigated O
the O
effect O
of O
OATP1B3 O
expression O
on O
cell O
viability O
after O
exposure O
to O
AR B
- I
67 I
carboxylate B
. O

In O
conclusion O
, O
BCRP O
- O
and O
MDR1 O
- O
mediated O
efflux O
of O
AR B
- I
67 I
lactone B
confers O
resistance O
to O
AR B
- I
67 I
, O
but O
OATP1B3 O
- O
mediated O
uptake O
of O
the O
AR B
- I
67 I
carboxylate B
does O
not O
sensitize O
OATP1B3 O
expressing O
tumor O
cells O
. O

In O
conclusion O
, O
BCRP O
- O
and O
MDR1 O
- O
mediated O
efflux O
of O
AR B
- I
67 I
lactone B
confers O
resistance O
to O
AR B
- I
67 I
, O
but O
OATP1B3 O
- O
mediated O
uptake O
of O
the O
AR B
- I
67 I
carboxylate B
does O
not O
sensitize O
OATP1B3 O
expressing O
tumor O
cells O
. O

In O
conclusion O
, O
BCRP O
- O
and O
MDR1 O
- O
mediated O
efflux O
of O
AR B
- I
67 I
lactone B
confers O
resistance O
to O
AR B
- I
67 I
, O
but O
OATP1B3 O
- O
mediated O
uptake O
of O
the O
AR B
- I
67 I
carboxylate B
does O
not O
sensitize O
OATP1B3 O
expressing O
tumor O
cells O
. O

Insertion O
of O
CO2 B
and O
COS B
into O
Bi B
- I
C I
Bonds O
: O
Reactivity O
of O
a O
Bismuth B
NCN I
Pincer O
Complex O
of O
an O
Oxyaryl B
Dianionic O
Ligand O
, O
[ B
2 I
, I
6 I
- I
( I
Me2NCH2 I
) I
2C6H3 I
] I
Bi I
( I
C6H2tBu2O I
) I
. O

The O
reactivity O
of O
the O
unusual O
oxyaryl B
dianionic O
ligand O
, O
( B
C6H2tBu2 I
- I
3 I
, I
5 I
- I
O I
- I
4 I
) I
2 I
- O
, O
in O
the O
Bi3 B
+ I
NCN I
pincer O
complex O
Ar B
' I
Bi I
( I
C6H2tBu2 I
- I
3 I
, I
5 I
- I
O I
- I
4 I
) I
, O
1 O
, O
[ O
Ar O
' O
= O
2 B
, I
6 I
- I
( I
Me2NCH2 I
) I
2C6H3 I
] O
has O
been O
explored O
with O
small O
molecule O
substrates O
and O
electrophiles O
. O

The O
first O
insertion O
reactions O
of O
CO2 B
and O
COS B
into O
Bi B
- I
C I
bonds O
are O
observed O
with O
this O
oxyaryl B
dianionic O
ligand O
complex O
. O

These O
react O
with O
additional O
R3SiX B
to O
generate O
Ar B
' I
BiX2 I
complexes O
and O
R3SiOC6H3tBu2 B
- I
2 I
, I
6 I
. O

The O
reaction O
of O
1 O
with O
I2 B
forms O
Ar B
' I
BiI2 I
and O
the O
coupled O
quinone B
, O
3 B
, I
3 I
' I
, I
5 I
, I
5 I
' I
- I
tetra I
- I
tert I
- I
butyl I
- I
4 I
, I
4 I
' I
- I
diphenoquinone I
, O
by O
oxidative O
coupling O
. O

Compound O
1 O
, O
a O
dimer O
composed O
of O
benzylisoquinoline B
and O
seco B
- I
aristolactam I
units O
, O
represents O
a O
new O
type O
of O
bisbenzylisoquinolin B
alkaloid I
, O
while O
compounds O
3 O
- O
6 O
are O
bisbenzylisoquinolin B
N I
- I
oxides I
. O

A O
series O
of O
pyrazolo B
[ I
1 I
, I
5 I
- I
a I
] I
pyrimidine I
linked O
2 B
- I
aminobenzothizole I
conjugates O
( O
6a O
- O
t O
) O
were O
synthesized O
and O
evaluated O
for O
their O
anticancer O
activity O
against O
five O
human O
cancer O
cell O
lines O
. O

The O
action O
of O
piperine B
( O
the O
pungent O
component O
of O
pepper O
) O
and O
its O
derivative O
SCT B
- I
66 I
( B
( I
2E I
, I
4E I
) I
- I
5 I
- I
( I
1 I
, I
3 I
- I
benzodioxol I
- I
5 I
- I
yl I
) I
) I
- I
N I
, I
N I
- I
diisobutyl I
- I
2 I
, I
4 I
- I
pentadienamide I
) I
on O
different O
gamma B
- I
aminobutyric I
acid I
( O
GABA B
) O
type O
A O
( O
GABAA O
) O
receptors O
, O
transient O
- O
receptor O
- O
potential O
- O
vanilloid O
- O
1 O
( O
TRPV1 O
) O
receptors O
and O
behavioral O
effects O
were O
investigated O
. O

Modulation O
of O
GABA B
- O
induced O
chloride B
currents O
( O
IGABA O
) O
by O
piperine B
and O
SCT B
- I
66 I
and O
activation O
of O
TRPV1 O
was O
studied O
using O
the O
two O
- O
microelectrode O
- O
voltage O
- O
clamp O
technique O
and O
fast O
perfusion O
. O

Replacing O
the O
piperidine B
ring O
by O
a O
N B
- I
di I
- I
isobutyl I
residue O
( O
SCT B
- I
66 I
) O
prevents O
interactions O
with O
TRPV1 O
and O
simultaneously O
increases O
the O
potency O
and O
efficiency O
of O
GABAA O
receptor O
modulation O
. O

SCT B
- I
66 I
displayed O
greater O
efficacy O
on O
GABAA O
receptors O
than O
piperine B
, O
with O
different O
subunit O
- O
dependence O
. O

Both O
compounds O
induced O
anxiolytic O
, O
anticonvulsant O
effects O
and O
reduced O
locomotor O
activity O
; O
however O
, O
SCT B
- I
66 I
induced O
stronger O
anxiolysis O
without O
decreasing O
body O
temperature O
and O
without O
the O
proconvulsive O
effects O
of O
TRPV1 O
activation O
and O
thus O
may O
serve O
as O
a O
scaffold O
for O
the O
development O
of O
novel O
GABAA O
receptor O
modulators O
. O

Metal B
- I
thiol I
complexes O
, O
particularly O
AuSCH3 B
, O
form O
a O
separate O
class O
. O

In O
the O
monolayer O
limit O
, O
transition B
metal I
dichalcogenides I
become O
direct O
- O
bandgap O
, O
light O
- O
emitting O
semiconductors O
. O

This O
issue O
is O
illustrated O
in O
the O
case O
of O
a O
fully O
epitaxial O
system O
: O
CoxNi1 B
- I
x I
nanowires O
in O
CeO2 B
/ O
SrTiO3 B
( O
001 O
) O
. O

The O
advantage O
brought O
by O
the O
ability O
to O
grow O
alloys O
is O
illustrated O
by O
the O
control O
of O
the O
magnetic O
anisotropy O
of O
the O
nanowires O
when O
passing O
from O
pure O
Ni B
wires O
to O
CoxNi1 B
- I
x I
alloys O
. O

For O
the O
P3HT B
: O
PC60BM B
polymer O
with O
a O
band O
edge O
of O
~ O
700 O
nm O
, O
the O
addition O
of O
the O
core O
/ O
shell O
nanorods O
with O
an O
aspect O
ratio O
( O
AR O
) O
of O
~ O
2 O
. O
5 O
( O
extinction O
peak O
~ O
670 O
nm O
) O
resulted O
in O
a O
7 O
. O
1 O
% O
improvement O
in O
PCE O
, O
while O
for O
the O
PBDTT B
- I
DPP I
: O
PC60BM B
polymer O
with O
a O
band O
edge O
~ O
860 O
nm O
, O
the O
addition O
of O
core O
/ O
shell O
nanorods O
with O
an O
AR O
of O
~ O
4 O
( O
extinction O
peak O
~ O
830 O
nm O
) O
resulted O
in O
a O
14 O
. O
4 O
% O
improvement O
in O
PCE O
. O

The O
addition O
of O
Au B
/ O
SiO2 B
core O
/ O
shell O
nanospheres O
to O
the O
P3HT B
: O
PC60BM B
- O
polymer O
resulted O
in O
a O
2 O
. O
7 O
% O
improvement O
in O
PCE O
, O
while O
their O
addition O
to O
a O
PBDTT B
- I
DPP I
: O
PC60BM B
polymer O
resulted O
in O
a O
9 O
. O
1 O
% O
improvement O
. O

Dendritic O
architectures O
based O
on O
bis B
- I
MPA I
: O
functional O
polymeric O
scaffolds O
for O
application O
- O
driven O
research O
. O

A O
dendritic O
family O
that O
fulfills O
these O
requirements O
is O
based O
on O
the O
2 B
, I
2 I
- I
bismethylolpropionic I
acid I
( O
bis B
- I
MPA I
) O
monomer O
. O

This O
critical O
review O
is O
the O
first O
of O
its O
kind O
to O
cover O
most O
of O
the O
research O
activities O
generated O
on O
aliphatic O
polyester O
dendritic O
architectures O
based O
on O
bis B
- I
MPA I
. O

In O
vivo O
FT O
- O
Raman O
spectroscopy O
reveals O
the O
presence O
of O
H2O2 B
, O
methionine B
sulfoxide I
, O
and O
tryptophan B
metabolites O
; O
i O
. O
e O
. O
, O
N B
- I
formylkynurenine I
and O
kynurenine B
, O
implying O
Fenton O
chemistry O
in O
the O
cascade O
( O
n O
= O
10 O
) O
. O

Matrix O
Metalloproteinase O
Inhibitors O
Based O
on O
the O
3 B
- I
Mercaptopyrrolidine I
Core O
. O

We O
have O
recently O
reported O
that O
a O
mono O
- O
hydroxylated O
metabolite O
of O
the O
synthetic O
aminoalkylindole B
cannabinoid O
JHW B
- I
073 I
( O
3 O
) O
exhibits O
neutral O
antagonist O
activity O
at O
CB1Rs O
and O
thus O
may O
serve O
as O
a O
promising O
lead O
for O
the O
development O
of O
novel O
alcohol B
abuse O
therapies O
. O

There O
were O
no O
significant O
changes O
in O
the O
plasma O
lipid O
levels O
and O
8 B
- I
isoprostane I
, O
a O
marker O
of O
oxidative O
stress O
. O

Primary O
kinetic O
isotope O
effects O
from O
substrate O
conversion O
measurements O
( O
k O
' O
obs O
( O
( O
H O
) O
) O
/ O
k O
' O
obs O
( O
( O
D O
) O
) O
= O
3 O
. O
3 O
+ O
/ O
- O
0 O
. O
3 O
) O
and O
from O
initial O
rate O
analysis O
( O
k2 O
( O
( O
H O
) O
) O
/ O
k2 O
( O
( O
D O
) O
) O
= O
2 O
. O
3 O
+ O
/ O
- O
0 O
. O
4 O
) O
indicate O
that O
a O
N B
- I
H I
bond O
is O
broken O
in O
the O
turnover O
- O
limiting O
and O
irreversible O
step O
of O
the O
catalytic O
cycle O
. O

A O
six O
- O
centered O
, O
concerted O
transition O
state O
for O
C B
- I
N I
and O
C B
- I
H I
bond O
formation O
and O
N B
- I
H I
bond O
cleavage O
involving O
two O
amidoalkene B
ligands O
is O
proposed O
as O
most O
consistent O
with O
the O
current O
data O
. O

A O
six O
- O
centered O
, O
concerted O
transition O
state O
for O
C B
- I
N I
and O
C B
- I
H I
bond O
formation O
and O
N B
- I
H I
bond O
cleavage O
involving O
two O
amidoalkene B
ligands O
is O
proposed O
as O
most O
consistent O
with O
the O
current O
data O
. O

A O
six O
- O
centered O
, O
concerted O
transition O
state O
for O
C B
- I
N I
and O
C B
- I
H I
bond O
formation O
and O
N B
- I
H I
bond O
cleavage O
involving O
two O
amidoalkene B
ligands O
is O
proposed O
as O
most O
consistent O
with O
the O
current O
data O
. O

Our O
results O
showed O
that O
cisplatin B
increased O
the O
levels O
of O
oxidant O
parameters O
such O
as O
lipid O
peroxidation O
( O
thio B
barbituric I
acid I
reactive O
substance O
( O
TBARS O
) O
) O
and O
myeloperoxidase O
( O
MPO O
) O
in O
brain O
tissue O
and O
suppressed O
the O
effects O
of O
antioxidants O
such O
as O
total O
glutathione B
( O
GSH B
) O
and O
superoxide B
dismutase O
( O
SOD O
) O
. O

In O
addition O
, O
the O
level O
of O
8 B
- I
Gua I
( O
guanine B
) O
, O
a O
product O
of O
DNA O
damage O
, O
was O
1 O
. O
7 O
+ O
/ O
- O
0 O
. O
12 O
8 B
- I
hydroxyl I
guanine I
( O
8 B
- I
OH I
Gua I
) O
/ O
105 O
Gua B
in O
brain O
tissue O
in O
the O
control O
group O
receiving O
cisplatin B
, O
compared O
with O
0 O
. O
97 O
+ O
/ O
- O
0 O
. O
03 O
8 O
- O
OH O
Gua B
/ O
105 O
Gua B
in O
the O
thiamine B
pyrophosphate I
( O
20 O
mg O
/ O
kg O
) O
group O
and O
1 O
. O
55 O
+ O
/ O
- O
0 O
. O
11 O
8 B
- I
OH I
Gua I
/ O
105 O
Gua B
in O
the O

At O
1mM O
clothianidin B
, O
cAMP B
effects O
were O
associated O
to O
alpha O
- O
bungarotoxin O
- O
insensitive O
receptors O
because O
clothianidin B
- O
induced O
currents O
were O
blocked O
by O
5 O
mu O
M O
mecamylamine B
and O
20 O
mu O
M O
d B
- I
tubocurarine I
. O

Electronic O
structure O
analysis O
of O
multistate O
reactivity O
in O
transition O
metal O
catalyzed O
reactions O
: O
the O
case O
of O
C B
- I
H I
bond O
activation O
by O
non O
- O
heme O
iron O
( O
iv O
) O
- O
oxo O
cores O
. O

These O
concepts O
are O
then O
used O
to O
analyze O
the O
electronic O
structure O
changes O
occurring O
in O
the O
reaction O
of O
C B
- I
H I
bond O
oxidation O
by O
Fe B
( I
IV I
) I
oxo I
species O
. O

We O
present O
single O
- O
ion O
- O
channel O
recordings O
performed O
with O
biomimetic O
lipid O
membranes O
which O
are O
directly O
attached O
to O
the O
surface O
of O
a O
complementary O
metal B
- I
oxide I
- O
semiconductor O
( O
CMOS O
) O
preamplifier O
chip O
. O

The O
aim O
of O
the O
present O
study O
was O
to O
develop O
a O
( B
68 I
) I
Ga I
labeled I
bis I
- I
DOTA I
derivative O
of O
benzylidene B
- I
bis I
- I
indole I
and O
compare O
the O
in O
vivo O
stability O
and O
biodistribution O
with O
that O
of O
the O
previously O
reported O
bis B
- I
DTPA I
derivate O
for O
in O
vivo O
imaging O
of O
necrosis O
using O
PET O
. O

We O
used O
atomic O
force O
microscopy O
( O
AFM O
) O
to O
study O
the O
dose O
- O
dependent O
change O
in O
conformational O
and O
mechanical O
properties O
of O
DNA O
treated O
with O
PT B
- I
ACRAMTU I
( B
[ I
PtCl I
( I
en I
) I
( I
ACRAMTU I
- I
S I
) I
] I
( I
NO3 I
) I
2 I
, O
( O
en O
= O
ethane B
- I
1 I
, I
2 I
- I
diamine I
, O
ACRAMTU B
= O
1 B
- I
[ I
2 I
- I
( I
acridin I
- I
9 I
- I
ylamino I
) I
ethyl I
] I
- I
1 I
, I
3 I
- I
dimethylthiourea I
. O

PT B
- I
ACRAMTU I
is O
the O
parent O
drug O
of O
a O
family O
of O
non O
- O
classical O
platinum B
- O
based O
agents O
that O
show O
potent O
activity O
in O
non O
- O
small O
cell O
lung O
cancer O
in O
vitro O
and O
in O
vivo O
. O

AFM O
images O
show O
that O
PT B
- I
ACRAMTU I
causes O
some O
DNA O
looping O
and O
aggregation O
at O
drug O
- O
to O
- O
base O
pair O
ratio O
( O
r O
b O
) O
of O
0 O
. O
1 O
and O
higher O
. O

Very O
significant O
lengthening O
of O
the O
DNA O
was O
observed O
with O
increasing O
doses O
of O
PT B
- I
ACRAMTU I
, O
and O
reached O
saturation O
at O
an O
r O
b O
of O
0 O
. O
15 O
. O

Analysis O
of O
the O
AFM O
images O
based O
on O
the O
worm O
- O
like O
chain O
( O
WLC O
) O
model O
showed O
that O
PT B
- I
ACRAMTU I
did O
not O
change O
the O
flexibility O
of O
( O
non O
- O
aggregated O
) O
DNA O
, O
despite O
the O
extreme O
lengthening O
. O

The O
persistence O
length O
of O
untreated O
DNA O
and O
DNA O
treated O
with O
PT B
- I
ACRAMTU I
was O
in O
the O
range O
of O
49 O
- O
65 O
nm O
. O

Structural O
revision O
of O
methyl B
tortuoate I
D I
, O
a O
bis B
- I
cembranoid I
from O
Hainan O
Sarcophyton O
tortuosum O
and O
its O
absolute O
stereochemistry O
. O

Structural O
revision O
of O
methyl B
tortuoate I
D I
, O
a O
bis B
- I
cembranoid I
from O
Hainan O
Sarcophyton O
tortuosum O
and O
its O
absolute O
stereochemistry O
. O

Methyl B
tortuoate I
D I
( O
1 O
) O
, O
together O
with O
five O
other O
known O
related O
bis B
- I
cembranoids I
, O
was O
isolated O
from O
Hainan O
soft O
coral O
Sarcophyton O
tortuosum O
. O

Methyl B
tortuoate I
D I
( O
1 O
) O
, O
together O
with O
five O
other O
known O
related O
bis B
- I
cembranoids I
, O
was O
isolated O
from O
Hainan O
soft O
coral O
Sarcophyton O
tortuosum O
. O

The O
structure O
of O
methyl B
tortuoate I
D I
( O
1a O
) O
, O
firstly O
isolated O
and O
reported O
by O
Li O
et O
al O
. O
from O
the O
title O
organism O
, O
was O
corrected O
as O
1 O
by O
an O
extensive O
analysis O
of O
its O
one O
- O
dimensional O
and O
two O
- O
dimensional O
nuclear O
magnetic O
resonance O
data O
and O
by O
comparison O
with O
those O
reported O
in O
the O
literature O
. O

Using O
E O
. O
coli O
cells O
with O
a O
special O
tRNA O
/ O
aminoacyl O
- O
tRNA O
synthetase O
pair O
, O
two O
PPAR O
alpha O
variants O
were O
prepared O
, O
in O
which O
Leu B
- O
258 O
or O
Phe B
- O
273 O
were O
site O
- O
specifically O
replaced O
by O
the O
genetically O
encoded O
photo O
- O
reactive O
amino B
acid I
para B
- I
benzoylphenylalanine I
( O
Bpa B
) O
. O

Cyfluthrin B
also O
increased O
the O
clearance O
of O
the O
antipyrine B
metabolites O
, O
norantipyrine B
, O
4 B
- I
hydroxyantipyrine I
and O
3 B
- I
hydroxymethylantipyr I
and O
the O
formation O
rate O
constants O
for O
each O
of O
the O
three O
metabolites O
measured O
in O
urine O
. O

Cyfluthrin B
also O
increased O
the O
clearance O
of O
the O
antipyrine B
metabolites O
, O
norantipyrine B
, O
4 B
- I
hydroxyantipyrine I
and O
3 B
- I
hydroxymethylantipyr I
and O
the O
formation O
rate O
constants O
for O
each O
of O
the O
three O
metabolites O
measured O
in O
urine O
. O

C12 B
- O
, O
( B
C12 I
) I
2 I
- O
and O
cholesteryl B
- I
sperminex I
- O
siRNA O
were O
capable O
of O
luciferase O
knockdown O
at O
nanomolar O
concentrations O
without O
vectorization O
( O
i O
. O
e O
. O
one O
to O
two O
orders O
of O
magnitude O
more O
potent O
than O
commercially O
available O
cholesteryl B
siRNA O
) O
. O

The O
amount O
of O
active O
phosphorylated O
AMPK O
and O
acetyl B
- I
CoA I
carboxylase O
in O
rat O
liver O
epithelial O
IAR O
- O
20 O
cells O
increased O
when O
the O
cells O
were O
incubated O
with O
the O
aforementioned O
compounds O
. O

A O
structure O
- O
activity O
relationship O
of O
the O
3 O
- O
and O
6 O
- O
positions O
of O
the O
pyrazolo B
[ I
1 I
, I
5 I
- I
a I
] I
pyrimidine I
scaffold O
of O
the O
known O
BMP O
inhibitors O
dorsomorphin B
, O
1 O
, O
LDN B
- I
193189 I
, O
2 O
, O
and O
DMH1 B
, O
3 O
, O
led O
to O
the O
identification O
of O
a O
potent O
and O
selective O
compound O
for O
ALK2 O
versus O
ALK3 O
. O

From O
these O
studies O
, O
a O
novel O
5 B
- I
quinoline I
molecule O
was O
identified O
and O
designated O
an O
MLPCN O
probe O
molecule O
, O
ML347 B
, O
which O
shows O
> O
300 O
- O
fold O
selectivity O
for O
ALK2 O
and O
presents O
the O
community O
with O
a O
selective O
molecular O
probe O
for O
further O
biological O
evaluation O
. O

2 B
, I
2 I
' I
, I
3 I
, I
3 I
' I
, I
4 I
, I
4 I
' I
, I
5 I
, I
5 I
' I
, I
6 I
, I
6 I
' I
- I
decabromodiphenyl I
ether I
( O
BDE209 B
) O
is O
commercially O
most O
important O
both O
in O
the O
production O
and O
in O
the O
use O
of O
polybrominated B
diphenyl I
ethers I
( O
PBDEs B
) O
. O

We O
found O
that O
platelet O
aggregation O
and O
secretion O
in O
response O
to O
2 B
- I
MeSADP I
and O
AYPGKF O
were O
diminished O
in O
the O
presence O
of O
Pyk2 O
inhibitors O
or O
in O
Pyk2 O
- O
deficient O
platelets O
, O
suggesting O
that O
Pyk2 O
plays O
a O
positive O
regulatory O
role O
in O
platelet O
functional O
responses O
. O

We O
found O
that O
Pyk2 O
was O
activated O
downstream O
of O
both O
G12 O
/ O
13 O
and O
integrin O
- O
mediated O
pathways O
, O
and O
both O
2 B
- I
MeSADP I
- O
and O
AYPGKF O
- O
induced O
TxA2 B
generation O
was O
significantly O
diminished O
in O
Pyk2 O
- O
deficient O
platelets O
. O

Furthermore O
, O
inhibition O
of O
2 B
- I
MeSADP I
- O
induced O
TxA2 B
generation O
by O
fibrinogen O
receptor O
antagonist O
was O
not O
rescued O
by O
co O
- O
stimulation O
of O
G12 O
/ O
13 O
pathways O
in O
the O
presence O
of O
Pyk2 O
inhibitor O
. O

Solution O
pH O
and O
Oligoamine O
Molecular O
Weight O
Dependence O
of O
the O
Transition O
from O
Monolayer O
to O
Multilayer O
Adsorption O
at O
the O
Air O
- O
Water O
Interface O
from O
Sodium B
Dodecyl I
Sulfate I
/ O
Oligoamine O
Mixtures O
. O

Neutron O
reflectivity O
and O
surface O
tension O
have O
been O
used O
to O
investigate O
the O
solution O
pH O
and O
oligoamine O
molecular O
weight O
dependence O
of O
the O
adsorption O
of O
sodium B
dodecyl I
sulfate I
( O
SDS B
) O
/ O
oligoamine O
mixtures O
at O
the O
air O
- O
water O
interface O
. O

Protein O
- O
resistant O
SS O
- O
PPEGMA B
and O
protein O
- O
adsorbing O
SS O
- O
PPFS B
surfaces O
were O
prepared O
by O
coupling O
of O
the O
respective O
azide B
- O
functionalized O
poly B
( I
poly I
( I
ethylene I
glycol I
) I
methyl I
ether I
methacrylate I
) I
( O
azido B
- I
PPEGMA I
) O
and O
poly B
( I
2 I
, I
3 I
, I
4 I
, I
5 I
, I
6 I
- I
pentafluorostyrene I
) I
( O
azido B
- I
PPFS I
) O
polymer O
brushes O
in O
azide B
- O
alkyne B
' O
click O
' O
reaction O
. O

Protein O
- O
resistant O
SS O
- O
PPEGMA B
and O
protein O
- O
adsorbing O
SS O
- O
PPFS B
surfaces O
were O
prepared O
by O
coupling O
of O
the O
respective O
azide B
- O
functionalized O
poly B
( I
poly I
( I
ethylene I
glycol I
) I
methyl I
ether I
methacrylate I
) I
( O
azido B
- I
PPEGMA I
) O
and O
poly B
( I
2 I
, I
3 I
, I
4 I
, I
5 I
, I
6 I
- I
pentafluorostyrene I
) I
( O
azido B
- I
PPFS I
) O
polymer O
brushes O
in O
azide B
- O
alkyne B
' O
click O
' O
reaction O
. O

Antifouling O
alkyne B
- O
functionalized O
poly B
( I
N I
- I
hydroxyethyl I
acrylamide I
) I
( O
alkynyl B
- I
PHEAA I
) O
and O
antibacterial O
alkyne B
- O
functionalized O
poly B
( I
2 I
- I
( I
methacryloyloxy I
) I
ethyl I
trimethylammonium I
chloride I
) I
( O
alkynyl B
- I
PMETA I
) O
polymer O
brushes O
were O
clicked O
on O
the O
SS O
- O
azide B
surface O
. O

Antifouling O
alkyne B
- O
functionalized O
poly B
( I
N I
- I
hydroxyethyl I
acrylamide I
) I
( O
alkynyl B
- I
PHEAA I
) O
and O
antibacterial O
alkyne B
- O
functionalized O
poly B
( I
2 I
- I
( I
methacryloyloxy I
) I
ethyl I
trimethylammonium I
chloride I
) I
( O
alkynyl B
- I
PMETA I
) O
polymer O
brushes O
were O
clicked O
on O
the O
SS O
- O
azide B
surface O
. O

Synthesis O
of O
Hollow O
Ag B
- I
Au I
Bimetallic O
Nanoparticles O
in O
Polyelectrolyte O
Multilayers O
. O

Ag B
nanoparticles O
of O
~ O
20 O
nm O
size O
and O
rather O
uniform O
size O
distribution O
were O
synthesized O
in O
polyelectrolyte O
multilayers O
( O
PEMs O
) O
via O
an O
ion O
- O
exchange O
/ O
reduction O
process O
in O
two O
stages O
( O
seeding O
and O
growth O
) O
, O
which O
were O
used O
as O
sacrificial O
templates O
to O
fabricate O
Ag B
- I
Au I
bimetallic O
hollow O
nanoparticles O
via O
galvanic O
replacement O
reaction O
. O

The O
morphology O
and O
structure O
of O
the O
nanoparticles O
were O
characterized O
by O
transmission O
electron O
microscopy O
( O
TEM O
) O
and O
energy O
dispersive O
X O
- O
ray O
spectroscopy O
, O
which O
confirmed O
the O
formation O
of O
hollow O
Ag B
- I
Au I
bimetallic O
nanoparticles O
. O

UV O
- O
vis O
absorbance O
spectroscopy O
and O
TEM O
results O
indicated O
that O
both O
size O
and O
optical O
properties O
of O
the O
Ag B
nanoparticles O
in O
the O
PEM O
can O
be O
controlled O
by O
manipulating O
ion O
content O
in O
the O
PEM O
and O
the O
number O
of O
the O
ion O
- O
exchange O
/ O
reduction O
cycle O
, O
whereas O
that O
of O
Ag B
- I
Au I
bimetallic O
nanoparticles O
were O
dependent O
on O
size O
of O
the O
Ag B
templates O
and O
the O
replacement O
reaction O
kinetics O
. O

The O
hollow O
Ag B
- I
Au I
bimetallic O
nanoparticles O
exhibited O
a O
significant O
red O
shift O
in O
the O
surface O
plasmon O
resonance O
to O
the O
near O
- O
infrared O
region O
. O

Arylpiperazine B
- O
mediated O
activation O
of O
Akt O
protects O
SH O
- O
SY5Y O
neuroblastoma O
cells O
from O
6 B
- I
hydroxydopamine I
- O
induced O
apoptotic O
and O
autophagic O
death O
. O

We O
investigated O
the O
ability O
of O
19 O
recently O
synthesized O
arylpiperazine B
compounds O
to O
protect O
human O
SH O
- O
SY5Y O
neuroblastoma O
cells O
from O
the O
neurotoxin O
6 B
- I
hydroxydopamine I
( O
6 B
- I
OHDA I
) O
. O

We O
investigated O
the O
ability O
of O
19 O
recently O
synthesized O
arylpiperazine B
compounds O
to O
protect O
human O
SH O
- O
SY5Y O
neuroblastoma O
cells O
from O
the O
neurotoxin O
6 B
- I
hydroxydopamine I
( O
6 B
- I
OHDA I
) O
. O

The O
compound O
with O
the O
most O
potent O
neuroprotective O
action O
was O
N B
- I
{ I
3 I
- I
[ I
2 I
- I
( I
4 I
- I
phenyl I
- I
piperazin I
- I
1 I
- I
yl I
) I
- I
ethyl I
] I
- I
phenyl I
} I
- I
picolinamide I
( O
6b O
) O
, O
which O
reduced O
6 B
- I
OHDA I
- O
induced O
apoptotic O
death O
through O
stabilization O
of O
mitochondrial O
membrane O
and O
subsequent O
prevention O
of O
superoxide B
production O
, O
caspase O
activation O
and O
DNA O
fragmentation O
. O

6 B
- I
OHDA I
- O
triggered O
autophagic O
response O
was O
also O
reduced O
by O
6b O
, O
which O
prevented O
inactivation O
of O
the O
main O
autophagy O
repressor O
mTOR O
, O
upregulation O
of O
pro O
- O
autophagic O
beclin O
- O
1 O
, O
conversion O
of O
microtubule O
- O
associated O
protein O
1 O
light O
chain O
3 O
( O
LC3 O
) O
- O
I O
to O
autophagosome O
- O
associated O
LC3 O
- O
II O
, O
as O
well O
as O
intracytoplasmic O
acidification O
induced O
by O
6 B
- I
OHDA I
. O

6 B
- I
OHDA I
- O
triggered O
autophagic O
response O
was O
also O
reduced O
by O
6b O
, O
which O
prevented O
inactivation O
of O
the O
main O
autophagy O
repressor O
mTOR O
, O
upregulation O
of O
pro O
- O
autophagic O
beclin O
- O
1 O
, O
conversion O
of O
microtubule O
- O
associated O
protein O
1 O
light O
chain O
3 O
( O
LC3 O
) O
- O
I O
to O
autophagosome O
- O
associated O
LC3 O
- O
II O
, O
as O
well O
as O
intracytoplasmic O
acidification O
induced O
by O
6 B
- I
OHDA I
. O

The O
inhibition O
of O
autophagy O
using O
LC3 O
beta O
gene O
silencing O
or O
pharmacological O
autophagy O
blockers O
3 B
- I
methyladenine I
or O
bafilomycin B
A1 I
, O
mimicked O
the O
cytoprotective O
effect O
of O
6b O
. O

While O
the O
treatment O
with O
6b O
had O
no O
effect O
on O
the O
phosphorylation O
of O
proapoptotic O
MAP O
kinases O
ERK O
and O
JNK O
, O
it O
markedly O
increased O
the O
phosphorylation O
of O
the O
prosurvival O
kinase O
Akt O
in O
6 B
- I
OHDA I
- O
treated O
cells O
. O

Akt O
inhibitor O
DEBC O
or O
RNA O
interference O
- O
mediated O
Akt O
silencing O
reduced O
the O
ability O
of O
6b O
to O
block O
6 B
- I
OHDA I
- O
triggered O
apoptotic O
and O
autophagic O
responses O
, O
thus O
confirming O
their O
dependency O
on O
Akt O
activation O
. O

The O
cytoprotective O
effect O
of O
6b O
was O
also O
observed O
in O
6 B
- I
OHDA I
- O
treated O
neuronal O
PC12 O
cells O
, O
but O
not O
in O
SH O
- O
SY5Y O
or O
PC12 O
cells O
exposed O
to O
1 B
- I
methyl I
- I
4 I
- I
phenylpyridinium I
, O
indicating O
that O
the O
observed O
neuroprotection O
was O
dependent O
on O
the O
cytotoxic O
stimulus O
. O

Because O
of O
the O
ability O
to O
prevent O
6 B
- I
OHDA I
induced O
apoptotic O
/ O
autophagic O
cell O
death O
through O
activation O
of O
Akt O
, O
the O
investigated O
arylpiperazines B
could O
be O
potential O
candidates O
for O
treatment O
of O
neurodegenerative O
diseases O
. O

The O
fatty B
acid I
amide I
hydrolase O
inhibitor O
, O
URB597 B
, O
promotes O
retinal B
ganglion O
cell O
neuroprotection O
in O
a O
rat O
model O
of O
optic O
nerve O
axotomy O
. O

The O
endocannabinoid O
, O
N B
- I
arachidonoylethanola I
( O
AEA B
) O
, O
is O
degraded O
by O
the O
enzyme O
fatty B
acid I
amide I
hydrolase O
( O
FAAH O
) O
. O

The O
endocannabinoid O
, O
N B
- I
arachidonoylethanola I
( O
AEA B
) O
, O
is O
degraded O
by O
the O
enzyme O
fatty B
acid I
amide I
hydrolase O
( O
FAAH O
) O
. O

Measurement O
of O
retinal B
endocannabinoid O
levels O
in O
URB597 B
- O
treated O
animals O
at O
2 O
weeks O
post O
- O
axotomy O
revealed O
a O
significant O
increase O
in O
AEA B
levels O
, O
accompanied O
by O
a O
decrease O
by O
a O
decrease O
in O
the O
AEA B
metabolite O
, O
N B
- I
arachidonoylglycine I
, O
in O
young O
animals O
but O
not O
aged O
animals O
. O

2 B
- I
arachidonoylglycerol I
levels O
were O
similar O
across O
all O
experimental O
groups O
. O

These O
effects O
were O
induced O
by O
a O
7 O
- O
minute O
HMI O
- O
1b11 O
treatment O
and O
specifically O
depended O
on O
PKC O
alpha O
activation O
, O
since O
pretreatment O
with O
the O
selective O
inhibitor O
G B
o I
6976 I
abolished O
the O
up O
- O
regulation O
of O
GAP O
- O
43 O
protein O
observed O
at O
12hours O
In O
parallel O
, O
we O
found O
that O
a O
7 O
- O
minute O
exposure O
to O
HMI O
- O
1b11 O
induced O
PKC O
alpha O
accumulation O
to O
the O
cytoskeleton O
, O
an O
effect O
that O
was O
again O
prevented O
by O
pretreatment O
with O
G B
o I
6976 I
. O

These O
effects O
were O
induced O
by O
a O
7 O
- O
minute O
HMI O
- O
1b11 O
treatment O
and O
specifically O
depended O
on O
PKC O
alpha O
activation O
, O
since O
pretreatment O
with O
the O
selective O
inhibitor O
G B
o I
6976 I
abolished O
the O
up O
- O
regulation O
of O
GAP O
- O
43 O
protein O
observed O
at O
12hours O
In O
parallel O
, O
we O
found O
that O
a O
7 O
- O
minute O
exposure O
to O
HMI O
- O
1b11 O
induced O
PKC O
alpha O
accumulation O
to O
the O
cytoskeleton O
, O
an O
effect O
that O
was O
again O
prevented O
by O
pretreatment O
with O
G B
o I
6976 I
. O

N B
- I
Alkylated I
2 I
, I
3 I
, I
3 I
- I
trimethylindolenines I
and O
2 B
- I
methylbenzothiazoles I
. O

The O
synthesis O
of O
a O
variety O
of O
N B
- I
alkylated I
2 I
, I
3 I
, I
3 I
- I
trimethylindolenines I
and O
2 B
- I
methylbenzothiazoles I
is O
reported O
herein O
. O

Among O
these O
compounds O
, O
6d O
, O
which O
possesses O
an O
ortho B
- I
nitro I
group O
at O
the O
benzene B
ring O
, O
exhibited O
potent O
inhibitory O
effect O
on O
the O
proliferation O
of O
HUVECs O
, O
A549 O
, O
K562 O
, O
PC O
- O
3 O
, O
HCT116 O
, O
MDA O
- O
MB O
- O
231 O
and O
MCF O
- O
7 O
cells O
( O
IC50 O
= O
5 O
. O
34 O
, O
40 O
. O
53 O
, O
10 O
. O
81 O
, O
52 O
. O
52 O
, O
10 O
. O
19 O
, O
21 O
. O
37 O
and O
2 O
. O
81 O
mu O
M O
, O
respectively O
) O
. O

Cytotoxicity O
was O
evaluated O
with O
methyl B
thiazole I
tetrazolium I
( O
MTT B
) O
. O

The O
neuritogenic O
and O
neuroprotective O
activities O
of O
six O
starfish O
polar O
steroids B
, O
asterosaponin B
P I
1 I
, O
( B
25S I
) I
- I
5 I
alpha I
- I
cholestane I
- I
3 I
beta I
, I
4 I
beta I
, I
6 I
alpha I
, I
7 I
alpha I
, I
8 I
, I
15 I
alpha I
, I
16 I
beta I
, I
26 I
- I
octaol I
, O
and O
( B
25S I
) I
- I
5 I
alpha I
- I
cholestane I
- I
3 I
beta I
, I
6 I
alpha I
, I
7 I
alpha I
, I
8 I
, I
15 I
alpha I
, I
16 I
beta I
, I
26 I
- I
heptaol I
( O
1 O
- O
3 O
) O
from O
the O
starfish O
Patiria O
pectinifera O
and O

